0001520138-23-000335.txt : 20230821 0001520138-23-000335.hdr.sgml : 20230821 20230821163045 ACCESSION NUMBER: 0001520138-23-000335 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230821 DATE AS OF CHANGE: 20230821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Reviv3 Procare Co CENTRAL INDEX KEY: 0001718500 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 474125218 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-56351 FILM NUMBER: 231189550 BUSINESS ADDRESS: STREET 1: 901 S. FREMONT AVE. STREET 2: UNIT 158 CITY: ALHAMBRA STATE: CA ZIP: 91803 BUSINESS PHONE: 888-638-8883 MAIL ADDRESS: STREET 1: 901 S. FREMONT AVE. STREET 2: UNIT 158 CITY: ALHAMBRA STATE: CA ZIP: 91803 10-K 1 rviv-20230531_10k.htm 10-K
0001718500 false 2023 FY 0001718500 2022-06-01 2023-05-31 0001718500 2022-11-30 0001718500 2023-08-09 0001718500 2023-05-31 0001718500 2022-05-31 0001718500 2021-06-01 2022-05-31 0001718500 us-gaap:PreferredStockMember 2021-05-31 0001718500 us-gaap:CommonStockMember 2021-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001718500 us-gaap:RetainedEarningsMember 2021-05-31 0001718500 2021-05-31 0001718500 us-gaap:PreferredStockMember 2022-05-31 0001718500 us-gaap:CommonStockMember 2022-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001718500 us-gaap:RetainedEarningsMember 2022-05-31 0001718500 us-gaap:PreferredStockMember 2021-06-01 2022-05-31 0001718500 us-gaap:CommonStockMember 2021-06-01 2022-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2022-05-31 0001718500 us-gaap:RetainedEarningsMember 2021-06-01 2022-05-31 0001718500 us-gaap:PreferredStockMember 2022-06-01 2023-05-31 0001718500 us-gaap:CommonStockMember 2022-06-01 2023-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2023-05-31 0001718500 us-gaap:RetainedEarningsMember 2022-06-01 2023-05-31 0001718500 us-gaap:PreferredStockMember 2023-05-31 0001718500 us-gaap:CommonStockMember 2023-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001718500 us-gaap:RetainedEarningsMember 2023-05-31 0001718500 rviv:AxilMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerMember 2021-06-01 2022-05-31 0001718500 rviv:OptionsMember 2021-06-01 2022-05-31 0001718500 us-gaap:FurnitureAndFixturesMember 2023-05-31 0001718500 us-gaap:FurnitureAndFixturesMember 2022-05-31 0001718500 us-gaap:ComputerEquipmentMember 2023-05-31 0001718500 us-gaap:ComputerEquipmentMember 2022-05-31 0001718500 srt:MinimumMember us-gaap:PropertyPlantAndEquipmentMember 2023-05-31 0001718500 srt:MaximumMember us-gaap:PropertyPlantAndEquipmentMember 2023-05-31 0001718500 us-gaap:PropertyPlantAndEquipmentMember 2023-05-31 0001718500 us-gaap:PropertyPlantAndEquipmentMember 2022-05-31 0001718500 us-gaap:AutomobilesMember 2023-05-31 0001718500 us-gaap:AutomobilesMember 2022-05-31 0001718500 rviv:LicensingRightsMember 2023-05-31 0001718500 us-gaap:CustomerRelationshipsMember 2023-05-31 0001718500 us-gaap:TradeNamesMember 2023-05-31 0001718500 rviv:WebsiteMember 2023-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2020-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2020-05-01 2020-05-18 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2021-06-01 2022-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2023-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2022-05-31 0001718500 rviv:InsuranceFinancingMember 2023-05-31 0001718500 rviv:InsuranceFinancingMember 2022-06-01 2023-05-31 0001718500 rviv:InsuranceFinancingMember 2022-05-31 0001718500 rviv:PaycheckProtectionProgram2Member 2023-05-31 0001718500 rviv:PaycheckProtectionProgram2Member 2022-05-31 0001718500 rviv:FinancingChargesMember 2023-05-31 0001718500 rviv:FinancingChargesMember 2022-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2023-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2022-05-31 0001718500 2022-06-13 0001718500 rviv:NonVotingSeriesAPreferredStockMember 2022-06-01 2023-05-31 0001718500 rviv:AssetsPurchaseAgreementMember 2022-06-01 2023-05-31 0001718500 rviv:SeveralPrivatePlacementAgreementsMember 2022-06-01 2023-05-31 0001718500 rviv:SeveralPrivatePlacementAgreementsMember 2023-05-31 0001718500 2022-05-10 0001718500 2022-11-01 0001718500 2023-01-01 2023-01-29 0001718500 2023-04-01 2023-04-30 0001718500 us-gaap:AccountsPayableMember 2023-05-31 0001718500 rviv:IntrepidMember 2023-05-31 0001718500 rviv:IntrepidMember 2022-05-31 0001718500 rviv:WestonT.HarrisMember 2022-06-01 2023-05-31 0001718500 rviv:AxilMember 2022-06-16 0001718500 rviv:JeffToghraieMember 2022-06-16 0001718500 2022-06-01 2022-06-16 0001718500 us-gaap:CommonStockMember 2022-06-01 2022-06-16 0001718500 us-gaap:PreferredStockMember 2022-06-01 2022-06-16 0001718500 2022-06-16 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerOneMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerTwoMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerThreeMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerOneMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerTwoMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember rviv:OutsideTheUnitedStatesMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CA 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:IT 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember rviv:OutsideTheUnitedStatesMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CA 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:IT 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:HairShampooMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:ShampooAndConditionerMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:BundledKitsMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:HairShampooMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:HairShampooAndConditionerMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:IntroductorykitMember 2021-06-01 2022-05-31 0001718500 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerMember 2022-06-01 2023-05-31 0001718500 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerMember 2021-06-01 2022-05-31 0001718500 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerOneMember 2021-06-01 2022-05-31 0001718500 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerTwoMember 2021-06-01 2022-05-31 0001718500 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerThreeMember 2021-06-01 2022-05-31 0001718500 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember rviv:CustomerFourMember 2021-06-01 2022-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 us-gaap:ProductConcentrationRiskMember rviv:PurchasesMember rviv:VendorsMember 2022-06-01 2023-05-31 0001718500 us-gaap:ProductConcentrationRiskMember rviv:PurchasesMember rviv:VendorOneMember 2022-06-01 2023-05-31 0001718500 us-gaap:ProductConcentrationRiskMember rviv:PurchasesMember rviv:VendorTwoMember 2022-06-01 2023-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember rviv:VendorThreeMember 2022-06-01 2023-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember rviv:VendorMember 2021-06-01 2022-05-31 0001718500 us-gaap:ProductConcentrationRiskMember rviv:PurchasesMember rviv:VendorOneMember 2021-06-01 2022-05-31 0001718500 us-gaap:ProductConcentrationRiskMember rviv:PurchasesMember rviv:VendorTwoMember 2021-06-01 2022-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember rviv:VendorThreeMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember rviv:AxilMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember rviv:OutsideTheUnitedStatesMember rviv:AxilMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember country:CA rviv:AxilMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:AxilMember rviv:EarBudsMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:ShampoosAndConditionersMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:ShampoosAndConditionersMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:AncillaryProductsMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:AncillaryProductsMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember us-gaap:ProductMember 2021-06-01 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:GhostStrykeMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:TrackrHeadmuffMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:OtherBluetoothAndEarBudsMember 2022-06-01 2023-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember rviv:AccessoriesOtherMember 2022-06-01 2023-05-31 0001718500 rviv:HairCareAndSkinCareMember 2022-06-01 2023-05-31 0001718500 rviv:HairCareAndSkinCareMember 2021-06-01 2022-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2022-06-01 2023-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2021-06-01 2022-05-31 0001718500 rviv:HairCareAndSkinCareMember 2023-05-31 0001718500 rviv:HairCareAndSkinCareMember 2022-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2023-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2022-05-31 0001718500 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember rviv:CustomersMember 2022-06-01 2023-05-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-K

 

xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE FISCAL YEAR ENDED MAY 31, 2023

 

OR

 

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM TO

 

Commission file number: 000-56351

 

REVIV3 PROCARE COMPANY 

(Exact name of registrant as specified in its charter)

 

Delaware   47-4125218
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

   

901 S Fremont Avenue, Unit 158,

Alhambra, CA

  91803
(Zip Code)
(Address of Principal Executive Offices)  

 

 

(888) 638-8883 

(Registrant’s telephone number including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  Trading symbol(s)  Name of each exchange on which registered
None  N/A  N/A

 

Securities registered pursuant to section 12(g) of the Act: Common stock, par value $0.0001 per share

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 

YES ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act: 

YES ☐ No ☒ 

 
 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ NO ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  ☐ Accelerated filer  ☐
Non-accelerated Filer  ☒ Smaller reporting company  ☒
    Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ¨ 

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ¨ 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES ☐ NO ☒

 

As of November 30, 2022 the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates was $5,037,204.13. For purposes of this computation, all officers, directors and 10% beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers, directors or 10% beneficial owners are, in fact, affiliates of the registrant.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

 

   Shares Outstanding
Title of Class  August 17, 2023
Common Stock   117,076,949 

 

Documents incorporated by reference: None

 

 
 
 

Table of Contents 

 

Cautionary Note Regarding Forward-Looking Information

 

PART I 1
ITEM 1. DESCRIPTION OF BUSINESS. 1
ITEM 1A. RISK FACTORS. 5
ITEM 1B. UNRESOLVED STAFF COMMENTS. 5
ITEM 2. PROPERTIES. 6
ITEM 3. LEGAL PROCEEDINGS. 6
ITEM 4. MINE SAFETY DISCLOSURES. 6
   
PART II 7
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. 7
ITEM 6. [RESERVED] 8
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 8
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. 13
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. 13
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. 13
ITEM 9A. CONTROLS AND PROCEDURES. 13
ITEM 9B. OTHER INFORMATION. 14
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.   14
   
PART III 15
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. 15
ITEM 11. EXECUTIVE COMPENSATION. 18
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. 19
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. 21
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES. 22
   
PART IV 23
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. 23
ITEM 16. FORM 10-K SUMMARY 25
   
SIGNATURES 25

 

 -i-

 

Cautionary Note Regarding Forward-Looking Information 

 

This Annual Report on Form 10-K, in particular Part II Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements represent our expectations, beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding our assumptions about financial performance; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the beauty and hair care industry and the hearing protection and ear bud business, all of which were subject to various risks and uncertainties.  

 

There are a number of factors that could cause our actual results to differ from those indicated in the forward-looking statements, many of which are outside of our control. They include: the impact of unstable market and general economic conditions on our business, financial condition and stock price, including inflationary cost pressures, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict, and other downturns in the business cycle or the economy; our financial performance and liquidity, including our ability to successfully generate sufficient revenue to support our operations; our ability to repay our outstanding loans; risks related to our operations and international markets, such as fluctuations in currency exchange rates, different regulatory environments, trade barriers and sanctions, exchange controls, and social and political instability; changes in the regulatory environment in which we operate, including environmental, health and safety regulations, including those related to climate change; our ability to protect and defend our intellectual property; continuity and security of information technology infrastructure and the potential impact of cybersecurity breaches or disruptions to our management information systems; competition; our ability to retain our management and employees and the potential impact of ongoing labor shortages; demands on management resources; availability and cost of the raw materials we use to manufacture our products, including the impacts of inflationary cost pressures and ongoing supply chain disruptions and constraints, which have been, and may continue to be, exacerbated by the Russia-Ukraine conflict; additional tax expenses or exposures; product liability claims; the potential outcome of any legal or regulatory proceedings; integrating acquisitions and achieving the expected savings and synergies, including our recent acquisition of hearing protection and ear bud businesses; global or regional catastrophic events, including the effects of natural disasters, which may be worsened by the impact of climate change; demand for and market acceptance of our products, as well as our ability to successfully anticipate consumer trends; business divestitures; labor relations; the potential impact of environmental, social and governance matters; and implementation of environmental remediation matters.

 

When used in this Annual Report on Form 10-K and other reports, statements, and information we have filed with the Securities and Exchange Commission (“SEC”), in our press releases, presentations to securities analysts or investors, in oral statements made by or with the approval of an executive officer, the words or phrases “believes,” “may,” “will,” “expect,” “should,” “could,” “would,” “continue,” “anticipate,” “intend,” “likely,” “estimate,” “project,” “plan,” “design,” “potential” or similar expressions and variations thereof are intended to identify such forward-looking statements. However, any statements contained in this Annual Report on Form 10-K that are not statements of historical fact may be deemed to be forward-looking statements. Furthermore, such forward-looking statements speak only as of the date of this Annual Report on Form 10-K. We caution that these statements by their nature involve risks and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of important factors. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict.

 

We do not assume the obligation to update any forward-looking statement, except as required by applicable law. You should carefully evaluate such statements in light of factors described in this annual report. In this Annual Report on Form 10-K, Reviv3 Procare Company (“Reviv3 Procare,” the “Company,” “we,” “us,” and “our”) has identified material factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties.

 

 -ii-

 

PART I

 

ITEM 1. DESCRIPTION OF BUSINESS.

 

General

 

Reviv3 is engaged in the manufacturing, marketing, sale and distribution of high-tech, innovative hearing and audio enhancement and protection products that provide cutting-edge solutions for people with varied applications across many industries and professional quality hair and skin care products under various trademarks and brands. The Company is not, and has not been at any time, a shell company. On June 16, 2022 we completed the acquisition of substantially all of the assets of Axil & Associated Brands Corp. (“AXIL”), a leader in hearing and audio enhancement and protection. We operate on a fiscal year ending May 31.

  

Our Segments

 

Following the AXIL acquisition, we conduct our business through two operating segments: hearing enhancement and protection, and hair care and skin care. See Note 15 to our Consolidated Financial Statements in this report for financial information for these segments. We concentrate on attracting new customers and retaining existing customers to increase our total revenue. For the fiscal year ended May 31, 2023, the hearing protection and enhancement segment and the hair care and skin care segment accounted for 93.0% and 7.0% of our revenue, respectively.

 

Our Strategy

 

The Company’s overall business strategy is to establish market awareness of our products through our direct-to-consumer campaigns. We believe the increase in awareness will allow the Company to increase distribution and gain customers through our distribution partners’ retail establishments, with the goal of helping us achieve growth in market share and diversify our sales channels.

 

Hearing Enhancement and Protection Segment

 

Following the June 16, 2022 AXIL acquisition and under the AXIL and related brands, we create high-tech, innovative hearing and audio enhancement and protection products to provide cutting-edge solutions for people with varied applications across many industries, including ear plugs, ear muffs and ear buds. Following the acquisition, the Company shifted its primary business focus to the sale of our premium audio enhancement and protection products sold under the AXIL brand. The Company designs, innovates, engineers, manufactures, markets and services specialized systems in hearing enhancement, hearing protection, wireless audio, and communication. We distribute our products through direct-to-consumer eCommerce channels and local, regional, and national retail chains. We serve the sporting goods market, military, federal agents, law enforcement, tactical, fitness, outdoor, industrial, sporting, and stadium events. We focus primarily on the U.S. markets, followed by Canada, Europe, Australia, New Zealand, and Africa.

 

Currently, through our hearing protection and enhancement segment we produce 22 products with 32 different stock keeping unit (“SKUs”) and have plans to continue expanding the product lines. The product line includes ear buds, ear muffs, ear plugs, outdoor speakers and ear care items. Some of the products incorporate Bluetooth technology that we continually developed to enhance the hearing experience while protecting the ears. AXIL engages product design services to align consumer preferences with the brand image, ensuring that all product lines will correlate. The majority of sales occur through direct-to-consumer via www.goaxil.com, third party platforms, dealers and distributors. Our intellectual property portfolio in this segment includes 3 active patents globally. For more information about our intellectual property see “—Intellectual Property” below.

 

Our products in this segment include GS Xtreme® sound enhancement and hearing protection ear buds, XCOR® True Wireless, digital ear buds with touch control, TRACKR™ Blu advanced sound enhancement, hearing protection, and Bluetooth audio earmuffs and X-PRO passive ear protection.

 

-1-

Our hearing protection and enhancement segment continues to grow as it enters into new distribution and licensing agreements. Our target markets include industrial, construction, farm and agriculture, aviation, forestry, and recreational markets (such as fitness, hiking, biking, auto racing, target shooting, hunting, power sports, power tools, motorcycling, stadium and concert events).

 

Hearing Enhancement and Protection Marketing and Sales:

 

AXIL is growing the business as it continues to enter into new distribution and licensing agreements. There is focus on public safety and security markets, as well as entertainment venues. AXIL’s sales are primarily driven through paid advertising and growth is expected to continue. The Company continues to expand our marketing footprint in organic social, affiliate, and search engine optimization. In addition to online sales, there is opportunity to increase distribution and retail sales. As a result, the business is currently allocating resources and intends to increase the sales team depending on available capital performance and opportunities.

 

Hearing Enhancement and Protection Competition:

 

The hearing enhancement and protection products are in a distinct market that overlaps between the consumer electronics and the hearing protection device sectors. We believe the global hearing protection devices market is growing due to the greater awareness of hearing loss and published statistics stating that 46% of workers in the manufacturing and industrial sector have been exposed to hazardous noises. Demand for innovative products for hearing protection is rising as consumers seek devices that are both comfortable and offer superior hearing protection.

 

The hearing protection and enhancement segment competes with ISOtunes, Walkers, Surefire, SordinAB and others. Many of our competitors in this market have more broadly diversified product lines, well established supply and distribution systems, loyal customer bases and significant financial, marketing, research and development, and other resources. We believe our principal competitive advantages include: brand recognition; product technology and innovation; product quality and safety; price; breadth of product lines; network of technology and content partners; access to third party retailers; sales channels, distributors, retailers and OEM partners; and patent protection. 

 

Hair Care and Skin Care Segment

 

Prior to the AXIL acquisition, our business consisted solely of manufacturing, marketing, sale and distribution of professional quality hair and skin care products under various trademarks and brands and has adopted and used trademarked products for distribution throughout the U.S., Canada, Europe and Asia pursuant to the terms of 12 exclusive distribution agreements with various parties throughout our targeted markets. Our manufacturing operations are outsourced and fulfilled through our co-packers and manufacturing partners. Approximately 95% of purchased inventories and products are sourced from 3 vendors totaling approximately $298,000 during the fiscal year ended May 31, 2023.

 

Currently, we produce 8 products with 16 SKUs and plan to expand our product lines over the next 12 months. Our intellectual property portfolio in this segment includes no patents and 1 trademark globally. For more information about our intellectual property see “—Intellectual Property” below.

 

Our hair and skin care segment is focused on expanding its business-to-business salon sales through its network of domestic and international distributors. We are also continuing our focus on direct-to-consumer marketing programs through our own e-commerce site and various third-party online platforms. In addition, we are exploring other revenue channels such as co-branding and private-label manufacturing.

 

Hair Care and Skin Care Marketing and Sales:

 

Reviv3 stands for skin health and benefits of healthy scalp and hair follicles. Currently, we sell our hair and skincare products under the Reviv3 brand which includes 7 distinct products. Our Reviv3 System is a series of products which are meant to be used together or on a stand-alone basis. The hair care products consist of PREP shampoo, PRIME conditioner, and TREAT maintenance care. We also sell an introductory kit which includes all three Reviv3 System products. In addition, we have products dedicated to hair treatment and repair. Currently we have 3 products in our treatment and repair line. BOOST is designed to deliver nutrients and increase circulation to the scalp, MEND Deep Hair Repair Mask for added moisture and PROTECT, a heat protectant product to prevent damage from irons and dryers. We also have a stand-alone Thickening Spray for giving hair more volume and body.

 

-2-

Reviv3 is focused on expanding its business-to-business salon sales through its network of domestic and international distributors. We are also continuing our focus on direct-to-consumer marketing programs through our own ecommerce site and various third-party online platforms. In addition, we are exploring other revenue channels such as co-branding and private-label manufacturing.

 

Hair Care and Skin Care Competition:

 

The personal care product industry boasts roughly 750 companies that generate a combined annual revenue of more than $40 billion. The 50 largest companies comprise almost 70% of the entire revenue. Still, we believe the market will bear competition from small companies able to offer specialized products or cater to particular niche markets.

 

Makeup, deodorant and nail products comprise 33% of health and beauty care industry revenue. Hair care products generate 25% of personal care product revenue, while creams and lotions comprise 21%. Perfumes, mouthwashes, shaving preparations and other products make up the remaining revenue for beauty skin care product revenues.

 

The hair care and skin car segment competes with Keranique, Zenagen, Revita and others. Many of our competitors in this market have more broadly diversified product lines, well established supply and distribution systems, loyal customer bases and significant financial, marketing, research and development and other resources. We believe our principal competitive advantages include product quality, online marketing, and a drug-free solution to thinning hair.

 

Key Customers

 

For the hearing enhancement and protection segment, no customers accounted for more than 10% of our net sales in the fiscal year ended May 31, 2023. Approximately 97% of our sales was direct-to-consumer via Shopify and Amazon for the fiscal year ended May 31, 2023.

 

For the hair care and skin care segment, three customers accounted for 61%, 12% and 21%, respectively, of our net sales in the fiscal year ended May 31, 2023. No other individual customer accounted for 10% or more of our net sales in the fiscal year ended May 31, 2023. We expect that these three customers along with a small number of other customers will, in the aggregate, continue to account for a large portion of our hair care and skin care segment net sales in the future.

 

As is customary in the industry, none of our customers is under any obligation to continue purchasing products from us in the future.

 

Customer Service and Support

 

Key elements of our customer service approach are listening to customers, empathizing with their concerns, responding timely to their requests, and following up with them to make sure any issues have been properly addressed. In order to ensure that sufficient quality of service is provided, we use a customer service platform that integrates all of our systems to provide complete and timely data, tracks all support tickets and conversations with customers. Our customer service manager performs regular monthly reviews of performance metrics and reviews processes. 

 

Governmental Regulation

 

We are subject to a variety of laws, rules and regulations in numerous jurisdictions within the U.S., Canada, Europe, Australia, New Zealand, and Africa. These laws, rules and regulations cover several diverse areas including consumer health and safety, and employee health and safety. These U.S. federal, state, and foreign laws and regulations, which in some cases can be enforced by private parties in addition to government entities, are constantly evolving and can be subject to significant change. The compliance costs and operational burdens imposed by these laws and regulations could be significant. As a result of the often rapidly evolving changes, the application, interpretation, and enforcement of these and other laws and regulations are often uncertain and may be interpreted and applied inconsistently from jurisdiction to jurisdiction and inconsistently with our current policies and practices. We are committed to conducting our business in accordance with applicable laws, rules and regulations.

 

Environmental Matters: We believe that we are in compliance with applicable foreign, federal, state, and local laws, rules and regulations relating to the protection of the environment, and that continued compliance will not have any material effect on our capital expenditures, earnings, or competitive position.

   

-3-

Intellectual Property

 

We intend to protect our technology by filing patent applications for the technologies that we consider important to our business. We also rely on trademarks, trade secrets, copyrights and unpatented know-how to protect our proprietary rights.

 

We believe our intellectual property has value, and we have taken in the past, and will take in the future, actions we deem appropriate to protect such property from misappropriation. There can be no assurance, however, that such actions will provide meaningful protection from competition. In the absence of intellectual property protection, we may be vulnerable to competitors who attempt to copy or imitate our products or processes.

 

While we believe that our patents and other proprietary rights are important to our business, we also believe that, due to the rapid pace of technological change in the markets we serve, the successful manufacture and sale of our products also depends upon our engineering, manufacturing, marketing and servicing skills.

 

It is our practice to require that all of our employees and third-party product development consultants assign to us all rights to inventions or other discoveries relating to our business that were made while working for us. In addition, all employees and third-party product development consultants agree not to disclose any private or confidential information relating to our technology, trade secrets or intellectual property.

 

At May 31, 2023, we held 3 active U.S. patents and had 2 pending U.S. patent applications covering various aspects of our technology. Our U.S. patents expire at various times beginning in 2035 and extending through 2038. During the fiscal year ended May 31, 2023, no U.S. patents were issued and no U.S. patents expired. We do not anticipate any expiration of any of our patents in the future years will have a material impact on our business.

 

We have 3 federally registered trademarks for which we consider to be of material importance to our business. The registrations for these trademarks are in good standing with the U.S. Patent & Trademark Office. Our trademark registrations must be renewed at various times, and we intend to renew our trademarks, as necessary, for the foreseeable future.

 

In addition, we own reviveprocare.com and www.goaxil.com. As with phone numbers, we do not have, and cannot acquire any property rights to an Internet address. The regulation of domain names in the United States and in other countries is also subject to change. Regulatory bodies could establish additional top-level domains, appoint additional domain name registrars or modify the requirements for holding domain names. As a result, we might not be able to maintain our domain names or obtain comparable domain names, which could harm our business.

 

Seasonality

 

We do not believe our business is subject to substantial seasonal fluctuations. We may experience lower sales in difficult economic scenarios, but we do not foresee the seasonality of our products to be a significant factor. In the future, seasonality trends could however have a material impact on our financial condition and results of operations, but we are not currently aware of the total impact that could affect our business.

 

Human Capital Management

 

As of May 31, 2023, we had 15 employees, all of whom were employed in the United States and none employed outside the United States. None of our employees are covered by collective bargaining agreements or work councils. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. Overall, we consider our employee relations to be good and believe our culture to be central to the success of the Company.

 

-4-

Health and Safety: The health and safety of our employees is of utmost importance to us. We are enhancing our safety program with additional training and internal risk and hazard assessments. We conduct policy and procedure reviews to ensure compliance with health and safety guidelines and regulatory requirements. We provide protective gear (e.g., eye protection, masks, and gloves) as required by applicable standards and as appropriate. Our goal is to achieve a level of work-related injuries as close to zero as possible through continuous investment in our safety program. 

 

Hiring Practices: We seek to recruit and hire the most qualified people for our open positions without regard to protected status (age, color, creed, disability, domestic violence victim status, gender identity, genetic predisposition or carrier status, marital status, national origin, pregnancy, race religion, sex, sexual orientation, status as a protected veteran or as a member of any other protected group or status).

 

Diversity and Inclusion: Recognizing and respecting our employees’ backgrounds and experiences, and our international presence, we strive to maintain a diverse workforce and inclusive work environment everywhere we operate. 

 

Compensation and Benefits: Our compensation and benefits program is designed to attract and reward individuals who demonstrate the ability and desire to enhance our workplace culture, support our values, drive our operational and strategic goals, and create long-term value for our stockholders.

 

Our Office and Corporate History

 

Our principal executive office is located at 901 Fremont Avenue, Unit 158, Alhambra, California, 91803. Our telephone number is (888) 638-8883. Reviv3 was incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC, which was organized on July 31, 2013.

 

Available Information

 

We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements and other information with the Securities and Exchange Commission (“SEC”). Our filings with the SEC are available on the SEC’s website at www.sec.gov. We also maintain a website at reviveprocare.com and www.goaxil.com. We make available, free of charge, in the Investor Relations section of our website, documents we file with or furnish to the SEC, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports. We make this information available as soon as reasonably practicable after we electronically file such materials with, or furnish such information to, the SEC. The information found on our website is not part of this or any other report we file with, or furnish to, the SEC. Copies of such documents are available in print at no charge to any stockholder who makes a request. Such requests should be made to our corporate secretary at our corporate headquarters, 901 Fremont Avenue, Unit 158, Alhambra, California, 91803.

 

ITEM 1A. RISK FACTORS.

 

As a smaller reporting company, we are not required to provide the information required by this Item 1A. 

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

None.

 

-5-

ITEM 2. PROPERTIES.

 

We currently lease approximately 3,296 square feet of office and warehouse space at 901 S Fremont Avenue, Unit 158, Alhambra, CA 91803 as our principal offices. We lease our offices pursuant to a lease dated November 9, 2022. The term of our lease began on December 1, 2022 and expires on November 30, 2024.  Our current monthly base rent is $6,098. We believe these facilities are in good condition and satisfy our operational requirements. We intend to seek additional leased space, which will include some warehouse facilities, as our business grows.

 

AXIL leases office and warehouse space at 120 E. 13065 S. #101, Draper, Utah, 84020 of approximately 2,750 square feet. AXIL operates on a month to month lease with current monthly base rent of $4,330. We believe AXIL’s office and warehouse are in good condition and satisfy AXIL’s operational requirements.

 

ITEM 3. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such pending or threatened legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our financial statements. These legal accruals may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of the loss is not estimable, we do not record an accrual, consistent with applicable accounting guidance. In the opinion of management, while the outcome of such claims and disputes cannot be predicted with certainty, our ultimate liability in connection with these matters is not expected to have a material adverse effect on our results of operations, financial position or cash flows, and the amounts accrued for any individual matter are not material. However, legal proceedings are inherently uncertain. As a result, the outcome of a particular matter or a combination of matters may be material to our results of operations for a particular period, depending upon the size of the loss or our income for that particular period.

 

On November 23, 2020, the Company was served a copy of a complaint filed by Jacksonfill, LLC in the Fourth Circuit Court for Duval County, Florida. The complaint alleges breach of Agreement for non-payments for certain products against the Company. The allegations arise from alleged discrepancies discovered by the Company in the manufacturing of certain product. The Company has retained counsel, has asserted a counterclaim against Jacksonfill, LLC, and intends to vigorously defend the allegations. Other than as disclosed herein, there have been no material developments in this matter through August 12, 2023. Please see Note 11—Commitments and Contingencies to our financial statements included herein for additional information about this matter.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

-6-

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

As of May 31, 2023, the Company’s common stock was quoted on the OTCQB operated by OTC Markets Group, Inc. under the symbol “RVIV.” The trading volume for our common stock is relatively limited. An active trading market may not continue to provide adequate liquidity for our existing stockholders or for persons who may acquire our common stock in the future. No assurance can be given that an active trading market for the Company’s common stock will develop or be maintained.

 

The range of high and low closing bid quotations for the Company’s common stock during each quarter of the calendar years ended May 31, 2023, and 2022, is shown below, as quoted on the OTCQB. Prices are inter-dealer quotations, without retail mark-up, markdown or commissions and may not represent actual transactions.

 

Stock Quotations

 

Quarter Ended   High     Low  
August 31, 2021     0.5275       0.2001  
November 30, 2021     0.325       0.1011  
February 28, 2022     0.20       0.10  
May 31, 2022     0.30       0.0551  
August 31, 2022     0.30       0.20  
November 30, 2022     0.30       0.20  
February 28, 2023     0.450       0.271  
May 31, 2023     0.60       0.285  

 

The future sale of the Company’s presently outstanding “unregistered” and “restricted” common stock by present members of management and persons who own more than five percent of the Company’s outstanding voting securities may have an adverse effect on the trading price of the Company’s common stock.

 

Securities outstanding and holders of record

 

On May 31, 2023, the total common shares issued and outstanding were 117,076,949 and we had 212 stockholders of record of our common stock.

 

Dividend Policy

 

We have never paid any cash dividends on our common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. Any future determination to pay dividends on our common stock will be at the discretion of our Board of Directors (the “Board”) and will depend on our financial condition, results of operations, capital requirements, applicable restrictions in our Articles of Incorporation, applicable restrictions in our Bylaws, contractual limitations, and other factors that our Board deems relevant.

 

-7-

Recent Sales of Unregistered Securities

 

On November 1, 2022, the Company issued to a former executive officer options to purchase 300,000 shares, of which 75,000 vested and the remaining were forfeited when the former executive officer resigned on April 21, 2023. These options were issued pursuant to an exemption from the registration requirements of the Securities Act, as provided by Rule 701, Regulation D and/or Section 4(a)(2) of the Securities Act, as applicable.

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion should be read in conjunction with our financial statements and the notes thereto included in this Report beginning on page 23. The results shown herein are not necessarily indicative of the results to be expected in any future periods. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Please see the section entitled “Cautionary Note Regarding Forward-Looking Information” above for more information regarding the risks associated with forward-looking information.

 

Overview

 

We are engaged in the manufacturing, marketing, sale and distribution of high-tech, innovative hearing and audio enhancement and protection products that provide cutting-edge solutions for people with varied applications across many industries and professional quality hair and skin care products under various trademarks and brands.

 

On May 1, 2022, we entered into an Asset Purchase Agreement dated May 1, 2022 and amended on June 15, 2022 and September 8, 2022 with AXIL, a Delaware corporation, and a leader in hearing protection and enhancement products, for the acquisition of both the hearing protection business of AXIL consisting of ear plugs and ear muffs, and AXIL’s ear bud business. These businesses constituted substantially all of the business operations of AXIL. The acquisition was completed subsequently on June 16, 2022. On September 8, 2022, the Company and AXIL entered into an amendment to the Asset Purchase Agreement which eliminated the provision in the Asset Purchase Agreement requiring the Company to effectuate a reverse stock split of our Common Stock and preferred stock pursuant to the Asset Purchase Agreement within a certain period of time.

 

As a result of the acquisition of AXIL’s assets, the Company has two reportable segments: hair care and skin care, and hearing enhancement and protection.

 

Through our hearing enhancement and protection segment, we design, innovate, engineer, manufacture, market and service specialized systems in hearing enhancement, hearing protection, wireless audio, and communication. Through our hair care and skin care segment, we manufacture, market, sell, and distribute professional quality hair and skin care products. 

 

The Company’s overall business strategy is to establish market awareness of our products through our direct-to-consumer campaigns. We believe the increase in awareness will allow the Company to increase distribution and gain customers through our distribution partners’ retail establishments, with the goal of helping us achieve growth in market share and diversify our sales channels.

 

-8-

Results of Operations

 

For the fiscal years ended May 31, 2023 and 2022

 

Our results of operations are summarized below.

 

   Fiscal Year
Ended
May 31,
2023		  Fiscal Year
Ended
May 31,
2022
Net sales  $23,521,027   $2,336,257 
Cost of sales  $5,810,216   $828,586 
Gross profit  $17,710,811   $1,507,671 
Total operating expenses  $15,726,600   $1,719,074 
Income (Loss) from operations  $1,984,211   $(211,403)
Net income (loss) after tax  $1,824,575   $(182,903)

 

Net sales increased by $21,184,770 or 907% for the fiscal year ended May 31, 2023, as compared to the fiscal year ended May 31, 2022, primarily due to the increase in sales of the new line of AXIL products post-acquisition.  The net sales increase was attributed to the AXIL segment of the business.

 

Cost of sales includes primarily the cost of products and freight-in costs. For the fiscal year ended May 31, 2023, the overall cost of sales increased by $4,981,630 or 601%, as compared to the comparable period in 2022 also due to the acquisition of the AXIL business and sales of those products. Cost of sales as a percentage of net revenues for the fiscal year ended May 31, 2023 was 24.7% as compared to 35.5% for the comparable period in 2022. The overall decrease in cost of sales, as a percentage of sales, is primarily attributable to the Company’s increased efficiencies in procurement and manufacturing systems, reduction in product cost, and the sales of higher margin AXIL products.

 

-9-

Gross profit, as a percentage of sales, for the fiscal years ended May 31, 2023 and 2022 was 75.3% and 64.5%, respectively. The increase in gross profit, as a percentage of sales, is primarily attributable to our continued increased focus on the direct sales to consumer channels, which have higher margins, which include the AXIL product sales contribution.

 

Operating expenses are costs related to marketing and selling expenses, compensation and related taxes, professional and consulting fees, and general and administrative costs. Operating expenses for the fiscal years ended May 31, 2023 and 2022 were $15,726,600 and $1,719,074, respectively. Operating expenses as a percentage of net revenues for the fiscal year ended May 31, 2023 were 66.9% as compared to 73.6% for the comparable period in 2022. Operating expenses increased by $14,007,526 or 814.8% due to an increase in advertising and marketing expenses by $10,903,316 in the AXIL spend for displaying our products through various advertising platforms and the remaining $3,104,210 of other business operating expenses that are primarily attributed to the AXIL brand operations. Other than an increase in advertising costs, which were aimed at procuring more customers, and reduction in consulting costs, the other operating expenses also decreased for the Reviv3 products.

 

Income from operations for the fiscal year ended May 31, 2023 was $1,984,211 and loss of $211,403 for the fiscal year ended May 31, 2022. The year over year increase in income from operations of $2,195,614 was primarily driven from the sales of the AXIL products introduced after acquisition.

 

Net income after tax for the fiscal year ended May 31, 2023 was $1,824,575 and a loss of $182,903 for the fiscal year ended May 31, 2022. The increase of $2,007,478 for the fiscal year ended May 31, 2023 was related to the AXIL product sales and revenue growth attributable to that business. 

 

Liquidity and Capital Resources 

 

We are currently engaged in our product sales and development. Although we earned a net income in the fiscal year ended May 31, 2023, we have incurred operating losses in the past. We currently expect to earn net income during the current fiscal year ending May 31, 2024. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL ’s assets, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying consolidated financial statements. Management is focused on growing the Company’s existing product lines, introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands, including those resulting from the purchase of AXIL’s assets in June 2022, may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying consolidated financial statements. 

 

Cash Flows For the Fiscal Years ended May 31, 2023 and 2022

 

The following table provides detailed information about our net cash flows: 

 

  

For the
Fiscal Year 

Ended
May 31,
2023 

 

For the
Fiscal Year 

Ended
May 31,
2022 

Cash Flows          
Net cash provided by (used in) operating activities  $2,918,136   $(126,055)
Net cash provided by investing activities   1,000,764    — 
Net cash provided by financing activities   540,051    2,849 
Net increase (decrease)  $4,458,951   $(123,206)

 

-10-

Operating Activities

 

For the Fiscal Years ended May 31, 2023 and 2022

 

Net cash provided by operating activities for the fiscal year ended May 31, 2023 was $2,918,136, attributable to a net income of $1,824,575 which was primarily driven by the AXIL acquisition and increased product revenues. The offset by non-cash items such as depreciation and amortization expense of $95,179 due to assets and intangibles acquired on acquisition, bad debts of $76,969 as related to the greater number of customers from the AXIL brand sales, inventory changes of $353,985 as higher levels from the new business line, stock-based compensation of $207,342, favorable changes in accounts payable, contract and current liabilities of $1,235,788 and increase in non-cash gain on debt settlement of $50,500. The net decrease in cash was increased by a net decrease in operating assets and liabilities of $825,203 primarily due to increase in prepaid expenses, accounts receivable and decrease in customer deposits.

 

Net cash used in operating activities for the fiscal year ended May 31, 2022 was $126,055, attributable to a net loss of $182,903 offset by non-cash items such as depreciation expense of $7,871, bad debts of $6,941, inventory write-off of $71,481, stock-based compensation of $21,967 and increase in non-cash gain on debt settlement of $35,000. The net loss was increased by a net decrease in operating assets and liabilities of $16,411 primarily due to increase in accounts receivable and decrease in customer deposits offset by a decrease in inventory purchases. 

 

Investing Activities

 

For the Fiscal Years ended May 31, 2023 and 2022

 

The Company invested $65,650 in the purchase of property and equipment and acquired $1,066,414 of cash as part of the AXIL asset acquisition during the fiscal year ended May 31, 2023. The Company did not make any material investments in the purchase of property and equipment during the fiscal year ended May 31, 2022.

 

Financing Activities

 

For the Fiscal Years ended May 31, 2023 and 2022

 

Net cash provided by financing activities for the fiscal year ended May 31, 2023 was $540,051 primarily attributable to the cash proceeds of $447,850 for the common stock issuance and $132,620 advances from related party, offset by repayments of equipment financing and repayment of note payable that totaled $40,419.

 

Net cash provided by financing activities for the fiscal year ended May 31, 2022 was $2,849 primarily attributable to the cash proceeds of $35,000 of grants received from US Small Business Administration pursuant to the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), offset by payments to a related party of $28,851 and repayment of equipment financing of $3,300.

 

As of May 31, 2023, we had the following secured loan outstanding, administered pursuant to the CARES Act: an Economic Injury Disaster Loan (“EIDL”) in the principal amount of $150,000. The Company continues to pay interest on the loan. 

 

During June 2022, we made an acquisition of a business, AXIL, a leader in hearing protection and enhancement products for the acquisition of both the hearing protection business of AXIL consisting of ear plugs and ear muffs, and AXIL’s ear bud business. We purchased the business pursuant to issuances of common stock and preferred stock.

 

We are dependent on our product sales to fund our operations and may require additional capital in the future, such as pursuant to the sale of additional common stock or of debt securities or entering into credit agreements or other borrowing arrangements with institutions or private individuals, to maintain operations, which may not be available on favorable terms, or at all, and could require us to sell certain assets or discontinue or curtail our operations. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. In addition, pursuant to a voting agreement, effective June 16, 2022, with AXIL and Intrepid Global Advisors, we are subject to certain limitations on our ability to sell our capital stock until June 2024. Our officers and directors have made no written commitments with respect to providing a source of liquidity in the form of cash advances, loans, and/or financial guarantees. We do not have any plans to seek additional financing at this time and anticipate that our existing cash equivalents and cash provided by operations will be sufficient to meet our working capital requirements. However, if the need arises for additional cash, there can be no assurance that we will be able to raise the capital we need for our operations on favorable terms, or at all. We may not be able to obtain additional capital or generate sufficient revenues to fund our operations. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon our business plans. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to cease operations. If we fail to raise funds, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.

 

-11-

Off-Balance Sheet Arrangements

 

As of May 31, 2023, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Critical Accounting Policies

 

Our discussion and analysis of our results of operations, liquidity and capital resources are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of lease liabilities and related right of use assets, the value of stock-based compensation, valuation of deferred tax assets, contract liability, allowance on sales returns, business combinations, segment reporting and the fair value of non-cash common stock issuances. We base our estimates on historical and anticipated results and trends and on various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results that differ from our estimates could have a significant adverse effect on our operating results and financial position. We believe that the following significant accounting policies and assumptions may involve a higher degree of judgment and complexity than others.

 

Accounts receivable and allowance for doubtful accounts

 

The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

Revenue recognition

 

The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard (new guidance) has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.

 

The Company sells a variety of hair and skin care products and electronic hearing and enhancement products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues. 

 

-12-

The five steps for revenue recognition are as follows:

 

Identify the contract with a customer. The Company generally considers completion of a sales order (which requires customer acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) or purchase orders from non-consumer customers as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving third party financier payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.

 

Identify the performance obligations in the contract. Product performance obligations include shipment of products and related accessories and service performance obligations include extended warranty coverage.

 

However, as the historical redemption rate under our warranty policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

 

Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 30-days and 60-days right of return that applies to AXIL and Reviv3 products, respectively. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.

 

Allocate the transaction price to the performance obligations in the contract. For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.

 

Recognize revenue when or as the Company satisfies a performance obligation. Revenue for products is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period. 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

As a smaller reporting company, we are not required to provide the information required by this Item 7A. 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

The financial statements of the Company and the related report of the Company’s independent registered public accounting firm thereon have been filed under Item 15 hereof.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Principal Executive Officer, and Chief Financial Officer (“CFO”) and Principal Financial and Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of our CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures as of May 31, 2023. Based on this evaluation of disclosure controls and procedures as of May 31, 2023, our CEO and CFO concluded that our disclosure controls and procedures were not effective.

 

-13-

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance to our management and Board regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our management, including our CEO and CFO, assessed the effectiveness of our internal control over financial reporting as of May 31, 2023 using criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework issued in 2013. Based on the assessment, our management has concluded that as of May 31, 2023, our internal control over financial reporting was not effective based on those criteria.  

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this annual report.

 

Remediation

 

The Company plans to initiate measures to improve the effectiveness of the internal controls over financial reporting and disclosure controls and procedures. As of the filing date, we have engaged a third-party to enhance the reporting in our accounting systems, as well as increase the level of review when any non-routine accounting entry is proposed. The Company hired additional accounting personnel to oversee the financial close and reporting process. The Company plans to hire additional staff to aid in segregation of duties to continue to improve our internal controls in the coming fiscal year. We have also started to develop an internal control structure and identify key procedures for financial reporting as required by Section 404 of the Sarbanes-Oxley Act of 2002 and we are currently in the process of documenting our internal control policies and procedures. We have drafted written policies and procedures that we will commence implementing during the fiscal year ending May 31, 2024. In addition, the company intends to establish controls related to corporate governance, including a Code of Business Conduct and Ethics that applies to all of our employees, including our CEO, CFO, and Board. 

 

Changes in Internal Controls

 

There has been no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) or 15d-15(d) under the Exchange Act that occurred during the fiscal quarter ended May 31, 2023 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting. Our management is currently taking corrective action to remedy the internal control weaknesses. See section entitled “Remediation” above.

 

ITEM 9B. OTHER INFORMATION.

 

None. 

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

Not applicable.

 

-14-

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

Directors

 

Our directors are elected by the Board to a term of one year and serve until their successor is duly elected and qualified, or until the earlier of their death, resignation or removal.

 

The names, ages and positions of our present directors are set forth below:

 

NAME  AGE  POSITION
Jeff Toghraie   56   Chief Executive Officer and Chairman
         
Nancy Hundt   55   Director

 

The names, ages and positions of our present officers are set forth below:

 

NAME  AGE  POSITION
Jeff Toghraie   56   Chief Executive Officer and Chairman
         
Monica Diaz Brickell   44   Chief Financial Officer
         
Jeff Brown   41   Chief Operating Officer
         
Donald Starace   69   President

   

Background of executive officers and directors

 

Jeff Toghraie –Chief Executive Officer and Chairman of the Board of Directors

 

Jeff Toghraie has been the Chairman of our Board since 2015 and our Chief Executive Officer since 2016. Mr. Toghraie is currently the Managing Director of Intrepid Global Advisors, one of our principal stockholders. Mr. Toghraie joined Intrepid Global Advisors in 2010 and is a principal of that firm. During the past 6 years, Mr. Toghraie has been involved with various privately held development stage companies as a director and/or in advisory positions. Mr. Toghraie was chosen as a director due to his experience with and knowledge of the Company and its operations, his background in working with development stage companies and his general business background.

 

Jeff Brown – Chief Operating Officer

 

Jeff Brown has been our Chief Operating Officer since March 2017. From 2015 to 2017, Mr. Brown held consulting positions at Polar Solar Inc., a company responsible for making commercial solar panels available to the residential market and Mind Fitness Lab, a technology company that developed and distributed mobile applications for mental health professionals. From 2012 to 2015, he was the President of RNA Pro, a company that distributed agricultural supplements. Mr. Brown holds an MBA from Pepperdine University and received his bachelor’s degree from University of California, Irvine.

 

-15-

Monica Diaz Brickell – Chief Financial Officer

  

Monica Diaz Brickell has been our Chief Financial Officer since April 2023. From 2007 to 2022, Ms. Brickell served as International Tax Manager for Top Golf Callaway Brands Corp. Ms. Brickell holds a Master of Science in Accountancy and a Bachelor of Business Administration in Accounting from the University of Notre Dame and has an active license as a Certified Public Accountant in the State of California. 

 

Donald Starace – President

 

Donald Starace has been our President since February 2015. Mr. Starace has over forty years of dedicated service in the beauty industry. Mr. Starace started his career in some of New York’s most prestigious salons, followed by ten years at Nioxin Research Labs and subsequently Proctor & Gamble in Sales and Education. Mr. Starace owned and operated various businesses through his career including roles in starting the Bank of New Jersey, which currently holds 10 locations, and has assets over $865 million. He was one of the initial investors for the bank and was very influential in raising capital. He also facilitated bringing Taiff (Brazil) professional appliances to the hair industry in the U.S. and Canada. Mr. Starace most recently was appointed as a member of the Board of Adjustments for the Borough of Fort Lee, New Jersey.

 

Nancy Hundt – Director

 

Nancy Hundt has served as our director since May 2015. Ms. Hundt has a diverse background in the retail industry and has served as a representative of the American Board of Opticianry, an optical industry retail group. Ms. Hundt serves as a consultant and a retail sales expert, and has served over the last five years as Chief Operating Officer of Academy Optical, Inc. Ms. Hundt was chosen as a director due to her relevant experience in retail sales and general business background.

 

Family Relationships

 

There are no family relationships among any of our directors or executive officers.

 

Involvement in Certain Legal Proceedings

 

We are not aware of any pending or threatened legal proceedings in which the aforementioned individuals are involved. To the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item 401(f) of Regulation S-K in the past 10 years.

 

Corporate Governance

 

Our Board currently consists of two directors, one of whom is female.
 

We do not have any standing audit, nominating or compensation committees of the Board, or committees performing similar functions. We may apply to be listed on a registered national securities exchange if our Board determines it is in the best interests of our Company and our stockholders. If we become listed on a registered national securities exchange, our Board intends to form three standing committees upon the effectiveness such listing: an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition of these committees will consist of independent directors consistent with applicable exchange listing requirements and SEC rules. We will adopt written charters for each of these committees and make these available on our website consistent with applicable requirements and rules. Our Board may establish other committees as it deems necessary or appropriate from time to time.

 

We do not currently have a Code of Ethics applicable to our principal executive, financial or accounting officer. We believe this approach is appropriate in light of the Company’s current capital structure and level of operations. During the fiscal year ended May 31, 2023, all Board actions were taken by unanimous written consent and the Board held no formal meetings.

 

-16-

Audit Committee and Audit Committee Financial Expert

 

We do not have an audit committee or an audit committee financial expert (as defined in Item 407 of Regulation S-K) serving on the Board. All current members of the Board lack sufficient financial expertise for overseeing financial reporting responsibilities. We have not yet employed an audit committee financial expert due to the inability to attract such a person.

  

Indemnification

 

Our Amended and Restated Certificate of Incorporation and our Bylaws, subject to certain provisions of Delaware Law, contain provisions which require or allow us to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he reasonably believed was in the best interest of the Company. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.  

 

Delinquent Section 16(a) Reports

 

Section 16(a) of the Exchange Act requires our officers, directors and persons who own more than 10% of our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. To our knowledge, based on solely a review of the copies of such reports, all of our officers, directors, and persons who own more than 10% of our common stock complied with the filing requirements of Section 16(a) of the Exchange Act during the fiscal year ended May 31, 2023 except for Jeff Toghraie, who did not file a Form 4 with respect to one transaction, Don Frank Nathaniel Vasquez, who did not file a Form 3, Intrepid Global Advisors, Inc., who did not file a Form 4 with respect to one transaction on two different occasions, and AXIL, who did not file a Form 3 and a Form 4 with respect to one transaction on seven occasions. Additionally, as of May 31, 2023, Intrepid Global Advisors, Inc. has not filed a Form 3 that was required to be filed during the fiscal year ended May 31, 2017.

 

-17-

ITEM 11. EXECUTIVE COMPENSATION.  

 

The following table sets forth the compensation paid by us for the last two fiscal years ended May 31, 2023, and 2022, to our named executive officers (each, an “NEO”), who for the fiscal year ended May 31,2023 were Jeff Toghraie, our Chief Executive Officer and Chairman (Principal Executive Officer), Jeff Brown, our Chief Operating Officer, Monica Diaz Brickell, our Chief Financial Officer, and Meenu Jain, our former Chief Financial Officer.

 

Summary Compensation Table

 

Name and Principal Position  Year  Salary ($)  Bonus ($)  Stock Awards ($)  Option Awards ($)(1)  Non-Equity Incentive Plan Compensation ($)  Nonqualified Deferred Compensation Earnings ($)  All Other Compensation  ($)  Totals ($)
                                              
 Jeff Toghraie   2022    —    —    —    279,000    —    —    —    279,000 
Chief Executive Officer and Chairman   2023    —    —    —    —    —    —    —    — 
                                              
Jeff Brown   2022    50,000    —    —    198,000    —    —    —    248,000 
Chief Operating Officer   2023    98,000    35,000    —    —    —    —    —    133,000 
                                              
Meenu Jain(2)   2023    81,667    —    —    15,000    —    —    —    96,667 
Former Chief Financial Officer                                             
                                              
Monica Diaz Brickell(3)   2023    17,500    —    —    —    —    —    —    17,500 
Chief Financial Officer                                             

 

(1)

The value of option awards in this table represents the fair value of such awards granted or modified during the fiscal year, as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. The assumptions used to determine the valuation of the awards are discussed in Note 10—Stockholders’ Equity to our financial statements included herein.
(2) Ms. Jain became our Chief Financial Officer on November 1, 2022 and resigned as our Chief Financial Officer on April 21, 2023.
(3) Ms. Diaz Brickell became our Chief Financial Officer on April 24, 2023. 

 

Our Chief Executive Officer, Jeff Toghraie, and our Chief Operating Officer, Jeff Brown, did not have formal employment agreements with the Company in place as of May 31, 2023. Mr. Toghraie is entitled to an annual performance bonus, health benefits and equity awards at the discretion of the Board. Mr. Brown receives a base salary of $98,000 per year and is entitled to annual performance bonus, paid vacation, optional health benefits and equity awards at the discretion of the Board.

 

Monica Diaz Brickell joined the Company as Chief Financial Officer in April 2023. Per her agreement with the Company, she receives a base salary of $140,000 per year and is entitled to paid vacation and optional health benefits. 

 

We did not pay any compensation to our non-employee director during the fiscal years ended May 31, 2023 and 2022.

 

As of May 31, 2023, we did not have any retirement, pension, or profit sharing plans for the benefit of our executive officers and directors.

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table sets forth certain information regarding outstanding equity awards held by the named executive officers as of May 31, 2023:

 

       Option Awards
Name  Grant Date   

Number of securities underlying unexercised options
(#) exercisable

    

Number of securities underlying unexercised options
(#) unexercisable

    

Option exercise price
($)

    

Option expiration date

Jeff Toghraie  5/10/22   1,550,000    1,550,000(1)   0.09   4/20/2032
Jeff Brown  5/10/22   1,100,000    1,100,000(1)   0.09   4/20/2032
Meenu Jain  11/01/22   75,000(2)   —   0.20   11/1/2032

 

(1)These options vest and become exercisable over time, with 25% of the options vesting on September 1, 2022 and thereafter vesting 1/24th on the 1st of every month.
(2) These options vested and become exercisable over time, with 75,000 vesting on February 1, 2023 and the remaining 225,000 options associated with this grant were forfeited on April 21, 2023 when the former executive resigned from the Company.

   

-18-

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The following table sets forth the ownership, as of August 17, 2023, of our common stock by each person known by us to be the beneficial owner of more than five percent (5%) of our outstanding common stock, our directors, our executive officers, and our directors and executive officers as a group. The persons named have sole voting and investment power with respect to such shares, except as otherwise noted Except as otherwise indicated below, the address of each beneficial owner is c/o Reviv3 Procare Company, 901 Fremont Avenue, Unit 158, Alhambra, California 91083.

 

Title of Class   Name/Position   Beneficial Ownership   Percentage of Class(1)
     Named Executive Officers:              
Common   Jeff Toghraie (2)     24,868,375 (4)   20.9%  
Common   Jeff Brown     1,746,595 (5)   1.5%  
Common   Monica Diaz Brickell     —     *  
Common   Meenu Jain (3)     325,000 (6)   *  
    Directors:              
Common   Nancy Hundt     2,145,455     1.8%  
    All Executive Officers and Directors as a group (six persons)     29,659,263 (7)   24.6%  
    5% Stockholders:              
Common   Shircoo, Inc.     11,685,000 (8)    9.9%  
Common   Intrepid Global Advisors, Inc.     22,834,000 (9)   19.5%  
Common   Don Frank Nathaniel Vasquez     25,525,004 (10)   21.8%  

 

(1)   The amounts reported by each person are as of August 17, 2023, with percentages based on 117,076,949 shares issued and outstanding as of that date, except where the person has the right to receive shares within the next 60 days (as indicated in the other footnotes to this table), which would increase the number of shares owned by such person and the number of shares outstanding. “Beneficial ownership” is deemed to include shares for which a person, directly or indirectly, has or shares voting or dispositive power, whether or not they are held for the person’s benefit, and includes shares that may be acquired within 60 days, including the right to acquire shares by the exercise of options. Shares that may be acquired within 60 days by the exercise of options are referred to in the footnotes to this table as “presently exercisable options.” Unless otherwise indicated in the other footnotes to this table, each stockholder named in the table has sole voting and sole dispositive power over all of the shares shown in the table.
     
(2)   Mr. Toghraie is also the Chairman of the Board.

 

(3)   Ms. Jain resigned as our Chief Financial Officer on April 21, 2023.
     
(4)   Includes (i) 2,034,375 shares of common stock underlying stock options that are presently exercisable within 60 days of August 17, 2023 and (ii) 22,834,000 shares held by Intrepid Global Advisors, Inc. (“Intrepid”) with offices at 355 S. Grand Avenue, Suite 2450, Los Angeles, CA 90071. Jeff Togharie, our Chief Executive Officer and Chairman, is the managing director of Intrepid.

 

(5)   Includes 1,443,750 shares of common stock underlying stock options that are presently exercisable within 60 days of August 17, 2023.
     
(6)   Includes 75,000 shares of common stock underlying stock options that are presently exercisable.
     
(7)   Includes 3,478,125 shares of common stock underlying stock options that are presently exercisable within 60 days of August 17, 2023.

 

(8)   Shircoo, Inc.’s address is 2350 E. Allview Terrace, Los Angeles, CA 90068.

 

(9)   Mr. Toghraie, our Chief Executive Officer and Chairman, is the is the managing director of Intrepid. Intrepid’s address is 355 S. Grand Avenue, Suite 2450, Los Angeles, CA, 90071.
     
(10)   Mr. Vasquez’s business address is 4700 Summerville Ln., Prosper, Texas, 75078.

 

-19-

Securities authorized for issuance under equity compensation plans 

 

The following table sets forth equity compensation plan information as of May 31, 2023:

 

Equity Compensation Plan Information

 

Plan category 

Number of securities to be issued upon exercise of outstanding options, warrants and rights

(a)

 

Weighted-average exercise price of outstanding options, warrants and rights

(b)

 

Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))

(c)

Equity compensation plans approved by security holders   —   $—    — 

Equity compensation plans not approved by security holders(1)

              
2022 Equity Incentive Plan     5,375,000     $ 0.09      4,625,000 
Total   5,375,000   $ 0.09    4,625,000 

 

(1)On March 21, 2022, the Board approved the 2022 Equity Incentive Plan (the “Plan”). The total number of shares available under the plan as of May 31, 2023 was 10,000,000 shares. The Plan provides for an annual increase on April 1 of each calendar year, beginning in 2022 and ending in 2031, subject to Board approval prior to such date. Such increase may be equal to the lesser of (i) 4% of the total number of shares of the Company’s common stock outstanding on May 31 of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board. The number of shares authorized for issuance under the Plan will not change unless the Board affirmatively approves an increase in the number of shares authorized for issuance prior to April 1 of the applicable year.

2022 Equity Incentive Plan

 

The Board approved the Company’s 2022 Equity Incentive Plan on March 21, 2022. Under this plan, equity-based awards may be made to employees, officers, directors, non-employee directors and consultants of the Company and its Affiliates (as defined in the plan) in the form of (i) Incentive Stock Options (to eligible employees only); (ii) Nonqualified Stock Options; (iii) Restricted Stock; (iv) Stock Awards; (v) Performance Shares; or (vi) any combination of the foregoing. The Plan will terminate upon the close of business on the day next preceding March 21, 2032, unless terminated earlier in accordance with the terms of the Plan. The Board serves as the Plan administrator and may amend or terminate the Plan without stockholder approval, subject to certain exceptions.

 

-20-

The total number of shares initially authorized for issuance under the Plan was 10 million shares. The Plan provides for an annual increase on April 1 of each calendar year, beginning in 2022 and ending in 2031, subject to Board approval prior to such date. Such increase may be equal to the lesser of (i) 4% of the total number of shares of the Company’s common stock outstanding on May 31 of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board. The number of shares authorized for issuance under the Plan will not change unless the Board affirmatively approves an increase in the number of shares authorized for issuance prior to April 1 of the applicable year. The Board has not approved an increase in the number of shares authorized for issuance under the Plan as of May 31, 2023. Shares surrendered or withheld to pay the exercise price of a stock option or to satisfy tax withholding requirements will not be added back to the number of shares available under the Plan. To the extent that any shares of common stock awarded or subject to issuance or purchase pursuant to awards under the Plan are not delivered or purchased, or are reacquired by the Company, for any reason, including a forfeiture of restricted stock or failure to earn performance shares, or the termination, expiration or cancellation of a stock option, or any other termination of an award without payment being made in the form of shares of common stock will be added to the number of shares available for awards under the Plan. The number of shares available for issuance under the Plan will be adjusted for any increase or decrease in the number of outstanding shares of common stock resulting from payment of a stock dividend on common stock, a stock split or subdivision or combination of shares of common stock, or a reorganization or reclassification of common stock, or any other change in the structure of shares of common stock, as determined by the Board. Shares available for awards under the Plan will consist of authorized and unissued shares.

 

Two types of options may be granted under these Plans: (1) Incentive Stock Options which may only be issued to eligible employees of the Company and are required to have the exercise price of the option not less than the fair market value of the common stock on the grant date; or in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110% of the fair market value of the Common stock at the grant date; and (2) Non-qualified Stock Options which may be issued to participants under the Plan and which may have an exercise price less than the fair market value of the common stock on the grant date, but not less than par value of the stock.

 

The Board may grant or sell restricted stock to participants (i.e., shares that are subject to a subject to restrictions or limitations as to the participant’s ability to sell, transfer, pledge or assign such shares) under the Plan. Except for these restrictions and any others imposed by the Board, upon the grant of restricted stock, the recipient generally will have rights of a stockholder with respect to the restricted stock. During the applicable restriction period, the recipient may not sell, exchange, transfer, pledge or otherwise dispose of the restricted stock. The Board may also grant awards of common stock to participants under the Plan, as well as awards of performance shares, which are awards for which the payout is subject to achievement of such performance objectives established by the Board. Performance shares may be settled in cash.

 

Each equity-based award granted under the Plan will be evidenced by an award agreement that specifies the terms of the award and such additional limitations, terms and conditions as the Board may determine, consistent with the provisions of the Plan.

 

Upon the occurrence of a change in control, unless otherwise provided in an award agreement: (i) all outstanding stock options will become immediately exercisable in full; (ii) all outstanding performance shares will vest in full as if the applicable performance conditions were achieved in full, subject to certain adjustments, and will be paid out as soon as practicable; and (iii) all restricted stock will immediately vest in full. The Plan defines a change in control as (i) the adoption of a plan of merger or consolidation of the Company with any other corporation or association as a result of which the holders of the voting capital stock of the Company as a group would receive less than 50% of the voting capital stock of the surviving or resulting corporation; (ii) the approval by the Board of an agreement providing for the sale or transfer (other than as security for obligations of the Company) of substantially all the assets of the Company; or (iii) in the absence of prior Board approval, the acquisition of more than 20% of the Company’s voting capital stock by any person within the meaning of Rule 13d-3 under the Exchange Act (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company).

 

Subject to the Plan’s terms, the Board has full power and authority to determine whether, to what extent and under what circumstances any outstanding award will be terminated, canceled, forfeited or suspended. Awards to that are subject to any restriction or have not been earned or exercised in full by the recipient will be terminated and canceled if such recipient is terminated for cause, as determined by the Board in its sole discretion.

 

Pursuant to the Plan, on May 10, 2022, the Company issued to two executive officers non-statutory stock options to purchase, in the aggregate, up to 5,300,000 shares of its Common Stock, at an exercise price of $0.09 per share and expiring on April 20, 2032. The options vest over time with 25% of the options vesting on September 1, 2022 and thereafter vesting 1/24th on the 1st of every month.  

 

Pursuant to the Plan, on November 1, 2022, the Company issued non-statutory stock options to a former executive officer, to purchase, in the aggregate, up to 300,000 shares of its Common Stock, at an exercise price of $0.20 per share and expiring on October 31, 2032. 75,000 shares vested as of January 29, 2023, and the remaining 225,000 options were forfeited in April 2023 when the executive officer left the Company.  

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

Director Independence

 

Because we are quoted on the OTCQB and not listed on a national securities exchange, we are currently not subject to certain corporate governance requirements that apply to exchange-listed companies. For purposes of evaluating the independence of our directors, our Board uses the rules of the SEC and Nasdaq Stock Market (“Nasdaq”). Our Board has determined that Nancy Hundt, is considered “independent” and Jeff Toghraie, Chairman of the Board of Directors, is not considered “independent” because he is employed by the Company under applicable SEC rules and regulations and the Nasdaq listing requirements and rules.

 

Related Party Transactions 

 

The following is a description of transactions or series of transactions since June 1, 2021, to which we were or will be a party, in which:

  • the amount involved in the transaction exceeds the lesser of (i) $120,000 or (ii) 1% of the average of our total assets at year end for the last two completed fiscal years; and
  • in which any of our executive officers, directors, director nominees or holders of 5% or more of any class of our voting capital stock, or any immediate family member of any of the foregoing, had or will have a direct or indirect material interest.

 

-21-

The Company’s Chief Executive Officer, Jeff Toghraie, is the managing director of Intrepid Global Advisors (“Intrepid”). Intrepid has, from time to time, provided advances to the Company for working capital purposes. At May 31, 2023, and 2022, the Company had amounts payable to Intrepid of $124,378 and $25,452, respectively. These advances were short-term in nature and non-interest bearing. Additionally, pursuant to a voting agreement, effective June 16, 2022 as amended effective November 7, 2022, with AXIL and Intrepid Global Advisors, we are subject to certain limitations on our ability to sell our capital stock until June 2024.  

 

During the fiscal year ended May 31, 2023, the Company paid $218,696 as consulting fee for product development to Weston T. Harris, a major stockholder of AXIL, and also paid $126,097 to immediate family members of the major stockholder as compensation for services relating to packaging design and affiliate marketing.

 

During the fiscal year ended May 31, 2023, the Company paid $135,484 as consulting fee for inventory management and operations consulting to an immediate family member of a major stockholder of AXIL, $74,620 to an immediate family member of the major stockholder in commissions and a contractor fee, and $15,928 to an immediate member of the major stockholder as compensation for services relating to travel and event coordination.

 

On June 16, 2022, the Company and its wholly owned subsidiary Reviv3 Acquisition Corporation completed the acquisition of both (i) the hearing protection business of AXIL, consisting of ear plugs and ear muffs, and (ii) AXIL’s ear bud business pursuant to the Asset Purchase Agreement, dated May 1, 2022, as amended on June 15, 2022, by and among the Company, Reviv3 Acquisition Corporation, AXIL and certain stockholders of AXIL. One of the stockholders of AXIL is Intrepid Global Advisors, Inc. As of May 31, 2023, Intrepid Global Advisors, Inc. held no outstanding common stock of AXIL and 19.50% of the outstanding common stock of the Company.

   

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

 

Pre-Approval Policy 

 

The SEC requires that before our independent registered public accounting firm is engaged by us to render any auditing or permitted non-audit related service, the engagement be either (i) approved by our audit committee (or equivalent body) or (ii) entered into pursuant to pre-approval policies and procedures established by the audit committee (or equivalent body), provided that the policies and procedures are detailed as to the particular service, the audit committee (or equivalent body) is informed of each service, and such policies and procedures do not include delegation of the audit committee’s (or equivalent body) responsibilities to management. Our Board pre-approves all services provided by our independent registered public accounting firm. 

 

Fees

 

All of the services provided and fees charged by our independent registered public accounting firm Salberg & Company, P.A. (“Salberg”), were pre-approved by our Board, as we do not have an audit committee. The following table shows us the fees paid to Salberg, for the fiscal years ended May 31, 2023 and 2022 were: 

 

   Fiscal Year Ended
May 31, 2023		  Fiscal Year Ended
May 31, 2022
Audit fees (1)  $117,100   $49,200 
Audit related fees (2)   700    — 
Tax fees   —    — 
All other fees   —    — 
Total  $117,800   $49,200 

 

(1)These fees relate to the audit of our annual financial statements and the review of our interim quarterly financial statements.
(2)These fees relate to audit related consulting.

 

-22-

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

 

REVIV3 PROCARE COMPANY AND SUBSIDIARY

 

CONSOLIDATED FINANCIAL STATEMENTS 

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS  

 

May 31, 2023 and 2022 

 

CONTENTS

 

Report of Independent Registered Public Accounting Firm (PCAOB ID: 106) F-1
   
Financial Statements:  
   
Consolidated Balance Sheets - As of May 31, 2023, and 2022 F-3
   
Consolidated Statements of Operations - For the fiscal years ended May 31, 2023, and 2022 F-4
   
Consolidated Statements of Changes in Stockholders’ Equity - For the fiscal years ended May 31, 2023, and 2022 F-5
   
Consolidated Statements of Cash Flows - For the fiscal years ended May 31, 2023, and 2022 F-6
   
 Notes to Consolidated Financial Statements F-7

 

-23-

(SALBERG & COMPANY, P.A LOGO)

 

Report of Independent Registered Public Accounting Firm  

 

To the Stockholders and the Board of Directors of:

Reviv3 Procare Company.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Reviv3 Procare Company and subsidiary (the “Company”) as of May 31, 2023 and 2022, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended May 31, 2023, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of May 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the two years in the period ended May 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

F-1

Business Combinations:

 

As described in footnote 2 Basis of Presentation and Summary of Significant Accounting Policies “Business Combinations” and in footnote 13 “Business Combinations”, to the consolidated financial statements, the Company closed on a business acquisition in fiscal 2023. The determination of fair values for assets acquired and liabilities assumed and fair value of portions of purchase consideration requires management to make significant estimates and assumptions such as those related to forecasts of future revenues, operating margins, discount rates and equity values. Changes in these assumptions could have a significant impact on the fair values.

 

We identified business combinations as a critical audit matter. Auditing management’s judgments regarding the above estimates involved a high degree of subjectivity.

 

The primary procedures we performed to address this critical audit matter included (a) evaluated management’s process for developing its estimates, (b) evaluated if the valuation method used by management was appropriate, (c) evaluated the reasonableness of management’s forecasts by comparing them to historical information, year to date current information and/or other supporting contracts or information, (d) assessed the reasonableness of the discount rates used by evaluating each component, (e) evaluated other estimates such as the equity value portions of purchase consideration, and (f) recomputed the valuation estimates. We agreed with management’s valuations.

 

 

 

/s/ Salberg & Company, P.A.

 

SALBERG & COMPANY, P.A.

We have served as the Company’s auditor since 2017.

Boca Raton, Florida

August 21, 2023

 

2295 NW Corporate Blvd., Suite 240 ● Boca Raton, FL 33431-7328
Phone: (561) 995-8270 ● Toll Free: (866) CPA-8500 ● Fax: (561) 995-1920
www.salbergco.com ● info@salbergco.com
Member National Association of Certified Valuation Analysts ● Registered with the PCAOB
Member CPAConnect with Affiliated Offices Worldwide ● Member AICPA Center for Audit Quality

 

F-2

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

 

           
   For the Fiscal Years Ended  
     May 31, 2023      May 31, 2022  
 ASSETS          
 CURRENT ASSETS:          
 Cash  $4,832,682   $373,731 
 Accounts receivable, net   417,016    105,921 
 Inventory, net   1,311,864    323,388 
 Prepaid expenses and other current assets   801,360    — 
           
 Total Current Assets   7,362,922    803,040 
           
 OTHER ASSETS:          
 Property and equipment, net   157,463    29,145 
 Intangible assets, net   382,674    — 
 Right of use asset   101,845    45,453 
 Other assets   12,195    16,277 
 Goodwill   2,152,215    — 
           
 Total Other Assets   2,806,392    90,875 
           
 TOTAL ASSETS  $10,169,314   $893,915 
           
 LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
 CURRENT LIABILITIES:          
 Accounts payable  $908,606   $458,263 
 Customer deposits   183,688    16,522 
 Equipment payable, current   2,200    3,300 
 Contract liabilities, current   827,106    — 
 Notes payable   172,588    156,300 
 Due to related party   158,072    25,452 
 Lease Liability, current   65,824    47,166 
 Income Tax Liability   230,913    — 
 Other current liabilities   305,664    — 
           
 Total Current Liabilities   2,854,661    707,003 
           
 LONG TERM LIABILITIES:          
 Equipment payable   —    2,200 
 Lease liability, long term   36,752    — 
 Contract liabilities, long term   605,942    — 
           
 Total Long Term Liabilities   642,694    2,200 
           
 Total Liabilities   3,497,355    709,203 
           
 Commitments and contingencies (see Note 11)   —    — 
           
 STOCKHOLDERS’ EQUITY:          
Preferred stock, $0.0001 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of May 31, 2023 and May 31, 2022, respectively   25,000    — 
Common stock, $0.0001 par value: 450,000,000 shares authorized; 117,076,949 and 41,945,881 shares issued, and outstanding as of May 31, 2023 and May 31, 2022, respectively   11,708    4,195 
Additional paid-in capital   10,102,243    5,472,084 
Accumulated deficit   (3,466,992)   (5,291,567)
           
 Total Stockholders’ Equity   6,671,959    184,712 
           
 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $10,169,314   $893,915 

 

See accompanying notes to these consolidated financial statements.

 

F-3

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS 

 

           
   For the Fiscal Years Ended
   May 31,  May 31,
    2023    2022 
           
 Sales, net  $23,521,027   $2,336,257 
           
 Cost of sales   5,810,216    828,586 
           
 Gross profit   17,710,811    1,507,671 
           
 OPERATING EXPENSES:          
 Marketing and selling expenses   11,675,206    1,199,305 
 Compensation and related taxes   1,347,839    15,129 
 Professional and consulting expenses   1,420,990    232,774 
 General and administrative   1,282,565    271,866 
           
 Total Operating Expenses   15,726,600    1,719,074 
           
 INCOME (LOSS) FROM OPERATIONS   1,984,211    (211,403)
           
OTHER INCOME (EXPENSE):          
 Gain on debt settlement   50,500    35,000 
 Other income   16,829    — 
 Interest income   6,469    36 
 Interest expense and other finance charges   (2,521)   (6,536)
           
Other Income (Expense), Net   71,277    28,500 
           
 INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES   2,055,488    (182,903)
           
 Provision for income taxes   230,913    — 
           
 NET INCOME (LOSS)  $1,824,575   $(182,903)
           
NET INCOME (LOSS) PER COMMON SHARE:          
 Basic  $0.02   $(0.00)
 Diluted  $0.01   $(0.00)
           
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:          
 Basic   112,895,411    41,945,881 
 Diluted   357,385,274    41,945,881 

 

See accompanying notes to these consolidated financial statements.

 

F-4

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
FOR THE FISCAL YEARS ENDED MAY 31, 2023 AND 2022 

 

                                    
   Preferred Stock  Common Stock
Issued		  Additional Paid-in  Accumulated  Total
Stockholders’
    Shares    Amount    Shares    Amount    Capital    Deficit    Equity  
Balance, May 31, 2021   —   $—   41,945,881   $4,195   $5,450,117   $(5,108,664)  $345,648 
                                    
Stock options expense   —    —    —    —    21,967    —    21,967 
                                    
Net loss for the fiscal year ended May 31, 2022   —    —    —    —    —    (182,903)   (182,903)
                                    
Balance, May 31, 2022   —    —    41,945,881    4,195    5,472,084    (5,291,567)   184,712 
                                    
Shares issued for acquisition of business   250,000,000    25,000    73,183,893    7,318    3,975,162    —    4,007,480 
                                    
Stock options expense   —    —    —    —    207,342    —    207,342 
                                    
Shares issued for cash   —    —    1,947,175    195    447,655    —    447,850 
                                    
Net income for the fiscal year ended May 31, 2023   —    —    —    —    —    1,824,575    1,824,575 
                                    
Balance, May 31, 2023   250,000,000   $25,000    117,076,949   $11,708   $10,102,243   $(3,466,992)  $6,671,959 

 

See accompanying notes to these consolidated financial statements.

 

F-5

REVIV3 PROCARE COMPANY AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS

 

           
   For the Fiscal Years Ended
    May 31, 2023    May 31, 2022 
           
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $1,824,575   $(182,903)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:          
     Depreciation and amortization   95,179    7,871 
     Bad debts   76,969    6,941 
     Inventory obsolescence   —    71,481 
     Stock based compensation   207,342    21,967 
     Gain on debt forgiveness   (50,500)   (35,000)
     Non cash lease expense   —    (1,713)
Change in operating assets and liabilities:          
Accounts receivable   (160,277)   (21,985)
Inventory   353,985    95,983 
Prepaid expenses and other current assets   (661,115)   2,430 
Deposits   (3,810)   — 
Accounts payable and accrued expenses   215,175    (701)
Other current liabilities   630,897    — 
Customer deposits   —    (90,426)
  Contract liabilities   389,716    — 
           
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES   2,918,136    (126,055)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Cash acquired on business acquisition   1,066,414    — 
Purchase of property and equipment   (65,650)   — 
           
NET CASH PROVIDED BY INVESTING ACTIVITIES   1,000,764    — 
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Cash raised for common stock to be issued   447,850    — 
Proceeds from loan payable   —    35,000 
Repayment of equipment financing   (3,300)   (3,300)
Repayment of note payable   (37,119)   — 
Advances (payments) from a related party   132,620    (28,851)
           
NET CASH PROVIDED BY FINANCING ACTIVITIES   540,051    2,849 
           
NET INCREASE (DECREASE) IN CASH   4,458,951    (123,206)
           
CASH - Beginning of year   373,731    496,937 
           
CASH - End of year  $4,832,682   $373,731 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the period for:          
Interest  $2,521   $500 
Income taxes  $—   $— 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Stock issued for business combination  $4,007,480   $— 
Right of use assets recognized as lease liability  $131,970   $— 
Tangible assets (excluding cash) acquired in business combination   $1,740,729   $— 
Intangible assets acquired in business combination  $456,945   $— 
Goodwill acquired in business combination  $2,152,215   $— 
Liabilities assumed in business combination  $1,408,823   $— 

 

See accompanying notes to these consolidated financial statements.

 

F-6

REVIV3 PROCARE COMPANY AND SUBSIDIARY
NOTES  TO CONSOLIDATED FINANCIAL STATEMENTS
MAY 31, 2023 AND 2022

 

Note 1 – Organization

 

Reviv3 Procare Company (“Reviv3”) was incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC which was organized on July 31, 2013. The Company has moved its corporate headquarters to 901 Fremont Avenue, Unit 158, Alhambra, California 91803. Its phone number (888) 638-8883. In March 2022, the Company incorporated a subsidiary “Reviv3 Acquisition Corporation” and in June 2022, completed the asset acquisition of the Axil & Associated Brand Corp. business (“AXIL”). The Company is now engaged in the manufacturing, marketing, sale and distribution of high-tech hearing and audio innovations that provide cutting edge solutions for consumers, with varied applications across many industries; as well as professional quality hair and skin care products. These products lines are both sold throughout the United States, Canada, Europe and Asia.

 

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements for the fiscal years ended May 31, 2023 and 2022 have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of the Company and its consolidated subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. 

  

Liquidity and Capital Resources

 

We are currently engaged in our product sales and development. Although we earned net income and had cash provided by operations in the fiscal year ended May 31, 2023, we had an accumulated deficit of $3,466,992 as of May 31, 2023 and have incurred operating losses and cash used in operations in the past. We currently expect to earn net income and positive cash flows from operations during the current fiscal year ending May 31, 2024. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL’s business, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying consolidated financial statements. Management is focused on growing the Company’s existing product, introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands, including those resulting from the purchase of AXIL’s assets in June 2022, may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying consolidated financial statements.

 

 

F-7

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Use of estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, contract liability, allowance on sales returns, valuation of lease liabilities and related right of use assets, fair value of securities issued for business combinations, fair value of assets acquired and liabilities assumed in business combinations and the fair value of non-cash Common Stock issuances. 

 

Cash and cash equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

 

Accounts receivable and allowance for doubtful accounts

 

Accounts receivables comprise of receivables from customers and receivables from merchant processors. The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

Prepaid expenses and other current assets

 

Prepaid expenses and other current assets consist primarily of cash prepayments to vendors for inventory and prepayments for trade shows and marketing events which will be utilized within a year, prepayments on credit cards and the right to recover assets (for the cost of goods sold) associated with the right of returns for products sold.

 

Inventory

 

The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations. The Company continuously evaluates the levels of inventory held and any inventory held above the expected level of sales in the next twelve months, is classified as non-current inventory.

 

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.

 

F-8

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Revenue recognition

 

The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard (new guidance) has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.

 

The Company sells a variety of hair and skin care products and electronic hearing and enhancement products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues.

 

The five steps for revenue recognition are as follows:

 

Identify the contract with a customer. The Company generally considers completion of a sales order (which requires customer acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) or purchase orders from non-consumer customers as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving third party financier payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.

 

Identify the performance obligations in the contract. Product performance obligations include shipment of products and related accessories and service performance obligations include extended warranty coverage.

 

However, as the historical redemption rate under our warranty policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

 

Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 30-days and 60-days right of return that applies to AXIL and Reviv3 products, respectively. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.

 

Allocate the transaction price to the performance obligations in the contract. For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.

 

Recognize revenue when or as the Company satisfies a performance obligation. Revenue for products is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period.

 

As of May 31, 2023 and May 31, 2022, contract liabilities amounted to $1,433,048 and $0, respectively. Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3.

 

Revenue recognized, during the fiscal year ended May 31, 2023, that was included in the contract liability balance at the beginning of period (acquisition of AXIL) was $391,204.

  

F-9

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Cost of Sales

 

The primary components of cost of sales include the cost of the product and shipping fees.

  

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $1,001,261 and $214,517 for the fiscal years ended May 31, 2023 and 2022, respectively.

 

Marketing, selling and advertising

 

Marketing, selling and advertising costs are expensed as incurred.

 

Customer Deposits

 

Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.

 

Fair value measurements and fair value of financial instruments

 

The Company adopted ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: 

 

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
   
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
   
Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

F-10

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Business Combinations

 

For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets acquired and liabilities assumed of the acquired business, at their fair values.

 

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates.

 

Goodwill

 

Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur, or circumstances indicate the fair value of a reporting unit is below its carrying value.

 

The Company performs its annual goodwill impairment assessment on May 31st of each year or as impairment indicators dictate.

 

When evaluating the potential impairment of goodwill, management first assesses a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the quantitative impairment testing methodology primarily using the income approach (discounted cash flow method).

 

Under the quantitative method we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized is recognized as the amount by which the carrying amount exceeds the fair value.

 

When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. 

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

  

F-11

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying consolidated balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

 

Impairment of long-lived assets  

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not record any impairment loss during the fiscal years ended May 31, 2023 and 2022.

 

Stock-based compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

For non-employee stock option based awards, the Company follows ASU 2018-7, which substantially aligns share based compensation for employees and non-employees.

 

Net income (loss) per share of common stock

 

Basic net income (loss) per share is computed by dividing the net income or loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At May 31, 2022, the Company had 5,300,000 options outstanding which were potentially dilutive securities, however they were excluded from the computation since their impact would be antidilutive.

 

For the fiscal year ended May 31, 2023, certain stock options were excluded from the computation of diluted common shares outstanding as they would have an anti-dilutive impact on the Company’s net income. The following table presents a reconciliation of basic and diluted net income per common share: 

 

F-12

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 
        
   For the Fiscal Year Ended    
   May 31, 2023  
        
Net income  $1,824,575   
        
Weighted average basic shares   112,895,411   
Dilutive securities:       
Convertible preferred stock   239,041,096   
Stock options   5,448,767   
Weighted average dilutive shares   357,385,274   
        
Earnings (loss) per share:       
Basic  $0.02   
Diluted  $0.01   

 

Lease Accounting

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02), which requires lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance (ASC Topic 840). Under the new guidance, codified as ASC Topic 842, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. The new guidance further requires that leases be classified at inception as either (a) operating leases or (b) finance leases. For operating leases, periodic expense generally is flat (straight-line) throughout the life of the lease. For finance leases, periodic expense declines over the life of the lease. The new standard, as amended, provides an option for entities to use the cumulative-effect transition method. As permitted, the Company adopted ASC Topic 842 effective June 1, 2019.

 

The Company renewed lease for its corporate headquarters commencing December 1, 2022, under lease agreements classified as an operating lease. Please see Note 11 – ‘Commitments and Contingencies’ under “Leases” below for more information about the Company’s leases.

 

Segment Reporting

 

The Company follows ASC Topic 280, Segment Reporting. The Company’s management reviews the Company’s consolidated financial results when making decisions about allocating resources and assessing the performance of the Company as a whole and has determined that the Company’s reportable segments are: (a) the sale of hearing protection and hearing enhancement products, and (b) the sale of hair care and skin care products. See Note 15 – “BUSINESS SEGMENT AND GEOGRAPHIC AREA INFORMATION” for more information about the Company’s reportable segments.

 


Reclassifications

 

Certain reclassifications have been made to the prior year’s data to conform with the current period’s presentation. Specifically, the accounts payable have been separated from the accrued expenses, to conform with the current period’s presentation.

 

F-13

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies (continued)

 

Recently Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain convertible instruments. Among other things, under ASU 2020-06, the embedded conversion features no longer must be separated from the host contract for convertible instruments with conversion features not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. ASU 2020-06 also eliminates the use of the treasury stock method when calculating the impact of convertible instruments on diluted Earnings per Share. For the Company, the provisions of ASU 2020-06 are effective for its fiscal year beginning on June 1, 2024. Early adoption is permitted, subject to certain limitations. The Company is evaluating the potential impact of adoption on its financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities (e.g. deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “Revenue from Contracts with Customers”. Generally, this new guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically, such amounts were recognized by the acquirer at fair value in purchase accounting. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company opted to adopt this ASU as of June 1, 2022. The adoption of the guidance did not have a material impact on the accompanying consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 

Note 3 – Accounts Receivable, net

 

Accounts receivable, consisted of the following:

 

          
   May 31, 2023  May 31, 2022
Customers Receivable  $345,264   $115,741 
Merchant Processor Receivable   167,232    — 
Less: Allowance for doubtful debts   (95,480)   (9,820)
Accounts receivable, net   $417,016   $105,921 

  

The Company recorded bad debt expense of $76,969 and $6,941 during the fiscal years ended May 31, 2023 and 2022, respectively.

 

Note 4 – Inventory, net

 

Inventory consisted of the following:

 

          
   May 31, 2023  May 31, 2022
Finished Goods  $1,198,218   $29,249 
Raw Materials  $113,646   $294,139 
Inventory, net  $1,311,864   $323,388 

 

At May 31, 2023 and 2022, inventory held at third party locations amounted to $0 and $16,940, respectively. At May 31, 2023 and 2022, there was $135,482 and $0 inventory in- transit, respectively.

 

During the fiscal years ended May 31, 2023 and 2022, the Company created an allowance of $0 and $71,481, respectively, on slow moving inventory included in cost of sales. As of May 31, 2023 and 2022, there was no slow moving inventory.

 

F-14

Note 5 – Property and Equipment

 

Property and equipment, stated at cost, consisted of the following:

 

             
   Estimated Life  May 31, 2023  May 31, 2022
Furniture and Fixtures  5 years  $14,598   $5,759 
Computer Equipment  3 years   33,146    17,392 
Plant Equipment  5-10 years   165,778    45,128 
Automobile  5 years   15,000    — 
Less: Accumulated Depreciation      (71,059)   (39,134)
      $157,463   $29,145 

 

Depreciation expense amounted to $20,908 and $7,871 for the fiscal years ended May 31, 2023 and 2022, respectively.

 

Note 6 – Intangible Assets

 

The Company acquired intangible assets through the Business Combination. (See Note 13). These intangible assets consisted of the following: 

         
   Estimated Life  May 31, 2023 
Licensing Rights  3 years  $11,945  
Customer Relationships  3 years   70,000  
Trade Names  10 years   275,000  
Website   5 years   100,000  
Less: Accumulated Amortization      (74,271) 
      $382,674  

 

Goodwill arising through the business combination was $2,152,215 at May 31, 2023 (see Note 13).

 

Amortization expense amounted to $74,271 and $0 for the fiscal years ended May 31, 2023 and 2022, respectively.

 

Note 7 – Other Current Liabilities

 

Other current liabilities comprised of the following:

 

     
    May 31, 2023 
Credit Cards   833 
Accrued Interest   10,343 
Royalty Payment Accrual   8,792 
Sales Tax Payable and Other Accrued Expenses   258,023 
Affiliate Accrual   27,673 
Other Current Liabilities   $305,664 

  

F-15

Note 8 – Equipment Payable

 

During the fiscal year ended May 31, 2019, the Company purchased a forklift under an installment purchase plan. The loan amount is $16,500 payable in 60 monthly installment payments of $317 comprising of principal payment of $275 and interest payment of $42. As at May 31, 2023 and 2022, the balance outstanding on the loan was $2,200 and $5,500, respectively, of which the $2,200 balance is payable within the next year. The Company recorded an interest expense of $500 and $500, associated with the equipment financing during the fiscal years ended May 31, 2023 and 2022, on the loan in the accompanying consolidated financial statements.

 

The amounts of loan payments due within the next fiscal year ended May 31, are as follows:

 

   
   Total
  2024     $ 2,200  
 Equipment Payable, Net    $2,200 

 

Note 9 – Notes Payable

 

During the fiscal year ended May 31, 2020, a commercial bank granted to the Company a loan (the “Loan”) in the amount of $150,000, which is administered under the authority and regulations of the U.S. Small Business Administration pursuant to the Economic Injury Disaster Loan Program (the “EIDL”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Loan, which is evidenced by a note dated May 18, 2020, bears interest at an annual rate of 3.75% and is payable installments of $731 per month, beginning May 18, 2021 until May 13, 2050. The Company has to maintain a hazard insurance policy including fire, lightning, and extended coverage on all items used to secure this loan to at least 80% of the insurable value. Proceeds from loans granted under the CARES Act are intended to be used for payroll, costs to continue employee group health care benefits, rent, utilities, and certain other qualified costs (collectively, “qualifying expenses”). The Company used the loan proceeds for qualifying expenses. The Company received a loan forgiveness for $10,000 during the fiscal year ended May 31, 2022. During the fiscal year ended May 31, 2022, the Company received additional $10,000 of borrowings under the program. The Company recorded an accrued interest of $10,342 and $11,684, as of May 31, 2023 and 2022, respectively.

 

During the fiscal year ended May 31, 2023 the Company obtained insurance financing of $53,337 on the general liability and excess liability insurance policies. The loan has a finance charge of $3,164 and is payable in 10 monthly installments of $5,650 each beginning November 1, 2022. As of May 31, 2023, six installments have been paid. As of May 31, 2023 outstanding balance of the loan amounted to $21,335.

 

      
Notes Payable as of May 31, 2023 and 2022      
       
   2023  2022
Insurance Financing  $21,335   $— 
Second Draw Paycheck Protection Program (PPP- 2)   —    6,300 
Financing Charges   1,253    — 
Economic Injury Disaster Loan Program (EIDL)   150,000    150,000 
Total  $172,588   $156,300 
Less: Current portion   (172,588)   (156,300)
Non-current portion  $—   $— 

 

The amounts of loan payments due in the next fiscal year ended May 31, are as follows:

 

   
   Total
  2024     $ 172,588  
 Total    $172,588 

 

F-16

Note 10 – Stockholders’ Equity

 

Shares Authorized

 

As of May 31, 2023, the authorized capital of the Company consists of 450,000,000 shares of common stock, par value $0.0001 per share and 300,000,000 shares of preferred stock, par value $0.0001 per share.

On June 13, 2022, the Company amended its amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock from 100,000,000 to 450,000,000 shares and to increase the number of authorized shares of preferred stock, par value $0.0001 per share (“Preferred Stock”), from 20,000,000 to 300,000,000 shares.

Preferred Stock

 

The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company is expressly authorized to provide for the issuance of all or any of the shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed until the resolution adopted by the Board of Directors providing the issuance of such shares. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.

 

During the fiscal year ended May 31, 2023, the Company issued 250,000,000 shares of non-voting Series A Preferred Stock, which are convertible into shares of Company Common Stock on a one-to-one ratio, pursuant to the Asset Purchase Agreement (See Note 13 and Common Stock section below). These 250,000,000 shares of non-voting Series A Preferred Stock were valued at the fair market value of $3,100,000 at issuance.

 

The holders of shares of Series A Preferred Stock shall have no rights to dividends with respect to such shares. No dividends or other distributions shall be declared or paid on the Common Stock unless and until dividends at the same rate shall have been paid or declared and set apart upon the Series A Preferred Stock, based upon the number of shares of Common Stock into which the Series A Preferred Stock may then be converted. Upon the dissolution, liquidation, or winding up of the Company, whether voluntary or involuntary, the holders of the Series A Preferred Stock are entitled to receive out of the assets of the Company the sum of $0.0001 per share before any payment or distribution shall be made on our shares of Common Stock. The Series A Preferred Stock shall not be subject to redemption at the option, election or request of the Corporation or any holder or holders of the Series A Preferred Stock. Each share of Series A Preferred Stock is convertible at the option of the holder thereof, at any time after the second anniversary of the date of the first issuance of the shares of Series A Preferred Stock into one fully paid and nonassessable share of Common Stock provided, however, that the holder may not convert that number of shares of Series A Preferred Stock which would cause the holder to become the beneficial owner of more than 5% of the Corporation’s Common Stock as determined in accordance with Sections 13(d) and (g) of the Securities and Exchange Act of 1934 and the applicable rules and regulations thereunder. 

 

As of May 31, 2023, 250,000,000 shares of Preferred Stock were issued and outstanding.

 

No shares of Preferred Stock were issued and outstanding as of May 31, 2022.

 

Common Stock

 

As of May 31, 2023, 117,076,949 shares of common stock were issued and outstanding. 

 

During the fiscal year ended May 31, 2023, the Company issued 73,183,893 shares of Common Stock, valued at $907,480, as consideration pursuant to the Asset Purchase agreement (See Note 13 and Preferred Stock section above).

 

During the fiscal year ended May 31, 2023, the Company sold 1,947,175 shares of Common Stock at $0.23 per share for a total of $447,850 under several private placement agreements.

 

No shares of Common Stock were issued during the fiscal year ended May 31, 2022.

 

F-17

Note 10 – Stockholders’ Equity (continued)

 

Stock Options

 

The Board approved the Company’s 2022 Equity Incentive Plan (the “Plan”) on March 21, 2022. Under the Plan, equity-based awards may be made to employees, officers, directors, non-employee directors and consultants of the Company and its Affiliates (as defined in the plan) in the form of (i) Incentive Stock Options (to eligible employees only); (ii) Nonqualified Stock Options; (iii) Restricted Stock; (iv) Stock Awards; (v) Performance Shares; or (vi) any combination of the foregoing. The Plan will terminate upon the close of business on the day next preceding March 21, 2032, unless terminated earlier in accordance with the terms of the Plan. The Board serves as the Plan administrator and may amend or terminate the Plan without stockholder approval, subject to certain exceptions.

 

The total number of shares initially authorized for issuance under the Plan was 10.0 million shares. The Plan provides for an annual increase on April 1 of each calendar year, beginning in 2022 and ending in 2031, subject to Board approval prior to such date. Such increase may be equal to the lesser of (i) 4% of the total number of shares of the Company’s common stock outstanding on May 31 of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board. The number of shares authorized for issuance under the Plan will not change unless the Board affirmatively approves an increase in the number of shares authorized for issuance prior to April 1 of the applicable year. Shares surrendered or withheld to pay the exercise price of a stock option or to satisfy tax withholding requirements will not be added back to the number of shares available under the Plan. To the extent that any shares of common stock awarded or subject to issuance or purchase pursuant to awards under the Plan are not delivered or purchased, or are reacquired by the Company, for any reason, including a forfeiture of restricted stock or failure to earn performance shares, or the termination, expiration or cancellation of a stock option, or any other termination of an award without payment being made in the form of shares of common stock will be added to the number of shares available for awards under the Plan. The number of shares available for issuance under the Plan will be adjusted for any increase or decrease in the number of outstanding shares of common stock resulting from payment of a stock dividend on common stock, a stock split or subdivision or combination of shares of common stock, or a reorganization or reclassification of common stock, or any other change in the structure of shares of common stock, as determined by the Board. Shares available for awards under the Plan will consist of authorized and unissued shares.

 

Two types of options may be granted under the Plan: (1) Incentive Stock Options, which may only be issued to eligible employees of the Company and are required to have exercise price of the option not less than the fair market value of the common stock on the grant date, or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110% of the fair market value of the common stock on the grant date; and (2) Non-qualified Stock Options, which may be issued to participants under the Plan and which may have an exercise price less than the fair market value of the common stock on the grant date, but not less than par value of the stock.

 

The Board may grant or sell restricted stock to participants (i.e., shares that are subject to a subject to restrictions or limitations as to the participant’s ability to sell, transfer, pledge or assign such shares) under the Plan. Except for these restrictions and any others imposed by the Board, upon the grant of restricted stock, the recipient generally will have rights of a stockholder with respect to the restricted stock. During the applicable restriction period, the recipient may not sell, exchange, transfer, pledge or otherwise dispose of the restricted stock. The Board may also grant awards of common stock to participants under the Plan, as well as awards of performance shares, which are awards for which the payout is subject to achievement of such performance objectives established by the Board. Performance shares may be settled in cash.

 

Each equity-based award granted under the Plan will be evidenced by an award agreement that specifies the terms of the award and such additional limitations, terms and conditions as the Board may determine, consistent with the provisions of the Plan.

 

F-18

Note 10 – Stockholders’ Equity (continued)

 

Upon the occurrence of a change in control, unless otherwise provided in an award agreement: (i) all outstanding stock options will become immediately exercisable in full; (ii) all outstanding performance shares will vest in full as if the applicable performance conditions were achieved in full, subject to certain adjustments, and will be paid out as soon as practicable; and (iii) all restricted stock will immediately vest in full. The Plan defines a change in control as (i) the adoption of a plan of merger or consolidation of the Company with any other corporation or association as a result of which the holders of the voting capital stock of the Company as a group would receive less than 50% of the voting capital stock of the surviving or resulting corporation; (ii) the approval by the Board of an agreement providing for the sale or transfer (other than as security for obligations of the Company) of substantially all the assets of the Company; or (iii) in the absence of prior Board approval, the acquisition of more than 20% of the Company’s voting capital stock by any person within the meaning of Rule 13d-3 under the Exchange Act (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company).

 

Subject to the Plan’s terms, the Board has full power and authority to determine whether, to what extent and under what circumstances any outstanding award will be terminated, canceled, forfeited or suspended. Awards to that are subject to any restriction or have not been earned or exercised in full by the recipient will be terminated and canceled if such recipient is terminated for cause, as determined by the Board in its sole discretion.

 

The Company estimates the fair value of share-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables such as the expected option term, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected option term and expected dividend yield rate over the expected option term. The Company believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors which are subject to ASC Topic 718 requirements. These amounts are estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award.

 

The Company utilizes the simplified method to estimate the expected life for stock options granted to employees. The simplified method was used as the Company does not have sufficient historical data regarding stock option exercises. The expected volatility is based on historical volatility. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased.

 

Pursuant to the Plan, on May 10, 2022, the Company issued to two Company officers non-statutory stock options to purchase, in the aggregate, up to 5,300,000 shares of its Common Stock, at an exercise price of $0.09 per share and expiring on April 20, 2032. The options vest over time with 25% of the options vesting on September 1, 2022 and thereafter vesting 1/24th on the 1st of every month. None of the options are vested as of May 31, 2022.

 

Pursuant to the Plan, on November 1, 2022, the Company issued non-statutory stock options, to a former executive officer of the Company, to purchase, in the aggregate, up to 300,000 shares of its Common Stock, at an exercise price of $0.20 per share and expiring on October 31, 2032. 75,000 shares vested as of January 29, 2023, and the remaining 225,000 options were forfeited in April 2023 when the executive officer left the Company. 

 

The Company computed the aggregate grant date fair value of $477,000 using the Black-Scholes option pricing model, which is being recorded as stock-based compensation expense over the vesting period. During the fiscal years ended May 31, 2023 and 2022, the Company recorded a stock-based compensation expense of $207,342 and $21,967 respectively, for these options in the accompanying financial statements. 

 

F-19

Note 10 – Stockholders’ Equity (continued)

 

The Black-Scholes options pricing model used the following assumptions:

 

          
    2023    2022 
Risk free interest rate   4.07%   2.99%
Expected life   6 years    5.75 years 
Expected volatility   457%   447%
Expected dividend   0%   0%

 

The following table summarizes the activity relating to the Company’s stock options held by executive officers:

 

               
    Number of Options    Weighted Average Exercise Price    Weighted Average Remaining Term 
                
Outstanding as June 1, 2021   —    —    — 
Granted   5,300,000   $0.09    10.0 
Exercised   —    —    — 
Outstanding at May 31, 2022   5,300,000   $0.09    9.92 
Granted   300,000   $0.20    9.68 
Less: Forfeited   (225,000)  $0.20    9.68 
Less: Unvested at May 31, 2023   (2,725,000)  $0.09    8.92 
Vested at May 31, 2023   2,650,000   $0.09    8.92 

 

Note 11 – Commitments and Contingencies

 

Leases

 

As discussed in Note 2 above, the Company adopted ASU No. 2016-02, Leases on June 1, 2019, which require lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance. The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent was $7,567 per month for the first year and increased by a certain amount each year. In November 2022, the Company entered into an extension of the lease for a two year term beginning December 1, 2022. The rent is $6,098 per month for the first year and will increase by a certain amount the following year.

 

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

 

F-20

Note 11 – Commitments and Contingencies (continued)

 

The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations.

 

Lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Variable payments change due to facts or circumstances occurring after the commencement date, other than the passage of time, and do not result in a remeasurement of lease liabilities. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants.

 

Pursuant to the new standard, the Company recorded an initial lease liability of $235,748 and an initial right of use asset in the same amount in 2019. The Company computed another initial lease liability of $131,970 for the new lease agreement and an initial ROU asset in the same amount which was recorded on books at the commencement of the new lease on December 1, 2022. During the fiscal years ended May 31, 2023 and 2022, the Company recorded a lease expense in the amount of $84,435 and $94,235, respectively. As of May 31, 2023, the lease liability balance was $102,576 and the right of use asset balance was $101,845. A lease term of three years and a discount rate of 12% was used.

 

Supplemental balance sheet information related to leases was as follows:

 

          
Assets   May 31, 2023    May 31, 2022 
Right of use assets  $131,970   $235,748 
Accumulated reduction   (30,125)   (190,295)
Operating lease assets, net  $101,845   $45,453 
           
Liabilities          
Lease Liability  $131,970   $235,748 
Accumulated reduction   (29,394)   (188,582)
Total lease liability, net  $102,576   $47,166 
Current portion   (65,824)   (47,166)
Non-current portion  $36,752   $— 
           

 

Maturities of operating lease liabilities were as follows as of May 31, 2023:

 

   
Operating Lease   
2024  $65,824 
2025   36,752 
Total  $102,576 
Less: Imputed interest  $— 
Present value of lease liabilities  $102,576 

  

Contingencies

 

On November 23, 2020, the Company was served a copy of a complaint filed by Jacksonfill, LLC in the Fourth Circuit Court for Duval County, Florida. The complaint alleges breach of Agreement for non-payments for certain products against the Company. The allegations arise from alleged discrepancies discovered by the Company in the manufacturing of certain product. The Company has retained counsel and intends to vigorously defend the allegations. The product was delivered to the Company, however, the Company believes that the product was defective. The litigation process has not progressed and the amount of the claim of $204,182 has been recorded as accounts payable, in the accompanying consolidated financial statements as of May 31, 2023.

 

F-21

Note 12 – Related Party Transactions

 

The Company’s Chief Executive Officer, Jeff Toghraie, is the managing director of Intrepid Global Advisors (“Intrepid”). Intrepid has, from time to time, provided advances to the Company for working capital purposes. At May 31, 2023, and 2022, the Company had amounts payable to Intrepid of $124,378 and $25,452, respectively. These advances were short-term in nature and non-interest bearing. Additionally, pursuant to a voting agreement, effective June 16, 2022 as amended effective November 7, 2022, with AXIL and Intrepid Global Advisors, we are subject to certain limitations on our ability to sell our capital stock until June 2024. 

 

During the fiscal year ended May 31, 2023, the Company paid $218,696 as consulting fee for product development to Weston T. Harris, a major stockholder of AXIL, and also paid $126,097 to immediate family members of the major stockholder as compensation for services relating to packaging design and affiliate marketing. 

 

During the fiscal year ended May 31, 2023, the Company paid $135,484 as consulting fee for inventory management and operations consulting to an immediate family member of a major stockholder of AXIL, $74,620 to an immediate family member of the major stockholder in commissions and a contractor fee, and $15,928 to an immediate member of the major stockholder as compensation for services relating to travel and event coordination. 

 

On June 16, 2022, the Company and its wholly owned subsidiary Reviv3 Acquisition Corporation completed the acquisition of both (i) the hearing protection business of AXIL, consisting of ear plugs and ear muffs, and (ii) AXIL’s ear bud business pursuant to the Asset Purchase Agreement, dated May 1, 2022, as amended on June 15, 2022, by and among the Company, Reviv3 Acquisition Corporation, AXIL and certain stockholders of AXIL. One of the stockholders of AXIL is Intrepid Global Advisors, Inc. As of May 31, 2023, Intrepid Global Advisors, Inc. held no outstanding common stock of AXIL and 19.50% of the outstanding common stock of the Company.

 
Note 13 – Business Combination

 

On June 16, 2022, the Company completed the acquisition of certain assets of Axil & Associated Brands Corp. (“AXIL”), a Delaware corporation, pursuant to the Asset Purchase Agreement dated May 1, 2022 and amended on June 15, 2022 and September 8, 2022. by and among the Company, its subsidiary, AXIL, and certain of AXIL’s stockholders, providing for the acquisition of AXIL’s hearing protection business and ear bud business. The business constituted substantially all of the business operations of AXIL but did not include AXIL’s hearing aid line of business.

 

One of the stockholders of AXIL is Intrepid Global Advisors (“Intrepid”). As of June 16, 2022, Intrepid held 4.68% of the outstanding common stock of AXIL and 22.33% of the outstanding Common Stock of the Company. As of May 31, 2023 Intrepid held no outstanding common shares of AXIL, as they were distributed with the Asset Purchase Agreement. Jeff Toghraie, Chairman and Chief Executive Officer of the Company, is a managing director of Intrepid.

 

As consideration for the Asset Purchase, AXIL received a total of 323,183,893 shares of the company comprised of (a) 73,183,893 shares of the Company’s Common Stock and (b) 250,000,000 shares of the company’s non-voting Series A Preferred Stock, which are convertible into shares of Company Common Stock on a one-to-one ratio. The Preferred Shares may not be converted or transferred for a period of two years following the closing of the acquisition. Thereafter, no holder of Preferred Shares may convert such shares into a number of shares of Company Common Stock that would cause the holder to beneficially own more than 5% of the Company’s Common Stock, as determined in accordance with Sections 13(d) and (g) of the Securities Exchange Act of 1934 (the “Exchange Act”). The purchase price was computed to be $4,007,480 based on a fair value of $0.0124 per common share on the date of acquisition.

 

The Company is utilizing the AXIL assets to expand into the hearing enhancement business through its newly incorporated subsidiary.

 

The acquisition is accounted for by the Company in accordance with the acquisition method of accounting pursuant to ASC 805 “Business Combinations” and pushdown accounting is applied to record the fair value of the assets acquired by the Company. Under this method, the purchase price is allocated to the identifiable assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. Any excess of the amount paid over the estimated fair values of the identifiable net assets acquired was allocated to goodwill.

 

F-22

Note 13 – Business Combination (continued)

 

The following is a summary of the fair value of the assets acquired and liabilities assumed at the date of acquisition:

 

     
Cash  $1,066,414 
Accounts receivable   227,786 
Inventory   1,342,461 
Prepaid expenses   62,452 
Other assets   108,030 
Accounts payable   (285,665)
Contract liabilities   (1,043,332)
Other current liabilities   (79,826)
Net tangible assets acquired  $1,398,320 
      
Identifiable intangible assets     
Licensing rights  $11,945 
Customer relationships   70,000 
Tradenames   275,000 
Website   100,000 
Total Identifiable intangible assets  $456,945 
      
Consideration paid  $4,007,480 
Total net assets acquired   1,855,265 
Goodwill purchased  $2,152,215 

 

Pro Forma Information (Unaudited)

 

The unaudited pro forma condensed combined financial statements are based on Reviv3 and AXIL’s unaudited historical consolidated financial statements as adjusted to give effect to the Asset Purchase Agreement. The unaudited pro forma combined statements of operations for the fiscal year ended May 31, 2023 and 2022, for Reviv3 and AXIL, give effect to the Asset Purchase Agreement as if it had occurred on June 1, 2022 and 2021, respectively. 

          
   For the fiscal year ended  For the fiscal year ended
   May 31, 2023  May 31, 2022
Revenue  $25,428,163   $18,356,862 
Net income (loss)   2,032,954    (3,212,320)
Earnings (loss) per common share          
Basic  $0.02   $(0.03)
Diluted  $0.01    — 

 

The pro forma financial information is not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that result in the future. 

 

F-23

Note 14 – Concentrations

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits, investments and cash equivalents instruments. The Company maintains its cash in bank deposits accounts. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At May 31, 2023 and 2022, the Company held cash in various accounts of approximately $4,582,682 and $123,731, respectively, in excess of federally insured limits. The Company has not experienced any losses in such accounts through May 31, 2023.

 

Concentration of Revenue, Accounts Receivable, Product Line, and Supplier – Hair and Skin Care Products

 

During the fiscal year ended May 31, 2023 hair and skin care product sales to three customers, which each represented over 10% of our total sales, aggregated to approximately 94% of the Company’s net sales at 61%, 12% and 21%. During the fiscal year ended May 31, 2022 sales to two customers, which each represented over 10% of our total sales, aggregated to approximately 31% of the Company’s net sales at 15% and 16%.

 

During the fiscal year ended May 31, 2023 hair and skin care product sales to customers outside the United States represented approximately 25% which consisted of 20% from Canada and 5% from Italy and during the fiscal year ended May 31, 2022 sales to customers outside the United States represented approximately 16% which consisted of 14% from Canada and 2% from Italy.

 

During the fiscal year ended May 31, 2023, hair and skin care product sales by product line which each represented over 10% of sales consisted of approximately 15% from sales of hair shampoo, and 10% from sales of hair conditioner and 7% from bundle kits. During the fiscal year ended May 31, 2022, hair and skin care product sales by product line which each represented over 10% of sales consisted of approximately 10% from sales of hair shampoo, 12% from sales of hair shampoo and conditioner, 25% from sale of introductory kit (shampoo, conditioner and treatment spray) and 29% from sale of bundle packs (shampoo, conditioner and spray).

 

During the fiscal years ended May 31, 2023 and 2022 sales for the hair and skin care product lines comprised of the following:

 

          
   For the Fiscal Years ended
Hair Care Products  May 31, 2023  May 31, 2022
Shampoos and Conditioners   77%   84%
Ancillary Products   23%   16%
Total   100%   100%

 

At May 31, 2023, hair and skin care product’s only accounts receivable from one customer accounted for more than 10% of sales transactions, which was Amazon and the second largest customer accounted for 8%, which is due to the fact that products are sold primarily through direct-to-consumer. At May 31, 2022, accounts receivable from four customers represented approximately 74% at 11%, 12%, 14% and 37%.

 

Hair and skin care product purchased inventories and products from three vendors totaling approximately $297,833, (95% of the purchases at 61%, 12% and 22%) during the fiscal year ended May 31, 2023 and four vendors totaling approximately $343,015 (97% of the purchases at 10%, 23%, 30% and 34%) during the fiscal year ended May 31, 2022.

 

Concentration of Revenue, Accounts Receivable, Product Line, and Supplier – Ear Protection and Enhancement Products

 

AXIL is sold direct-to-consumer, therefore, during the fiscal year ended May 31, 2023, 97.3% of sales was direct to customers. There was no single customer that accounted for greater than 2% of total sales.

 

During the fiscal year ended May 31, 2023 AXIL sales to customers outside the United States represented approximately 4.5% which consisted of 3.7% from Canada and the remaining from various countries.

 

Manufacturing is outsourced primarily overseas via a number of third party vendors, the two largest vendors accounting for 82% and 10% of all purchases. 

 

During the fiscal year ended May 31, 2023, AXIL sale of ear buds for PSAP (personal sound amplification product) and hearing protection by product line which each represented over 10% of sales consisted approximately 87% from Ghost Stryke Extreme model GS-X ($18.1M) and 9% of sales of Trackr earmuffs ($1.9M).

 

F-24

Note 14 – Concentrations (continued)

 

During the fiscal year ended May 31, 2023 sales by hearing enhancement and protection products comprised of the following:  

 

     
   For the fiscal year ended
Ear Protection & Enhancement Products  May 31, 2023
Ghost Stryke   86.7%
Trackr Earmuffs   9.1%
Other Bluetooth and ear buds   3.9%
Accessories, other   0.3%
Total   100.0%

 

Note 15 – Business Segment and Geographic Area Information

 

Business Segments

 

The Company, directly or through its subsidiaries, markets and sells its products and services directly to consumers and through its dealers. In June 2022, the Company acquired a hearing enhancement and hearing protection business. The Company’s determination of its reportable segments is based on how its chief operating decision makers manage the business.

 

The Company’s segment information is as follows: 

          
   The fiscal years ended
Net Sales   May 31, 2023    May 31, 2022 
Hair care and skin care  $1,588,958   $2,336,257 
Hearing enhancement and protection   21,932,069    — 
Total net sales  $23,521,027   $2,336,257 
           
Operating earnings (loss)          
Segment gross profit:          
Hair care and skin care  $1,076,834   $1,507,671 
Hearing enhancement and protection   16,633,977    — 
Total segment gross profit  $17,710,811   $1,507,671 
Selling and Marketing   11,675,206    1,199,305 
General and Administrative   4,051,394    519,769 
Consolidated operating income (loss)  $1,984,211   $(211,403)
           
Total Assets:          
Hair care and skin care  $3,785,732   $893,915 
Hearing enhancement and protection   6,383,582    — 
Consolidated total assets  $10,169,314   $893,915 
           
Payments for property and equipment          
Hair care and skin care  $—   $— 
Hearing enhancement and protection   65,650    — 
Consolidated total payments for property and equipment  $65,650   $— 
           
Depreciation and amortization          
Hair care and skin care  $5,675   $7,872 
Hearing enhancement and protection   89,504    — 
Consolidated total depreciation and amortization  $95,179   $7,872 

 

F-25

Note 15 – Business Segment and Geographic Area Information (continued)

 

Geographic Area Information

 

During the fiscal year ended May 31, 2023, approximately 94% of our consolidated net sales were to customers located in the U.S. (based on the customer’s shipping address). All Company assets are located in the U.S.

 

Note 16 – Income Taxes

 

The Company has incurred aggregate net operating losses of approximately $1,500,000 for income tax purposes as of May 31, 2023. The net operating loss carries forward for United States and California income taxes, which may be available to reduce future years’ taxable income. Management believes that the realization of the benefits from these losses appears more than likely due to the Company’s current year net income results and should be able to fully utilize that benefit in the current year tax filings. Management will not provide a valuation allowance for the losses as they appear to be fully realized.

 

The items accounting for the difference between income taxes at the effective statutory rate and the provision for income were as follows: 

 

          
   For the Fiscal Years Ended May 31,
    2023    2022 
Tax expense (benefit) computed at statutory rate of 21%  $431,653   $(38,410)
State tax expense (benefit) blended rate   297,928    (15,289)
Change in federal tax rate estimate for prior years   —    (46,109)
Non-deductible expenses: Stock-based compensation   —    6,590 
Non deductible expense: Other   —    2,082 
Non taxable: COVID related grants/loan forgiveness   —    (10,500)

Benefit of tax amortization of intangibles

   (49,773)   — 

Deferred tax true up

   3,929    — 
Net operating loss benefit   (452,824)   — 
Tax expense (benefit)   230,913   — 
           
Increase (decrease) in valuation allowance   (101,636)   101,636 
Change in deferred tax asset   101,636      
Net income tax (benefit)/expense  $230,913   $— 

 

The Company has a deferred tax asset which is summarized as follows at:

 

Deferred tax assets:

 

          
    May 31, 2023    May 31, 2022 
Net operating loss carryover  $—   $452,824 

Less: valuation allowance

   —    (452,824)
Net deferred tax asset  $—   $—  

 

Due to the net income at May 31, 2023 the Company reversed the valuation allowance against the deferred income tax asset at May 31, 2023 as current year taxable income will be sufficient to utilize the total loss carryforward. There is no remaining deferred tax asset at May 31, 2023.

 

The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2020, 2021 and 2022 Corporate Income Tax Returns are subject to Internal Revenue Service examination.

 

F-26

(b) Exhibits

 

             Incorporated by Reference 
Exhibit Number  Exhibit Description  Filed herewith  

Furnished herewith

  Form  Period Ending  Exhibit  Filing Date
2.1+   Asset Purchase Agreement, dated as of May 1, 2022, among Reviv3 Procare Company, Reviv3 Acquisition Corporation, Axil & Associated Brands Corp., and Certain Stockholders of Axil & Associated Brands Corp.           8-K       10.1   6/22/2022
2.2  Amendment Number 1 to Asset Purchase Agreement, effective as of June 10, 2022, among Reviv3 Procare Company, Reviv3 Acquisition Corporation, Axil & Associated Brands Corp., and Certain Stockholders of Axil & Associated Brands Corp.         8-K     10.2  6/22/2022
2.3  Amendment to Asset Purchase Agreement, dated September 8, 2022, between Reviv3 Procare Company, Reviv3 Acquisition Corporation, and Axil & Associated Brands Corp. and Certain Stockholders of Axil & Associated Brands Corp.         10-Q  8/31/2022  10.2  10/12/2022
3.1  Amended and Restated Certificate of Incorporation         S-1     3.3  10/6/2017
3.2  Bylaws         S-1     3.2  10/6/2017
3.3  Certificate of Amendment to the Amended and Restated Certificate of Incorporation         10-K  5/31/2022  3.3  8/25/2022
4.1  Description of the Company’s Registered Securities         10-K  5/31/2022  4.1  8/25/2022
4.2  Form of common stock Certificate of REVIV3 PROCARE COMPANY         S-1/A     4.2  11/17/2017
10.1  Contribution Agreement between Reviv3 Procare, LLC and Reviv3 Procare Company, dated June 1, 2015         S-1     10.1  10/6/2017
10.2  Voting Agreement, dated June 16, 2022, between Reviv3 Procare Company, Intrepid Global Advisors, and Axil & Associated Brands Corp.         8-K     10.3  6/22/2022
10.2.1  Amendment Number 1 to Voting Agreement, dated November 7, 2022, by and among Reviv3 Procare Company, Intrepid Global Advisors, Inc. and Axil & Associated Brands Corp.         8-K     10.1  11/9/2022
10.3  Second Draw Paycheck Protection Program Term Note, dated February 7, 2021         10-K  5/31/2022  10.4  8/25/2022
10.4+  Loan Authorization and Agreement (Economic Injury Disaster Loan), dated May 18, 2020, between the U.S. Small Business Administration and the Company         10-K  5/31/2022  10.5  8/25/2022
10.5  Note (Secured Disaster Loans), entered into by the Company, as Borrower, for the benefit of the U.S. Small Business Administration, as of May 18, 2020         10-K  5/31/2022  10.6  8/25/2022
10.6  Security Agreement, dated May 18, 2020, between the U.S. Small Business Administration and the Company         10-K  5/31/2022  10.7  8/25/2022
10.7  Equity Incentive Plan (March 2022)         10-K  5/31/2022  10.8  8/25/2022
10.8  Form of Option Award Agreement         10-K  5/31/2022  10.9  8/25/2022
10.9  Form of Stock Option Agreement  X                
10.10  Form of Restricted Stock Grant Agreement  X                
10.11  Form of Performance Restricted Stock Unit Agreement  X                
10.12+  Standard Industrial/Commercial Multi-Tenant Lease, dated November 9, 2022, between Vicky Lien and Reviv3 Procare Company         10-Q  11/30/2022  10.4  1/10/2023
10.13  Form of Securities Purchase Agreement         10-Q  11/30/2022  10.5  1/10/2023
10.14  Form of Securities Purchase Agreement         8-K     10.1  3/3/2023
10.15  Executive Employment Agreement, dated April 24, 2023, by and between Reviv3 Procare Company and Monica Diaz Brickell         8-K     10.1  4/27/2023
21.1  Subsidiaries of the Company         10-K  5/31/2022  21.1  8/25/2022
31.1  Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  X                
31.2  Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002  X                
32.1  Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    X            
32.2  Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002    X            
101  The following consolidated financial statements from the Annual Report on Form 10-K for the fiscal year ended May 31, 2023 are formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Changes in Stockholders’ Equity, (iv) Statements of Cash Flows, and (v) the Notes to Financial Statements  X                
104  Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)  X                

 

*Management compensatory plan or arrangement.
+The schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K and the Company agrees to furnish to the SEC a copy of any omitted schedules or exhibits upon request.

 

-24-

ITEM 16. Form 10-K Summary

 

Not Applicable.

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 21st day of August 2023.

 

  REVIV3 PROCARE COMPANY
   
     
  BY: /s/ Jeff Toghraie
    Jeff Toghraie
    Chief Executive Officer and Chairman of the Board of Directors (principal executive officer)
     

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature Title Date
     
/s/ Jeff Toghraie Chief Executive Officer and Chairman of the Board of Directors (principal executive officer) August 21, 2023
Jeff Toghraie  
     
/s/ Monica Diaz Brickell Chief Financial Officer (principal accounting officer and principal financial officer) August 21, 2023
Monica Diaz Brickell  
     
/s/ Nancy Hundt Director August 21, 2023
Nancy Hundt    

 

-25-

 EX-10.9 2 rviv-20230531_10kex10z9.htm EXHIBIT 10.9

Exhibit 10.9 

 

REVIV3 PROCARE CO.

 

2022 EQUITY INCENTIVE PLAN

 

FORM OF STOCK OPTION AGREEMENT

 

Unless otherwise defined herein, the terms in the Stock Option Agreement (the “Option Agreement”) have the same meanings as defined in the REVIV3 PROCARE CO. 2022 Equity Incentive Plan (as amended from time to time)(the “Plan”).

 

I.NOTICE OF STOCK OPTION GRANT

 

Participant’s Name: «Option_Holder» (the “Participant”)

 

Address: ___________________________________

 

You have been granted an Option to purchase Common Stock of the Company (the “Option”), subject to the terms and conditions of the Plan and this Option Agreement, as follows:

 

Grant Date: «Grant Date»

 

Vesting Commencement Date: «Vesting Start Date»

 

Exercise Price per Share: $ «Exercise Price»

 

Total Number of Shares Granted: «Options»

 

Total Exercise Price: «Aggregate_Exercise_Price»

 

Type of Option: «Incentive Stock Option/Nonqualified Stock Option»

 

Expiration Date: «Expiration Date»

 

Vesting Schedule: 1/4th of such Options vest on the first, second, third and fourth anniversaries of the Grant Date, subject to the terms hereof and the Plan.

 

To the extent vested, this Option will be exercisable for three (3) months following the Termination of Service of the Participant, unless termination is due to the Participant’s death or Disability, in which case this Option will be exercisable for twelve (12) months following the Termination of Service of the Participant. In the event of termination due to the Participant’s death, the Company shall use commercially reasonable efforts to notify the Participant’s estate of the exercisability of the Option following the Participant’s death. Notwithstanding the foregoing sentence, in no event may this Option be exercised following the Termination of Service of the Participant as determined by the Company’s Board to be for Cause or after the Expiration Date as provided above and this Option may be subject to earlier termination as provided in the Plan.

 

“Cause” has the meaning ascribed to such term or words of similar import in the Participant’s written employment or service contract with the Company or its parent or any subsidiary and, in the absence of such agreement or definition, means the Participant’s (i) conviction of, or plea of nolo contendere to, a felony or any other crime involving moral turpitude; (ii) fraud on or misappropriation of any funds or property of the Company or its subsidiaries, or any affiliate, customer or vendor; (iii) personal dishonesty, incompetence, willful misconduct, willful violation of any law, rule or regulation (other than minor traffic violations or similar offenses), or breach of fiduciary duty which involves personal profit; (iv) willful misconduct in connection with the Participant’s duties or willful failure to perform the Participant’s responsibilities in the best interests of the Company or its subsidiaries; (v) illegal use or distribution of drugs; (vi) violation of any material rule, regulation, procedure or policy of the Company or its subsidiaries, the violation of which could have a material detriment to the Company; or (vii) material breach of any provision of any employment, non-disclosure, non-competition, non-solicitation or other similar agreement executed by the Participant for the benefit of the Company or its subsidiaries, all as reasonably determined by the Company’s Board of Directors, which determination will be conclusive.

 

 

 

Legends.

 

(a)    All certificates representing the Shares issued upon exercise of this Option shall, prior to such date as the Plan and Common Stock hereunder are covered by a valid Form S-8 or similar U.S. federal registration statement, where applicable, have endorsed thereon the following legend:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY BE OFFERED AND SOLD ONLY IF REGISTERED AND QUALIFIED PURSUANT TO THE RELEVANT PROVISIONS OF U.S. FEDERAL, STATE AND FOREIGN SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION AND QUALIFICATION UNDER U.S. FEDERAL, STATE AND FOREIGN SECURITIES LAWS IS NOT REQUIRED.

 

(b)   If the Option is an incentive stock option (ISO), then the following legend will be included:

 

THE SHARES REPRESENTED BY THIS CERTIFICATE WERE ISSUED UPON EXERCISE OF AN INCENTIVE STOCK OPTION, AND THE COMPANY MUST BE NOTIFIED IF THE SHARES SHALL BE TRANSFERRED BEFORE THE LATER OF THE TWO (2) YEAR ANNIVERSARY OF THE DATE OF GRANT OF THE OPTION OR THE ONE (1) YEAR ANNIVERSARY OF THE DATE ON WHICH THE OPTION WAS EXERCISED. THE REGISTERED HOLDER MAY RECOGNIZE ORDINARY INCOME IF THE SHARES ARE TRANSFERRED BEFORE SUCH DATE.

 

II.AGREEMENT

 

1.      Grant of Option. The Administrator grants to the Participant named in the Notice of Stock Option Grant in Part I of this Option Agreement, an Option to purchase the number of Shares set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option Grant (the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan prevail.

 

If designated in the Notice of Stock Option Grant as an Incentive Stock Option, this Option is intended to qualify as an Incentive Stock Option as defined in Code section 422. Nevertheless, to the extent that it exceeds the $100,000 rule of Code section 422(d), this Option will be treated as a Non-Qualified Stock Option.

 

2.      Exercise of Option.

 

(a)    Right to Exercise. This Option is exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Stock Option Grant and with the applicable provisions of the Plan and this Option Agreement.

 

(b)   Method of Exercise. This Option is exercisable by (i) delivery of an exercise notice in the form attached as Exhibit A (the “Exercise Notice”) or in a manner and pursuant to procedures as the Administrator may determine, which will state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised, and other representations and agreements as may be required by the Company and (ii) paying the Company in full the aggregate Exercise Price as to all Shares being acquired, together with any applicable tax withholding.

 

 

 

This Option will be deemed to be exercised upon receipt by the Company of a fully executed Exercise Notice accompanied by the aggregate Exercise Price, together with any applicable tax withholding.

 

No Shares will be issued pursuant to the exercise of an Option unless the issuance and exercise of Shares complies with Applicable Laws. Assuming compliance, for income tax purposes the Shares will be considered transferred to the Participant on the date on which the Option is exercised with respect to the Shares.

 

3.      Method of Payment. The aggregate Exercise Price may be paid by any of the following, or a combination thereof, at the election of the Participant:

 

(a)    cash;

 

(b)   check;

 

(c)    to the extent not prohibited by Section 402 of the Sarbanes-Oxley Act of 2002, a promissory note;

 

(d)   other shares of Common Stock, provided Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which said Option will be exercised;

 

(e)    by asking the Company to withhold Shares from the total Shares to be delivered upon exercise equal to the number of Shares having a value equal to the aggregate Exercise Price of the Shares being acquired;

 

(f)    any combination of the foregoing methods of payment; or

 

(g)   such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws.

 

4.      Restrictions on Exercise. This Option may not be exercised if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any Applicable Laws. The Company will be relieved of any liability with respect to any delayed issuance of shares or its failure to issue shares if such delay or failure is necessary to comply with Applicable Laws.

 

5.      Non-Transferability of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of the Participant only by the Participant. The terms of the Plan and this Option Agreement are binding upon the executors, administrators, heirs, successors and assigns of the Participant.

 

6.      Term of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised during the term only in accordance with the Plan and the terms of this Option.

 

7.      Tax Obligations.

 

(a)    Withholding Taxes. The Participant agrees to arrange for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable to the Option exercise. The Participant acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if withholding amounts are not delivered at the time of exercise.

 

(b)   Notice of Disqualifying Disposition of ISO Shares. If the Option granted to the Participant is an Incentive Stock Option (“ISO”), and if the Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Grant Date, or (ii) the date one (1) year after the date of exercise, the Participant must immediately notify the Company of the disposition in writing. The Participant agrees that the Participant may be subject to income tax withholding by the Company on the compensation income recognized by the Participant.

 

 

 

(c)    Code Section 409A. Under Code section 409A, an Option that was granted with a per Share exercise price that is determined by the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on the Grant Date (a “discount option”) may be considered deferred compensation. An Option that is a discount option may result in (i) income recognition by the Participant prior to the exercise of the Option, (ii) an additional twenty percent (20%) tax, and (iii) potential penalty and interest charges. The Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share Exercise Price of this Option equals or exceeds Fair Market Value of a Share on the Grant Date in a later examination. The Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the Fair Market Value of a Share on the Grant Date, the Participant will be solely responsible for any and all resulting tax consequences.

 

8.      No Guarantee of Continued Service. THE PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS AN EMPLOYEE OR DIRECTOR AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING THE PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS AN EMPLOYEE OR DIRECTOR FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND WILL NOT INTERFERE IN ANY WAY WITH THE PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING OPTIONEE) TO TERMINATE OPTIONEE’S RELATIONSHIP AS AN EMPLOYEE OR DIRECTOR AT ANY TIME, WITH OR WITHOUT CAUSE.

 

9.      Notices. All notices or other communications which are required or permitted hereunder will be in writing and sufficient if (i) personally delivered or sent by telecopy, (ii) sent by nationally-recognized overnight courier or (iii) sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

(a)    if to the Participant, to the address (or telecopy number) set forth on the Notice of Stock Option Grant; and

 

(b)   if to the Company, to its principal executive office as specified in any report filed by the Company with the Securities and Exchange Commission or to such address as the Company may have specified to the Participant in writing, Attention: Corporate Secretary;

 

or to any other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any communication will be deemed to have been given (i) when delivered, if personally delivered, or when telecopied, if telecopied, (ii) on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally-recognized overnight courier and (iii) on the fourth Business Day following the date on which the piece of mail containing the communication is posted, if sent by mail. As used herein, “Business Day” means a day that is not a Saturday, Sunday or a day on which banking institutions in the city to which the notice or communication is to be sent are not required to be open.

 

10.   Specific Performance. The Participant expressly agrees that the Company will be irreparably damaged if the provisions of this Option Agreement and the Plan are not specifically enforced. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Option Agreement or the Plan by the Participant, the Company will, in addition to all other remedies, be entitled to a temporary or permanent injunction, without showing any actual damage, and/or decree for specific performance, in accordance with the provisions hereof and thereof. The Administrator has the power to determine what constitutes a breach or threatened breach of this Option Agreement or the Plan. The Administrator’s determinations will be final and conclusive and binding upon the Participant.

 

11.   No Waiver. No waiver of any breach or condition of this Option Agreement will be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

 

12.   Participant Undertaking. The Participant agrees to take whatever additional actions and execute whatever additional documents the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on the Participant pursuant to the express provisions of this Option Agreement.

 

 

 

13.   Modification of Rights. The rights of the Participant are subject to modification and termination in certain events as provided in this Option Agreement and the Plan.

 

14.   Governing Law. This Agreement is governed by, and construed in accordance with, the laws of the State of Texas, without giving effect to its conflict or choice of law principles that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

 

15.   Counterparts; Facsimile Execution. This Option Agreement may be executed in one or more counterparts, each of which will be deemed to be an original, but all of which together constitute one and the same instrument. Facsimile execution and delivery of this Option Agreement is legal, valid and binding execution and delivery for all purposes.

 

16.   Entire Agreement. The Plan, this Option Agreement, and upon execution, the Exercise Notice, constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and the Participant.

 

17.   Severability. In the event one or more of the provisions of this Option Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Option Agreement, and this Option Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

 

18.   WAIVER OF JURY TRIAL. THE OPTIONEE EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS OPTION AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN.

 

[Remainder of page left intentionally blank.]

 

 

 

The Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and accepts this Option subject to all of the terms and provisions thereof. The Participant has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. The Participant agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. The Participant further agrees to notify the Company upon any change in the residence address indicated below.

 

PARTICIPANT     REVIV3 PROCARE CO.  
         
Signature     By:  
         
Print Name: «Option_Holder»     Print Name:  
         
Address:     Address:  
         
           
         
Date Signed:     Date Signed:  

 

 

EXHIBIT A

 

REVIV3 PROCARE CO.

 

2022 EQUITY INCENTIVE PLAN

 

EXERCISE NOTICE

 

REVIV3 PROCARE CO.

 

[Address]

 

Attention: REVIV3 PROCARE CO., Corporate Secretary

 

1.      Exercise of Option. Effective as of today, _____________, _____, the undersigned (the “Participant”) elects to exercise the Participant’s option to purchase ___________ shares of the Common Stock (the “Shares”) of REVIV3 PROCARE CO. (the “Company”) under and pursuant to the REVIV3 PROCARE CO. 2023 Equity Incentive Plan (the “Plan”) and the Stock Option Agreement dated and effective _________ (the “Option Agreement”).

 

2.      Delivery of Payment. The Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option.

 

3.      Representations of Participant. The Participant acknowledges that the Participant has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.

 

4.      Rights as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder exists with respect to the Optioned Stock, notwithstanding the exercise of the Option. Subject to the requirements of Section 6 below, the Shares will be issued to the Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in the Plan.

 

5.      Tax Consultation. The Participant understands that the Participant may suffer adverse tax consequences as a result of the Participant’s purchase or disposition of the Shares. The Participant represents that the Participant has consulted with any tax consultants the Participant deems advisable in connection with the purchase or disposition of the Shares and that the Participant is not relying on the Company for any tax advice.

 

6.      Refusal to Transfer. The Company will not (i) transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice, or (ii) be required to treat as owner of such Shares or to accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares have been so transferred.

 

7.      Successors and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise Notice inures to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Exercise Notice is binding upon the Participant and his or her heirs, executors, administrators, successors and assigns.

 

8.      Interpretation. Any dispute regarding the interpretation of this Exercise Notice will be submitted by the Participant or by the Company forthwith to the Administrator for review at its next regular meeting. The resolution of disputes by the Administrator will be final and binding on all parties.

 

9.      Governing Law; Severability. This Exercise Notice is governed by, and construed in accordance with, the laws of the State of Texas, without giving effect to its conflict or choice of law principles that might otherwise refer construction or interpretation of this Exercise to the substantive law of another jurisdiction. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice will continue in full force and effect.

 

 

 

10.   Participant Representations.

 

(a)    (With respect to a transaction occurring prior to such date as the Plan and Common Stock thereunder are covered by a valid Form S-8 or similar U.S. federal registration statement, the Participant agrees that in no event shall the Participant make a disposition of any of the Common Stock, unless and until: (i) the Participant shall have notified the Company of the proposed disposition and shall have furnished the Company with a statement of the circumstances surrounding the proposed disposition; and (ii) the Participant shall have furnished the Company with an opinion of counsel satisfactory to the Company to the effect that (A) such disposition will not require registration or qualification of such Common Stock under applicable U.S. federal, state or foreign securities laws or (B) appropriate action necessary for compliance with the U.S. federal, state or foreign securities laws has been taken; or (iii) the Company shall have waived, expressly and in writing, its rights under clauses (i) and (ii) of this Subsection.

 

(b)   (The Participant understands that if a registration statement covering the Common Stock under the Securities Act is not in effect when the Participant desires to sell the Common Stock, the Participant may be required to hold the Common Stock for an indeterminate period. The Participant also acknowledges that the Participant understands that any sale of the Common Stock which might be made by the Participant in reliance upon Rule 144 under the Securities Act may be made only in limited amounts in accordance with the terms and conditions of that Rule.

 

11.   Other Documents. The Participant hereby acknowledges receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act of 1933, as amended, including, but not limited to, the information required by Part I of Form S-8, if applicable.

 

12.   Notices. Any notice required or permitted hereunder will be provided in writing and deemed effective if provided in the manner specified in the Option Agreement.

 

13.   Further Instruments. The parties agree to execute any further instruments and to take any further action as may be reasonably necessary to carry out the purposes and intent of the Option Agreement and this Exercise Notice.

 

14.   Entire Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, and the Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing signed by the Company and the Participant.

 

[Signature page follows.]

 

 

 

Submitted by:     Accepted by:    
           
PARTICIPANT   REVIV3 PROCARE CO.  
           
Signature     By:    
           
Print Name:     Print Name:    
           
Address:          
           
      Date Received:    
           

 

 EX-10.10 3 rviv-20230531_10kex10z10.htm EXHIBIT 10.10

 Exhibit 10.10

 

REVIV3 PROCARE CO.

 

2022 EQUITY INCENTIVE PLAN

 

NOTICE OF RESTRICTED STOCK GRANT

 

Capitalized but otherwise undefined terms in this Notice of Restricted Stock Grant and the attached Restricted Stock Grant Agreement shall have the same defined meanings as in the REVIV3 PROCARE CO. 2022 Equity Incentive Plan (as amended from time to time)(the “Plan”).

 

Participant’s Name:     (the “Participant”)

 

Address:     

 

You have been granted Restricted Stock subject to the terms and conditions of the Plan and the attached Restricted Stock Grant Agreement, as follows:

 

Date of Grant:     

  

Vesting Commencement Date:     

 

Price Per Share:     

 

Total Number of Shares Granted:     

 

Total Value of Shares Granted:     

 

Total Purchase Price:     

 

Agreement Date:     

 

Vesting Schedule:     

 

 

 

REVIV3 PROCARE CO.

 

2022 EQUITY INCENTIVE PLAN

 

RESTRICTED STOCK GRANT AGREEMENT

 

This RESTRICTED STOCK GRANT AGREEMENT (“Agreement”), dated as of the Agreement Date specified on the Notice of Restricted Stock Grant is made by and between REVIV3 PROCARE CO., a Delaware corporation (the “Company”), and the grantee named in the Notice of Restricted Stock Grant (the “Participant,” which term as used herein shall be deemed to include any successor to Participant by will or by the laws of descent and distribution, unless the context shall otherwise require).

 

BACKGROUND

 

Pursuant to the Plan, the Board (or an authorized Committee thereof), approved the issuance to the Participant, effective as of the date set forth above, of an award of the number of shares of Restricted Stock as is set forth in the attached Notice of Restricted Stock Grant (which is expressly incorporated herein and made a part hereof, the “Notice of Restricted Stock Grant”) at the purchase price per share of Restricted Stock (the “Purchase Price”), if any, set forth in the attached Notice of Restricted Stock Grant, upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in consideration of the mutual premises and undertakings hereinafter set forth, the parties agree as follows:

 

1.      Grant and Purchase of Restricted Stock. The Company hereby grants to the Participant, and the Participant hereby accepts the Restricted Stock set forth in the Notice of Restricted Stock Grant, subject to the payment by the Participant of the total purchase price, if any, set forth in the Notice of Restricted Stock Grant.

 

2.      Stockholder Rights.

 

(a)    Voting Rights. Until such time as all or any part of the Restricted Stock are forfeited to the Company under this Agreement, if ever, the Participant (or any successor in interest) has the rights of a stockholder, including voting rights, with respect to the Restricted Stock subject, however, to the transfer restrictions or any other restrictions set forth in the Plan.

 

(b)   Dividends and Other Distributions. During the period of restriction, the Participany is entitled to all regular cash dividends or other distributions paid with respect to all shares while they are so held. If any such dividends or distributions are paid in shares, such shares will be subject to the same restrictions on transferability and forfeitability as the Restricted Stock with respect to which they were paid.

 

3.      Vesting of Restricted Stock.

 

(a)    The Restricted Stock are restricted and subject to forfeiture until vested. The Restricted Stock which have vested and are no longer subject to forfeiture are referred to as “Vested Shares.” All Restricted Stock which have not become Vested Shares are referred to as “Nonvested Shares.”

 

(b)   Restricted Stock will vest and become nonforfeitable in accordance with the vesting schedule contained in the Notice of Restricted Stock Grant.

 

(c)    Any Nonvested Shares of the Participant will automatically vest and become nonforfeitable if the Participant’s service with the Company ceases owing to the Participant’s (a) death, (b) Disability, or (c) Retirement, unless the Board (or an authorized committee thereof) provides otherwise.

 

(d)   In the event of a Change of Control, the Board (or an authorized committee thereof), in its discretion, may accelerate the time at which all or any portion of the Participant’s Restricted Stock will vest.

 

 

 

(e)    Terms used in Section 3 and Section 4 have the following meanings:

 

(i)    “Cause” has the meaning ascribed to such term or words of similar import in the Participant’s written employment or service contract with the Company or its subsidiaries and, in the absence of such agreement or definition, means the Participant’s (i) conviction of, or plea of nolo contendere to, a felony or crime involving moral turpitude; (ii) fraud on or misappropriation of any funds or property of the Company or its subsidiaries, or any affiliate, customer or vendor; (iii) personal dishonesty, incompetence, willful misconduct, willful violation of any law, rule or regulation (other than minor traffic violations or similar offenses), or breach of fiduciary duty which involves personal profit; (iv) willful misconduct in connection with the Participant’s duties or willful failure to perform the Participant’s responsibilities in the best interests of the Company or its subsidiaries; (v) illegal use or distribution of drugs; (vi) violation of any material rule, regulation, procedure or policy of the Company or its subsidiaries, the violation of which could have a material detriment to the Company; or (vii) material breach of any provision of any employment, non-disclosure, non-competition, non-solicitation or other similar agreement executed by the Participant for the benefit of the Company or its subsidiaries, all as reasonably determined by the Board of Directors of the Company, which determination will be conclusive.

 

(ii)   “Retirement” means the Participant’s retirement from Company employ at or above the age 65 as determined in accordance with the policies of the Company or its subsidiaries, if any, in good faith by the Board of Directors of the Company, which determination will be final and binding on all parties concerned.

 

(f)    Nonvested Shares may not be sold, transferred, assigned, pledged, or otherwise disposed of, directly or indirectly, whether by operation of law or otherwise. The restrictions set forth in this Section will terminate upon a Change of Control.

 

4.      Forfeiture of Nonvested Shares. Except as provided herein, if the Participant’s service with the Company ceases for any reason other than the Participant’s (a) death, (b) Disability, or (c) Retirement, any Nonvested Shares will be automatically forfeited to the Company; provided, however, that the Board (or an authorized committee thereof) may cause any Nonvested Shares immediately to vest and become nonforfeitable if the Participant’s service with the Company is terminated by the Company without Cause.

 

(a)    Legend. Each certificate representing Restricted Stock granted pursuant to the Notice of Restricted Stock Grant may bear a legend substantially as follows:

 

“THE SALE OR OTHER TRANSFER OF THE SHARES REPRESENTED BY THIS CERTIFICATE, WHETHER VOLUNTARY, INVOLUNTARY OR BY OPERATION OF LAW, IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN THE REVIV3 PROCARE CO. 2022 EQUITY INCENTIVE PLAN AND IN A RESTRICTED SHARE GRANT AGREEMENT. A COPY OF SUCH PLAN AND SUCH AGREEMENT MAY BE OBTAINED FROM REVIV3 PROCARE CO. “

 

(b)   Escrow of Nonvested Shares. The Company has the right to retain the certificates representing Nonvested Shares in the Company’s possession until such time as all restrictions applicable to such shares have been satisfied.

 

(c)    Removal of Restrictions. The Participant is entitled to have the legend removed from certificates representing Vested Shares.

 

5.      Recapitalizations, Exchanges, Mergers, Etc. The provisions of this Agreement apply to the full extent set forth herein with respect to any and all shares of capital stock of the Company or successor of the Company which may be issued in respect of, in exchange for, or in substitution for the Restricted Stock by reason of any stock dividend, split, reverse split, combination, recapitalization, reclassification, merger, consolidation or otherwise which does not terminate this Agreement. Except as otherwise provided herein, this Agreement is not intended to confer upon any other person except the parties hereto any rights or remedies hereunder.

 

 

 

6.      Participant Representations.

 

The Participant represents to the Company the following:

 

(a)    Restrictions on Transfer. The Participant acknowledges that the Restricted Stock to be issued to the Participant must be held indefinitely unless subsequently registered and qualified under the Securities Act of 1933, as amended (the “Securities Act”) or unless an exemption from registration and qualification is otherwise available. In addition, the Participant understands that the certificate representing the Restricted Stock will be imprinted with a legend which prohibits the transfer of such Restricted Stock unless they are sold in a transaction in compliance with the Securities Act or are registered and qualified or such registration and qualification are not required in the opinion of counsel acceptable to the Company.

 

(b)   Relationship to the Company; Experience. The Participant either has a preexisting business or personal relationship with the Company or any of its officers, directors or controlling persons or, by reason of the Participant’s business or financial experience or the business or financial experience of the Participant’s personal representative(s), if any, who are unaffiliated with and who are not compensated by the Company or any affiliate or selling agent, directly or indirectly, has the capacity to protect the Participant’s own interests in connection with the Participant’s acquisition of the Restricted Stock to be issued to the Participant hereunder. The Participant and/or the Participant’s personal representative(s) have such knowledge and experience in financial, tax and business matters to enable the Participant and/or them to utilize the information made available to the Participant and/or them in connection with the acquisition of the Restricted Stock to evaluate the merits and risks of the prospective investment and to make an informed investment decision with respect thereto.

 

(c)    Participant’s Liquidity. In reaching the decision to invest in the Restricted Stock, the Participant has carefully evaluated the Participant’s financial resources and investment position and the risks associated with this investment, and the Participant acknowledges that the Participant is able to bear the economic risks of the investment. the Participant (i) has adequate means of providing for the Participant’s current needs and possible personal contingencies, (ii) has no need for liquidity in the Participant’s investment, (iii) is able to bear the substantial economic risks of an investment in the Restricted Stock for an indefinite period and (iv) at the present time, can afford a complete loss of such investment. The Participant’s commitment to investments which are not readily marketable is not disproportionate to the Participant’s net worth and the Participant’s investment in the Restricted Stock will not cause the Participant’s overall commitment to become excessive.

 

(d)   Access to Data. The Participant acknowledges that during the course of this transaction and before deciding to acquire the Restricted Stock, the Participant has been provided with financial and other written information about the Company. The Participant has been given the opportunity by the Company to obtain any information and ask questions concerning the Company, the Restricted Stock, and the Participant’s investment that the Participant felt necessary; and to the extent the Participant availed himself/herself of that opportunity, the Participant has received satisfactory information and answers concerning the business and financial condition of the Company in response to all inquiries in respect thereof.

 

(e)    Risks. The Participant acknowledges and understands that (i) an investment in the Company constitutes a high risk, (ii) the Restricted Stock are highly speculative, and (iii) there can be no assurance as to what investment return, if any, there may be. The Participant is aware that the Company may issue additional securities in the future which could result in the dilution of the Participant’s ownership interest in the Company.

 

(f)    Valid Agreement. This Agreement when executed and delivered by the Participant will constitute a valid and legally binding obligation of the Participant which is enforceable in accordance with its terms.

 

(g)   Residence. The address set forth on the Notice of Restricted Stock Grant is the Participant’s current address and accurately sets forth the Participant’s place of residence.

 

(h)   Tax Consequences. The Participant has reviewed with the Participant’s own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that the Participant (and not the Company) is responsible for the Participant’s own tax liability that may arise as a result of the transactions contemplated by this Agreement. The Participant understands that Section 83 of the Internal Revenue Code of 1986, as amended (the “Code”), taxes as ordinary income the difference between the purchase price for the Restricted Stock and the fair market value of the Restricted Stock as of the date any restrictions on the Restricted Stock lapse. The Participant understands that the Participant may elect to be taxed at the time the Restricted Stock is purchased rather than when and as the restrictions lapse by filing an election under Section 83(b) of the Code with the Internal Revenue Service within 30 days from the date of purchase. The form for making this election is attached as Exhibit A hereto.

 

THE PARTICIPANT ACKNOWLEDGES THAT IT IS THE PARTICIPANT’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY ANY ELECTION UNDER SECTION 83(b), EVEN IF THE PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON GRANTEE’S BEHALF.

 

 

 

7.      No Employment Contract Created. The issuance of the Restricted Stock is not to be construed as granting to the Participant any right with respect to continuance of employment or any service with the Company or any of its subsidiaries. The right of the Company or any of its subsidiaries to terminate at will the Participant’s employment or terminate the Participant’s service at any time (whether by dismissal, discharge or otherwise), with or without cause, is specifically reserved, subject to any other written employment or other agreement to which the Company and the Participant may be a party.

 

8.      Tax Withholding. The Company has the power and the right to deduct or withhold, or require the Participant to remit to the Company, an amount sufficient to satisfy Federal, state and local taxes (including the Participant’s FICA obligation) required by law to be withheld with respect to the grant and vesting of the Restricted Stock.

 

9.      Interpretation. The Restricted Stock are being issued pursuant to the terms of the Plan, and are to be interpreted in accordance therewith. The Board (or an authorized committee thereof) will interpret and construe this Agreement and the Plan, and any action, decision, interpretation or determination made in good faith by the Board (or an authorized committee thereof) will be final and binding on the Company and the Participant.

 

10.   Notices. All notices or other communications which are required or permitted hereunder will be in writing and sufficient if (i) personally delivered or sent by telecopy, (ii) sent by nationally-recognized overnight courier or (iii) sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

(a)    if to the Participant, to the address (or telecopy number) set forth on the Notice of Grant; and

 

(b)   if to the Company, to its principal executive office as specified in any report filed by the Company with the Securities and Exchange Commission or to such address as the Company may have specified to the Participant in writing, Attention: Corporate Secretary;

 

or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such communication will be deemed to have been given (i) when delivered, if personally delivered, or when telecopied, if telecopied, (ii) on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally-recognized overnight courier and (iii) on the fifth Business Day following the date on which the piece of mail containing such communication is posted, if sent by mail. As used herein, “Business Day” means a day that is not a Saturday, Sunday or a day on which banking institutions in the city to which the notice or communication is to be sent are not required to be open.

 

11.   Specific Performance. The Participant expressly agrees that the Company will be irreparably damaged if the provisions of this Agreement and the Plan are not specifically enforced. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Agreement or the Plan by the Participant, the Company will, in addition to all other remedies, be entitled to a temporary or permanent injunction, without showing any actual damage, and/or decree for specific performance, in accordance with the provisions hereof and thereof. The Board (or an authorized committee thereof) has the power to determine what constitutes a breach or threatened breach of this Agreement or the Plan. Any such determinations will be final and conclusive and binding upon the Participant.

 

 

 

12.   No Waiver. No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

 

13.   Participant Undertaking. The Participant hereby agrees to take whatever additional actions and execute whatever additional documents the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on the Participant pursuant to the express provisions of this Agreement.

 

14.   Modification of Rights. The rights of the Participant are subject to modification and termination in certain events as provided in this Agreement and the Plan.

 

15.   Governing Law. This Agreement is governed by, and construed in accordance with, the laws of the State of Nevada, without giving effect to its conflict or choice of law principles that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

 

16.   Counterparts; Facsimile Execution. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original, but all of which together will constitute one and the same instrument. Facsimile execution and delivery of this Agreement is legal, valid and binding execution and delivery for all purposes.

 

17.   Entire Agreement. This Agreement (including the Notice of Restricted Stock Grant) and the Plan, constitute the entire agreement between the parties with respect to the subject matter hereof, and supersedes all previously written or oral negotiations, commitments, representations and agreements with respect thereto.

 

18.   Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

 

19.   WAIVER OF JURY TRIAL. THE PARTICIPANT HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN.

 

[Signature Page Follows]

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Restricted Share Grant Agreement as of the date first written above.

 

REVIV3 PROCARE CO.

 

By:     

 

Name:     

 

Title:     

 

PARTICIPANT:

 

Name:     

 

 

SPOUSE’S CONSENT TO AGREEMENT

 

(Required where Participant resides in a community property state)

 

I acknowledge that I have read the Agreement and the Plan and that I know and understand the contents of both. I am aware that my spouse has agreed therein to the imposition of certain forfeiture provisions and restrictions on transferability with respect to the Restricted Stock that are the subject of the Agreement, including with respect to my community interest therein, if any, on the occurrence of certain events described in the Agreement. I hereby consent to and approve of the provisions of the Agreement, and agree that I will abide by the Agreement and bequeath any interest in the Restricted Stock which represents a community interest of mine to my spouse or to a trust subject to my spouse’s control or for my spouse’s benefit or the benefit of our children if I predecease my spouse.

 

Dated:     

  

   
Signature  
   
Print Name  

 

 

 

Exhibit A

 

ELECTION UNDER SECTION 83(b)

OF THE INTERNAL REVENUE CODE OF 1986

 

The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in the taxpayer’s gross income or alternative minimum taxable income, as the case may be, for the current taxable year, as compensation for services the excess (if any) of the fair market value of the shares described below over the amount paid for those shares:

 

1.      The name, address, social security number and taxable year of the undersigned are as follows:

 

Taxpayer Name:  
Address:  
Social Security Number:  
Taxable Year:  
   

2.      The property with respect to which the election is made is described as follows: __________ shares (the “Shares”) of the Common Stock of REVIV3 PROCARE CO., a Delaware corporation (the “Company”).

 

3.      The date on which the property was transferred is:___________________ ,______.

 

4.      The property is subject to the following restrictions:

 

The Shares may not be transferred and are subject to forfeiture under the terms of an agreement between the taxpayer and the Company. These restrictions lapse upon the satisfaction of certain conditions contained in such agreement.

 

5.      The fair market value of the property at the time of transfer (determined without regard to any restriction other than a nonlapse restriction as defined in § 1.83-3(h) of the Income Tax Regulations) is: $_______ per share x ________ shares = $___________.

 

6.      For the property transferred, the undersigned paid $______ per share x _________ shares = $______________.

 

7.      The amount to include in gross income is $______________. [The result of the amount reported in Item 5 minus the amount reported in Item 6.]

 

The undersigned taxpayer will file this election with the Internal Revenue Service office with which taxpayer files his or her annual income tax return not later than 30 days after the date of transfer of the property. A copy of the election also will be furnished to the person for whom the services were performed. The undersigned is the person performing the services in connection with which the property was transferred.

 

The undersigned understands that the foregoing election may not be revoked except with the consent of the Commissioner.

 

   
Dated: ______________________, _____ The undersigned spouse of taxpayer joins in this election.
   
   
____________________________________ Dated: ______________________, _____
Taxpayer  
   
  ____________________________________
  Spouse of Taxpayer

 

 

 EX-10.11 4 rviv-20230531_10kex10z11.htm EXHIBIT 10.11

Exhibit 10.11 

 

REVIV3 PROCARE CO.

 

2022 EQUITY INCENTIVE PLAN

 

NOTICE OF RESTRICTED STOCK UNITS GRANT

 

Capitalized but otherwise undefined terms in this Notice of Restricted Stock Units Grant and the attached Restricted Stock Units Grant Agreement shall have the same defined meanings as in the REVIV3 PROCARE CO. 2022 Equity Incentive Plan (as amended from time to time) (the “Plan”).

 

 

Participant’s Name:     (the “Participant”)

 

Address:     

 

You have been granted Performance Shares (referred herein and in the attached Restricted Stock Units Grant Agreement as “Restricted Stock Units”) subject to the terms and conditions of the Plan and the attached Restricted Stock Grant Agreement, as follows:

 

Date of Grant:     

  

Vesting Commencement Date:     

 

Price Per Share:     

 

Total Number of Shares Granted:     

 

Total Value of Shares Granted:     

 

Total Purchase Price:     

 

Agreement Date:     

 

Termination Date: 10-year anniversary of the Date of Grant

 

Vesting Schedule: All RSUs Granted shall vest on the date of the listing of the Company’s securities on a national securities exchange prior to the Termination Date (the “Vesting Date”), subject to Participant’s continued employment with the Company through the one year anniversary of the Vesting Commencement Date set forth above (the “Employment Date”).

 

 

 

REVIV3 PROCARE CO.

 

2022 EQUITY INCENTIVE PLAN

 

RESTRICTED STOCK UNITS GRANT AGREEMENT

 

This RESTRICTED STOCK UNITS GRANT AGREEMENT (“Agreement”), dated as of the Agreement Date specified on the Notice of Restricted Stock Units Grant is made by and between REVIV3 PROCARE CO., a Delaware corporation (the “Company”), and the grantee named in the Notice of Restricted Stock Units Grant (the “Participant,” which term as used herein shall be deemed to include any successor to Participant by will or by the laws of descent and distribution, unless the context shall otherwise require).

 

BACKGROUND

 

Pursuant to the Plan, the Board (or an authorized Committee thereof), approved the issuance to the Participant, effective as of the date set forth above, of an award of Performance Shares (referred herein and in the Notice of Restricted Stock Units Grant as “Restricted Stock Units”) as is set forth in the attached Notice of Restricted Stock Units Grant (which is expressly incorporated herein and made a part hereof, the “Notice of Restricted Stock Units Grant”) at the purchase price per Restricted Stock Unit (the “Purchase Price”), if any, set forth in the attached Notice of Restricted Stock Units Grant, upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in consideration of the mutual premises and undertakings hereinafter set forth, the parties agree as follows:

 

1.      Grant and Purchase of Restricted Stock Units. The Company hereby grants to the Participant, and the Participant hereby accepts the Restricted Stock Units set forth in the Notice of Restricted Stock Units Grant, subject to the payment by the Participant of the total purchase price, if any, set forth in the Notice of Restricted Stock Units Grant.

 

2.      Vesting of Restricted Stock Units.

 

(a)    The Restricted Stock Units will vest in accordance with the vesting schedule contained in the Notice of Restricted Stock Units Grant. In the event

 

(b)   In the event of the death or termination without Cause of the Participant before the Employment Date, or a Change of Control of the Company before the Vesting Date, the Board (or an authorized committee thereof), in its discretion, may accelerate the time at which all or any portion of the Participant’s Restricted Stock Units will vest.

 

(c)    For purposes of this Agreement, “Cause” has the meaning ascribed to such term or words of similar import in the Participant’s written employment or service contract with the Company or its subsidiaries and, in the absence of such agreement or definition, means the Participant’s (i) conviction of, or plea of nolo contendere to, a felony or crime involving moral turpitude; (ii) fraud on or misappropriation of any funds or property of the Company or its subsidiaries, or any affiliate, customer or vendor; (iii) personal dishonesty, incompetence, willful misconduct, willful violation of any law, rule or regulation (other than minor traffic violations or similar offenses), or breach of fiduciary duty which involves personal profit; (iv) willful misconduct in connection with the Participant’s duties or willful failure to perform the Participant’s responsibilities in the best interests of the Company or its subsidiaries; (v) illegal use or distribution of drugs; (vi) violation of any material rule, regulation, procedure or policy of the Company or its subsidiaries, the violation of which could have a material detriment to the Company; or (vii) material breach of any provision of any employment, non-disclosure, non-competition, non-solicitation or other similar agreement executed by the Participant for the benefit of the Company or its subsidiaries, all as reasonably determined by the Board of Directors of the Company, which determination will be conclusive.

 

3.      Settlement. If the Restricted Stock Units vest prior to the Termination Date, subject to compliance with Section 8, the Company shall deliver to the Participant the number of Restricted Stock Units that have vested in Shares (less the number of Shares to be deducted pursuant to Section 8, if applicable) no later March 15 of the calendar year immediately following the calendar year that includes the Vesting Date (or in the event of vesting due to the Participant’s death or termination without Cause, or a Change in Control, no later March 15 of the calendar year immediately following the calendar year that includes the date of the Participant death or termination without Cause, or the Change in Control or such other earlier date on which the Restricted Stock Units vest for any reason).

 

 

 

4.      Stockholder Rights. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder exists with respect to the Stock underlying the Restricted Stock Units. Subject to the requirements of Section 3, the Shares will be issued to the Participant as soon as practicable after the vesting of the Restricted Stock Units in accordance with the Agreement. No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in the Plan.

 

5.      Non-Transferability. The Restricted Stock Units may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of the Participant only by the Participant. The terms of the Plan and this Agreement are binding upon the executors, administrators, heirs, successors and assigns of the Participant.

 

6.      Term of Restricted Stock Units. If the Restricted Stock Units do not vest before the Termination Date, the Restricted Stock Units will be permanently forfeited and no longer capable of vesting.

 

7.      No Employment Contract Created. The issuance of the Restricted Stock Units is not to be construed as granting to the Participant any right with respect to continuance of employment or any service with the Company or any of its subsidiaries. The right of the Company or any of its subsidiaries to terminate at will the Participant’s employment or terminate the Participant’s service at any time (whether by dismissal, discharge or otherwise), with or without cause, is specifically reserved, subject to any other written employment or other agreement to which the Company and the Participant may be a party.

 

8.      Tax Withholding. The Company has the power and the right to deduct or withhold, or require the Participant to remit to the Company, an amount sufficient to satisfy Federal, state and local taxes (including the Participant’s FICA obligation) required by law to be withheld with respect to the vesting or settlement of the Restricted Stock Units. The Participant agrees to arrange for the satisfaction of all Federal, state, local and foreign income and employment tax withholding requirements applicable to the vesting and settlement of the Restricted Stock Units. The Participant may choose to satisfy such Federal, state, local and foreign income and employment tax withholding requirements by instructing the Company to deduct a number Shares with a fair market value equal to amount of the required tax withholding. The Participant acknowledges and agrees that the Company may refuse to deliver the Shares if withholding amounts are not timely delivered and that any delay in settlement may have adverse tax consequences to the Participant.

 

9.      Interpretation. The Restricted Stock Units are being issued pursuant to the terms of the Plan, and are to be interpreted in accordance therewith. The Board (or an authorized committee thereof) will interpret and construe this Agreement and the Plan, and any action, decision, interpretation or determination made in good faith by the Board (or an authorized committee thereof) will be final and binding on the Company and the Participant.

 

10.   Notices. All notices or other communications which are required or permitted hereunder will be in writing and sufficient if (i) personally delivered or sent by telecopy, (ii) sent by nationally-recognized overnight courier or (iii) sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:

 

(a)    if to the Participant, to the address (or telecopy number) set forth on the Notice of Grant; and

 

(b)   if to the Company, to its principal executive office as specified in any report filed by the Company with the Securities and Exchange Commission or to such address as the Company may have specified to the Participant in writing, Attention: Corporate Secretary;

 

or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such communication will be deemed to have been given (i) when delivered, if personally delivered, or when telecopied, if telecopied, (ii) on the first Business Day (as hereinafter defined) after dispatch, if sent by nationally-recognized overnight courier and (iii) on the fifth Business Day following the date on which the piece of mail containing such communication is posted, if sent by mail. As used herein, “Business Day” means a day that is not a Saturday, Sunday or a day on which banking institutions in the city to which the notice or communication is to be sent are not required to be open.

 

 

 

11.   Specific Performance. The Participant expressly agrees that the Company will be irreparably damaged if the provisions of this Agreement and the Plan are not specifically enforced. Upon a breach or threatened breach of the terms, covenants and/or conditions of this Agreement or the Plan by the Participant, the Company will, in addition to all other remedies, be entitled to a temporary or permanent injunction, without showing any actual damage, and/or decree for specific performance, in accordance with the provisions hereof and thereof. The Board (or an authorized committee thereof) has the power to determine what constitutes a breach or threatened breach of this Agreement or the Plan. Any such determinations will be final and conclusive and binding upon the Participant.

 

12.   No Waiver. No waiver of any breach or condition of this Agreement will be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature.

 

13.   Participant Undertaking. The Participant hereby agrees to take whatever additional actions and execute whatever additional documents the Company may in its reasonable judgment deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on the Participant pursuant to the express provisions of this Agreement.

 

14.   Modification of Rights. The rights of the Participant are subject to modification and termination in certain events as provided in this Agreement and the Plan.

 

15.   Governing Law. This Agreement is governed by, and construed in accordance with, the laws of the State of Nevada, without giving effect to its conflict or choice of law principles that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction.

 

16.   Counterparts; Facsimile Execution. This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original, but all of which together will constitute one and the same instrument. Facsimile execution and delivery of this Agreement is legal, valid and binding execution and delivery for all purposes.

 

17.   Entire Agreement. This Agreement (including the Notice of Restricted Stock Units Grant) and the Plan, constitute the entire agreement between the parties with respect to the subject matter hereof, and supersedes all previously written or oral negotiations, commitments, representations and agreements with respect thereto.

 

18.   Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

 

19.   WAIVER OF JURY TRIAL. THE PARTICIPANT HEREBY EXPRESSLY, IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AND FOR ANY COUNTERCLAIM THEREIN.

 

20.   Code Section 409A. The Restricted Stock Units are intended to be exempt from Code section 409A pursuant to the short-term deferral exemption thereto, and the Plan and this Agreement will be interpreted and administered consistent with such intention. Notwithstanding the foregoing, the Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the Restricted Stock Units qualify for the exemption from Code section 409A. The Participant agrees that if the IRS determines that the Restricted Stock Units do not qualify for an exemption from Code section 409A and violate the requirements of such section, the Participant will be solely responsible for any and all resulting tax consequences.

 

[Signature Page Follows]

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Units Grant Agreement as of the date first written above.

 

REVIV3 PROCARE CO.

 

By:     

 

Name:     

 

Title:     

 

PARTICIPANT:

 

Name:     

 

SPOUSE’S CONSENT TO AGREEMENT

 

(Required where Participant resides in a community property state)

 

I acknowledge that I have read the Agreement and the Plan and that I know and understand the contents of both. I am aware that my spouse has agreed therein to the imposition of certain forfeiture provisions and restrictions on transferability with respect to the Restricted Stock Units that are the subject of the Agreement, including with respect to my community interest therein, if any, on the occurrence of certain events described in the Agreement. I hereby consent to and approve of the provisions of the Agreement, and agree that I will abide by the Agreement and bequeath any interest in the Restricted Stock Units which represents a community interest of mine to my spouse or to a trust subject to my spouse’s control or for my spouse’s benefit or the benefit of our children if I predecease my spouse.

 

Dated:     

  

   
Signature  
   
Print Name  

 

 

 

 

 

 

 EX-31.1 5 rviv-20230531_10kex31z1.htm EXHIBIT 31.1

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jeff Toghraie, certify that: 

 

  1. I have reviewed this annual report on Form 10-K of Reviv3 Procare Company

  

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

  

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 21, 2023 By: /s/ Jeff Toghraie
  Name: Jeff Toghraie
  Title: Chief Executive Officer (principal executive officer)

 

 EX-31.2 6 rviv-20230531_10kex31z2.htm EXHIBIT 31.2

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Monica Diaz Brickell, certify that: 

 

  1. I have reviewed this annual report on Form 10-K of Reviv3 Procare Company;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 21, 2023 By: /s/ Monica Diaz Brickell
  Name: Monica Diaz Brickell
  Title: Chief Financial Officer (principal accounting officer and principal financial officer)

 

 EX-32.1 7 rviv-20230531_10kex32z1.htm EXHIBIT 32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Reviv3 Procare Company (the “Company”) for the year ended May 31, 2023 (the “Report”), I, Jeff Toghraie, Chief Executive Officer, certify as follows:

 

  A) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m or 78o(d)), and

 

  B) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods covered by the Report.

 

This statement is authorized to be attached as an exhibit to the Report so that this statement will accompany the Report at such time as the Report is filed with the Securities and Exchange Commission, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. Pursuant to Securities and Exchange Commission Release 33-8238, dated June 5, 2003, this certification is being furnished and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any registration statement of the Company filed under the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. 

 

Date: August 21, 2023 By: /s/ Jeff Toghraie
  Name: Jeff Toghraie
  Title: Chief Executive Officer (principal executive officer)

 

 EX-32.2 8 rviv-20230531_10kex32z2.htm EXHIBIT 32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Reviv3 Procare Company (the “Company”) for the year ended May 31, 2023 (the “Report”), I, Monica Diaz Brickell, Chief Financial Officer, certify as follows:

 

A)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m or 78o(d)), and

 

B)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods covered by the Report.

 

This statement is authorized to be attached as an exhibit to the Report so that this statement will accompany the Report at such time as the Report is filed with the Securities and Exchange Commission, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. Pursuant to Securities and Exchange Commission Release 33-8238, dated June 5, 2003, this certification is being furnished and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any registration statement of the Company filed under the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: August 21, 2023 By: /s/ Monica Diaz Brickell
  Name: Monica Diaz Brickell
  Title: Chief Financial Officer (principal accounting officer
and principal financial officer)

 

 

 GRAPHIC 9 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X 02D9)1@ ! @ 9 !D #_[ 11'5C:WD 0 $ 9 _^X #D%D M;V)E &3 ?_; (0 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$" M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# M P,# P,# P,#_\ $0@ ,@&0 P$1 (1 0,1 ?_$ ,4 (" @(# 0 M (!PD&"@0% 0,+ @$ @(# 0$! 4&!P,$" (!"1 M < 0,"!0("!0@'"0 0(#! 4&!P@ $1(3"2$6UE>7%!4B%S%!.'@*43(D M-#4WMYAA<8%B(U,VT8(S8V0E9;88$0 " 0,$ ,$!P,)!08' ! @,1! 4 M(1(&,2(309,4!U$RTB-3TU1A<15"4F(SLW06-@B!D324-:&QLB1UEO#QHD-S M1!?_V@ , P$ A$#$0 _ ,8T7@9Q5<:+H3I_[[6(5=\[OER>/*RM$6 R]==/ M+').7$&N92YE.9>*55% XB =S$'^@/AU^DW7>SYQL':F7Y>7-PWHK21'M65P M I!"IXBFQ6H\"2:D\LS=0ZU+*TH[-:$,Q/U6WJ2?9+3_=0?0 -M)SRRXWXU M@6-R>C8_[N6>\G[LRFH&-:9-1&LS&6&28RKXC60ET':EEDTR-X1N85U0,E_$ M0.W@R1BGBP2K'Z/^\Z1YWKF&Q>,DO;'. MV]W$P/+'DSIU=QW#7>BZ!HEH54)%0$5-."=D M4"@=W(2+]RNBPB8IBD/FNY<*)HI%^)C!U/.UI\N>F8>7-YZTLHK2)&:GIKR> ME/*@I5C4C8?3J%XV#+9>\6QQZRRW3^"K4F@\3X^ ]I.P]NK*9'B=@V&R"U7Y M>>[K U#2V+9).>S?CQ2KYR%<52964%)6'G;A"O8FL_KH=5)0KPB)E (8H 4P M]P$:3Q';E'-<\'4'DK<6B'E>@\K/RWIMYA-])]JY3E)'6);V_?=9S7DE:X1B MM(-LGN:-HQS3)-)NB550B4-+R,H=(#=Q[+J))MB_ #J%^(]12Y^;B=2OX[+O MW319VB>2:41I)YR#0AU"1\*E:E5)H#0%MM/<7T6+L%H'Z_F8;F\ !97CFMC0 M_5XH[2/7V$$['Q.JE>6N5\O>%>JNL1WRTS=>T5M4:W<7,7#W?]_;M(RU,UG< M))?1XAV MC0GG&652:;5-* D4)U"\WB,UUO()C\M5+AE5N(?EY3X5*L1O]%:Z^H5PB>.I M#AMQ5?/G"SMZ\X\8ZY=NG!Q47 MRW\,*A8EO)@ -@ )&H!^P:[(ZP2>N6!.Y^#A_P# NFAZ0Z>Z0R)Y&[KNUGU& M/XOT'-AH>47N>RY_J6PV2PM(VZ7ZIBDWMK&CUJGQ;Y\YK]9F#FCG$BZ=( J[ M25!%)0J8B::18CK6-M[:3L-Q"@C,,+LGJS$K&[J5#+&$JY"DL"].)9"H\:CM.-/)W5M(UO7./F^ MX62.9V[/9=2'A9(L:RD*V=N[;/$2NFCDX) M*!W#N/SL/6\7C\/9Y_"7IN\;=RRQ\718IHGB$;,LB"23V2"C \6I4?LQ83L5 M[?YB[P64M/AKZU"N&63U8I(W)"LK%48-MYE*[5H&)#4ESE7O\'Q0MUI5*#*ITZ*1;)+NG$K:K&Y;,6Z:1#G,HN'8/ATGZYA MI>P9NVQ$7(>M( Q KP0;NY_8B L2=@!4Z9]@S$.!Q$^4G.T2;"E>3'95 !!- M6('B-MZ@:X?$3D57^67&G&N0];21:,M1H\187T4BMZP05@,C^ELU?,<3&5\H M2?;.6P>IV4$J8"8 $>W7SL6(; 9VZPSMR:VF9*_2!N*_MH17]NO6!RT6=P]O MEX*".XB#@ D@5]E2%.W[0-*!SDYO<@^*FV\9\SI&(9CHU9Y4:7$9!2+//:?/ MU:6K=U71.^F'-I@6M)EVZM>;1?99%5H[.N MWD%Y86KS".."-U8!6*^=IE/BM&7@-CLWCJ-=G[3E\!E+*TBM8);2]G])6,K* MP8\ .0],\15CX&ITA-:(2HL,13[X\5(+3*S -L?:0 M?!:;PO+9_L%GV*VPMC9VTD%QR8.\S(>"J2QH(VH5(\-^0(H?&F?8_P \+Z'* M*+X:PE V'/=+PT6!/9NIY+^(8N'TUG62(PS0O(>"\DY.*,X)6C4XTW)K3- M9]DOAGA@,U:K;32QEX9%D]1)>-"RBJ(05!WKO7P&X.HAG., MN#665Q.W,[Y/[C:*S"3>>6"=3KL4!HY+.9>18V1.5.*3AOV41+Z9C%5,4 M2B+G$]1^7<_58.T9K)9*VA>]:WD1+>.4J?2:1>)YK7=0"2-P:@ U 5R=OS)[ M4W4K:SMWR"VIGY&9U01AE6I)AW-7446M"?'8Z8?+]SYMRFNV+(MDXZY#0W#C M&YS0\ZNU/U:T7BFRUIB;%#P)*E;7*U#@7]?*J66!QZB2+A4Z1#"F0WB8 C78 M,/TJ.R:_ZK?7D]O'=1Q,+B)(WXLCL9557(*DK102"*'E2HHXMLQGSDGQE]8Q MH_PS2QNDI:-V4J/3+&,%3YMR0?I (WTL7&_GGSFY15[D/)YSQ?P!&P\<]MM6 M&3M,G=VMC!_;+)3TX]S)/*[,AFJL(S8/6L@46QGBB0^7P/XAW$)+V+I?0>O9 M+&P7.3R0QUY:)-))\+$Q3D2-E$X/$4]@9@*T#';2G#=J['F[>[>VQT"W-K,T M1C:X(8NH!H#Z)7VTJ6 _;3?3G<'N:=9YI9Y<9]O2++D^F9-H4_DNUX_<5&KF MPYQH5=4*+J+4DF( PFHJ09JIN63U("%<('\O O\ 7#>X]1GZE?1Q":.ZQES$ M);>XCV66,@;TJ2K"M&4[J=CO4![UGLD/8K:4F)H,A;RF.:)M^#CZ&H ZD;AA M^W;1?^72JVX2?&#CS1T]FV^KP499M-.[L"57S'%(*>!7Y=6TNWD9R[XMAL ) MBJQA(UD\D5VY164*@CXJ#CM.LA<,.P9N5[3&2$K!2,O)<.I'(1K55"H#5G=U M'\E>35 +KL#-E/X-AXA=7ZBLIYA8H![!*P#L'.W% A)&YH!K"--VOG3AD-(Z M'9^/&6;CG4"4\E:8/!+Q9VNO0]=;I"O)RL!5+S MH:].(M AC_HF[]H\<@'9 M)/R^'3&PQ72,OPL;:]O;7*NBA6GCC-NTOM4NC\T4[!6*MO\ 6IK U]VRR!N+ MRTM;BV7ZRV\C^K2GBJR*JMN#Y>0)J*5(W9[CAOE(Y18CGF^YPE-(4C3(922@J5!\Q"A!OO8Y@_I,% MYA9%*+7DM:%"R^4BM2H-@'4!U+-'1HT@K;EMH&Y7BYTSAQGE9T2L9I8GU,O^ M^Z+8W];Q]M>8HWIS=)H98.,EK#IVK9 MB9=0K=K)73,;,QC+2K5W#I0I#R,6XD :"8HKI$*/F#7$=2P?:IKBTZ[?M%E M1\/;72!6N!M54FC)C$@]BN$##P8G;2[(]ES/78XKC/6D;V3L5>6V9W]*BU4L MC(#1F'$'E05%:4J9PU3EG 5.SY_E685:4V/=-4JPWJG9O"ND(5"*H1#-2+Z) MI5ED4U&=!I""SLB!'"Z2SIX['].U;KK=RA&\7@S>127U]*+7$PDJTK"O)Z5$ M42U'J2MX\00 M69E45T^R&;BL[F''P1O/DYU+)&HH HV+R/]5$!(J35CX*K' M;40:?LON%X]".M!<<9,7W.H0R"C^S4+%M5M##76<2W16M90W,4=&9896]3CXMQ5HZ.4'])2]*@"M!F%*YE1_)?B M-*\EN%S"NZI.MHB35P;Y?!JLLR*28I&*,K**LC\5 H0=MZ&NN)[AW^KOC,YB!4?BW:'=MSI&2K$U>+\3X>!!\0&!&CJG9(NT8H9%$]*4.4=*EN+"A'F MXK6JE6\-JT.^I>Y?\G*-PWXV:[R3T0X'KF65&0G@C"N"-G5BFO$&M=J\>H<# M!^XV.;70:(_ W8ZO?MV >E_7,#>]GS=M@L<*W=S*$&Q-*^+$#>BBI/[!K>SV M8AP.*ERDXY",>5:TYN315!H:)V&EAF>7/)B']O(O- ^(Y.O=V66.- MTF MGWE_9:'5G&%;9GG(['\\W/*9D)_/-.K$?:ZO)BD9NLHP?D'S M;/6I^YVDC'.DU&[E$W<4G"1R#W[=^JYS&)OL%DYL3DD,=[ Y5@01^XBH!HPH MRFFX(.I_C7&$U:/_;5 M^-ELAXBO2JYW0'TNJKE>0TW>H=-9!-NK7&-ZBGD8W<(**I. 1!0!_B[=2/L? M2W6430=';I*"0"@81'I7UO&XK+WPQ^1N9+:67R M0L(^:F5MD#T8,%+4!(4^-:BF[3L63O,-B9@.;H7*'TUW=E(1ZLJ[@ M$ $ [C7:\3>56.\T,*I'(/#K$E/TBZ, 4%$XIIS%:G&WBE-52RL2G.>,L,"] M\D7")OZP Y1,0Q3#@[!@(Y39(ZW MU7*=(RF?DN[R+L&.$)] 11/$ZS.(E<.9$?CZA ?RU0.M!)0G2G(YS)V78;3# M16\+P7@D*R&5E(])0S\E$3"M#Y:,>5-RNHZLG.S=K-DH_24D/$PM%GGZ#JG6L MAT6X[-BY[^3,V;@3P&.+A&C^59.8 M.UN6\LYG;B0>5% ,5#*S+Q$99:D[$BE9EY7\D.0>.ZWQUS'$:5V\-2E.80"0@O05(%!7VT%30?0*G]^E.YN[EJ M/&CCCI.^9A1:?I"^35B9O-HJ-LL\G4CR=6@&*K^4" E8^%G$AFD4$C'31<)D M25 HE\RF$.\GZ=B\/G.P6V&S#W4<-U.D2M;HDC\Y&X*.#LH-6*BO+;?8^Q-V M#(7^*QLN1L88Y_11G=6D,?E45)4\6!( )H:>&QKMI(V7N$\MH7C)FW,^T\0* M?>./MRS. UNX-<4V-Y.:YFE'F8E&>=3+JEVRDUZ(N(P<2MZKQO'R9%D@3.(> M7B/4ZO?E]U9>R9#I\.3NK7LEM=&&%+N!!%,P8)Z?JQ2N5D=C6,F/@00M>1U% M(NV]D_@T789,9%)BWC$C>E<,94CW)-W;R%&'LJ/:*TJ"-P:;@C4\LKR#(6<5];$FWFC5U)%#Q85%1[- M0=SNY8QG"KC#I&_NJ^O=)JK1Z2--H3(5_P!RO-L?*@G&5R/3:)K.SJK)E564 M%,AC)H(G/V[%'IEU3KTO:,Y#B40BC'B["HV&P\?$C2SLF;CP&*> M_(#W!(2)#7SRMLJ^4$_230> .IIPK6ZYO6,Y?M%1<).:YJ%&K=UBE$5 53(A M/1;=\=MYE,8!.S75.B?X]P.00'X]+P_LJ-QOL=; MF(R,&7Q=OE+5@T$\2N" 0#4?0=QO].I7Z7:8Z^<_JUY_P];?4]-;V_'>?#RV M-]#NJ-H=L+M6BL'5B3LDD69<,2FLR1P9*R *&2 2E$$Q#N #U^F/6<5_J+N< M!:387-X"/&&%0BFR(*@"E&\N[ ^+;AC4@FNN5OC?E&X#C'Y,*=P.2>'LI1S0 M?1[:>.^DPY7VSV=I;')-CPQS/EI6=T/-0)XB8UZT0DG2D8!-\0UC1=LV,Y(+ MJ/5X[N5N()_PJ=A$0#JP>JXSY\VN9B?MV4PMW@N8]58K=HI>._U&I2I-/'Z- MB-).PW'RZDQ4BX*UOXLG5>#2,I3Q'*M&)^K6G[=6"^W=39K'?9)]RKE[DB#Q MKNUEGHW&/G.)7 )^CY$P6J"=P5@5FR*K^(7>M;8^5=*D,F<4R)*>0 B4>J,^ M:.5L.U?/W%]0[%/-#UJT!8H061YE#%=M@58JIW#4/)?;IMUJPR.(Z#?]GQ2< M\M))'$CHOGBMRZ&=BS%:!ALQ0FBJI()!UK5E .W] _Q=^_<3"8?(3"(]Q, M8PCW$1^(B/?KMJ&**WA6W@4) @ 51L !X4_^-]5 Q9F);ZVLWS;2+UCU^J>I M9C9Y:F:!1IAI/5:T0;I1E)QZ:R1_))9(YB'*)1$.DG9 M.M8CM6*EQ.8A26WD0KN!R%?H)&V_L\#[1K/:W4UI,LT+%75@10D4(\#M[1[" M-]6A^\=RRS_G#?N,O)2J3,,YNUPXK56 VRKQWB#ZE:E3YR:8349+)%;("B63 M%V9VR#R4#]$HF &^'7/'R5ZYV'IF%[+U/)0SQX>W>=[=G4\2'3P62I5BJ_7" M@;^K_Y;L/[G#_9KIJNH]I[K7OO^#>ZM MP-V'6KSP+99ERJXS[)I=FV.;XZ:=,)U.\9S;[<[&1M;.@V5R]8(/8:8>&,NF M0SD#$5_I1.8?(UU6.4^7';<';V':FFQW8+.WC@CN(QR295#GE-1&J5;@!45X M$J&'$:JF\LNX]/DO+OK4$-[A7=I5MM_55G*\A&M5%!YCQ#&HWXEB:NMP&]P6 M)Y@6C2,UT[ ;OQ>Y;XQ%1 :?D6C1Z!Y4*O+NEBQMBI]I(V;C9*8YE2' !* $ M26.40%0#@H,)[1T^;KMI:Y.VNH+W!WO+TI8CXL@4LKI4F-EY4HQKLP(!! E/ M7.QVV6=S5A-G(K*6WN;NUL297]"%Y@MQQ^[1R@HK*A9@IJ"SKRX\=0#[/\ M%/H M/)7FAP;K:%WCL7Z'@9\D?4KTZ$$C% M:IM?2<@!.W80Z9?,_%37>(Q_9^=DTL4,=G<^A<17),RJ2KF6"L9#(#4%VD4_ M6J*'2GY?W]M99*\ZVL!_\ 4U_[TU>%U4.K2UKX J=FNA.+O)$K2'NL_(5B!68'?Q19%968BXF<>(ND$/XDB V.5 M0WP$0_IZO3Y>I8/\J.W"_DDCCY6/U$#&GJU!W9:^:@IML2:[4U7?96R8[CB? MX4L+7/HSU]4L%"T\Q\HJ2!4@;5.VN3J^NZOEGN&<7=@]PK$J_2\R:.K%B?%K M5,1MBU]H%9U3:6S&.DQW+]_BX&SP\A,-8Q..AEFK0&!%#J&/YJ"7QU;#$8G* M](O<3TJY:?)GA$R3>4^L'^]Y4"E"HXJ1[34CB7&][31??7V-[C.();K(N_;XSEI M-0*ND0>:&A(\FKJN4)-*6GXZ5:O?6>$!'].1(#]U//R $!R8?'8&_\ E%QS M5_\ <B\PC$E3%)/Z"K% M6!RRN4D'+U0BA>._,G;2=O5CD1"00"](W\Y]/>M 20*J"=M M6C>UM1:+_(^_,Q\+2BL; MRY2SBE8+ZKJS(I) !8)5@-R:@&E/#VB=9F^NL;8->6EN;J1-R@=(_+0EFY/Y M:*!OJ$?;]VJH\B.*V=;)G>-+X1G=\4L4]1Z"Z=P;AR2%?V"1=.9Y=K7@_;8E M6?GUGK@6H"8Y/+S-V$_B7>[;8S8WL-S97%XM]<1N TPY^8@#;S@-5113X@$4 M4D $K>HY*++81+ZWM?@[9W?@G)6!'(U8<: !GY;4_;X$:BKF*^;\D]*9^VV! M8^.K^UX3>=*VVVO$6CZ6A+E43BVS0ZQ4 MSJBGXONK6O\ !,1)\P)5,CVEY'#;H" #,R,YDDH>7IQJ "!3D\BK4"NM3/S- MD\G%U-#%\-R R?M^$')NV'695[D+0HX/0@:+=)J ):H(_CK1*N]O(U0\B^T(_$M1P!7FZL4!"H\)V"ZZ[DX^E M]E!%5 M+LU$2.[;K?>2=*V#(*=F)./&A MQ^5?N]6NDA;FE_LBU=C+<]G84KV'AEHJMHP5@8%(FX*=R+E14AA#TQ[P[L_7 M\5A+*SNK&>:$/)D"R ,Q]7FC>%%XT(K4'4NQ.5OLA>7-K:MXL>:<0.3^@U!04;33,%U6R5Y8.WDC, M1%*F7D>L41^ '2R6%C<-P@ENXE9OH!< G7CMUU=6/5\ MA>62EKN.SE9 "%)8(:48[ _M]FEQ]GF*K\5[9O#OY;%-5I*Y%&6!^^!$$EY2 MP3S^1E+%)OC>)3N'[N9(H M?'_=X:T/E^J+TW'A*4,%?WGD:DGQ)^DFI/TZL)MU3K=\JUBI-QAF-BJ=MA9. MN62!DT0<1TQ"3#-5A)QKU WP4;/&BYR&#X#V'X=AZB5O<36EPEU;MQGC=64_ M0RD$'_80#J57-O%=V\EK.*PRHR,*D55@014;C8^(U3S[=SV&FN?ONL!*D*G= M,PT+!\8IL8Y,N=Q5<)K&5M7]/@H?U^_IP3V8?.GI@*8WFNIY&_J[VAW474?2 M.NN%].SNH[F=P&H);@S%3,8R:JW"B!@ I"D+X'5<=,X/VO.O._.\26*- S*S MK"BD G^T99:LOQGD%,5Y MFD9."BM+LM:F&]FE4$2^2#1]8B-%W2Y4RD]3X#XCX!U;/8I3E^A=>ED59
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end EX-101.SCH 10 rviv-20230531.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Accounts Receivable, net link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventory, net link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equipment Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Concentrations link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Business Segment and Geographic Area Information link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accounts Receivable, net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Inventory, net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Equipment Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Concentrations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Business Segment and Geographic Area Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Accounts Receivable, net (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Accounts Receivable, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Inventory, net (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Inventory, net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Equipment Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Notes Payable (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Commitments and Contingencies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Asset Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Asset Purchase Agreement (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Business Combination (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Concentrations (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Concentrations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Business Segment and Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - Business Segment and Geographic Area Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - Income taxes (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 rviv-20230531_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 rviv-20230531_def.xml XBRL DEFINITION FILE EX-101.LAB 13 rviv-20230531_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Business Acquisition [Axis] Axil [Member] Customer [Axis] Customer [Member] Antidilutive Securities [Axis] Options [Member] Long-Lived Tangible Asset [Axis] Furniture and Fixtures [Member] Computer Equipment [Member] Statistical Measurement [Axis] Minimum [Member] Property, Plant and Equipment [Member] Maximum [Member] Automobiles [Member] Finite-Lived Intangible Assets by Major Class [Axis] Licensing Rights [Member] Customer Relationships [Member] Trade Names [Member] Website [Member] Long-Term Debt, Type [Axis] Economic Injury Disaster Loan Program [Member] Underlying Asset Class [Axis] Insurance Financing [Member] Second Draw Paycheck Protection Program [Member] Financing Charges [Member] Class of Stock [Axis] Non Voting Series A Preferred Stock [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Assets Purchase Agreement [Member] Transaction Type [Axis] Several Private Placement Agreements [Member] Balance Sheet Location [Axis] Accounts Payable [Member] Counterparty Name [Axis] Intrepid [Member] Related Party, Type [Axis] Weston T. Harris [Member] Investment, Name [Axis] Jeff Toghraie [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] Geographic Concentration Risk [Member] Geographical [Axis] Outside The United States [Member] CANADA ITALY Product Concentration Risk [Member] Product and Service [Axis] Hair Shampoo [Member] Shampoo And Conditioner [Member] Bundled Kits [Member] Hair Shampoo And Conditioner [Member] Introductorykit [Member] Accounts Receivable [Member] Customer Four [Member] Purchases [Member] Vendors [Member] Vendors One [Member] Vendors Two [Member] Vendors Three [Member] Vendor [Member] Ear Buds [Member] Shampoos and Conditioners [Member] Ancillary Products [Member] Product [Member] Ghost Stryke [Member] Trackr Headmuff [Member] Other Bluetooth And Ear Buds [Member] Accessories Other [Member] Segments [Axis] Hair Care And Skin Care [Member] Hearing Enhancement And Protection [Member] Customers [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract]  ASSETS  CURRENT ASSETS:  Cash  Accounts receivable, net  Inventory, net  Prepaid expenses and other current assets  Total Current Assets  OTHER ASSETS:  Property and equipment, net  Intangible assets, net  Right of use asset  Other assets  Goodwill  Total Other Assets  TOTAL ASSETS  LIABILITIES AND STOCKHOLDERS’ EQUITY  CURRENT LIABILITIES:  Accounts payable  Customer deposits  Equipment payable, current  Contract liabilities, current  Notes payable  Due to related party  Lease Liability, current  Income Tax Liability  Other current liabilities  Total Current Liabilities  LONG TERM LIABILITIES:  Equipment payable  Lease liability, long term  Contract liabilities, long term  Total Long Term Liabilities  Total Liabilities  Commitments and contingencies (see Note 11)  STOCKHOLDERS’ EQUITY: Preferred stock, $0.0001 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of May 31, 2023 and May 31, 2022, respectively Common stock, $0.0001 par value: 450,000,000 shares authorized; 117,076,949 and 41,945,881 shares issued, and outstanding as of May 31, 2023 and May 31, 2022, respectively Additional paid-in capital Accumulated deficit  Total Stockholders’ Equity  TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract]  Sales  Cost of sales  Gross profit  OPERATING EXPENSES:  Marketing and selling expenses  Compensation and related taxes  Professional and consulting expenses  General and administrative  Total Operating Expenses  INCOME (LOSS) FROM OPERATIONS OTHER INCOME (EXPENSE):  Gain on debt settlement  Other income  Interest income  Interest expense and other finance charges Other Income (Expense), Net  INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES  Provision for income taxes  NET INCOME (LOSS) NET INCOME (LOSS) PER COMMON SHARE:  Basic  Diluted WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:  Basic  Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, Shares Shares issued for acquisition of business Shares issued for acquisition of business, Shares Stock options expense Shares issued for cash Shares issued for cash, Shares Net income Ending balance, value Ending balance, Shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      Depreciation and amortization      Bad debts      Inventory obsolescence      Stock based compensation      Gain on debt forgiveness      Non cash lease expense Change in operating assets and liabilities: Accounts receivable Inventory Prepaid expenses and other current assets Deposits Accounts payable and accrued expenses Other current liabilities Customer deposits   Contract liabilities NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Cash acquired on business acquisition Purchase of property and equipment NET CASH PROVIDED BY INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Cash raised for common stock to be issued Proceeds from loan payable Repayment of equipment financing Repayment of note payable Advances (payments) from a related party NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE (DECREASE) IN CASH CASH - Beginning of year CASH - End of year SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid during the period for: Interest Income taxes SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Stock issued for business combination Right of use assets recognized as lease liability Tangible assets (excluding cash) acquired in business combination Intangible assets acquired in business combination Goodwill acquired in business combination Liabilities assumed in business combination Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Credit Loss [Abstract] Accounts Receivable, net Inventory Disclosure [Abstract] Inventory, net Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Other Current Liabilities Equipment Payable Equipment Payable Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Stockholders’ Equity Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Business Combination and Asset Acquisition [Abstract] Business Combination Risks and Uncertainties [Abstract] Concentrations Segment Reporting [Abstract] Business Segment and Geographic Area Information Income Tax Disclosure [Abstract] Income Taxes Basis of Presentation and Principles of Consolidation Liquidity and Capital Resources Use of estimates Cash and cash equivalents Accounts receivable and allowance for doubtful accounts Prepaid expenses and other current assets Inventory Property and Equipment Revenue recognition Cost of Sales Shipping and Handling Costs Marketing, selling and advertising Customer Deposits Fair value measurements and fair value of financial instruments Business Combinations Goodwill Income Taxes Impairment of long-lived assets Stock-based compensation Net income (loss) per share of common stock Lease Accounting Segment Reporting Reclassifications Recently Issued Accounting Pronouncements Schedule of net loss per share Schedule of accounts receivable Schedule of Inventory Schedule of Property and Equipment Schedule of intangible assets Schedule of other current liabilities Schedule of loan payment due Schedule of notes payable Schedule of notes payments due in the next five years Schedule of stock option assumptions Schedule of summarizes relating to the Company’s stock Schedule of Supplemental balance sheet information Schedule of maturities of operating lease liabilities Schedule of estimated fair value of the assets acquired Schedule of proforma information Schedule of Sales by Product Line Schedule of sales by product comprised Schedule of segment information Schedule of effective statutory rate and the provision for income Schedule of deferred tax asset Weighted average basic shares Dilutive securities: Convertible preferred stock Stock options Weighted average dilutive shares Earnings (loss) per share: Basic Diluted Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Retained Earnings (Accumulated Deficit) Contract liabilities Contract Liabilities Description Revenue recognition Selling and marketing expense Impairment loss Antidilutive shares Customers Receivable Merchant Processor Receivable Less: Allowance for doubtful debts Accounts receivable, net  Bad debt expense Finished Goods Raw Materials Inventory, net Inventory held at third party location Inventory in-transit Inventory valuation reserves Inventory, non-current Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Plant Equipment Less:Accumulated Depreciation Property and equipment, net Depreciation Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible Assets useful life Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Goodwill Amortization expense Credit Cards Accrued Interest Royalty Payment Accrual Sales Tax Payable and Other Accrued Expenses Affiliate Accrual Other Current Liabilities  2024 Equipment Payable, Net Schedule of Guarantor Obligations [Table] Guarantor Obligations [Line Items] Total Less: Current portion Non-current portion 2024 Total Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Face Amount Interest rate Additional borrowings Loan forgiveness Accrued interest Insurance financing Finance charges Notes Payable Risk free interest rate Expected life Expected volatility Expected dividend Number of option outstanding, beginning Weighted average exercise price, beginning Number of option outstanding, granted Weighted average exercise price, granted Weighted average remaining term, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Number of option outstanding, ending Weighted average exercise price, ending Weighted average remaining term, ending Number of option outstanding, forfeited Weighted average exercise price, forfeited Weighted average remaining term, forfeited Unvested number of option Unvested weighted average exercise price Unvested weighted average remaining term Vested number of option Vested weighted average exercise price Vested weighted average remaining term Schedule of Stock by Class [Table] Class of Stock [Line Items] Common stock, par or stated value per share Preferred stock, par or stated value per share Shares issued during the period Shares issued value during the period Number of common stock sold Share price Value of common stock sold Number of option issued Exercise price Shares vested Shares forfeited Aggregate grant date fair value Share-Based Payment Arrangement, Noncash Expense Assets Right of use assets Accumulated reduction Operating lease assets, net Liabilities Lease Liability Accumulated reduction Total lease liability, net Current portion Non-current portion 2024 2025 Total Less: Imputed interest Present value of lease liabilities Loss Contingencies [Table] Loss Contingencies [Line Items] Lessee, Operating Lease, Description Monthly base rent Initial lease liability Initial right of use asset Lease expense Lease liability Right of use asset Discount rate Claim amount Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Payable to related party Consulting fee Compensation paid for services Commissions and contractor fee Bonus for services paid Cash Accounts receivable Inventory Prepaid expenses Other assets Accounts payable Contract liabilities Other current liabilities Net tangible assets acquired Identifiable intangible assets Licensing rights Customer relationships Tradenames Website Total Identifiable intangible assets Consideration paid Total net assets acquired Goodwill purchased Revenue Net income (loss) Earnings (loss) per common share Basic Diluted Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Equity Method Investment, Ownership Percentage Shares consideration Acquisition Costs, Period Cost Acquisition price per share Concentration Risk [Table] Concentration Risk [Line Items] Total Cash, FDIC insured amount Cash, uninsured amount Concentration risk, percentage Purchased inventories and products Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Total net sales Total segment gross profit Selling and Marketing General and Administrative Consolidated operating income (loss) Consolidated total assets Consolidated total payments for property and equipment Consolidated total depreciation and amortization Schedule of Revenue by Major Customers, by Reporting Segments [Table] Revenue, Major Customer [Line Items] Concentration Risk, Percentage Tax expense (benefit) computed at statutory rate of 21% State tax expense (benefit) blended rate Change in federal tax rate estimate for prior years Non-deductible expenses: Stock-based compensation Non deductible expense: Other Non taxable: COVID related grants/loan forgiveness Benefit of tax amortization of intangibles Deferred tax true up Net operating loss benefit Tax expense (benefit) Increase (decrease) in valuation allowance Change in deferred tax asset Net income tax (benefit)/expense Net operating loss carryover Less: valuation allowance Net deferred tax asset Net Operating Loss Carryforward Deferred tax assets Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities [Default Label] Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Deposit Assets Net Cash Provided by (Used in) Operating Activities CashAcquiredOnBusinessAcquisition Net Cash Provided by (Used in) Investing Activities Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents EquipmentFinancingPayableTextBlock Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] RevenueRecognition Accounts Receivable, Allowance for Credit Loss Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization Other Liabilities Long-Term Debt Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares AccumulatedReduction OperatingLeaseLiabilityCurrentPortion Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Basic Earnings Per Share, Pro Forma Diluted Earnings Per Share Pro Forma Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount Deferred Tax Assets, Valuation Allowance EX-101.PRE 14 rviv-20230531_pre.xml XBRL PRESENTATION FILE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - USD ($)
 12 Months Ended
May 31, 2023
Aug. 09, 2023
Nov. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date May 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --05-31    
Entity File Number 000-56351    
Entity Registrant Name REVIV3 PROCARE COMPANY    
Entity Central Index Key 0001718500    
Entity Tax Identification Number 47-4125218    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 901 S Fremont Avenue    
Entity Address, Address Line Two Unit 158    
Entity Address, City or Town Alhambra    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91803    
City Area Code (888)    
Local Phone Number 638-8883    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 5,037,204
Entity Common Stock, Shares Outstanding   117,076,949  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 106    
Auditor Name SALBERG & COMPANY, P.A.    
Auditor Location Boca Raton, Florida    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEETS - USD ($)
May 31, 2023
May 31, 2022
 CURRENT ASSETS:    
 Cash $ 4,832,682 $ 373,731
 Accounts receivable, net 417,016 105,921
 Inventory, net 1,311,864 323,388
 Prepaid expenses and other current assets 801,360
 Total Current Assets 7,362,922 803,040
 OTHER ASSETS:    
 Property and equipment, net 157,463 29,145
 Intangible assets, net 382,674
 Right of use asset 101,845 45,453
 Other assets 12,195 16,277
 Goodwill 2,152,215
 Total Other Assets 2,806,392 90,875
 TOTAL ASSETS 10,169,314 893,915
 CURRENT LIABILITIES:    
 Accounts payable 908,606 458,263
 Customer deposits 183,688 16,522
 Equipment payable, current 2,200 3,300
 Contract liabilities, current 827,106
 Notes payable 172,588 156,300
 Due to related party 158,072 25,452
 Lease Liability, current 65,824 47,166
 Income Tax Liability 230,913
 Other current liabilities 305,664
 Total Current Liabilities 2,854,661 707,003
 LONG TERM LIABILITIES:    
 Equipment payable 2,200
 Lease liability, long term 36,752
 Contract liabilities, long term 605,942
 Total Long Term Liabilities 642,694 2,200
 Total Liabilities 3,497,355 709,203
 Commitments and contingencies (see Note 11)
 STOCKHOLDERS’ EQUITY:    
Preferred stock, $0.0001 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of May 31, 2023 and May 31, 2022, respectively 25,000
Common stock, $0.0001 par value: 450,000,000 shares authorized; 117,076,949 and 41,945,881 shares issued, and outstanding as of May 31, 2023 and May 31, 2022, respectively 11,708 4,195
Additional paid-in capital 10,102,243 5,472,084
Accumulated deficit (3,466,992) (5,291,567)
 Total Stockholders’ Equity 6,671,959 184,712
 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 10,169,314 $ 893,915
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
May 31, 2023
Jun. 13, 2022
May 31, 2022
Statement of Financial Position [Abstract]      
Preferred stock, par value $ 0.0001 $ 0.0001 $ 0.0001
Preferred stock, shares authorized 300,000,000 300,000,000 300,000,000
Preferred stock, shares issued 250,000,000   0
Preferred stock, shares outstanding 250,000,000   0
Common stock, par value $ 0.0001   $ 0.0001
Common stock, shares authorized 450,000,000 450,000,000 450,000,000
Common stock, shares issued 117,076,949   41,945,881
Common stock, shares outstanding 117,076,949   41,945,881
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Income Statement [Abstract]    
 Sales $ 23,521,027 $ 2,336,257
 Cost of sales 5,810,216 828,586
 Gross profit 17,710,811 1,507,671
 OPERATING EXPENSES:    
 Marketing and selling expenses 11,675,206 1,199,305
 Compensation and related taxes 1,347,839 15,129
 Professional and consulting expenses 1,420,990 232,774
 General and administrative 1,282,565 271,866
 Total Operating Expenses 15,726,600 1,719,074
 INCOME (LOSS) FROM OPERATIONS 1,984,211 (211,403)
OTHER INCOME (EXPENSE):    
 Gain on debt settlement 50,500 35,000
 Other income 16,829
 Interest income 6,469 36
 Interest expense and other finance charges (2,521) (6,536)
Other Income (Expense), Net 71,277 28,500
 INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES 2,055,488 (182,903)
 Provision for income taxes 230,913
 NET INCOME (LOSS) $ 1,824,575 $ (182,903)
NET INCOME (LOSS) PER COMMON SHARE:    
 Basic $ 0.02 $ (0.00)
 Diluted $ 0.01 $ (0.00)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
 Basic 112,895,411 41,945,881
 Diluted 357,385,274 41,945,881
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at May. 31, 2021 $ 4,195 $ 5,450,117 $ (5,108,664) $ 345,648
Beginning balance, Shares at May. 31, 2021 41,945,881      
Stock options expense 21,967 21,967
Net income (182,903) (182,903)
Ending balance, value at May. 31, 2022 $ 4,195 5,472,084 (5,291,567) 184,712
Ending balance, Shares at May. 31, 2022 41,945,881      
Shares issued for acquisition of business $ 25,000 $ 7,318 3,975,162 4,007,480
Shares issued for acquisition of business, Shares 250,000,000 73,183,893      
Stock options expense 207,342 207,342
Shares issued for cash $ 195 447,655 447,850
Shares issued for cash, Shares   1,947,175      
Net income 1,824,575 1,824,575
Ending balance, value at May. 31, 2023 $ 25,000 $ 11,708 $ 10,102,243 $ (3,466,992) $ 6,671,959
Ending balance, Shares at May. 31, 2023 250,000,000 117,076,949      
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ 1,824,575 $ (182,903)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
     Depreciation and amortization 95,179 7,871
     Bad debts 76,969 6,941
     Inventory obsolescence 71,481
     Stock based compensation 207,342 21,967
     Gain on debt forgiveness (50,500) (35,000)
     Non cash lease expense (1,713)
Change in operating assets and liabilities:    
Accounts receivable (160,277) (21,985)
Inventory 353,985 95,983
Prepaid expenses and other current assets (661,115) 2,430
Deposits (3,810)
Accounts payable and accrued expenses 215,175 (701)
Other current liabilities 630,897
Customer deposits (90,426)
  Contract liabilities 389,716
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 2,918,136 (126,055)
CASH FLOWS FROM INVESTING ACTIVITIES    
Cash acquired on business acquisition 1,066,414
Purchase of property and equipment (65,650)
NET CASH PROVIDED BY INVESTING ACTIVITIES 1,000,764
CASH FLOWS FROM FINANCING ACTIVITIES    
Cash raised for common stock to be issued 447,850
Proceeds from loan payable 35,000
Repayment of equipment financing (3,300) (3,300)
Repayment of note payable (37,119)
Advances (payments) from a related party 132,620 (28,851)
NET CASH PROVIDED BY FINANCING ACTIVITIES 540,051 2,849
NET INCREASE (DECREASE) IN CASH 4,458,951 (123,206)
CASH - Beginning of year 373,731 496,937
CASH - End of year 4,832,682 373,731
Cash paid during the period for:    
Interest 2,521 500
Income taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Stock issued for business combination 4,007,480
Right of use assets recognized as lease liability 131,970
Tangible assets (excluding cash) acquired in business combination 1,740,729
Intangible assets acquired in business combination 456,945
Goodwill acquired in business combination 2,152,215
Liabilities assumed in business combination $ 1,408,823
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Organization
 12 Months Ended
May 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization

Note 1 – Organization

 

Reviv3 Procare Company (“Reviv3”) was incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC which was organized on July 31, 2013. The Company has moved its corporate headquarters to 901 Fremont Avenue, Unit 158, Alhambra, California 91803. Its phone number (888) 638-8883. In March 2022, the Company incorporated a subsidiary “Reviv3 Acquisition Corporation” and in June 2022, completed the asset acquisition of the Axil & Associated Brand Corp. business (“AXIL”). The Company is now engaged in the manufacturing, marketing, sale and distribution of high-tech hearing and audio innovations that provide cutting edge solutions for consumers, with varied applications across many industries; as well as professional quality hair and skin care products. These products lines are both sold throughout the United States, Canada, Europe and Asia.

 
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies
 12 Months Ended
May 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies

Note 2 – Basis of Presentation and Summary of Significant Accounting Policies

 

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements for the fiscal years ended May 31, 2023 and 2022 have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of the Company and its consolidated subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. 

  

Liquidity and Capital Resources

 

We are currently engaged in our product sales and development. Although we earned net income and had cash provided by operations in the fiscal year ended May 31, 2023, we had an accumulated deficit of $3,466,992 as of May 31, 2023 and have incurred operating losses and cash used in operations in the past. We currently expect to earn net income and positive cash flows from operations during the current fiscal year ending May 31, 2024. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL’s business, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying consolidated financial statements. Management is focused on growing the Company’s existing product, introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands, including those resulting from the purchase of AXIL’s assets in June 2022, may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying consolidated financial statements.

 

 

Use of estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, contract liability, allowance on sales returns, valuation of lease liabilities and related right of use assets, fair value of securities issued for business combinations, fair value of assets acquired and liabilities assumed in business combinations and the fair value of non-cash Common Stock issuances. 

 

Cash and cash equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

 

Accounts receivable and allowance for doubtful accounts

 

Accounts receivables comprise of receivables from customers and receivables from merchant processors. The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 

Prepaid expenses and other current assets

 

Prepaid expenses and other current assets consist primarily of cash prepayments to vendors for inventory and prepayments for trade shows and marketing events which will be utilized within a year, prepayments on credit cards and the right to recover assets (for the cost of goods sold) associated with the right of returns for products sold.

 

Inventory

 

The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations. The Company continuously evaluates the levels of inventory held and any inventory held above the expected level of sales in the next twelve months, is classified as non-current inventory.

 

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.

 

Revenue recognition

 

The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard (new guidance) has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.

 

The Company sells a variety of hair and skin care products and electronic hearing and enhancement products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues.

 

The five steps for revenue recognition are as follows:

 

Identify the contract with a customer. The Company generally considers completion of a sales order (which requires customer acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) or purchase orders from non-consumer customers as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving third party financier payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.

 

Identify the performance obligations in the contract. Product performance obligations include shipment of products and related accessories and service performance obligations include extended warranty coverage.

 

However, as the historical redemption rate under our warranty policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

 

Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 30-days and 60-days right of return that applies to AXIL and Reviv3 products, respectively. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.

 

Allocate the transaction price to the performance obligations in the contract. For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.

 

Recognize revenue when or as the Company satisfies a performance obligation. Revenue for products is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period.

 

As of May 31, 2023 and May 31, 2022, contract liabilities amounted to $1,433,048 and $0, respectively. Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3.

 

Revenue recognized, during the fiscal year ended May 31, 2023, that was included in the contract liability balance at the beginning of period (acquisition of AXIL) was $391,204.

  

Cost of Sales

 

The primary components of cost of sales include the cost of the product and shipping fees.

  

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $1,001,261 and $214,517 for the fiscal years ended May 31, 2023 and 2022, respectively.

 

Marketing, selling and advertising

 

Marketing, selling and advertising costs are expensed as incurred.

 

Customer Deposits

 

Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.

 

Fair value measurements and fair value of financial instruments

 

The Company adopted ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: 

 

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
   
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
   
Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

Business Combinations

 

For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets acquired and liabilities assumed of the acquired business, at their fair values.

 

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates.

 

Goodwill

 

Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur, or circumstances indicate the fair value of a reporting unit is below its carrying value.

 

The Company performs its annual goodwill impairment assessment on May 31st of each year or as impairment indicators dictate.

 

When evaluating the potential impairment of goodwill, management first assesses a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the quantitative impairment testing methodology primarily using the income approach (discounted cash flow method).

 

Under the quantitative method we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized is recognized as the amount by which the carrying amount exceeds the fair value.

 

When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. 

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

  

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying consolidated balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

 

Impairment of long-lived assets  

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not record any impairment loss during the fiscal years ended May 31, 2023 and 2022.

 

Stock-based compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

For non-employee stock option based awards, the Company follows ASU 2018-7, which substantially aligns share based compensation for employees and non-employees.

 

Net income (loss) per share of common stock

 

Basic net income (loss) per share is computed by dividing the net income or loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At May 31, 2022, the Company had 5,300,000 options outstanding which were potentially dilutive securities, however they were excluded from the computation since their impact would be antidilutive.

 

For the fiscal year ended May 31, 2023, certain stock options were excluded from the computation of diluted common shares outstanding as they would have an anti-dilutive impact on the Company’s net income. The following table presents a reconciliation of basic and diluted net income per common share: 

 

        
   For the Fiscal Year Ended    
   May 31, 2023  
        
Net income  $1,824,575   
        
Weighted average basic shares   112,895,411   
Dilutive securities:       
Convertible preferred stock   239,041,096   
Stock options   5,448,767   
Weighted average dilutive shares   357,385,274   
        
Earnings (loss) per share:       
Basic  $0.02   
Diluted  $0.01   

 

Lease Accounting

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02), which requires lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance (ASC Topic 840). Under the new guidance, codified as ASC Topic 842, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. The new guidance further requires that leases be classified at inception as either (a) operating leases or (b) finance leases. For operating leases, periodic expense generally is flat (straight-line) throughout the life of the lease. For finance leases, periodic expense declines over the life of the lease. The new standard, as amended, provides an option for entities to use the cumulative-effect transition method. As permitted, the Company adopted ASC Topic 842 effective June 1, 2019.

 

The Company renewed lease for its corporate headquarters commencing December 1, 2022, under lease agreements classified as an operating lease. Please see Note 11 – ‘Commitments and Contingencies’ under “Leases” below for more information about the Company’s leases.

 

Segment Reporting

 

The Company follows ASC Topic 280, Segment Reporting. The Company’s management reviews the Company’s consolidated financial results when making decisions about allocating resources and assessing the performance of the Company as a whole and has determined that the Company’s reportable segments are: (a) the sale of hearing protection and hearing enhancement products, and (b) the sale of hair care and skin care products. See Note 15 – “BUSINESS SEGMENT AND GEOGRAPHIC AREA INFORMATION” for more information about the Company’s reportable segments.

 


Reclassifications

 

Certain reclassifications have been made to the prior year’s data to conform with the current period’s presentation. Specifically, the accounts payable have been separated from the accrued expenses, to conform with the current period’s presentation.

 

Recently Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain convertible instruments. Among other things, under ASU 2020-06, the embedded conversion features no longer must be separated from the host contract for convertible instruments with conversion features not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. ASU 2020-06 also eliminates the use of the treasury stock method when calculating the impact of convertible instruments on diluted Earnings per Share. For the Company, the provisions of ASU 2020-06 are effective for its fiscal year beginning on June 1, 2024. Early adoption is permitted, subject to certain limitations. The Company is evaluating the potential impact of adoption on its financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities (e.g. deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “Revenue from Contracts with Customers”. Generally, this new guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically, such amounts were recognized by the acquirer at fair value in purchase accounting. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company opted to adopt this ASU as of June 1, 2022. The adoption of the guidance did not have a material impact on the accompanying consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Accounts Receivable, net
 12 Months Ended
May 31, 2023
Credit Loss [Abstract]  
Accounts Receivable, net

Note 3 – Accounts Receivable, net

 

Accounts receivable, consisted of the following:

 

          
   May 31, 2023  May 31, 2022
Customers Receivable  $345,264   $115,741 
Merchant Processor Receivable   167,232    — 
Less: Allowance for doubtful debts   (95,480)   (9,820)
Accounts receivable, net   $417,016   $105,921 

  

The Company recorded bad debt expense of $76,969 and $6,941 during the fiscal years ended May 31, 2023 and 2022, respectively.

 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory, net
 12 Months Ended
May 31, 2023
Inventory Disclosure [Abstract]  
Inventory, net

Note 4 – Inventory, net

 

Inventory consisted of the following:

 

          
   May 31, 2023  May 31, 2022
Finished Goods  $1,198,218   $29,249 
Raw Materials  $113,646   $294,139 
Inventory, net  $1,311,864   $323,388 

 

At May 31, 2023 and 2022, inventory held at third party locations amounted to $0 and $16,940, respectively. At May 31, 2023 and 2022, there was $135,482 and $0 inventory in- transit, respectively.

 

During the fiscal years ended May 31, 2023 and 2022, the Company created an allowance of $0 and $71,481, respectively, on slow moving inventory included in cost of sales. As of May 31, 2023 and 2022, there was no slow moving inventory.

 
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment
 12 Months Ended
May 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 5 – Property and Equipment

 

Property and equipment, stated at cost, consisted of the following:

 

             
   Estimated Life  May 31, 2023  May 31, 2022
Furniture and Fixtures  5 years  $14,598   $5,759 
Computer Equipment  3 years   33,146    17,392 
Plant Equipment  5-10 years   165,778    45,128 
Automobile  5 years   15,000    — 
Less: Accumulated Depreciation      (71,059)   (39,134)
      $157,463   $29,145 

 

Depreciation expense amounted to $20,908 and $7,871 for the fiscal years ended May 31, 2023 and 2022, respectively.

 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible Assets
 12 Months Ended
May 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 6 – Intangible Assets

 

The Company acquired intangible assets through the Business Combination. (See Note 13). These intangible assets consisted of the following: 

         
   Estimated Life  May 31, 2023 
Licensing Rights  3 years  $11,945  
Customer Relationships  3 years   70,000  
Trade Names  10 years   275,000  
Website   5 years   100,000  
Less: Accumulated Amortization      (74,271) 
      $382,674  

 

Goodwill arising through the business combination was $2,152,215 at May 31, 2023 (see Note 13).

 

Amortization expense amounted to $74,271 and $0 for the fiscal years ended May 31, 2023 and 2022, respectively.

 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Liabilities
 12 Months Ended
May 31, 2023
Payables and Accruals [Abstract]  
Other Current Liabilities

Note 7 – Other Current Liabilities

 

Other current liabilities comprised of the following:

 

     
    May 31, 2023 
Credit Cards   833 
Accrued Interest   10,343 
Royalty Payment Accrual   8,792 
Sales Tax Payable and Other Accrued Expenses   258,023 
Affiliate Accrual   27,673 
Other Current Liabilities   $305,664 

  
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Equipment Payable
 12 Months Ended
May 31, 2023
Equipment Payable  
Equipment Payable

Note 8 – Equipment Payable

 

During the fiscal year ended May 31, 2019, the Company purchased a forklift under an installment purchase plan. The loan amount is $16,500 payable in 60 monthly installment payments of $317 comprising of principal payment of $275 and interest payment of $42. As at May 31, 2023 and 2022, the balance outstanding on the loan was $2,200 and $5,500, respectively, of which the $2,200 balance is payable within the next year. The Company recorded an interest expense of $500 and $500, associated with the equipment financing during the fiscal years ended May 31, 2023 and 2022, on the loan in the accompanying consolidated financial statements.

 

The amounts of loan payments due within the next fiscal year ended May 31, are as follows:

 

   
   Total
  2024     $ 2,200  
 Equipment Payable, Net    $2,200 

 
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable
 12 Months Ended
May 31, 2023
Debt Disclosure [Abstract]  
Notes Payable

Note 9 – Notes Payable

 

During the fiscal year ended May 31, 2020, a commercial bank granted to the Company a loan (the “Loan”) in the amount of $150,000, which is administered under the authority and regulations of the U.S. Small Business Administration pursuant to the Economic Injury Disaster Loan Program (the “EIDL”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Loan, which is evidenced by a note dated May 18, 2020, bears interest at an annual rate of 3.75% and is payable installments of $731 per month, beginning May 18, 2021 until May 13, 2050. The Company has to maintain a hazard insurance policy including fire, lightning, and extended coverage on all items used to secure this loan to at least 80% of the insurable value. Proceeds from loans granted under the CARES Act are intended to be used for payroll, costs to continue employee group health care benefits, rent, utilities, and certain other qualified costs (collectively, “qualifying expenses”). The Company used the loan proceeds for qualifying expenses. The Company received a loan forgiveness for $10,000 during the fiscal year ended May 31, 2022. During the fiscal year ended May 31, 2022, the Company received additional $10,000 of borrowings under the program. The Company recorded an accrued interest of $10,342 and $11,684, as of May 31, 2023 and 2022, respectively.

 

During the fiscal year ended May 31, 2023 the Company obtained insurance financing of $53,337 on the general liability and excess liability insurance policies. The loan has a finance charge of $3,164 and is payable in 10 monthly installments of $5,650 each beginning November 1, 2022. As of May 31, 2023, six installments have been paid. As of May 31, 2023 outstanding balance of the loan amounted to $21,335.

 

      
Notes Payable as of May 31, 2023 and 2022      
       
   2023  2022
Insurance Financing  $21,335   $— 
Second Draw Paycheck Protection Program (PPP- 2)   —    6,300 
Financing Charges   1,253    — 
Economic Injury Disaster Loan Program (EIDL)   150,000    150,000 
Total  $172,588   $156,300 
Less: Current portion   (172,588)   (156,300)
Non-current portion  $—   $— 

 

The amounts of loan payments due in the next fiscal year ended May 31, are as follows:

 

   
   Total
  2024     $ 172,588  
 Total    $172,588 

 
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity
 12 Months Ended
May 31, 2023
Equity [Abstract]  
Stockholders’ Equity

Note 10 – Stockholders’ Equity

 

Shares Authorized

 

As of May 31, 2023, the authorized capital of the Company consists of 450,000,000 shares of common stock, par value $0.0001 per share and 300,000,000 shares of preferred stock, par value $0.0001 per share.

On June 13, 2022, the Company amended its amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock from 100,000,000 to 450,000,000 shares and to increase the number of authorized shares of preferred stock, par value $0.0001 per share (“Preferred Stock”), from 20,000,000 to 300,000,000 shares.

Preferred Stock

 

The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company is expressly authorized to provide for the issuance of all or any of the shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed until the resolution adopted by the Board of Directors providing the issuance of such shares. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.

 

During the fiscal year ended May 31, 2023, the Company issued 250,000,000 shares of non-voting Series A Preferred Stock, which are convertible into shares of Company Common Stock on a one-to-one ratio, pursuant to the Asset Purchase Agreement (See Note 13 and Common Stock section below). These 250,000,000 shares of non-voting Series A Preferred Stock were valued at the fair market value of $3,100,000 at issuance.

 

The holders of shares of Series A Preferred Stock shall have no rights to dividends with respect to such shares. No dividends or other distributions shall be declared or paid on the Common Stock unless and until dividends at the same rate shall have been paid or declared and set apart upon the Series A Preferred Stock, based upon the number of shares of Common Stock into which the Series A Preferred Stock may then be converted. Upon the dissolution, liquidation, or winding up of the Company, whether voluntary or involuntary, the holders of the Series A Preferred Stock are entitled to receive out of the assets of the Company the sum of $0.0001 per share before any payment or distribution shall be made on our shares of Common Stock. The Series A Preferred Stock shall not be subject to redemption at the option, election or request of the Corporation or any holder or holders of the Series A Preferred Stock. Each share of Series A Preferred Stock is convertible at the option of the holder thereof, at any time after the second anniversary of the date of the first issuance of the shares of Series A Preferred Stock into one fully paid and nonassessable share of Common Stock provided, however, that the holder may not convert that number of shares of Series A Preferred Stock which would cause the holder to become the beneficial owner of more than 5% of the Corporation’s Common Stock as determined in accordance with Sections 13(d) and (g) of the Securities and Exchange Act of 1934 and the applicable rules and regulations thereunder. 

 

As of May 31, 2023, 250,000,000 shares of Preferred Stock were issued and outstanding.

 

No shares of Preferred Stock were issued and outstanding as of May 31, 2022.

 

Common Stock

 

As of May 31, 2023, 117,076,949 shares of common stock were issued and outstanding. 

 

During the fiscal year ended May 31, 2023, the Company issued 73,183,893 shares of Common Stock, valued at $907,480, as consideration pursuant to the Asset Purchase agreement (See Note 13 and Preferred Stock section above).

 

During the fiscal year ended May 31, 2023, the Company sold 1,947,175 shares of Common Stock at $0.23 per share for a total of $447,850 under several private placement agreements.

 

No shares of Common Stock were issued during the fiscal year ended May 31, 2022.

 

Stock Options

 

The Board approved the Company’s 2022 Equity Incentive Plan (the “Plan”) on March 21, 2022. Under the Plan, equity-based awards may be made to employees, officers, directors, non-employee directors and consultants of the Company and its Affiliates (as defined in the plan) in the form of (i) Incentive Stock Options (to eligible employees only); (ii) Nonqualified Stock Options; (iii) Restricted Stock; (iv) Stock Awards; (v) Performance Shares; or (vi) any combination of the foregoing. The Plan will terminate upon the close of business on the day next preceding March 21, 2032, unless terminated earlier in accordance with the terms of the Plan. The Board serves as the Plan administrator and may amend or terminate the Plan without stockholder approval, subject to certain exceptions.

 

The total number of shares initially authorized for issuance under the Plan was 10.0 million shares. The Plan provides for an annual increase on April 1 of each calendar year, beginning in 2022 and ending in 2031, subject to Board approval prior to such date. Such increase may be equal to the lesser of (i) 4% of the total number of shares of the Company’s common stock outstanding on May 31 of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board. The number of shares authorized for issuance under the Plan will not change unless the Board affirmatively approves an increase in the number of shares authorized for issuance prior to April 1 of the applicable year. Shares surrendered or withheld to pay the exercise price of a stock option or to satisfy tax withholding requirements will not be added back to the number of shares available under the Plan. To the extent that any shares of common stock awarded or subject to issuance or purchase pursuant to awards under the Plan are not delivered or purchased, or are reacquired by the Company, for any reason, including a forfeiture of restricted stock or failure to earn performance shares, or the termination, expiration or cancellation of a stock option, or any other termination of an award without payment being made in the form of shares of common stock will be added to the number of shares available for awards under the Plan. The number of shares available for issuance under the Plan will be adjusted for any increase or decrease in the number of outstanding shares of common stock resulting from payment of a stock dividend on common stock, a stock split or subdivision or combination of shares of common stock, or a reorganization or reclassification of common stock, or any other change in the structure of shares of common stock, as determined by the Board. Shares available for awards under the Plan will consist of authorized and unissued shares.

 

Two types of options may be granted under the Plan: (1) Incentive Stock Options, which may only be issued to eligible employees of the Company and are required to have exercise price of the option not less than the fair market value of the common stock on the grant date, or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110% of the fair market value of the common stock on the grant date; and (2) Non-qualified Stock Options, which may be issued to participants under the Plan and which may have an exercise price less than the fair market value of the common stock on the grant date, but not less than par value of the stock.

 

The Board may grant or sell restricted stock to participants (i.e., shares that are subject to a subject to restrictions or limitations as to the participant’s ability to sell, transfer, pledge or assign such shares) under the Plan. Except for these restrictions and any others imposed by the Board, upon the grant of restricted stock, the recipient generally will have rights of a stockholder with respect to the restricted stock. During the applicable restriction period, the recipient may not sell, exchange, transfer, pledge or otherwise dispose of the restricted stock. The Board may also grant awards of common stock to participants under the Plan, as well as awards of performance shares, which are awards for which the payout is subject to achievement of such performance objectives established by the Board. Performance shares may be settled in cash.

 

Each equity-based award granted under the Plan will be evidenced by an award agreement that specifies the terms of the award and such additional limitations, terms and conditions as the Board may determine, consistent with the provisions of the Plan.

 

Upon the occurrence of a change in control, unless otherwise provided in an award agreement: (i) all outstanding stock options will become immediately exercisable in full; (ii) all outstanding performance shares will vest in full as if the applicable performance conditions were achieved in full, subject to certain adjustments, and will be paid out as soon as practicable; and (iii) all restricted stock will immediately vest in full. The Plan defines a change in control as (i) the adoption of a plan of merger or consolidation of the Company with any other corporation or association as a result of which the holders of the voting capital stock of the Company as a group would receive less than 50% of the voting capital stock of the surviving or resulting corporation; (ii) the approval by the Board of an agreement providing for the sale or transfer (other than as security for obligations of the Company) of substantially all the assets of the Company; or (iii) in the absence of prior Board approval, the acquisition of more than 20% of the Company’s voting capital stock by any person within the meaning of Rule 13d-3 under the Exchange Act (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company).

 

Subject to the Plan’s terms, the Board has full power and authority to determine whether, to what extent and under what circumstances any outstanding award will be terminated, canceled, forfeited or suspended. Awards to that are subject to any restriction or have not been earned or exercised in full by the recipient will be terminated and canceled if such recipient is terminated for cause, as determined by the Board in its sole discretion.

 

The Company estimates the fair value of share-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables such as the expected option term, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected option term and expected dividend yield rate over the expected option term. The Company believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors which are subject to ASC Topic 718 requirements. These amounts are estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award.

 

The Company utilizes the simplified method to estimate the expected life for stock options granted to employees. The simplified method was used as the Company does not have sufficient historical data regarding stock option exercises. The expected volatility is based on historical volatility. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased.

 

Pursuant to the Plan, on May 10, 2022, the Company issued to two Company officers non-statutory stock options to purchase, in the aggregate, up to 5,300,000 shares of its Common Stock, at an exercise price of $0.09 per share and expiring on April 20, 2032. The options vest over time with 25% of the options vesting on September 1, 2022 and thereafter vesting 1/24th on the 1st of every month. None of the options are vested as of May 31, 2022.

 

Pursuant to the Plan, on November 1, 2022, the Company issued non-statutory stock options, to a former executive officer of the Company, to purchase, in the aggregate, up to 300,000 shares of its Common Stock, at an exercise price of $0.20 per share and expiring on October 31, 2032. 75,000 shares vested as of January 29, 2023, and the remaining 225,000 options were forfeited in April 2023 when the executive officer left the Company. 

 

The Company computed the aggregate grant date fair value of $477,000 using the Black-Scholes option pricing model, which is being recorded as stock-based compensation expense over the vesting period. During the fiscal years ended May 31, 2023 and 2022, the Company recorded a stock-based compensation expense of $207,342 and $21,967 respectively, for these options in the accompanying financial statements. 

 

The Black-Scholes options pricing model used the following assumptions:

 

          
    2023    2022 
Risk free interest rate   4.07%   2.99%
Expected life   6 years    5.75 years 
Expected volatility   457%   447%
Expected dividend   0%   0%

 

The following table summarizes the activity relating to the Company’s stock options held by executive officers:

 

               
    Number of Options    Weighted Average Exercise Price    Weighted Average Remaining Term 
                
Outstanding as June 1, 2021   —    —    — 
Granted   5,300,000   $0.09    10.0 
Exercised   —    —    — 
Outstanding at May 31, 2022   5,300,000   $0.09    9.92 
Granted   300,000   $0.20    9.68 
Less: Forfeited   (225,000)  $0.20    9.68 
Less: Unvested at May 31, 2023   (2,725,000)  $0.09    8.92 
Vested at May 31, 2023   2,650,000   $0.09    8.92 

 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
 12 Months Ended
May 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 11 – Commitments and Contingencies

 

Leases

 

As discussed in Note 2 above, the Company adopted ASU No. 2016-02, Leases on June 1, 2019, which require lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance. The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent was $7,567 per month for the first year and increased by a certain amount each year. In November 2022, the Company entered into an extension of the lease for a two year term beginning December 1, 2022. The rent is $6,098 per month for the first year and will increase by a certain amount the following year.

 

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

 

The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations.

 

Lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Variable payments change due to facts or circumstances occurring after the commencement date, other than the passage of time, and do not result in a remeasurement of lease liabilities. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants.

 

Pursuant to the new standard, the Company recorded an initial lease liability of $235,748 and an initial right of use asset in the same amount in 2019. The Company computed another initial lease liability of $131,970 for the new lease agreement and an initial ROU asset in the same amount which was recorded on books at the commencement of the new lease on December 1, 2022. During the fiscal years ended May 31, 2023 and 2022, the Company recorded a lease expense in the amount of $84,435 and $94,235, respectively. As of May 31, 2023, the lease liability balance was $102,576 and the right of use asset balance was $101,845. A lease term of three years and a discount rate of 12% was used.

 

Supplemental balance sheet information related to leases was as follows:

 

          
Assets   May 31, 2023    May 31, 2022 
Right of use assets  $131,970   $235,748 
Accumulated reduction   (30,125)   (190,295)
Operating lease assets, net  $101,845   $45,453 
           
Liabilities          
Lease Liability  $131,970   $235,748 
Accumulated reduction   (29,394)   (188,582)
Total lease liability, net  $102,576   $47,166 
Current portion   (65,824)   (47,166)
Non-current portion  $36,752   $— 
           

 

Maturities of operating lease liabilities were as follows as of May 31, 2023:

 

   
Operating Lease   
2024  $65,824 
2025   36,752 
Total  $102,576 
Less: Imputed interest  $— 
Present value of lease liabilities  $102,576 

  

Contingencies

 

On November 23, 2020, the Company was served a copy of a complaint filed by Jacksonfill, LLC in the Fourth Circuit Court for Duval County, Florida. The complaint alleges breach of Agreement for non-payments for certain products against the Company. The allegations arise from alleged discrepancies discovered by the Company in the manufacturing of certain product. The Company has retained counsel and intends to vigorously defend the allegations. The product was delivered to the Company, however, the Company believes that the product was defective. The litigation process has not progressed and the amount of the claim of $204,182 has been recorded as accounts payable, in the accompanying consolidated financial statements as of May 31, 2023.

 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions
 12 Months Ended
May 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 12 – Related Party Transactions

 

The Company’s Chief Executive Officer, Jeff Toghraie, is the managing director of Intrepid Global Advisors (“Intrepid”). Intrepid has, from time to time, provided advances to the Company for working capital purposes. At May 31, 2023, and 2022, the Company had amounts payable to Intrepid of $124,378 and $25,452, respectively. These advances were short-term in nature and non-interest bearing. Additionally, pursuant to a voting agreement, effective June 16, 2022 as amended effective November 7, 2022, with AXIL and Intrepid Global Advisors, we are subject to certain limitations on our ability to sell our capital stock until June 2024. 

 

During the fiscal year ended May 31, 2023, the Company paid $218,696 as consulting fee for product development to Weston T. Harris, a major stockholder of AXIL, and also paid $126,097 to immediate family members of the major stockholder as compensation for services relating to packaging design and affiliate marketing. 

 

During the fiscal year ended May 31, 2023, the Company paid $135,484 as consulting fee for inventory management and operations consulting to an immediate family member of a major stockholder of AXIL, $74,620 to an immediate family member of the major stockholder in commissions and a contractor fee, and $15,928 to an immediate member of the major stockholder as compensation for services relating to travel and event coordination. 

 

On June 16, 2022, the Company and its wholly owned subsidiary Reviv3 Acquisition Corporation completed the acquisition of both (i) the hearing protection business of AXIL, consisting of ear plugs and ear muffs, and (ii) AXIL’s ear bud business pursuant to the Asset Purchase Agreement, dated May 1, 2022, as amended on June 15, 2022, by and among the Company, Reviv3 Acquisition Corporation, AXIL and certain stockholders of AXIL. One of the stockholders of AXIL is Intrepid Global Advisors, Inc. As of May 31, 2023, Intrepid Global Advisors, Inc. held no outstanding common stock of AXIL and 19.50% of the outstanding common stock of the Company.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combination
 12 Months Ended
May 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combination

 
Note 13 – Business Combination

 

On June 16, 2022, the Company completed the acquisition of certain assets of Axil & Associated Brands Corp. (“AXIL”), a Delaware corporation, pursuant to the Asset Purchase Agreement dated May 1, 2022 and amended on June 15, 2022 and September 8, 2022. by and among the Company, its subsidiary, AXIL, and certain of AXIL’s stockholders, providing for the acquisition of AXIL’s hearing protection business and ear bud business. The business constituted substantially all of the business operations of AXIL but did not include AXIL’s hearing aid line of business.

 

One of the stockholders of AXIL is Intrepid Global Advisors (“Intrepid”). As of June 16, 2022, Intrepid held 4.68% of the outstanding common stock of AXIL and 22.33% of the outstanding Common Stock of the Company. As of May 31, 2023 Intrepid held no outstanding common shares of AXIL, as they were distributed with the Asset Purchase Agreement. Jeff Toghraie, Chairman and Chief Executive Officer of the Company, is a managing director of Intrepid.

 

As consideration for the Asset Purchase, AXIL received a total of 323,183,893 shares of the company comprised of (a) 73,183,893 shares of the Company’s Common Stock and (b) 250,000,000 shares of the company’s non-voting Series A Preferred Stock, which are convertible into shares of Company Common Stock on a one-to-one ratio. The Preferred Shares may not be converted or transferred for a period of two years following the closing of the acquisition. Thereafter, no holder of Preferred Shares may convert such shares into a number of shares of Company Common Stock that would cause the holder to beneficially own more than 5% of the Company’s Common Stock, as determined in accordance with Sections 13(d) and (g) of the Securities Exchange Act of 1934 (the “Exchange Act”). The purchase price was computed to be $4,007,480 based on a fair value of $0.0124 per common share on the date of acquisition.

 

The Company is utilizing the AXIL assets to expand into the hearing enhancement business through its newly incorporated subsidiary.

 

The acquisition is accounted for by the Company in accordance with the acquisition method of accounting pursuant to ASC 805 “Business Combinations” and pushdown accounting is applied to record the fair value of the assets acquired by the Company. Under this method, the purchase price is allocated to the identifiable assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. Any excess of the amount paid over the estimated fair values of the identifiable net assets acquired was allocated to goodwill.

 

The following is a summary of the fair value of the assets acquired and liabilities assumed at the date of acquisition:

 

     
Cash  $1,066,414 
Accounts receivable   227,786 
Inventory   1,342,461 
Prepaid expenses   62,452 
Other assets   108,030 
Accounts payable   (285,665)
Contract liabilities   (1,043,332)
Other current liabilities   (79,826)
Net tangible assets acquired  $1,398,320 
      
Identifiable intangible assets     
Licensing rights  $11,945 
Customer relationships   70,000 
Tradenames   275,000 
Website   100,000 
Total Identifiable intangible assets  $456,945 
      
Consideration paid  $4,007,480 
Total net assets acquired   1,855,265 
Goodwill purchased  $2,152,215 

 

Pro Forma Information (Unaudited)

 

The unaudited pro forma condensed combined financial statements are based on Reviv3 and AXIL’s unaudited historical consolidated financial statements as adjusted to give effect to the Asset Purchase Agreement. The unaudited pro forma combined statements of operations for the fiscal year ended May 31, 2023 and 2022, for Reviv3 and AXIL, give effect to the Asset Purchase Agreement as if it had occurred on June 1, 2022 and 2021, respectively. 

          
   For the fiscal year ended  For the fiscal year ended
   May 31, 2023  May 31, 2022
Revenue  $25,428,163   $18,356,862 
Net income (loss)   2,032,954    (3,212,320)
Earnings (loss) per common share          
Basic  $0.02   $(0.03)
Diluted  $0.01    — 

 

The pro forma financial information is not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that result in the future. 

 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations
 12 Months Ended
May 31, 2023
Risks and Uncertainties [Abstract]  
Concentrations

Note 14 – Concentrations

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits, investments and cash equivalents instruments. The Company maintains its cash in bank deposits accounts. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At May 31, 2023 and 2022, the Company held cash in various accounts of approximately $4,582,682 and $123,731, respectively, in excess of federally insured limits. The Company has not experienced any losses in such accounts through May 31, 2023.

 

Concentration of Revenue, Accounts Receivable, Product Line, and Supplier – Hair and Skin Care Products

 

During the fiscal year ended May 31, 2023 hair and skin care product sales to three customers, which each represented over 10% of our total sales, aggregated to approximately 94% of the Company’s net sales at 61%, 12% and 21%. During the fiscal year ended May 31, 2022 sales to two customers, which each represented over 10% of our total sales, aggregated to approximately 31% of the Company’s net sales at 15% and 16%.

 

During the fiscal year ended May 31, 2023 hair and skin care product sales to customers outside the United States represented approximately 25% which consisted of 20% from Canada and 5% from Italy and during the fiscal year ended May 31, 2022 sales to customers outside the United States represented approximately 16% which consisted of 14% from Canada and 2% from Italy.

 

During the fiscal year ended May 31, 2023, hair and skin care product sales by product line which each represented over 10% of sales consisted of approximately 15% from sales of hair shampoo, and 10% from sales of hair conditioner and 7% from bundle kits. During the fiscal year ended May 31, 2022, hair and skin care product sales by product line which each represented over 10% of sales consisted of approximately 10% from sales of hair shampoo, 12% from sales of hair shampoo and conditioner, 25% from sale of introductory kit (shampoo, conditioner and treatment spray) and 29% from sale of bundle packs (shampoo, conditioner and spray).

 

During the fiscal years ended May 31, 2023 and 2022 sales for the hair and skin care product lines comprised of the following:

 

          
   For the Fiscal Years ended
Hair Care Products  May 31, 2023  May 31, 2022
Shampoos and Conditioners   77%   84%
Ancillary Products   23%   16%
Total   100%   100%

 

At May 31, 2023, hair and skin care product’s only accounts receivable from one customer accounted for more than 10% of sales transactions, which was Amazon and the second largest customer accounted for 8%, which is due to the fact that products are sold primarily through direct-to-consumer. At May 31, 2022, accounts receivable from four customers represented approximately 74% at 11%, 12%, 14% and 37%.

 

Hair and skin care product purchased inventories and products from three vendors totaling approximately $297,833, (95% of the purchases at 61%, 12% and 22%) during the fiscal year ended May 31, 2023 and four vendors totaling approximately $343,015 (97% of the purchases at 10%, 23%, 30% and 34%) during the fiscal year ended May 31, 2022.

 

Concentration of Revenue, Accounts Receivable, Product Line, and Supplier – Ear Protection and Enhancement Products

 

AXIL is sold direct-to-consumer, therefore, during the fiscal year ended May 31, 2023, 97.3% of sales was direct to customers. There was no single customer that accounted for greater than 2% of total sales.

 

During the fiscal year ended May 31, 2023 AXIL sales to customers outside the United States represented approximately 4.5% which consisted of 3.7% from Canada and the remaining from various countries.

 

Manufacturing is outsourced primarily overseas via a number of third party vendors, the two largest vendors accounting for 82% and 10% of all purchases. 

 

During the fiscal year ended May 31, 2023, AXIL sale of ear buds for PSAP (personal sound amplification product) and hearing protection by product line which each represented over 10% of sales consisted approximately 87% from Ghost Stryke Extreme model GS-X ($18.1M) and 9% of sales of Trackr earmuffs ($1.9M).

 

During the fiscal year ended May 31, 2023 sales by hearing enhancement and protection products comprised of the following:  

 

     
   For the fiscal year ended
Ear Protection & Enhancement Products  May 31, 2023
Ghost Stryke   86.7%
Trackr Earmuffs   9.1%
Other Bluetooth and ear buds   3.9%
Accessories, other   0.3%
Total   100.0%

 
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Business Segment and Geographic Area Information
 12 Months Ended
May 31, 2023
Segment Reporting [Abstract]  
Business Segment and Geographic Area Information

Note 15 – Business Segment and Geographic Area Information

 

Business Segments

 

The Company, directly or through its subsidiaries, markets and sells its products and services directly to consumers and through its dealers. In June 2022, the Company acquired a hearing enhancement and hearing protection business. The Company’s determination of its reportable segments is based on how its chief operating decision makers manage the business.

 

The Company’s segment information is as follows: 

          
   The fiscal years ended
Net Sales   May 31, 2023    May 31, 2022 
Hair care and skin care  $1,588,958   $2,336,257 
Hearing enhancement and protection   21,932,069    — 
Total net sales  $23,521,027   $2,336,257 
           
Operating earnings (loss)          
Segment gross profit:          
Hair care and skin care  $1,076,834   $1,507,671 
Hearing enhancement and protection   16,633,977    — 
Total segment gross profit  $17,710,811   $1,507,671 
Selling and Marketing   11,675,206    1,199,305 
General and Administrative   4,051,394    519,769 
Consolidated operating income (loss)  $1,984,211   $(211,403)
           
Total Assets:          
Hair care and skin care  $3,785,732   $893,915 
Hearing enhancement and protection   6,383,582    — 
Consolidated total assets  $10,169,314   $893,915 
           
Payments for property and equipment          
Hair care and skin care  $—   $— 
Hearing enhancement and protection   65,650    — 
Consolidated total payments for property and equipment  $65,650   $— 
           
Depreciation and amortization          
Hair care and skin care  $5,675   $7,872 
Hearing enhancement and protection   89,504    — 
Consolidated total depreciation and amortization  $95,179   $7,872 

 

Geographic Area Information

 

During the fiscal year ended May 31, 2023, approximately 94% of our consolidated net sales were to customers located in the U.S. (based on the customer’s shipping address). All Company assets are located in the U.S.

 
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes
 12 Months Ended
May 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 16 – Income Taxes

 

The Company has incurred aggregate net operating losses of approximately $1,500,000 for income tax purposes as of May 31, 2023. The net operating loss carries forward for United States and California income taxes, which may be available to reduce future years’ taxable income. Management believes that the realization of the benefits from these losses appears more than likely due to the Company’s current year net income results and should be able to fully utilize that benefit in the current year tax filings. Management will not provide a valuation allowance for the losses as they appear to be fully realized.

 

The items accounting for the difference between income taxes at the effective statutory rate and the provision for income were as follows: 

 

          
   For the Fiscal Years Ended May 31,
    2023    2022 
Tax expense (benefit) computed at statutory rate of 21%  $431,653   $(38,410)
State tax expense (benefit) blended rate   297,928    (15,289)
Change in federal tax rate estimate for prior years   —    (46,109)
Non-deductible expenses: Stock-based compensation   —    6,590 
Non deductible expense: Other   —    2,082 
Non taxable: COVID related grants/loan forgiveness   —    (10,500)

Benefit of tax amortization of intangibles

   (49,773)   — 

Deferred tax true up

   3,929    — 
Net operating loss benefit   (452,824)   — 
Tax expense (benefit)   230,913   — 
           
Increase (decrease) in valuation allowance   (101,636)   101,636 
Change in deferred tax asset   101,636      
Net income tax (benefit)/expense  $230,913   $— 

 

The Company has a deferred tax asset which is summarized as follows at:

 

Deferred tax assets:

 

          
    May 31, 2023    May 31, 2022 
Net operating loss carryover  $—   $452,824 

Less: valuation allowance

   —    (452,824)
Net deferred tax asset  $—   $—  

 

Due to the net income at May 31, 2023 the Company reversed the valuation allowance against the deferred income tax asset at May 31, 2023 as current year taxable income will be sufficient to utilize the total loss carryforward. There is no remaining deferred tax asset at May 31, 2023.

 

The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2020, 2021 and 2022 Corporate Income Tax Returns are subject to Internal Revenue Service examination.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
May 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The consolidated financial statements for the fiscal years ended May 31, 2023 and 2022 have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of the Company and its consolidated subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation. 

  
Liquidity and Capital Resources

Liquidity and Capital Resources

 

We are currently engaged in our product sales and development. Although we earned net income and had cash provided by operations in the fiscal year ended May 31, 2023, we had an accumulated deficit of $3,466,992 as of May 31, 2023 and have incurred operating losses and cash used in operations in the past. We currently expect to earn net income and positive cash flows from operations during the current fiscal year ending May 31, 2024. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL’s business, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying consolidated financial statements. Management is focused on growing the Company’s existing product, introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands, including those resulting from the purchase of AXIL’s assets in June 2022, may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying consolidated financial statements.

 

 
Use of estimates

Use of estimates

 

The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, contract liability, allowance on sales returns, valuation of lease liabilities and related right of use assets, fair value of securities issued for business combinations, fair value of assets acquired and liabilities assumed in business combinations and the fair value of non-cash Common Stock issuances. 

 
Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.

 
Accounts receivable and allowance for doubtful accounts

Accounts receivable and allowance for doubtful accounts

 

Accounts receivables comprise of receivables from customers and receivables from merchant processors. The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

 
Prepaid expenses and other current assets

Prepaid expenses and other current assets

 

Prepaid expenses and other current assets consist primarily of cash prepayments to vendors for inventory and prepayments for trade shows and marketing events which will be utilized within a year, prepayments on credit cards and the right to recover assets (for the cost of goods sold) associated with the right of returns for products sold.

 
Inventory

Inventory

 

The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations. The Company continuously evaluates the levels of inventory held and any inventory held above the expected level of sales in the next twelve months, is classified as non-current inventory.

 
Property and Equipment

Property and Equipment

 

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.

 
Revenue recognition

Revenue recognition

 

The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard (new guidance) has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.

 

The Company sells a variety of hair and skin care products and electronic hearing and enhancement products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues.

 

The five steps for revenue recognition are as follows:

 

Identify the contract with a customer. The Company generally considers completion of a sales order (which requires customer acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) or purchase orders from non-consumer customers as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving third party financier payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.

 

Identify the performance obligations in the contract. Product performance obligations include shipment of products and related accessories and service performance obligations include extended warranty coverage.

 

However, as the historical redemption rate under our warranty policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.

 

Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 30-days and 60-days right of return that applies to AXIL and Reviv3 products, respectively. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.

 

Allocate the transaction price to the performance obligations in the contract. For contracts that contain multiple performance obligations, the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.

 

Recognize revenue when or as the Company satisfies a performance obligation. Revenue for products is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period.

 

As of May 31, 2023 and May 31, 2022, contract liabilities amounted to $1,433,048 and $0, respectively. Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3.

 

Revenue recognized, during the fiscal year ended May 31, 2023, that was included in the contract liability balance at the beginning of period (acquisition of AXIL) was $391,204.

  
Cost of Sales

Cost of Sales

 

The primary components of cost of sales include the cost of the product and shipping fees.

  
Shipping and Handling Costs

Shipping and Handling Costs

 

The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $1,001,261 and $214,517 for the fiscal years ended May 31, 2023 and 2022, respectively.

 
Marketing, selling and advertising

Marketing, selling and advertising

 

Marketing, selling and advertising costs are expensed as incurred.

 
Customer Deposits

Customer Deposits

 

Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.

 
Fair value measurements and fair value of financial instruments

Fair value measurements and fair value of financial instruments

 

The Company adopted ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: 

 

Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
   
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
   
Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 

The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 
Business Combinations

Business Combinations

 

For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets acquired and liabilities assumed of the acquired business, at their fair values.

 

Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates.

 
Goodwill

Goodwill

 

Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur, or circumstances indicate the fair value of a reporting unit is below its carrying value.

 

The Company performs its annual goodwill impairment assessment on May 31st of each year or as impairment indicators dictate.

 

When evaluating the potential impairment of goodwill, management first assesses a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the quantitative impairment testing methodology primarily using the income approach (discounted cash flow method).

 

Under the quantitative method we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized is recognized as the amount by which the carrying amount exceeds the fair value.

 

When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. 

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

  

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying consolidated balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

 
Impairment of long-lived assets

Impairment of long-lived assets  

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did not record any impairment loss during the fiscal years ended May 31, 2023 and 2022.

 
Stock-based compensation

Stock-based compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

For non-employee stock option based awards, the Company follows ASU 2018-7, which substantially aligns share based compensation for employees and non-employees.

 
Net income (loss) per share of common stock

Net income (loss) per share of common stock

 

Basic net income (loss) per share is computed by dividing the net income or loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At May 31, 2022, the Company had 5,300,000 options outstanding which were potentially dilutive securities, however they were excluded from the computation since their impact would be antidilutive.

 

For the fiscal year ended May 31, 2023, certain stock options were excluded from the computation of diluted common shares outstanding as they would have an anti-dilutive impact on the Company’s net income. The following table presents a reconciliation of basic and diluted net income per common share: 

 

        
   For the Fiscal Year Ended    
   May 31, 2023  
        
Net income  $1,824,575   
        
Weighted average basic shares   112,895,411   
Dilutive securities:       
Convertible preferred stock   239,041,096   
Stock options   5,448,767   
Weighted average dilutive shares   357,385,274   
        
Earnings (loss) per share:       
Basic  $0.02   
Diluted  $0.01   

 
Lease Accounting

Lease Accounting

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02), which requires lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance (ASC Topic 840). Under the new guidance, codified as ASC Topic 842, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. The new guidance further requires that leases be classified at inception as either (a) operating leases or (b) finance leases. For operating leases, periodic expense generally is flat (straight-line) throughout the life of the lease. For finance leases, periodic expense declines over the life of the lease. The new standard, as amended, provides an option for entities to use the cumulative-effect transition method. As permitted, the Company adopted ASC Topic 842 effective June 1, 2019.

 

The Company renewed lease for its corporate headquarters commencing December 1, 2022, under lease agreements classified as an operating lease. Please see Note 11 – ‘Commitments and Contingencies’ under “Leases” below for more information about the Company’s leases.

 
Segment Reporting

Segment Reporting

 

The Company follows ASC Topic 280, Segment Reporting. The Company’s management reviews the Company’s consolidated financial results when making decisions about allocating resources and assessing the performance of the Company as a whole and has determined that the Company’s reportable segments are: (a) the sale of hearing protection and hearing enhancement products, and (b) the sale of hair care and skin care products. See Note 15 – “BUSINESS SEGMENT AND GEOGRAPHIC AREA INFORMATION” for more information about the Company’s reportable segments.

 
Reclassifications


Reclassifications

 

Certain reclassifications have been made to the prior year’s data to conform with the current period’s presentation. Specifically, the accounts payable have been separated from the accrued expenses, to conform with the current period’s presentation.

 
Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain convertible instruments. Among other things, under ASU 2020-06, the embedded conversion features no longer must be separated from the host contract for convertible instruments with conversion features not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. ASU 2020-06 also eliminates the use of the treasury stock method when calculating the impact of convertible instruments on diluted Earnings per Share. For the Company, the provisions of ASU 2020-06 are effective for its fiscal year beginning on June 1, 2024. Early adoption is permitted, subject to certain limitations. The Company is evaluating the potential impact of adoption on its financial statements.

 

In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities (e.g. deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “Revenue from Contracts with Customers”. Generally, this new guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically, such amounts were recognized by the acquirer at fair value in purchase accounting. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. The Company opted to adopt this ASU as of June 1, 2022. The adoption of the guidance did not have a material impact on the accompanying consolidated financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
May 31, 2023
Accounting Policies [Abstract]  
Schedule of net loss per share
        
   For the Fiscal Year Ended    
   May 31, 2023  
        
Net income  $1,824,575   
        
Weighted average basic shares   112,895,411   
Dilutive securities:       
Convertible preferred stock   239,041,096   
Stock options   5,448,767   
Weighted average dilutive shares   357,385,274   
        
Earnings (loss) per share:       
Basic  $0.02   
Diluted  $0.01   
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Accounts Receivable, net (Tables)
 12 Months Ended
May 31, 2023
Credit Loss [Abstract]  
Schedule of accounts receivable
          
   May 31, 2023  May 31, 2022
Customers Receivable  $345,264   $115,741 
Merchant Processor Receivable   167,232    — 
Less: Allowance for doubtful debts   (95,480)   (9,820)
Accounts receivable, net   $417,016   $105,921 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory, net (Tables)
 12 Months Ended
May 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory
          
   May 31, 2023  May 31, 2022
Finished Goods  $1,198,218   $29,249 
Raw Materials  $113,646   $294,139 
Inventory, net  $1,311,864   $323,388 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment (Tables)
 12 Months Ended
May 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
             
   Estimated Life  May 31, 2023  May 31, 2022
Furniture and Fixtures  5 years  $14,598   $5,759 
Computer Equipment  3 years   33,146    17,392 
Plant Equipment  5-10 years   165,778    45,128 
Automobile  5 years   15,000    — 
Less: Accumulated Depreciation      (71,059)   (39,134)
      $157,463   $29,145 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible Assets (Tables)
 12 Months Ended
May 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets
         
   Estimated Life  May 31, 2023 
Licensing Rights  3 years  $11,945  
Customer Relationships  3 years   70,000  
Trade Names  10 years   275,000  
Website   5 years   100,000  
Less: Accumulated Amortization      (74,271) 
      $382,674  
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Liabilities (Tables)
 12 Months Ended
May 31, 2023
Payables and Accruals [Abstract]  
Schedule of other current liabilities
     
    May 31, 2023 
Credit Cards   833 
Accrued Interest   10,343 
Royalty Payment Accrual   8,792 
Sales Tax Payable and Other Accrued Expenses   258,023 
Affiliate Accrual   27,673 
Other Current Liabilities   $305,664 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Equipment Payable (Tables)
 12 Months Ended
May 31, 2023
Equipment Payable  
Schedule of loan payment due
   
   Total
  2024     $ 2,200  
 Equipment Payable, Net    $2,200 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable (Tables)
 12 Months Ended
May 31, 2023
Debt Disclosure [Abstract]  
Schedule of notes payable
      
Notes Payable as of May 31, 2023 and 2022      
       
   2023  2022
Insurance Financing  $21,335   $— 
Second Draw Paycheck Protection Program (PPP- 2)   —    6,300 
Financing Charges   1,253    — 
Economic Injury Disaster Loan Program (EIDL)   150,000    150,000 
Total  $172,588   $156,300 
Less: Current portion   (172,588)   (156,300)
Non-current portion  $—   $— 
Schedule of notes payments due in the next five years
   
   Total
  2024     $ 172,588  
 Total    $172,588 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Tables)
 12 Months Ended
May 31, 2023
Equity [Abstract]  
Schedule of stock option assumptions
          
    2023    2022 
Risk free interest rate   4.07%   2.99%
Expected life   6 years    5.75 years 
Expected volatility   457%   447%
Expected dividend   0%   0%
Schedule of summarizes relating to the Company’s stock
               
    Number of Options    Weighted Average Exercise Price    Weighted Average Remaining Term 
                
Outstanding as June 1, 2021   —    —    — 
Granted   5,300,000   $0.09    10.0 
Exercised   —    —    — 
Outstanding at May 31, 2022   5,300,000   $0.09    9.92 
Granted   300,000   $0.20    9.68 
Less: Forfeited   (225,000)  $0.20    9.68 
Less: Unvested at May 31, 2023   (2,725,000)  $0.09    8.92 
Vested at May 31, 2023   2,650,000   $0.09    8.92 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Tables)
 12 Months Ended
May 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Supplemental balance sheet information
          
Assets   May 31, 2023    May 31, 2022 
Right of use assets  $131,970   $235,748 
Accumulated reduction   (30,125)   (190,295)
Operating lease assets, net  $101,845   $45,453 
           
Liabilities          
Lease Liability  $131,970   $235,748 
Accumulated reduction   (29,394)   (188,582)
Total lease liability, net  $102,576   $47,166 
Current portion   (65,824)   (47,166)
Non-current portion  $36,752   $— 
           
Schedule of maturities of operating lease liabilities
   
Operating Lease   
2024  $65,824 
2025   36,752 
Total  $102,576 
Less: Imputed interest  $— 
Present value of lease liabilities  $102,576 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combination (Tables)
 12 Months Ended
May 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of estimated fair value of the assets acquired
     
Cash  $1,066,414 
Accounts receivable   227,786 
Inventory   1,342,461 
Prepaid expenses   62,452 
Other assets   108,030 
Accounts payable   (285,665)
Contract liabilities   (1,043,332)
Other current liabilities   (79,826)
Net tangible assets acquired  $1,398,320 
      
Identifiable intangible assets     
Licensing rights  $11,945 
Customer relationships   70,000 
Tradenames   275,000 
Website   100,000 
Total Identifiable intangible assets  $456,945 
      
Consideration paid  $4,007,480 
Total net assets acquired   1,855,265 
Goodwill purchased  $2,152,215 
Schedule of proforma information
          
   For the fiscal year ended  For the fiscal year ended
   May 31, 2023  May 31, 2022
Revenue  $25,428,163   $18,356,862 
Net income (loss)   2,032,954    (3,212,320)
Earnings (loss) per common share          
Basic  $0.02   $(0.03)
Diluted  $0.01    — 
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations (Tables)
 12 Months Ended
May 31, 2023
Risks and Uncertainties [Abstract]  
Schedule of Sales by Product Line
          
   For the Fiscal Years ended
Hair Care Products  May 31, 2023  May 31, 2022
Shampoos and Conditioners   77%   84%
Ancillary Products   23%   16%
Total   100%   100%
Schedule of sales by product comprised
     
   For the fiscal year ended
Ear Protection & Enhancement Products  May 31, 2023
Ghost Stryke   86.7%
Trackr Earmuffs   9.1%
Other Bluetooth and ear buds   3.9%
Accessories, other   0.3%
Total   100.0%

 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Business Segment and Geographic Area Information (Tables)
 12 Months Ended
May 31, 2023
Segment Reporting [Abstract]  
Schedule of segment information
          
   The fiscal years ended
Net Sales   May 31, 2023    May 31, 2022 
Hair care and skin care  $1,588,958   $2,336,257 
Hearing enhancement and protection   21,932,069    — 
Total net sales  $23,521,027   $2,336,257 
           
Operating earnings (loss)          
Segment gross profit:          
Hair care and skin care  $1,076,834   $1,507,671 
Hearing enhancement and protection   16,633,977    — 
Total segment gross profit  $17,710,811   $1,507,671 
Selling and Marketing   11,675,206    1,199,305 
General and Administrative   4,051,394    519,769 
Consolidated operating income (loss)  $1,984,211   $(211,403)
           
Total Assets:          
Hair care and skin care  $3,785,732   $893,915 
Hearing enhancement and protection   6,383,582    — 
Consolidated total assets  $10,169,314   $893,915 
           
Payments for property and equipment          
Hair care and skin care  $—   $— 
Hearing enhancement and protection   65,650    — 
Consolidated total payments for property and equipment  $65,650   $— 
           
Depreciation and amortization          
Hair care and skin care  $5,675   $7,872 
Hearing enhancement and protection   89,504    — 
Consolidated total depreciation and amortization  $95,179   $7,872 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Tables)
 12 Months Ended
May 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of effective statutory rate and the provision for income
          
   For the Fiscal Years Ended May 31,
    2023    2022 
Tax expense (benefit) computed at statutory rate of 21%  $431,653   $(38,410)
State tax expense (benefit) blended rate   297,928    (15,289)
Change in federal tax rate estimate for prior years   —    (46,109)
Non-deductible expenses: Stock-based compensation   —    6,590 
Non deductible expense: Other   —    2,082 
Non taxable: COVID related grants/loan forgiveness   —    (10,500)

Benefit of tax amortization of intangibles

   (49,773)   — 

Deferred tax true up

   3,929    — 
Net operating loss benefit   (452,824)   — 
Tax expense (benefit)   230,913   — 
           
Increase (decrease) in valuation allowance   (101,636)   101,636 
Change in deferred tax asset   101,636      
Net income tax (benefit)/expense  $230,913   $— 
Schedule of deferred tax asset
          
    May 31, 2023    May 31, 2022 
Net operating loss carryover  $—   $452,824 

Less: valuation allowance

   —    (452,824)
Net deferred tax asset  $—   $—  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Accounting Policies [Abstract]    
Net income $ 1,824,575 $ (182,903)
Weighted average basic shares 112,895,411  
Dilutive securities:    
Convertible preferred stock 239,041,096  
Stock options 5,448,767  
Weighted average dilutive shares 357,385,274  
Earnings (loss) per share:    
Basic $ 0.02  
Diluted $ 0.01  
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Restructuring Cost and Reserve [Line Items]    
Retained Earnings (Accumulated Deficit) $ 3,466,992 $ 5,291,567
Contract liabilities $ 1,433,048 0
Contract Liabilities Description Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3.  
Selling and marketing expense $ 11,675,206 1,199,305
Impairment loss 0 $ 0
Options [Member]    
Restructuring Cost and Reserve [Line Items]    
Antidilutive shares   5,300,000
Customer [Member]    
Restructuring Cost and Reserve [Line Items]    
Selling and marketing expense 1,001,261 $ 214,517
Axil [Member]    
Restructuring Cost and Reserve [Line Items]    
Revenue recognition $ 391,204  
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Accounts Receivable, net (Details) - USD ($)
May 31, 2023
May 31, 2022
Credit Loss [Abstract]    
Customers Receivable $ 345,264 $ 115,741
Merchant Processor Receivable 167,232
Less: Allowance for doubtful debts (95,480) (9,820)
Accounts receivable, net  $ 417,016 $ 105,921
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Accounts Receivable, net (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Credit Loss [Abstract]    
Bad debt expense $ 76,969 $ 6,941
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory, net (Details) - USD ($)
May 31, 2023
May 31, 2022
Inventory Disclosure [Abstract]    
Finished Goods $ 1,198,218 $ 29,249
Raw Materials 113,646 294,139
Inventory, net $ 1,311,864 $ 323,388
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Inventory, net (Details Narrative) - USD ($)
May 31, 2023
May 31, 2022
Inventory Disclosure [Abstract]    
Inventory held at third party location $ 0 $ 16,940
Inventory in-transit 135,482 0
Inventory valuation reserves 0 71,481
Inventory, non-current $ 0 $ 0
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment (Details) - USD ($)
May 31, 2023
May 31, 2022
Property, Plant and Equipment [Line Items]    
Less:Accumulated Depreciation $ (71,059) $ (39,134)
Property and equipment, net $ 157,463 29,145
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
Plant Equipment $ 14,598 5,759
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 3 years  
Plant Equipment $ 33,146 17,392
Property, Plant and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Plant Equipment $ 165,778 45,128
Property, Plant and Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
Property, Plant and Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 10 years  
Automobiles [Member]    
Property, Plant and Equipment [Line Items]    
Property, Plant and Equipment, Useful Life 5 years  
Plant Equipment $ 15,000
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation $ 20,908 $ 7,871
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible Assets (Details) - USD ($)
May 31, 2023
May 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Finite-Lived Intangible Assets, Accumulated Amortization $ (74,271)  
Finite-Lived Intangible Assets, Net $ 382,674
Licensing Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets useful life 3 years  
Finite-Lived Intangible Assets, Gross $ 11,945  
Customer Relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets useful life 3 years  
Finite-Lived Intangible Assets, Gross $ 70,000  
Trade Names [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets useful life 10 years  
Finite-Lived Intangible Assets, Gross $ 275,000  
Website [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible Assets useful life 5 years  
Finite-Lived Intangible Assets, Gross $ 100,000  
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Intangible Assets (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Jun. 16, 2022
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill $ 2,152,215   $ 2,152,215
Amortization expense $ 74,271 $ 0  
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Other Current Liabilities (Details)
May 31, 2023
USD ($)
Payables and Accruals [Abstract]  
Credit Cards $ 833
Accrued Interest 10,343
Royalty Payment Accrual 8,792
Sales Tax Payable and Other Accrued Expenses 258,023
Affiliate Accrual 27,673
Other Current Liabilities  $ 305,664
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Equipment Payable (Details) - USD ($)
May 31, 2023
May 31, 2022
Equipment Payable    
2024 $ 2,200 $ 3,300
Equipment Payable, Net $ 2,200  
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable (Details) - USD ($)
May 31, 2023
May 31, 2022
Guarantor Obligations [Line Items]    
Total $ 172,588 $ 156,300
Less: Current portion (172,588) (156,300)
Non-current portion
Insurance Financing [Member]    
Guarantor Obligations [Line Items]    
Total 21,335
Second Draw Paycheck Protection Program [Member]    
Guarantor Obligations [Line Items]    
Total 6,300
Financing Charges [Member]    
Guarantor Obligations [Line Items]    
Total 1,253
Economic Injury Disaster Loan Program [Member]    
Guarantor Obligations [Line Items]    
Total $ 150,000 $ 150,000
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable (Details 1)
May 31, 2023
USD ($)
Debt Disclosure [Abstract]  
2024 $ 172,588
Total $ 172,588
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.23.2
Notes Payable (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
May 18, 2020
May 31, 2023
May 31, 2022
May 31, 2020
Debt Instrument [Line Items]        
Accrued interest   $ 10,343    
Notes Payable   172,588 $ 156,300  
Insurance Financing [Member]        
Debt Instrument [Line Items]        
Insurance financing   53,337    
Finance charges   3,164    
Notes Payable   21,335  
Economic Injury Disaster Loan Program [Member]        
Debt Instrument [Line Items]        
Face Amount       $ 150,000
Interest rate 3.75%      
Additional borrowings     10,000  
Loan forgiveness     10,000  
Accrued interest   $ 10,342 $ 11,684  
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Details)
 12 Months Ended
May 31, 2023
May 31, 2022
Equity [Abstract]    
Risk free interest rate 2.99% 4.07%
Expected life 5 years 9 months 6 years
Expected volatility 447.00% 457.00%
Expected dividend 0.00% 0.00%
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Details 1) - $ / shares
 1 Months Ended 12 Months Ended
Jan. 29, 2023
May 31, 2023
May 31, 2022
Equity [Abstract]      
Number of option outstanding, beginning   5,300,000
Weighted average exercise price, beginning   $ 0.09
Number of option outstanding, granted   300,000 5,300,000
Weighted average exercise price, granted   $ 0.20 $ 0.09
Weighted average remaining term, granted   9 years 8 months 4 days 10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period    
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price    
Number of option outstanding, ending     5,300,000
Weighted average exercise price, ending     $ 0.09
Weighted average remaining term, ending     9 years 11 months 1 day
Number of option outstanding, forfeited   (225,000)  
Weighted average exercise price, forfeited   $ 0.20  
Weighted average remaining term, forfeited   9 years 8 months 4 days  
Unvested number of option   (2,725,000)  
Unvested weighted average exercise price   $ 0.09  
Unvested weighted average remaining term   8 years 11 months 1 day  
Vested number of option 75,000 2,650,000  
Vested weighted average exercise price   $ 0.09  
Vested weighted average remaining term   8 years 11 months 1 day  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders’ Equity (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Apr. 30, 2023
Jan. 29, 2023
May 31, 2023
May 31, 2022
Nov. 01, 2022
Jun. 13, 2022
May 10, 2022
May 31, 2021
Class of Stock [Line Items]                
Common stock, shares authorized     450,000,000 450,000,000   450,000,000    
Common stock, par or stated value per share     $ 0.0001 $ 0.0001        
Preferred stock, shares authorized     300,000,000 300,000,000   300,000,000    
Preferred stock, par or stated value per share     $ 0.0001 $ 0.0001   $ 0.0001    
Shares issued value during the period     $ 447,850          
Preferred stock, shares issued     250,000,000 0        
Preferred stock, shares outstanding     250,000,000 0        
Common stock, shares issued     117,076,949 41,945,881        
Common stock, shares outstanding     117,076,949 41,945,881        
Number of option issued         300,000   5,300,000  
Exercise price       $ 0.09 $ 0.20   $ 0.09
Shares vested   75,000 2,650,000          
Shares forfeited 225,000              
Aggregate grant date fair value     $ 477,000          
Share-Based Payment Arrangement, Noncash Expense     $ 207,342 $ 21,967        
Several Private Placement Agreements [Member]                
Class of Stock [Line Items]                
Number of common stock sold     1,947,175          
Share price     $ 0.23          
Value of common stock sold     $ 447,850          
Assets Purchase Agreement [Member]                
Class of Stock [Line Items]                
Shares issued during the period     73,183,893          
Shares issued value during the period     $ 907,480          
Non Voting Series A Preferred Stock [Member]                
Class of Stock [Line Items]                
Shares issued during the period     250,000,000          
Shares issued value during the period     $ 3,100,000          
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details) - USD ($)
May 31, 2023
May 31, 2022
Assets    
Right of use assets $ 131,970 $ 235,748
Accumulated reduction (30,125) (190,295)
Operating lease assets, net 101,845 45,453
Liabilities    
Lease Liability 131,970 235,748
Accumulated reduction (29,394) (188,582)
Total lease liability, net 102,576 47,166
Current portion (65,824) (47,166)
Non-current portion $ 36,752
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details 1) - USD ($)
May 31, 2023
May 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
2024 $ 65,824  
2025 36,752  
Total 102,576  
Less: Imputed interest  
Present value of lease liabilities $ 102,576 $ 47,166
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Loss Contingencies [Line Items]    
Lessee, Operating Lease, Description The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent was $7,567 per month for the first year and increased by a certain amount each year. In November 2022, the Company entered into an extension of the lease for a two  
Monthly base rent $ 6,098  
Initial lease liability 235,748  
Initial right of use asset 131,970  
Lease expense 84,435 $ 94,235
Lease liability 102,576 47,166
Right of use asset $ 101,845 $ 45,453
Discount rate 12.00%  
Accounts Payable [Member]    
Loss Contingencies [Line Items]    
Claim amount $ 204,182  
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.23.2
Related Party Transactions (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Related Party Transaction [Line Items]    
Consulting fee $ 135,484  
Compensation paid for services 126,097  
Commissions and contractor fee 74,620  
Bonus for services paid 15,928  
Weston T. Harris [Member]    
Related Party Transaction [Line Items]    
Consulting fee 218,696  
Intrepid [Member]    
Related Party Transaction [Line Items]    
Payable to related party $ 124,378 $ 25,452
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.23.2
Asset Purchase Agreement (Details) - USD ($)
May 31, 2023
Jun. 16, 2022
Business Combination and Asset Acquisition [Abstract]    
Cash   $ 1,066,414
Accounts receivable   227,786
Inventory   1,342,461
Prepaid expenses   62,452
Other assets   108,030
Accounts payable   (285,665)
Contract liabilities   (1,043,332)
Other current liabilities   (79,826)
Net tangible assets acquired   1,398,320
Identifiable intangible assets    
Licensing rights   11,945
Customer relationships   70,000
Tradenames   275,000
Website   100,000
Total Identifiable intangible assets   456,945
Consideration paid   4,007,480
Total net assets acquired   1,855,265
Goodwill purchased $ 2,152,215 $ 2,152,215
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.23.2
Asset Purchase Agreement (Details 1) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Business Combination and Asset Acquisition [Abstract]    
Revenue $ 25,428,163 $ 18,356,862
Net income (loss) $ 2,032,954 $ (3,212,320)
Earnings (loss) per common share    
Basic $ 0.02 $ (0.03)
Diluted $ 0.01
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combination (Details Narrative)
 1 Months Ended
Jun. 16, 2022
USD ($)
$ / shares
shares
Business Acquisition [Line Items]  
Shares consideration 323,183,893
Acquisition Costs, Period Cost | $ $ 4,007,480
Acquisition price per share | $ / shares $ 0.0124
Common Stock [Member]  
Business Acquisition [Line Items]  
Shares consideration 73,183,893
Preferred Stock [Member]  
Business Acquisition [Line Items]  
Shares consideration 250,000,000
Axil [Member]  
Business Acquisition [Line Items]  
Equity Method Investment, Ownership Percentage 4.68%
Jeff Toghraie [Member]  
Business Acquisition [Line Items]  
Equity Method Investment, Ownership Percentage 22.33%
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations (Details) - Revenue Benchmark [Member] - Product Concentration Risk [Member]
 12 Months Ended
May 31, 2023
May 31, 2022
Shampoos and Conditioners [Member]    
Concentration Risk [Line Items]    
Total 77.00% 84.00%
Ancillary Products [Member]    
Concentration Risk [Line Items]    
Total 23.00% 16.00%
Product [Member]    
Concentration Risk [Line Items]    
Total 100.00% 100.00%
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations (Details 1) - Revenue Benchmark [Member] - Product Concentration Risk [Member]
 12 Months Ended
May 31, 2023
May 31, 2022
Ghost Stryke [Member]    
Concentration Risk [Line Items]    
Total 86.70%  
Trackr Headmuff [Member]    
Concentration Risk [Line Items]    
Total 9.10%  
Other Bluetooth And Ear Buds [Member]    
Concentration Risk [Line Items]    
Total 3.90%  
Accessories Other [Member]    
Concentration Risk [Line Items]    
Total 0.30%  
Product [Member]    
Concentration Risk [Line Items]    
Total 100.00% 100.00%
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.23.2
Concentrations (Details Narrative) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Concentration Risk [Line Items]    
Cash, FDIC insured amount $ 250,000  
Cash, uninsured amount $ 4,582,682 $ 123,731
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 94.00% 31.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 61.00% 15.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 12.00% 16.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Three [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 21.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Axil [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 97.30%  
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Outside The United States [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 25.00% 16.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | CANADA    
Concentration Risk [Line Items]    
Concentration risk, percentage 20.00% 14.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | ITALY    
Concentration Risk [Line Items]    
Concentration risk, percentage 5.00% 2.00%
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Axil [Member] | Outside The United States [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 4.50%  
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Axil [Member] | CANADA    
Concentration Risk [Line Items]    
Concentration risk, percentage 3.70%  
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Hair Shampoo [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 15.00% 10.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Shampoo And Conditioner [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 10.00%  
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Bundled Kits [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 7.00%  
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Hair Shampoo And Conditioner [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   12.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Introductorykit [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   25.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Axil [Member] | Ear Buds [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 87.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 8.00% 74.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   11.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   12.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   14.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Four [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   37.00%
Purchases [Member] | Product Concentration Risk [Member]    
Concentration Risk [Line Items]    
Purchased inventories and products $ 297,833 $ 343,015
Purchases [Member] | Product Concentration Risk [Member] | Vendors [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 95.00%  
Purchases [Member] | Product Concentration Risk [Member] | Vendors One [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 61.00% 10.00%
Purchases [Member] | Product Concentration Risk [Member] | Vendors Two [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 12.00% 23.00%
Purchases [Member] | Product Concentration Risk [Member] | Vendors Three [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 22.00% 34.00%
Purchases [Member] | Product Concentration Risk [Member] | Vendor [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage   97.00%
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.23.2
Business Segment and Geographic Area Information (Details) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Segment Reporting Information [Line Items]    
Total net sales $ 23,521,027 $ 2,336,257
Total segment gross profit 17,710,811 1,507,671
Selling and Marketing 11,675,206 1,199,305
General and Administrative 4,051,394 519,769
Consolidated operating income (loss) 1,984,211 (211,403)
Consolidated total assets 10,169,314 893,915
Consolidated total payments for property and equipment 65,650
Consolidated total depreciation and amortization 95,179 7,872
Hair Care And Skin Care [Member]    
Segment Reporting Information [Line Items]    
Total net sales 1,588,958 2,336,257
Total segment gross profit 1,076,834 1,507,671
Consolidated total assets 3,785,732 893,915
Consolidated total payments for property and equipment
Consolidated total depreciation and amortization 5,675 7,872
Hearing Enhancement And Protection [Member]    
Segment Reporting Information [Line Items]    
Total net sales 21,932,069
Total segment gross profit 16,633,977
Consolidated total assets 6,383,582
Consolidated total payments for property and equipment 65,650
Consolidated total depreciation and amortization $ 89,504
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.23.2
Business Segment and Geographic Area Information (Details Narrative)
 12 Months Ended
May 31, 2023
Revenue Benchmark [Member] | Geographic Concentration Risk [Member] | Customers [Member]  
Revenue, Major Customer [Line Items]  
Concentration Risk, Percentage 94.00%
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.23.2
Income taxes (Details) - USD ($)
 12 Months Ended
May 31, 2023
May 31, 2022
Income Tax Disclosure [Abstract]    
Tax expense (benefit) computed at statutory rate of 21% $ 431,653 $ (38,410)
State tax expense (benefit) blended rate 297,928 (15,289)
Change in federal tax rate estimate for prior years (46,109)
Non-deductible expenses: Stock-based compensation 6,590
Non deductible expense: Other 2,082
Non taxable: COVID related grants/loan forgiveness 10,500
Benefit of tax amortization of intangibles (49,773)
Deferred tax true up 3,929
Net operating loss benefit (452,824)
Tax expense (benefit) 230,913
Increase (decrease) in valuation allowance (101,636) 101,636
Change in deferred tax asset 101,636  
Net income tax (benefit)/expense $ 230,913
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.23.2
Income taxes (Details 1) - USD ($)
May 31, 2023
May 31, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carryover $ 452,824
Less: valuation allowance (452,824)
Net deferred tax asset $ 0 $ 0
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Details Narrative) - USD ($)
May 31, 2023
May 31, 2022
Income Tax Disclosure [Abstract]    
Net Operating Loss Carryforward $ 1,500,000  
Deferred tax assets $ 0 $ 0
XML 85 rviv-20230531_10k_htm.xml IDEA: XBRL DOCUMENT 0001718500 2022-06-01 2023-05-31 0001718500 2022-11-30 0001718500 2023-08-09 0001718500 2023-05-31 0001718500 2022-05-31 0001718500 2021-06-01 2022-05-31 0001718500 us-gaap:PreferredStockMember 2021-05-31 0001718500 us-gaap:CommonStockMember 2021-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001718500 us-gaap:RetainedEarningsMember 2021-05-31 0001718500 2021-05-31 0001718500 us-gaap:PreferredStockMember 2022-05-31 0001718500 us-gaap:CommonStockMember 2022-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001718500 us-gaap:RetainedEarningsMember 2022-05-31 0001718500 us-gaap:PreferredStockMember 2021-06-01 2022-05-31 0001718500 us-gaap:CommonStockMember 2021-06-01 2022-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2022-05-31 0001718500 us-gaap:RetainedEarningsMember 2021-06-01 2022-05-31 0001718500 us-gaap:PreferredStockMember 2022-06-01 2023-05-31 0001718500 us-gaap:CommonStockMember 2022-06-01 2023-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2023-05-31 0001718500 us-gaap:RetainedEarningsMember 2022-06-01 2023-05-31 0001718500 us-gaap:PreferredStockMember 2023-05-31 0001718500 us-gaap:CommonStockMember 2023-05-31 0001718500 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001718500 us-gaap:RetainedEarningsMember 2023-05-31 0001718500 rviv:AxilMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerMember 2021-06-01 2022-05-31 0001718500 rviv:OptionsMember 2021-06-01 2022-05-31 0001718500 us-gaap:FurnitureAndFixturesMember 2023-05-31 0001718500 us-gaap:FurnitureAndFixturesMember 2022-05-31 0001718500 us-gaap:ComputerEquipmentMember 2023-05-31 0001718500 us-gaap:ComputerEquipmentMember 2022-05-31 0001718500 srt:MinimumMember us-gaap:PropertyPlantAndEquipmentMember 2023-05-31 0001718500 srt:MaximumMember us-gaap:PropertyPlantAndEquipmentMember 2023-05-31 0001718500 us-gaap:PropertyPlantAndEquipmentMember 2023-05-31 0001718500 us-gaap:PropertyPlantAndEquipmentMember 2022-05-31 0001718500 us-gaap:AutomobilesMember 2023-05-31 0001718500 us-gaap:AutomobilesMember 2022-05-31 0001718500 rviv:LicensingRightsMember 2023-05-31 0001718500 us-gaap:CustomerRelationshipsMember 2023-05-31 0001718500 us-gaap:TradeNamesMember 2023-05-31 0001718500 rviv:WebsiteMember 2023-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2020-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2020-05-01 2020-05-18 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2021-06-01 2022-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2023-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2022-05-31 0001718500 rviv:InsuranceFinancingMember 2023-05-31 0001718500 rviv:InsuranceFinancingMember 2022-06-01 2023-05-31 0001718500 rviv:InsuranceFinancingMember 2022-05-31 0001718500 rviv:PaycheckProtectionProgram2Member 2023-05-31 0001718500 rviv:PaycheckProtectionProgram2Member 2022-05-31 0001718500 rviv:FinancingChargesMember 2023-05-31 0001718500 rviv:FinancingChargesMember 2022-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2023-05-31 0001718500 rviv:EconomicInjuryDisasterLoanProgramMember 2022-05-31 0001718500 2022-06-13 0001718500 rviv:NonVotingSeriesAPreferredStockMember 2022-06-01 2023-05-31 0001718500 rviv:AssetsPurchaseAgreementMember 2022-06-01 2023-05-31 0001718500 rviv:SeveralPrivatePlacementAgreementsMember 2022-06-01 2023-05-31 0001718500 rviv:SeveralPrivatePlacementAgreementsMember 2023-05-31 0001718500 2022-05-10 0001718500 2022-11-01 0001718500 2023-01-01 2023-01-29 0001718500 2023-04-01 2023-04-30 0001718500 us-gaap:AccountsPayableMember 2023-05-31 0001718500 rviv:IntrepidMember 2023-05-31 0001718500 rviv:IntrepidMember 2022-05-31 0001718500 rviv:WestonT.HarrisMember 2022-06-01 2023-05-31 0001718500 rviv:AxilMember 2022-06-16 0001718500 rviv:JeffToghraieMember 2022-06-16 0001718500 2022-06-01 2022-06-16 0001718500 us-gaap:CommonStockMember 2022-06-01 2022-06-16 0001718500 us-gaap:PreferredStockMember 2022-06-01 2022-06-16 0001718500 2022-06-16 0001718500 rviv:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:OutsideTheUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 country:CA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 country:IT us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:OutsideTheUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 country:CA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 country:IT us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:HairShampooMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:ShampooAndConditionerMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:BundledKitsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:HairShampooMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:HairShampooAndConditionerMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:IntroductorykitMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:VendorsMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:VendorOneMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:VendorTwoMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:VendorThreeMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:VendorMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:VendorOneMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:VendorTwoMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:VendorThreeMember rviv:PurchasesMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:AxilMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:AxilMember rviv:OutsideTheUnitedStatesMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:AxilMember country:CA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:AxilMember rviv:EarBudsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:ShampoosAndConditionersMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:ShampoosAndConditionersMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:AncillaryProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:AncillaryProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 us-gaap:ProductMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 us-gaap:ProductMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-06-01 2022-05-31 0001718500 rviv:GhostStrykeMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:TrackrHeadmuffMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:OtherBluetoothAndEarBudsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:AccessoriesOtherMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-06-01 2023-05-31 0001718500 rviv:HairCareAndSkinCareMember 2022-06-01 2023-05-31 0001718500 rviv:HairCareAndSkinCareMember 2021-06-01 2022-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2022-06-01 2023-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2021-06-01 2022-05-31 0001718500 rviv:HairCareAndSkinCareMember 2023-05-31 0001718500 rviv:HairCareAndSkinCareMember 2022-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2023-05-31 0001718500 rviv:HearingEnhancementAndProtectionMember 2022-05-31 0001718500 rviv:CustomersMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2022-06-01 2023-05-31 iso4217:USD shares iso4217:USD shares pure 0001718500 false 2023 FY 10-K true 2023-05-31 --05-31 false 000-56351 REVIV3 PROCARE COMPANY DE 47-4125218 901 S Fremont Avenue Unit 158 Alhambra CA 91803 (888) 638-8883 No No Yes Yes Non-accelerated Filer true false false false false 5037204 117076949 None 106 SALBERG & COMPANY, P.A. Boca Raton, Florida 4832682 373731 417016 105921 1311864 323388 801360 7362922 803040 157463 29145 382674 101845 45453 12195 16277 2152215 2806392 90875 10169314 893915 908606 458263 183688 16522 2200 3300 827106 172588 156300 158072 25452 65824 47166 230913 305664 2854661 707003 2200 36752 605942 642694 2200 3497355 709203 0.0001 0.0001 300000000 300000000 250000000 250000000 0 0 25000 0.0001 0.0001 450000000 450000000 117076949 117076949 41945881 41945881 11708 4195 10102243 5472084 -3466992 -5291567 6671959 184712 10169314 893915 23521027 2336257 5810216 828586 17710811 1507671 11675206 1199305 1347839 15129 1420990 232774 1282565 271866 15726600 1719074 1984211 -211403 50500 35000 16829 6469 36 2521 6536 71277 28500 2055488 -182903 230913 1824575 -182903 0.02 -0.00 0.01 -0.00 112895411 41945881 357385274 41945881 41945881 4195 5450117 -5108664 345648 21967 21967 -182903 -182903 41945881 4195 5472084 -5291567 184712 250000000 25000 73183893 7318 3975162 4007480 207342 207342 1947175 195 447655 447850 1824575 1824575 250000000 25000 117076949 11708 10102243 -3466992 6671959 1824575 -182903 95179 7871 76969 6941 71481 207342 21967 50500 35000 -1713 160277 21985 -353985 -95983 661115 -2430 3810 215175 -701 630897 -90426 389716 2918136 -126055 -1066414 65650 1000764 447850 35000 -3300 -3300 37119 132620 -28851 540051 2849 4458951 -123206 373731 496937 4832682 373731 2521 500 4007480 131970 1740729 456945 2152215 1408823 <p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zYxbcad8JJd8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 1 – <span id="xdx_826_zMKCDVcxx29i">Organization</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reviv3 Procare Company (“Reviv3”) was incorporated in the State of Delaware on May 21, 2015 as a reorganization of Reviv3 Procare, LLC which was organized on July 31, 2013. The Company has moved its corporate headquarters to 901 Fremont Avenue, Unit 158, Alhambra, California 91803. Its phone number (888) 638-8883. <span style="background-color: white">In March 2022, the Company incorporated a subsidiary “Reviv3 Acquisition Corporation” and in June 2022, completed the asset acquisition of the Axil &amp; Associated Brand Corp. business (“AXIL”). </span>The Company is now engaged in the manufacturing, marketing, sale and distribution of high-tech hearing and audio innovations that provide cutting edge solutions for consumers, with varied applications across many industries; as well as professional quality hair and skin care products. These products lines are both sold throughout the United States, Canada, Europe and Asia.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zUqe5SAlN8Ze" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 2 – <span id="xdx_829_zK8jRWORfZT1">Basis of Presentation and Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z7JxxqN3rUAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86D_zt3HJIrmneVj">Basis of Presentation and Principles of Consolidation</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements for the fiscal years ended May 31, 2023 and 2022 have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) <span style="background-color: white">and include the accounts of the Company and its consolidated subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <i> </i></p> <p id="xdx_841_ecustom--LiquidityAndCapitalResourcesPolicyTextBlock_zgl3kN2yJbSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_865_zMGS1VodyzQg">Liquidity and Capital Resources</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white">We are currently engaged in our product sales and development. Although we earned net income and had cash provided by operations in the fiscal year ended May 31, 2023, we had an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230531_zif0bab4fiIi">3,466,992</span></span><span style="font-size: 10pt; background-color: white"> as of May 31, 2023 and have incurred operating losses and cash used in operations in the past. We currently expect to earn net income and positive cash flows from operations during the current fiscal year ending May 31, 2024. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL’s business, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying consolidated financial statements. Management is focused on growing the Company’s existing product, introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands, including those resulting from the purchase of AXIL’s assets in June 2022, may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying consolidated financial statements.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--UseOfEstimates_zdICZ2r1PMwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_865_zq2KfvjZclJ8">Use of estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, contract liability, allowance on sales returns, valuation of lease liabilities and related right of use assets, fair value of securities issued for business combinations, fair value of assets acquired and liabilities assumed in business combinations and the fair value of non-cash Common Stock issuances. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zg47ZcQxRvn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_861_zTibRMD8LwUk">Cash and cash equivalents</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.9pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p id="xdx_843_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcR8DhRkYRw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86F_zzZUrECN5l39">Accounts receivable and allowance for doubtful accounts</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivables comprise of receivables from customers and receivables from merchant processors. The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_840_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zNDQ2dfX58Yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86D_zgdyFhm7cbu5">Prepaid expenses and other current assets</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Prepaid expenses and other current assets consist primarily of cash prepayments to vendors for inventory and prepayments for trade shows and marketing events which will be utilized within a year, prepayments on credit cards and the right to recover assets (for the cost of goods sold) associated with the right of returns for products sold.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zUOrTci3TICg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_867_zSS8v13uZTfi">Inventory</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations. The Company continuously evaluates the levels of inventory held and any inventory held above the expected level of sales in the next twelve months, is classified as non-current inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeBiPSSA0Til" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_868_z96LWtE8IRZc">Property and Equipment</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_zNVy0fhnWoyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_862_zCO0w5uDDCe4">Revenue recognition</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard (new guidance) has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company sells a variety of hair and skin care products and electronic hearing and enhancement products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The five steps for revenue recognition are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Identify the contract with a customer. </i>The Company generally considers completion of a sales order (which requires customer<i> </i>acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) or purchase orders from non-consumer customers as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving third party financier payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Identify the performance obligations in the contract</i>. Product performance obligations include shipment of products and related accessories and service performance obligations include extended warranty coverage.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, as the historical redemption rate under our warranty policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts<i> </i>consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 30-days and 60-days right of return that applies to AXIL and Reviv3 products, respectively. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Allocate the transaction price to the performance obligations in the contract</i>. For contracts that contain multiple performance obligations,<i> </i>the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recognize revenue when or as the Company satisfies a performance obligation</i>. Revenue for products is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 31, 2023 and May 31, 2022, contract liabilities amounted to $<span id="xdx_909_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20230531_zkTYwaxXuS56" title="Contract liabilities">1,433,048</span> and $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20220531_zru8BVGWe5Ni" title="Contract liabilities">0</span>, respectively. <span id="xdx_90A_ecustom--ContractLiabilitiesDescription_c20220601__20230531" title="Contract Liabilities Description">Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue recognized, during the fiscal year ended May 31, 2023, that was included in the contract liability balance at the beginning of period (acquisition of AXIL) was $<span id="xdx_901_ecustom--RevenueRecognition_pp0p0_c20220601__20230531__us-gaap--BusinessAcquisitionAxis__custom--AxilMember_z9aa8hUAnCCe" title="Revenue recognition">391,204</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p id="xdx_84A_eus-gaap--CostOfSalesPolicyTextBlock_zSUlXUURcZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z67ZB5gVCafg">Cost of Sales</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.65pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The primary components of cost of sales include the cost of the product and shipping fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <i> </i></p> <p id="xdx_84B_ecustom--ShippingAndHandlingCostsPolicyTextBlock_z1P8tfICBiIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z3IRigtSO10h">Shipping and Handling Costs</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $<span id="xdx_908_eus-gaap--SellingAndMarketingExpense_pp0p0_c20220601__20230531__srt--MajorCustomersAxis__custom--CustomerMember_zKji6qP8N3Jk" title="Selling and marketing expense">1,001,261</span> and $<span id="xdx_909_eus-gaap--SellingAndMarketingExpense_pp0p0_c20210601__20220531__srt--MajorCustomersAxis__custom--CustomerMember_zQa6ikSm3TDi" title="Selling and marketing expense">214,517</span> for the fiscal years ended May 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_843_eus-gaap--AdvertisingCostsPolicyTextBlock_zC47V4etwCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86E_z3jaf4cnrrr8">Marketing, selling and advertising</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marketing, selling and advertising costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_ecustom--CustomerDepositPolicytextBlock_z9KMGuKeCKJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86A_z6q479BExJW2">Customer Deposits</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZyaOImEa391" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_861_zjt2IPJ378he">Fair value measurements and fair value of financial instruments</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 7%">Level 1:</td> <td style="width: 93%; text-align: justify">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td>Level 2:</td> <td style="text-align: justify">Observable market-based inputs or unobservable inputs that are corroborated by market data</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td>Level 3:</td> <td style="text-align: justify">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_z16hiADl47Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_860_ziRWzzwOZDbi">Business Combinations</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets acquired and liabilities assumed of the acquired business, at their fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z3AQiYvqh7G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_864_zk7w31QfCxYa">Goodwill</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur, or circumstances indicate the fair value of a reporting unit is below its carrying value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company performs its annual goodwill impairment assessment on May 31st of each year or as impairment indicators dictate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When evaluating the potential impairment of goodwill, management first assesses a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the quantitative impairment testing methodology primarily using the income approach (discounted cash flow method).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the quantitative method we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized is recognized as the amount by which the carrying amount exceeds the fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zn0sRSyMRUpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_869_z9RhGZw3hQIg">Income Taxes</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>  </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying consolidated balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_znIV2jTqWwoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86D_zcITBCLNMSFh">Impairment of long-lived assets</span></span></i>  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did <span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_do_c20220601__20230531_zehMR7TMPnjk" title="Impairment loss"><span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_do_c20210601__20220531_zHilKbPtTySd" title="Impairment loss">no</span></span>t record any impairment loss during the fiscal years ended May 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhG2bED6R07c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_864_zmxH1fqCklca">Stock-based compensation</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">For non-employee stock option based awards, the Company follows ASU 2018-7, which substantially aligns share based compensation for employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zKBLQrLcxPue" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86C_zErP5U6y8aRh">Net income (loss) per share of common stock</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net income (loss) per share is computed by dividing the net income or loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At May 31, 2022, the Company had <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_z8vgtPYnzhq4" title="Antidilutive shares">5,300,000 </span>options outstanding which were potentially dilutive securities, however they were excluded from the computation since their impact would be antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the fiscal year ended May 31, 2023, certain stock options were excluded from the computation of diluted common shares outstanding as they would have an anti-dilutive impact on the Company’s net income. The following table presents a reconciliation of basic and diluted net income per common share: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zHMHqvMUYxec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-left: 5.4pt"><span id="xdx_8B2_zSXPMzFxR3Uc" style="display: none">Schedule of net loss per share</span> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220601__20230531_z0UpVObGZL97" style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">For the Fiscal Year Ended</td> <td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">May 31, 2023</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: left; padding-left: 5.4pt">Net income</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,824,575</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WeightedAverageBasicShares_z6Cej580xR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Weighted average basic shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,895,411</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DilutiveSecuritiesAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Dilutive securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239,041,096</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 5.4pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,448,767</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WeightedAverageDilutiveShares_i01_z9IJHASb8Kqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Weighted average dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">357,385,274</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EarningsPerShareAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--Basic_i01_zttZq7Ym9ZKk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--Diluted_i01_z1bdewTSWGec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84F_eus-gaap--LoansAndLeasesReceivableLeaseFinancingPolicy_ziQCq0Ac2jS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86B_z5WyeiGGjgO5">Lease Accounting</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases</i> (“ASU 2016-02), which requires lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance (ASC Topic 840). Under the new guidance, codified as ASC Topic 842, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. The new guidance further requires that leases be classified at inception as either (a) operating leases or (b) finance leases. For operating leases, periodic expense generally is flat (straight-line) throughout the life of the lease. For finance leases, periodic expense declines over the life of the lease. The new standard, as amended, provides an option for entities to use the cumulative-effect transition method. As permitted, the Company adopted ASC Topic 842 effective June 1, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company renewed lease for its corporate headquarters commencing December 1, 2022, under lease agreements classified as an operating lease. Please see Note 11 – ‘Commitments and Contingencies’ under “Leases” below for more information about the Company’s leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zV1ZmMrwXTl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86B_zU2ko8Yo2gD">Segment Reporting</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company follows ASC Topic 280, <i>Segment Reporting</i>. The Company’s management reviews the Company’s consolidated financial results when making decisions about allocating resources and assessing the performance of the Company as a whole and has determined that the Company’s reportable segments are: (a) the sale of hearing protection and hearing enhancement products, and (b) the sale of hair care and skin care products. See Note 15 – “BUSINESS SEGMENT AND GEOGRAPHIC AREA INFORMATION” for more information about the Company’s reportable segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"> </span></p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_za6TBBcUsI35" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><br/> <span id="xdx_86B_zozO6UFIERzd">Reclassifications</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain reclassifications have been made to the prior year’s data to conform with the current period’s presentation. Specifically, the accounts payable have been separated from the accrued expenses, to conform with the current period’s presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBa5eG61roX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_863_zRkdME9k1Sr5">Recently Issued Accounting Pronouncements</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the FASB issued ASU No. 2020-06, <i>Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity</i> (ASU 2020-06), which simplifies the accounting for certain convertible instruments. Among other things, under ASU 2020-06, the embedded conversion features no longer must be separated from the host contract for convertible instruments with conversion features not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. ASU 2020-06 also eliminates the use of the treasury stock method when calculating the impact of convertible instruments on diluted Earnings per Share. For the Company, the provisions of ASU 2020-06 are effective for its fiscal year beginning on June 1, 2024. Early adoption is permitted, subject to certain limitations. The Company is evaluating the potential impact of adoption on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities (e.g. deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “Revenue from Contracts with Customers”. Generally, this new guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically, such amounts were recognized by the acquirer at fair value in purchase accounting. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. <span style="background-color: white">The Company opted to adopt this ASU as of June 1, 2022. The adoption of the guidance did not have a material impact on the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_z7JxxqN3rUAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86D_zt3HJIrmneVj">Basis of Presentation and Principles of Consolidation</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements for the fiscal years ended May 31, 2023 and 2022 have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) <span style="background-color: white">and include the accounts of the Company and its consolidated subsidiary. All significant intercompany accounts and transactions have been eliminated in consolidation.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <i> </i></p> <p id="xdx_841_ecustom--LiquidityAndCapitalResourcesPolicyTextBlock_zgl3kN2yJbSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_865_zMGS1VodyzQg">Liquidity and Capital Resources</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt; background-color: white">We are currently engaged in our product sales and development. Although we earned net income and had cash provided by operations in the fiscal year ended May 31, 2023, we had an accumulated deficit of $<span id="xdx_901_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230531_zif0bab4fiIi">3,466,992</span></span><span style="font-size: 10pt; background-color: white"> as of May 31, 2023 and have incurred operating losses and cash used in operations in the past. We currently expect to earn net income and positive cash flows from operations during the current fiscal year ending May 31, 2024. We believe our current cash balances, coupled with anticipated cash flow from operating activities, will be sufficient to meet our working capital requirements for at least one year from the date of issuance of the accompanying consolidated financial statements. We intend to continue to control our cash expenses as a percentage of expected revenue on an annual basis and thus may use our cash balances in the short-term to invest in revenue growth. As a result of the acquisition of AXIL’s business, we have generated and expect we will continue to generate sufficient cash for our operational needs, including any required debt payments, for at least one year from the date of issuance of the accompanying consolidated financial statements. Management is focused on growing the Company’s existing product, introducing new products, as well as expanding its customer base, to increase its revenues. The Company cannot give assurance that it can increase its cash balances or limit its cash consumption and thus maintain sufficient cash balances for its planned operations or future acquisitions. Future business demands, including those resulting from the purchase of AXIL’s assets in June 2022, may lead to cash utilization at levels greater than recently experienced. The Company cannot provide any assurance that it will be able to raise additional capital or obtain necessary financing on acceptable terms, or at all. Subject to the foregoing, management believes that the Company has sufficient capital and liquidity to fund its operations for at least one year from the date of issuance of the accompanying consolidated financial statements.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> -3466992 <p id="xdx_847_eus-gaap--UseOfEstimates_zdICZ2r1PMwk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_865_zq2KfvjZclJ8">Use of estimates</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. Significant estimates made by management include, but are not limited to, the allowance for doubtful accounts, inventory valuations and classifications, the useful life of property and equipment, the valuation of deferred tax assets, the value of stock-based compensation, contract liability, allowance on sales returns, valuation of lease liabilities and related right of use assets, fair value of securities issued for business combinations, fair value of assets acquired and liabilities assumed in business combinations and the fair value of non-cash Common Stock issuances. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zg47ZcQxRvn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_861_zTibRMD8LwUk">Cash and cash equivalents</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -9.9pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments and other short-term investments with maturities of three months or less, when purchased, to be cash equivalents. The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p id="xdx_843_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zcR8DhRkYRw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86F_zzZUrECN5l39">Accounts receivable and allowance for doubtful accounts</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivables comprise of receivables from customers and receivables from merchant processors. The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p id="xdx_840_ecustom--PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_zNDQ2dfX58Yg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86D_zgdyFhm7cbu5">Prepaid expenses and other current assets</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Prepaid expenses and other current assets consist primarily of cash prepayments to vendors for inventory and prepayments for trade shows and marketing events which will be utilized within a year, prepayments on credit cards and the right to recover assets (for the cost of goods sold) associated with the right of returns for products sold.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zUOrTci3TICg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_867_zSS8v13uZTfi">Inventory</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company values inventory, consisting of finished goods and raw materials, at the lower of cost and net realizable value. Cost is determined using an average cost method. The Company reduces inventory for the diminution of value, resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its net realizable value. The Company evaluates its current level of inventory considering historical sales and other factors and, based on this evaluation, classifies inventory markdowns in the statement of operations as a component of cost of goods sold. These markdowns are estimates, which could vary significantly from actual requirements if future economic conditions, customer demand or competition differ from expectations. The Company continuously evaluates the levels of inventory held and any inventory held above the expected level of sales in the next twelve months, is classified as non-current inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zeBiPSSA0Til" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_868_z96LWtE8IRZc">Property and Equipment</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed, and any resulting gains or losses are included in the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_zNVy0fhnWoyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_862_zCO0w5uDDCe4">Revenue recognition</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows Accounting Standards Codification (“ASC”) 606, Revenue From Contracts With Customers. This revenue recognition standard (new guidance) has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; and e) Recognize revenue when (or as) performance obligations are satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company sells a variety of hair and skin care products and electronic hearing and enhancement products. The Company recognizes revenue for the agreed upon sales price when a purchase order is received from the customer and subsequently the product is shipped to the customer, which satisfies the performance obligation. Consideration paid to the customer to promote and sell the Company’s products is typically recorded as a reduction in revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The five steps for revenue recognition are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Identify the contract with a customer. </i>The Company generally considers completion of a sales order (which requires customer<i> </i>acceptance of the Company’s click-through terms and conditions for website sales and authorization of payment through credit card or another form of payment for sales made over the phone) or purchase orders from non-consumer customers as a customer contract provided that collection is considered probable. For payments that are not made upfront by credit card, the Company assesses customer creditworthiness based on credit checks, payment history, and/or other circumstances. For payments involving third party financier payors, the Company validates customer eligibility and reimbursement amounts prior to shipping the product.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Identify the performance obligations in the contract</i>. Product performance obligations include shipment of products and related accessories and service performance obligations include extended warranty coverage.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, as the historical redemption rate under our warranty policy has been low, the option is not accounted for as a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determine the transaction price and allocation to performance obligations. The transaction price in the Company’s customer contracts<i> </i>consists of both fixed and variable consideration. Fixed consideration includes amounts to be contractually billed to the customer while variable consideration includes the 30-days and 60-days right of return that applies to AXIL and Reviv3 products, respectively. To estimate product returns, the Company analyzes historical return levels, current economic trends, and changes in customer demand. Based on this information, the Company reserves a percentage of product sale revenue and accounts for the estimated impact as a reduction in the transaction price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Allocate the transaction price to the performance obligations in the contract</i>. For contracts that contain multiple performance obligations,<i> </i>the Company allocates the transaction price to the performance obligations on a relative standalone selling price basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Recognize revenue when or as the Company satisfies a performance obligation</i>. Revenue for products is recognized at a point in time, which is generally upon shipment. Revenue for services (extended warranty) is recognized over time on a ratable basis over the warranty period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 31, 2023 and May 31, 2022, contract liabilities amounted to $<span id="xdx_909_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20230531_zkTYwaxXuS56" title="Contract liabilities">1,433,048</span> and $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20220531_zru8BVGWe5Ni" title="Contract liabilities">0</span>, respectively. <span id="xdx_90A_ecustom--ContractLiabilitiesDescription_c20220601__20230531" title="Contract Liabilities Description">Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue recognized, during the fiscal year ended May 31, 2023, that was included in the contract liability balance at the beginning of period (acquisition of AXIL) was $<span id="xdx_901_ecustom--RevenueRecognition_pp0p0_c20220601__20230531__us-gaap--BusinessAcquisitionAxis__custom--AxilMember_z9aa8hUAnCCe" title="Revenue recognition">391,204</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> 1433048 0 Contract liabilities associated with product invoiced but not received by customers at the balance sheet date was $0 and $0, respectively; contract liabilities associated with unfulfilled performance obligations for warranty services offered for a period of one to three years was $1,320,401 and $0, respectively, and contract liabilities associated with unfulfilled performance obligations for customers’ right of return was $112,647 and $0, respectively. Our contract liabilities amounts are expected to be recognized over a period of one year to three years. Approximately $827,106 is expected to be recognized in year 1, $420,629 is expected to be recognized in year 2, and $185,313 is expected to be recognized in year 3. 391204 <p id="xdx_84A_eus-gaap--CostOfSalesPolicyTextBlock_zSUlXUURcZa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z67ZB5gVCafg">Cost of Sales</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 39.65pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The primary components of cost of sales include the cost of the product and shipping fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <i> </i></p> <p id="xdx_84B_ecustom--ShippingAndHandlingCostsPolicyTextBlock_z1P8tfICBiIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z3IRigtSO10h">Shipping and Handling Costs</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for shipping and handling fees in accordance with ASC 606. While amounts charged to customers for shipping products are included in revenues, the related costs of shipping products to customers are classified in marketing and selling expenses as incurred. Shipping costs included in marketing and selling expense were $<span id="xdx_908_eus-gaap--SellingAndMarketingExpense_pp0p0_c20220601__20230531__srt--MajorCustomersAxis__custom--CustomerMember_zKji6qP8N3Jk" title="Selling and marketing expense">1,001,261</span> and $<span id="xdx_909_eus-gaap--SellingAndMarketingExpense_pp0p0_c20210601__20220531__srt--MajorCustomersAxis__custom--CustomerMember_zQa6ikSm3TDi" title="Selling and marketing expense">214,517</span> for the fiscal years ended May 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> 1001261 214517 <p id="xdx_843_eus-gaap--AdvertisingCostsPolicyTextBlock_zC47V4etwCh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86E_z3jaf4cnrrr8">Marketing, selling and advertising</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Marketing, selling and advertising costs are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_ecustom--CustomerDepositPolicytextBlock_z9KMGuKeCKJc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86A_z6q479BExJW2">Customer Deposits</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Customer deposits consisted of prepayments from customers to the Company. The Company will recognize the prepayments as revenue upon delivery of products in compliance with its revenue recognition policy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zZyaOImEa391" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_861_zjt2IPJ378he">Fair value measurements and fair value of financial instruments</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 7%">Level 1:</td> <td style="width: 93%; text-align: justify">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td>Level 2:</td> <td style="text-align: justify">Observable market-based inputs or unobservable inputs that are corroborated by market data</td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td>Level 3:</td> <td style="text-align: justify">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain financial instruments, including prepaid expenses, deposits, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--BusinessCombinationsPolicy_z16hiADl47Yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_860_ziRWzzwOZDbi">Business Combinations</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets acquired and liabilities assumed of the acquired business, at their fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: (1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or (2) if the contingent consideration is classified as a liability, the changes in fair value and accretion costs are recognized in earnings. The increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z3AQiYvqh7G1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_864_zk7w31QfCxYa">Goodwill</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur, or circumstances indicate the fair value of a reporting unit is below its carrying value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company performs its annual goodwill impairment assessment on May 31st of each year or as impairment indicators dictate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When evaluating the potential impairment of goodwill, management first assesses a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the quantitative impairment testing methodology primarily using the income approach (discounted cash flow method).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the quantitative method we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized is recognized as the amount by which the carrying amount exceeds the fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zn0sRSyMRUpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_869_z9RhGZw3hQIg">Income Taxes</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i>  </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tax positions that meet the more likely than not recognition threshold are measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying consolidated balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_841_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_znIV2jTqWwoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86D_zcITBCLNMSFh">Impairment of long-lived assets</span></span></i>  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. The Company did <span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_do_c20220601__20230531_zehMR7TMPnjk" title="Impairment loss"><span id="xdx_90F_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pp0p0_do_c20210601__20220531_zHilKbPtTySd" title="Impairment loss">no</span></span>t record any impairment loss during the fiscal years ended May 31, 2023 and 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0 0 <p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zhG2bED6R07c" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_864_zmxH1fqCklca">Stock-based compensation</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">For non-employee stock option based awards, the Company follows ASU 2018-7, which substantially aligns share based compensation for employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zKBLQrLcxPue" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86C_zErP5U6y8aRh">Net income (loss) per share of common stock</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net income (loss) per share is computed by dividing the net income or loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period. At May 31, 2022, the Company had <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210601__20220531__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_z8vgtPYnzhq4" title="Antidilutive shares">5,300,000 </span>options outstanding which were potentially dilutive securities, however they were excluded from the computation since their impact would be antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the fiscal year ended May 31, 2023, certain stock options were excluded from the computation of diluted common shares outstanding as they would have an anti-dilutive impact on the Company’s net income. The following table presents a reconciliation of basic and diluted net income per common share: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zHMHqvMUYxec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-left: 5.4pt"><span id="xdx_8B2_zSXPMzFxR3Uc" style="display: none">Schedule of net loss per share</span> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220601__20230531_z0UpVObGZL97" style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">For the Fiscal Year Ended</td> <td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">May 31, 2023</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: left; padding-left: 5.4pt">Net income</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,824,575</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WeightedAverageBasicShares_z6Cej580xR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Weighted average basic shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,895,411</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DilutiveSecuritiesAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Dilutive securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239,041,096</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 5.4pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,448,767</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WeightedAverageDilutiveShares_i01_z9IJHASb8Kqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Weighted average dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">357,385,274</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EarningsPerShareAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--Basic_i01_zttZq7Ym9ZKk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--Diluted_i01_z1bdewTSWGec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 5300000 <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zHMHqvMUYxec" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-left: 5.4pt"><span id="xdx_8B2_zSXPMzFxR3Uc" style="display: none">Schedule of net loss per share</span> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20220601__20230531_z0UpVObGZL97" style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td> </td> <td colspan="2" style="text-align: center; vertical-align: bottom">For the Fiscal Year Ended</td> <td style="text-align: center; vertical-align: bottom"> </td> <td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">May 31, 2023</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 77%; text-align: left; padding-left: 5.4pt">Net income</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,824,575</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--WeightedAverageBasicShares_z6Cej580xR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Weighted average basic shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112,895,411</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DilutiveSecuritiesAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Dilutive securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncrementalCommonSharesAttributableToConversionOfPreferredStock_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 5.4pt">Convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">239,041,096</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 5.4pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,448,767</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--WeightedAverageDilutiveShares_i01_z9IJHASb8Kqf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Weighted average dilutive shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">357,385,274</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--EarningsPerShareAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Earnings (loss) per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--Basic_i01_zttZq7Ym9ZKk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--Diluted_i01_z1bdewTSWGec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td> <td style="text-align: left"> </td></tr> </table> 1824575 112895411 239041096 5448767 357385274 0.02 0.01 <p id="xdx_84F_eus-gaap--LoansAndLeasesReceivableLeaseFinancingPolicy_ziQCq0Ac2jS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><span id="xdx_86B_z5WyeiGGjgO5">Lease Accounting</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases</i> (“ASU 2016-02), which requires lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance (ASC Topic 840). Under the new guidance, codified as ASC Topic 842, the lease liability must be measured initially based on the present value of future lease payments, subject to certain conditions. The right-of-use asset must be measured initially based on the amount of the liability, plus certain initial direct costs. The new guidance further requires that leases be classified at inception as either (a) operating leases or (b) finance leases. For operating leases, periodic expense generally is flat (straight-line) throughout the life of the lease. For finance leases, periodic expense declines over the life of the lease. The new standard, as amended, provides an option for entities to use the cumulative-effect transition method. As permitted, the Company adopted ASC Topic 842 effective June 1, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company renewed lease for its corporate headquarters commencing December 1, 2022, under lease agreements classified as an operating lease. Please see Note 11 – ‘Commitments and Contingencies’ under “Leases” below for more information about the Company’s leases.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zV1ZmMrwXTl7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i><span style="text-decoration: underline"><span id="xdx_86B_zU2ko8Yo2gD">Segment Reporting</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company follows ASC Topic 280, <i>Segment Reporting</i>. The Company’s management reviews the Company’s consolidated financial results when making decisions about allocating resources and assessing the performance of the Company as a whole and has determined that the Company’s reportable segments are: (a) the sale of hearing protection and hearing enhancement products, and (b) the sale of hair care and skin care products. See Note 15 – “BUSINESS SEGMENT AND GEOGRAPHIC AREA INFORMATION” for more information about the Company’s reportable segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"> </span></p> <p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_za6TBBcUsI35" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline"><br/> <span id="xdx_86B_zozO6UFIERzd">Reclassifications</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain reclassifications have been made to the prior year’s data to conform with the current period’s presentation. Specifically, the accounts payable have been separated from the accrued expenses, to conform with the current period’s presentation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBa5eG61roX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_863_zRkdME9k1Sr5">Recently Issued Accounting Pronouncements</span></span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, the FASB issued ASU No. 2020-06, <i>Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity</i> (ASU 2020-06), which simplifies the accounting for certain convertible instruments. Among other things, under ASU 2020-06, the embedded conversion features no longer must be separated from the host contract for convertible instruments with conversion features not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. ASU 2020-06 also eliminates the use of the treasury stock method when calculating the impact of convertible instruments on diluted Earnings per Share. For the Company, the provisions of ASU 2020-06 are effective for its fiscal year beginning on June 1, 2024. Early adoption is permitted, subject to certain limitations. The Company is evaluating the potential impact of adoption on its financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.” This ASU requires contract assets and contract liabilities (e.g. deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, “Revenue from Contracts with Customers”. Generally, this new guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. Historically, such amounts were recognized by the acquirer at fair value in purchase accounting. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued. <span style="background-color: white">The Company opted to adopt this ASU as of June 1, 2022. The adoption of the guidance did not have a material impact on the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_800_eus-gaap--AccountsAndNontradeReceivableTextBlock_z3qtXplS0q6e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 3 – <span id="xdx_827_zIhrgThARkGg">Accounts Receivable, net</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable, consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_z700068mCLfi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable, net (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B2_z4zeYzFs1GB7" style="display: none">Schedule of accounts receivable</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20230531_zXUYsXyZgY7g" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220531_zqSlJoPzARo8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td></tr> <tr id="xdx_407_ecustom--CustomersReceivable_iI_pp0p0_maARNzY0D_zaoW4lRSbVEb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Customers Receivable</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">345,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">115,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--MerchantProcessorReceivable_iI_pp0p0_maARNzY0D_zSls7k6326Wi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Merchant Processor Receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pp0p0_di_msARNzY0D_zac9j6jX0Dc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Allowance for doubtful debts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(95,480</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,820</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--AccountsReceivableNet_iTI_pp0p0_mtARNzY0D_zeoX5a2H9dy8" style="vertical-align: bottom; background-color: White"> <td style="color: White; padding-bottom: 3.5pt">Accounts receivable, net </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">417,016</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">105,921</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded bad debt expense of $<span id="xdx_906_eus-gaap--ProvisionForDoubtfulAccounts_c20220601__20230531_pp0p0" title="Bad debt expense">76,969</span> and $<span id="xdx_904_eus-gaap--ProvisionForDoubtfulAccounts_c20210601__20220531_pp0p0" title="Bad debt expense">6,941</span> during the fiscal years ended May 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_z700068mCLfi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable, net (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B2_z4zeYzFs1GB7" style="display: none">Schedule of accounts receivable</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20230531_zXUYsXyZgY7g" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20220531_zqSlJoPzARo8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td></tr> <tr id="xdx_407_ecustom--CustomersReceivable_iI_pp0p0_maARNzY0D_zaoW4lRSbVEb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Customers Receivable</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">345,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">115,741</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--MerchantProcessorReceivable_iI_pp0p0_maARNzY0D_zSls7k6326Wi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Merchant Processor Receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167,232</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0594">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pp0p0_di_msARNzY0D_zac9j6jX0Dc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Allowance for doubtful debts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(95,480</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,820</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--AccountsReceivableNet_iTI_pp0p0_mtARNzY0D_zeoX5a2H9dy8" style="vertical-align: bottom; background-color: White"> <td style="color: White; padding-bottom: 3.5pt">Accounts receivable, net </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">417,016</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">105,921</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 345264 115741 167232 95480 9820 417016 105921 76969 6941 <p id="xdx_801_eus-gaap--InventoryDisclosureTextBlock_zIAgmNF8cV19" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 4 – <span id="xdx_82E_zrUBqyKf6Gp5">Inventory, net</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventory consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zbbuOQU7w4R2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory, net (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_8B0_zh2PxIO5NRSa" style="display: none">Schedule of Inventory</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_49E_20230531_zDPntLS5aAac" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_498_20220531_zZar4rUdEN82" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzQET_zWtGWCekgs49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Finished Goods</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,198,218</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">29,249</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzQET_zQ98VynEKZIb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Raw Materials</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">113,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">294,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryNet_iTI_pp0p0_mtINzQET_zo9Gz3iH6Z2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); padding-bottom: 3.5pt">Inventory, net</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">1,311,864</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">323,388</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At May 31, 2023 and 2022, inventory held at third party locations amounted to $<span id="xdx_901_ecustom--InventoryHeldAtThirdPartyLocation_c20230531_pp0p0" title="Inventory held at third party location">0</span> and $<span id="xdx_90E_ecustom--InventoryHeldAtThirdPartyLocation_c20220531_pp0p0" title="Inventory held at third party location">16,940</span>, respectively. At May 31, 2023 and 2022, there was $<span id="xdx_90E_eus-gaap--OtherInventoryInTransit_iI_pp0p0_c20230531_zMOo3WbTSrdh" title="Inventory in-transit">135,482</span> and $<span id="xdx_904_eus-gaap--OtherInventoryInTransit_c20220531_pp0p0" title="Inventory in-transit">0</span> inventory in- transit, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal years ended May 31, 2023 and 2022, the Company created an allowance of $<span id="xdx_90A_eus-gaap--InventoryValuationReserves_c20230531_pp0p0" title="Inventory valuation reserves">0</span> and $<span id="xdx_90B_eus-gaap--InventoryValuationReserves_c20220531_pp0p0" title="Inventory valuation reserves">71,481</span>, respectively, on slow moving inventory included in cost of sales. As of May 31, 2023 and 2022, there was <span id="xdx_90B_eus-gaap--InventoryNoncurrent_iI_pp0p0_do_c20230531_zpyNlArIpZ2d" title="Inventory, non-current"><span id="xdx_90E_eus-gaap--InventoryNoncurrent_iI_pp0p0_do_c20220531_zP5HAYkuco0g" title="Inventory, non-current">no</span></span> slow moving inventory.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zbbuOQU7w4R2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventory, net (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_8B0_zh2PxIO5NRSa" style="display: none">Schedule of Inventory</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_49E_20230531_zDPntLS5aAac" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_498_20220531_zZar4rUdEN82" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzQET_zWtGWCekgs49" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Finished Goods</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,198,218</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">29,249</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzQET_zQ98VynEKZIb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Raw Materials</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">113,646</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">294,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InventoryNet_iTI_pp0p0_mtINzQET_zo9Gz3iH6Z2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="color: rgb(204,238,255); padding-bottom: 3.5pt">Inventory, net</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">1,311,864</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">323,388</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 1198218 29249 113646 294139 1311864 323388 0 16940 135482 0 0 71481 0 0 <p id="xdx_801_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_znUjywdYpI1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 5 – <span id="xdx_82F_zqAxeyjuQqB2">Property and Equipment</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment, stated at cost, consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVpTffYqbjpa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BE_zFOZy8JpxJF" style="display: none">Schedule of Property and Equipment</span></td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Life</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left">Furniture and Fixtures</td><td style="width: 5%"> </td> <td style="width: 21%; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8BJKOzem9Pi" title="Property, Plant and Equipment, Useful Life">5</span> years</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="width: 19%; text-align: right" title="Plant Equipment">14,598</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="width: 19%; text-align: right" title="Plant Equipment">5,759</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer Equipment</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIvkiaq3fvB7" title="Property, Plant and Equipment, Useful Life">3</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">33,146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">17,392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Plant Equipment</td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zmaNq9xn3hFh" title="Property, Plant and Equipment, Useful Life">5</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zR0OWvQ9z0r5" title="Property, Plant and Equipment, Useful Life">10</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">165,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">45,128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Automobile</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--AutomobilesMember_z5kzEOxB6kgh" title="Property, Plant and Equipment, Useful Life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--AutomobilesMember_zl6ON1InN9s4" style="text-align: right" title="Plant Equipment">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--AutomobilesMember_zI7oFxXdkxgi" style="text-align: right" title="Plant Equipment"><span style="-sec-ix-hidden: xdx2ixbrl0663">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230531_z969byVb0xx" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less:Accumulated Depreciation">(71,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220531_zgO55eubGnqh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less:Accumulated Depreciation">(39,134</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, net">157,463</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20220531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, net">29,145</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense amounted to $<span id="xdx_907_eus-gaap--Depreciation_c20220601__20230531_pp0p0" title="Depreciation">20,908</span> and $<span id="xdx_909_eus-gaap--Depreciation_c20210601__20220531_pp0p0" title="Depreciation">7,871</span> for the fiscal years ended May 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zVpTffYqbjpa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BE_zFOZy8JpxJF" style="display: none">Schedule of Property and Equipment</span></td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Life</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left">Furniture and Fixtures</td><td style="width: 5%"> </td> <td style="width: 21%; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z8BJKOzem9Pi" title="Property, Plant and Equipment, Useful Life">5</span> years</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="width: 19%; text-align: right" title="Plant Equipment">14,598</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="width: 19%; text-align: right" title="Plant Equipment">5,759</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer Equipment</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zIvkiaq3fvB7" title="Property, Plant and Equipment, Useful Life">3</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">33,146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">17,392</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Plant Equipment</td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MinimumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zmaNq9xn3hFh" title="Property, Plant and Equipment, Useful Life">5</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__srt--RangeAxis__srt--MaximumMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_zR0OWvQ9z0r5" title="Property, Plant and Equipment, Useful Life">10</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">165,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--PropertyPlantAndEquipmentMember_pp0p0" style="text-align: right" title="Plant Equipment">45,128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Automobile</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--AutomobilesMember_z5kzEOxB6kgh" title="Property, Plant and Equipment, Useful Life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--AutomobilesMember_zl6ON1InN9s4" style="text-align: right" title="Plant Equipment">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20220531__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--AutomobilesMember_zI7oFxXdkxgi" style="text-align: right" title="Plant Equipment"><span style="-sec-ix-hidden: xdx2ixbrl0663">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230531_z969byVb0xx" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less:Accumulated Depreciation">(71,059</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220531_zgO55eubGnqh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less:Accumulated Depreciation">(39,134</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentNet_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, net">157,463</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20220531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Property and equipment, net">29,145</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> P5Y 14598 5759 P3Y 33146 17392 P5Y P10Y 165778 45128 P5Y 15000 71059 39134 157463 29145 20908 7871 <p id="xdx_806_eus-gaap--IntangibleAssetsDisclosureTextBlock_zIXFpfEg4UQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 6 – <span id="xdx_823_z0Y7XwHqO5e3">Intangible Assets</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The Company acquired intangible assets through the Business Combination. (See Note 13). These intangible assets consisted of the following:</span> </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_z8UdChSQN5re" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B9_zqokc9CRObI2" style="display: none">Schedule of intangible assets</span></td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Life</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 31%; text-align: left">Licensing Rights</td><td style="width: 6%"> </td> <td style="width: 12%; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_zBl5dXntO43d" title="Intangible Assets useful life">3</span> years</td><td style="width: 6%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_pp0p0" style="width: 12%; text-align: right">11,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer Relationships</td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zUAG9ysQXrG9" title="Intangible Assets useful life">3</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="text-align: right">70,000</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade Names</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdbaT4TU77B4" title="Intangible Assets useful life">10</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pp0p0" style="text-align: right">275,000</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Website</td><td> </td> <td style="text-align: center"> <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zAOLP4kNCsbi" title="Intangible Assets useful life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_pp0p0" style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20230531_zK5FZgcyN4a3" style="border-bottom: Black 1.5pt solid; text-align: right">(74,271</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right">382,674</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill arising through the business combination was $<span id="xdx_907_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0_c20230531_z2XzDKElJa15" title="Goodwill">2,152,215</span> at May 31, 2023 (see Note 13).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense amounted to $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_c20220601__20230531_pp0p0" title="Amortization expense">74,271</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20210601__20220531_pp0p0" title="Amortization expense">0</span> for the fiscal years ended May 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfImpairedIntangibleAssetsTextBlock_z8UdChSQN5re" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B9_zqokc9CRObI2" style="display: none">Schedule of intangible assets</span></td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Estimated Life</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 31%; text-align: left">Licensing Rights</td><td style="width: 6%"> </td> <td style="width: 12%; text-align: center"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_zBl5dXntO43d" title="Intangible Assets useful life">3</span> years</td><td style="width: 6%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensingRightsMember_pp0p0" style="width: 12%; text-align: right">11,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer Relationships</td><td> </td> <td style="text-align: center"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zUAG9ysQXrG9" title="Intangible Assets useful life">3</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pp0p0" style="text-align: right">70,000</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade Names</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdbaT4TU77B4" title="Intangible Assets useful life">10</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pp0p0" style="text-align: right">275,000</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Website</td><td> </td> <td style="text-align: center"> <span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_zAOLP4kNCsbi" title="Intangible Assets useful life">5</span> years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20230531__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_pp0p0" style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_c20230531_zK5FZgcyN4a3" style="border-bottom: Black 1.5pt solid; text-align: right">(74,271</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right">382,674</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> </tr> </table> P3Y 11945 P3Y 70000 P10Y 275000 P5Y 100000 74271 382674 2152215 74271 0 <p id="xdx_80F_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zdoBSLblKusl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 7 – <span id="xdx_82A_zWzJ9c8PzJoc">Other Current Liabilities</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other current liabilities comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zJWK0ifNjli5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Other Current Liabilities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt"><span id="xdx_8B9_zXJNwRjn4OQ6" style="display: none">Schedule of other current liabilities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230531_z6AYioqnZpk5" style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr id="xdx_405_ecustom--CreditCards_iI_pp0p0_maOLCzMgT_z2NIPCPd0zJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify; padding-left: 5.4pt">Credit Cards</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">833</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_404_eus-gaap--InterestPayableCurrent_iI_pp0p0_maOLCzMgT_zyxOXSzkEG4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,343</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40A_ecustom--RoyaltyPaymentAccrual_iI_pp0p0_maOLCzMgT_zQWK4cJBWhJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Royalty Payment Accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,792</td><td style="text-align: left"> </td> </tr> <tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maOLCzMgT_ztQPla8ECBMl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Sales Tax Payable and Other Accrued Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,023</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40E_ecustom--AffiliateAccrual_iI_pp0p0_maOLCzMgT_zSq8Di1y9Ff3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify; padding-left: 5.4pt">Affiliate Accrual</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,673</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr id="xdx_402_eus-gaap--OtherLiabilities_iTI_pp0p0_mtOLCzMgT_zKzmnE2CJTi3" style="vertical-align: bottom; background-color: White"> <td style="color: rgb(204,238,255); padding-bottom: 3.5pt; padding-left: 5.4pt"><span style="color: Black">Other Current Liabilities </span></td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">305,664</td><td style="padding-bottom: 3.5pt; text-align: left"> </td> </tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zJWK0ifNjli5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Other Current Liabilities (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt"><span id="xdx_8B9_zXJNwRjn4OQ6" style="display: none">Schedule of other current liabilities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230531_z6AYioqnZpk5" style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr id="xdx_405_ecustom--CreditCards_iI_pp0p0_maOLCzMgT_z2NIPCPd0zJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: justify; padding-left: 5.4pt">Credit Cards</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">833</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_404_eus-gaap--InterestPayableCurrent_iI_pp0p0_maOLCzMgT_zyxOXSzkEG4l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,343</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40A_ecustom--RoyaltyPaymentAccrual_iI_pp0p0_maOLCzMgT_zQWK4cJBWhJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Royalty Payment Accrual</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,792</td><td style="text-align: left"> </td> </tr> <tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maOLCzMgT_ztQPla8ECBMl" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Sales Tax Payable and Other Accrued Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">258,023</td><td style="text-align: left"> </td> </tr> <tr id="xdx_40E_ecustom--AffiliateAccrual_iI_pp0p0_maOLCzMgT_zSq8Di1y9Ff3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify; padding-left: 5.4pt">Affiliate Accrual</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,673</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> </tr> <tr id="xdx_402_eus-gaap--OtherLiabilities_iTI_pp0p0_mtOLCzMgT_zKzmnE2CJTi3" style="vertical-align: bottom; background-color: White"> <td style="color: rgb(204,238,255); padding-bottom: 3.5pt; padding-left: 5.4pt"><span style="color: Black">Other Current Liabilities </span></td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">305,664</td><td style="padding-bottom: 3.5pt; text-align: left"> </td> </tr> </table> 833 10343 8792 258023 27673 305664 <p id="xdx_80E_ecustom--EquipmentFinancingPayableTextBlock_zlbhDEuwjF9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 8 – <span id="xdx_82A_zl7QvtF57pPk">Equipment Payable</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended May 31, 2019, the Company purchased a forklift under an installment purchase plan. The loan amount is $16,500 payable in 60 monthly installment payments of $317 comprising of principal payment of $275 and interest payment of $42. As at May 31, 2023 and 2022, the balance outstanding on the loan was $2,200 and $5,500, respectively, of which the $2,200 balance is payable within the next year. The Company recorded an interest expense of $500 and $500, associated with the equipment financing during the fiscal years ended May 31, 2023 and 2022, on the loan in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amounts of loan payments due within the next fiscal year ended May 31, are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfLoanPaymentDueTableTextBlock_zc2DZrFd48Lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment Payable (Details)"> <tr style="vertical-align: bottom"> <td colspan="3"><span id="xdx_8B5_znxNAUymj4r1" style="display: none">Schedule of loan payment due</span></td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="vertical-align: top; width: 73%; text-align: left">2024</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="padding-bottom: 1.5pt; width: 12%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98E_ecustom--EquipmentFinancingPayableCurrent_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="2024">2,200</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="color: White; text-align: left">Equipment Payable, Net </td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquipmentFinancingPayable_c20230531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Equipment Payable, Net">2,200</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfLoanPaymentDueTableTextBlock_zc2DZrFd48Lb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equipment Payable (Details)"> <tr style="vertical-align: bottom"> <td colspan="3"><span id="xdx_8B5_znxNAUymj4r1" style="display: none">Schedule of loan payment due</span></td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="vertical-align: top; width: 73%; text-align: left">2024</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="padding-bottom: 1.5pt; width: 12%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td> <td id="xdx_98E_ecustom--EquipmentFinancingPayableCurrent_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="2024">2,200</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="color: White; text-align: left">Equipment Payable, Net </td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--EquipmentFinancingPayable_c20230531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Equipment Payable, Net">2,200</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 2200 2200 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zn9jZwBLmA9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 9 – <span id="xdx_82C_zFQq9IrUmQtg">Notes Payable</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2020, a commercial bank granted to the Company a loan (the “Loan”) in the amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_c20200531__us-gaap--LongtermDebtTypeAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" title="Face Amount">150,000</span>, which is administered under the authority and regulations of the U.S. Small Business Administration pursuant to the Economic Injury Disaster Loan Program (the “EIDL”) of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Loan, which is evidenced by a note dated May 18, 2020, bears interest at an annual rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20200501__20200518__us-gaap--LongtermDebtTypeAxis__custom--EconomicInjuryDisasterLoanProgramMember_pdd" title="Interest rate">3.75%</span> and is payable installments of $731 per month, beginning May 18, 2021 until May 13, 2050. The Company has to maintain a hazard insurance policy including fire, lightning, and extended coverage on all items used to secure this loan to at least 80% of the insurable value. Proceeds from loans granted under the CARES Act are intended to be used for payroll, costs to continue employee group health care benefits, rent, utilities, and certain other qualified costs (collectively, “qualifying expenses”). The Company used the loan proceeds for qualifying expenses. The Company received a loan forgiveness for $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfDebt_c20210601__20220531__us-gaap--LongtermDebtTypeAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" title="Additional borrowings">10,000</span> during the fiscal year ended May 31, 2022. During the fiscal year ended May 31, 2022, the Company received additional $<span id="xdx_902_ecustom--LoanForgiveness_c20210601__20220531__us-gaap--LongtermDebtTypeAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" title="Loan forgiveness">10,000</span> of borrowings under the program. The Company recorded an accrued interest of $<span id="xdx_908_eus-gaap--InterestPayableCurrent_c20230531__us-gaap--LongtermDebtTypeAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" title="Accrued interest">10,342 </span>and $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_c20220531__us-gaap--LongtermDebtTypeAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" title="Accrued interest">11,684</span>, as of May 31, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023 the Company obtained insurance financing of $<span id="xdx_90C_ecustom--InsuranceFinancing_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_pp0p0" title="Insurance financing">53,337 </span>on the general liability and excess liability insurance policies. The loan has a finance charge of $<span id="xdx_90F_ecustom--FinanceCharges_c20220601__20230531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_pp0p0" title="Finance charges">3,164 </span>and is payable in 10 monthly installments of $5,650 each beginning November 1, 2022. As of May 31, 2023, six installments have been paid. As of May 31, 2023 outstanding balance of the loan amounted to $<span id="xdx_90C_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_pp0p0" title="Notes Payable">21,335</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zKfrwwmum1lg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom; font-weight: bold"> <td><span id="xdx_8B7_zUARCnbNW4d3" style="display: none">Schedule of notes payable</span></td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>Notes Payable as of May 31, 2023 and 2022</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Insurance Financing</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_zmK0g7wCdkmj" style="width: 12%; text-align: right" title="Total">21,335</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_zGCeIcqdMxB7" style="width: 12%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0749">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Draw Paycheck Protection Program (PPP- 2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--PaycheckProtectionProgram2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0751">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--PaycheckProtectionProgram2Member_pp0p0" style="text-align: right" title="Total">6,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financing Charges</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--FinancingChargesMember_pp0p0" style="text-align: right" title="Total">1,253</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--FinancingChargesMember_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0757">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Economic Injury Disaster Loan Program (EIDL)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayable_c20230531_pp0p0" style="text-align: right" title="Total">172,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_c20220531_pp0p0" style="text-align: right" title="Total">156,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iNI_pp0p0_di_c20230531_zSnimJdGAbJ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(172,588</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iNI_pp0p0_di_c20220531_zRXChwwCPthl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(156,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermNotesPayable_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current portion"><span style="-sec-ix-hidden: xdx2ixbrl0771">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermNotesPayable_c20220531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current portion"><span style="-sec-ix-hidden: xdx2ixbrl0773">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_z0zoXlNlaP69" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amounts of loan payments due in the next fiscal year ended May 31, are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zEtc7ErGu4Hi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)"> <tr style="vertical-align: bottom"> <td colspan="3"><span id="xdx_8BF_zJvO0rO1Vcs8" style="display: none">Schedule of notes payments due in the next five years</span></td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="vertical-align: top; width: 73%; text-align: left">2024</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="padding-bottom: 1.5pt; width: 12%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_c20230531_z6UpJUoLdj8f" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="2024">172,588</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="color: White; text-align: left">Total </td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LongTermDebt_iI_pp0p0_c20230531_zQhBEzI5TFpa" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">172,588</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z6kkfVKDWzhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 150000 0.0375 10000 10000 10342 11684 53337 3164 21335 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfDebtTableTextBlock_zKfrwwmum1lg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom; font-weight: bold"> <td><span id="xdx_8B7_zUARCnbNW4d3" style="display: none">Schedule of notes payable</span></td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td>Notes Payable as of May 31, 2023 and 2022</td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Insurance Financing</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_zmK0g7wCdkmj" style="width: 12%; text-align: right" title="Total">21,335</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NotesPayable_iI_pp0p0_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--InsuranceFinancingMember_zGCeIcqdMxB7" style="width: 12%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0749">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Second Draw Paycheck Protection Program (PPP- 2)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--PaycheckProtectionProgram2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0751">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--PaycheckProtectionProgram2Member_pp0p0" style="text-align: right" title="Total">6,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financing Charges</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--FinancingChargesMember_pp0p0" style="text-align: right" title="Total">1,253</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--FinancingChargesMember_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0757">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Economic Injury Disaster Loan Program (EIDL)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_c20230531__us-gaap--UnderlyingAssetClassAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_c20220531__us-gaap--UnderlyingAssetClassAxis__custom--EconomicInjuryDisasterLoanProgramMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">150,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayable_c20230531_pp0p0" style="text-align: right" title="Total">172,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_c20220531_pp0p0" style="text-align: right" title="Total">156,300</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayableCurrent_iNI_pp0p0_di_c20230531_zSnimJdGAbJ8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(172,588</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayableCurrent_iNI_pp0p0_di_c20220531_zRXChwwCPthl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: Current portion">(156,300</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Non-current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermNotesPayable_c20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current portion"><span style="-sec-ix-hidden: xdx2ixbrl0771">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermNotesPayable_c20220531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non-current portion"><span style="-sec-ix-hidden: xdx2ixbrl0773">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 21335 6300 1253 150000 150000 172588 156300 172588 156300 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zEtc7ErGu4Hi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)"> <tr style="vertical-align: bottom"> <td colspan="3"><span id="xdx_8BF_zJvO0rO1Vcs8" style="display: none">Schedule of notes payments due in the next five years</span></td><td style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="vertical-align: top; width: 73%; text-align: left">2024</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td> <td style="padding-bottom: 1.5pt; width: 12%"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0_c20230531_z6UpJUoLdj8f" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="2024">172,588</td> <td style="padding-bottom: 1.5pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="color: White; text-align: left">Total </td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LongTermDebt_iI_pp0p0_c20230531_zQhBEzI5TFpa" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">172,588</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 172588 172588 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2Vhrd79DA2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 10 – <span id="xdx_820_zynZBQ9BAKI2">Stockholders’ Equity</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span style="text-decoration: underline">Shares Authorized</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify">As of May 31, 2023, the authorized capital of the Company consists of <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20230531_pdd" title="Common stock, shares authorized">450,000,000</span> shares of common stock, par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230531_pdd" title="Common stock, par or stated value per share">0.0001</span> per share and <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20230531_pdd" title="Preferred stock, shares authorized">300,000,000</span> shares of preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230531_pdd" title="Preferred stock, par or stated value per share">0.0001</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 10pt; text-align: justify"><span style="background-color: white">On June 13, 2022, the Company amended its amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock from 100,000,000 to <span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20220613_pdd" title="Common stock, shares authorized">450,000,000</span> shares and to increase the number of authorized shares of preferred stock, par value $<span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20220613_pdd" title="Preferred stock, par or stated value per share">0.0001</span> per share (“Preferred Stock”), from 20,000,000 to <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20220613_pdd" title="Preferred stock, shares authorized">300,000,000</span> shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Preferred Stock</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company is expressly authorized to provide for the issuance of all or any of the shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter, for each such series, such voting powers, full or limited, or no voting powers and such designations, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed until the resolution adopted by the Board of Directors providing the issuance of such shares. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issue of shares of that series. In case the number of shares of any such series shall be so decreased, the decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">During the fiscal year ended May 31, 2023, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220601__20230531__us-gaap--StatementClassOfStockAxis__custom--NonVotingSeriesAPreferredStockMember_zGB8tGO0chcl" title="Stock issued">250,000,000</span></span><span style="background-color: white"> shares of non-voting Series A Preferred Stock, which are convertible into shares of Company Common Stock on a one-to-one ratio, pursuant to the Asset Purchase <span style="background-color: white">Agreement (See Note 13 and Common Stock section below)</span>. These 250,000,000 shares of non-voting Series A Preferred Stock were valued at the fair market value of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20220601__20230531__us-gaap--StatementClassOfStockAxis__custom--NonVotingSeriesAPreferredStockMember_zHByINdm5Qf9" title="Valuie of stock issued">3,100,000</span></span><span style="background-color: white"> at issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The holders of shares of Series A Preferred Stock shall have no rights to dividends with respect to such shares. No dividends or other distributions shall be declared or paid on the Common Stock unless and until dividends at the same rate shall have been paid or declared and set apart upon the Series A Preferred Stock, based upon the number of shares of Common Stock into which the Series A Preferred Stock may then be converted. Upon the dissolution, liquidation, or winding up of the Company, whether voluntary or involuntary, the holders of the Series A Preferred Stock are entitled to receive out of the assets of the Company the sum of $0.0001 per share before any payment or distribution shall be made on our shares of Common Stock. The Series A Preferred Stock shall not be subject to redemption at the option, election or request of the Corporation or any holder or holders of the Series A Preferred Stock. Each share of Series A Preferred Stock is convertible at the option of the holder thereof, at any time after the second anniversary of the date of the first issuance of the shares of Series A Preferred Stock into one fully paid and nonassessable share of Common Stock provided, however, that the holder may not convert that number of shares of Series A Preferred Stock which would cause the holder to become the beneficial owner of more than 5% of the Corporation’s Common Stock as determined in accordance with Sections 13(d) and (g) of the Securities and Exchange Act of 1934 and the applicable rules and regulations thereunder. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 31, 2023, <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_c20230531_pdd" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_c20230531_pdd" title="Preferred stock, shares outstanding">250,000,000</span></span> shares of Preferred Stock were issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_do_c20220531_z1jO9popVzxf" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220531_zCaRmJMTiXN9" title="Preferred stock, shares outstanding">No</span></span> shares of Preferred Stock were issued and outstanding as of May 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Common Stock</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of May 31, 2023, <span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20230531_pdd" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20230531_pdd" title="Common stock, shares outstanding">117,076,949</span></span> shares of common stock were issued and outstanding. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220601__20230531__us-gaap--TypeOfArrangementAxis__custom--AssetsPurchaseAgreementMember_pdd" title="Shares issued during the period">73,183,893</span> shares of Common Stock, valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220601__20230531__us-gaap--TypeOfArrangementAxis__custom--AssetsPurchaseAgreementMember_pp0p0" title="Shares issued value during the period">907,480</span>, as consideration pursuant to the Asset Purchase agreement (See Note 13 and Preferred Stock section above).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023, the Company sold <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220601__20230531__us-gaap--TransactionTypeAxis__custom--SeveralPrivatePlacementAgreementsMember_pdd" title="Number of common stock sold">1,947,175</span> shares of Common Stock at $<span id="xdx_90A_eus-gaap--SharePrice_c20230531__us-gaap--TransactionTypeAxis__custom--SeveralPrivatePlacementAgreementsMember_pdd" title="Share price">0.23</span> per share for a total of $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220601__20230531__us-gaap--TransactionTypeAxis__custom--SeveralPrivatePlacementAgreementsMember_pp0p0" title="Value of common stock sold">447,850</span> under several private placement agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shares of Common Stock were issued during the fiscal year ended May 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Stock Options</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board approved the Company’s 2022 Equity Incentive Plan (the “Plan”) on March 21, 2022. Under the Plan, equity-based awards may be made to employees, officers, directors, non-employee directors and consultants of the Company and its Affiliates (as defined in the plan) in the form of (i) Incentive Stock Options (to eligible employees only); (ii) Nonqualified Stock Options; (iii) Restricted Stock; (iv) Stock Awards; (v) Performance Shares; or (vi) any combination of the foregoing. The Plan will terminate upon the close of business on the day next preceding March 21, 2032, unless terminated earlier in accordance with the terms of the Plan. The Board serves as the Plan administrator and may amend or terminate the Plan without stockholder approval, subject to certain exceptions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total number of shares initially authorized for issuance under the Plan was 10.0 million shares. The Plan provides for an annual increase on April 1 of each calendar year, beginning in 2022 and ending in 2031, subject to Board approval prior to such date. Such increase may be equal to the lesser of (i) 4% of the total number of shares of the Company’s common stock outstanding on May 31 of the immediately preceding fiscal year and (ii) such smaller number of shares as determined by the Board. The number of shares authorized for issuance under the Plan will not change unless the Board affirmatively approves an increase in the number of shares authorized for issuance prior to April 1 of the applicable year. Shares surrendered or withheld to pay the exercise price of a stock option or to satisfy tax withholding requirements will not be added back to the number of shares available under the Plan. To the extent that any shares of common stock awarded or subject to issuance or purchase pursuant to awards under the Plan are not delivered or purchased, or are reacquired by the Company, for any reason, including a forfeiture of restricted stock or failure to earn performance shares, or the termination, expiration or cancellation of a stock option, or any other termination of an award without payment being made in the form of shares of common stock will be added to the number of shares available for awards under the Plan. The number of shares available for issuance under the Plan will be adjusted for any increase or decrease in the number of outstanding shares of common stock resulting from payment of a stock dividend on common stock, a stock split or subdivision or combination of shares of common stock, or a reorganization or reclassification of common stock, or any other change in the structure of shares of common stock, as determined by the Board. Shares available for awards under the Plan will consist of authorized and unissued shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two types of options may be granted under the Plan: (1) Incentive Stock Options, which may only be issued to eligible employees of the Company and are required to have exercise price of the option not less than the fair market value of the common stock on the grant date, or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110% of the fair market value of the common stock on the grant date; and (2) Non-qualified Stock Options, which may be issued to participants under the Plan and which may have an exercise price less than the fair market value of the common stock on the grant date, but not less than par value of the stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Board may grant or sell restricted stock to participants (i.e., shares that are subject to a subject to restrictions or limitations as to the participant’s ability to sell, transfer, pledge or assign such shares) under the Plan. Except for these restrictions and any others imposed by the Board, upon the grant of restricted stock, the recipient generally will have rights of a stockholder with respect to the restricted stock. During the applicable restriction period, the recipient may not sell, exchange, transfer, pledge or otherwise dispose of the restricted stock. The Board may also grant awards of common stock to participants under the Plan, as well as awards of performance shares, which are awards for which the payout is subject to achievement of such performance objectives established by the Board. Performance shares may be settled in cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each equity-based award granted under the Plan will be evidenced by an award agreement that specifies the terms of the award and such additional limitations, terms and conditions as the Board may determine, consistent with the provisions of the Plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the occurrence of a change in control, unless otherwise provided in an award agreement: (i) all outstanding stock options will become immediately exercisable in full; (ii) all outstanding performance shares will vest in full as if the applicable performance conditions were achieved in full, subject to certain adjustments, and will be paid out as soon as practicable; and (iii) all restricted stock will immediately vest in full. The Plan defines a change in control as (i) the adoption of a plan of merger or consolidation of the Company with any other corporation or association as a result of which the holders of the voting capital stock of the Company as a group would receive less than 50% of the voting capital stock of the surviving or resulting corporation; (ii) the approval by the Board of an agreement providing for the sale or transfer (other than as security for obligations of the Company) of substantially all the assets of the Company; or (iii) in the absence of prior Board approval, the acquisition of more than 20% of the Company’s voting capital stock by any person within the meaning of Rule 13d-3 under the Exchange Act (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to the Plan’s terms, the Board has full power and authority to determine whether, to what extent and under what circumstances any outstanding award will be terminated, canceled, forfeited or suspended. Awards to that are subject to any restriction or have not been earned or exercised in full by the recipient will be terminated and canceled if such recipient is terminated for cause, as determined by the Board in its sole discretion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimates the fair value of share-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables such as the expected option term, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected option term and expected dividend yield rate over the expected option term. The Company believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors which are subject to ASC Topic 718 requirements. These amounts are estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company utilizes the simplified method to estimate the expected life for stock options granted to employees. The simplified method was used as the Company does not have sufficient historical data regarding stock option exercises. The expected volatility is based on historical volatility. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt">Pursuant to the Plan, on May 10, 2022, the Company issued to two Company officers non-statutory stock options to purchase, in the aggregate, up to <span id="xdx_90C_ecustom--NumberOfOptionIssued_c20220510_pdd" title="Number of option issued">5,300,000</span> shares of its Common Stock, at an exercise price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220510_pdd" title="Exercise price">0.09</span> per share and expiring on April 20, 2032. The options vest over time with 25% of the options vesting on September 1, 2022 and thereafter vesting 1/24</span><span style="font-size: 7.5pt"><sup>th</sup></span><span style="font-size: 10pt"> on the 1</span><span style="font-size: 7.5pt"><sup>st </sup></span><span style="font-size: 10pt">of every month. None of the options are vested as of May 31, 2022.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"> </span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Pursuant to the Plan, on November 1, 2022, the Company issued non-statutory stock options, to a former executive officer of the Company, to purchase, in the aggregate, up to <span id="xdx_909_ecustom--NumberOfOptionIssued_c20221101_pdd" title="Number of option issued">300,000</span> shares of its Common Stock, at an exercise price of $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20221101_pdd" title="Exercise price">0.20</span> per share and expiring on October 31, 2032. <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20230129_zgpv5FJmGtEl" title="Shares vested">75,000</span> shares vested as of January 29, 2023, and the remaining <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_c20230401__20230430_zAA0zBfgGcth" title="Shares forfeited">225,000</span> options were forfeited in April 2023 when the executive officer left the Company.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computed the aggregate grant date fair value of $<span id="xdx_90A_ecustom--AggregateGrantDateFairValue_iI_pp0p0_c20230531_zyavd8ts16p6" title="Aggregate grant date fair value">477,000 </span>using the Black-Scholes option pricing model, which is being recorded as stock-based compensation expense over the vesting period. During the fiscal years ended May 31, 2023 and 2022, the Company recorded a stock-based compensation expense of $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_c20220601__20230531_pp0p0">207,342 </span>and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20210601__20220531_pp0p0">21,967 </span>respectively, for these options in the accompanying financial statements. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Black-Scholes options pricing model used the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBsvmVOLHan4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt"><span id="xdx_8B6_zmppLdcI9MIk" style="display: none">Schedule of stock option assumptions</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-left: 5.4pt">Risk free interest rate</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210601__20220531_zzHLkueyfsLh" title="Risk free interest rate">4.07</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220601__20230531_zWhi7Cltzsmf" title="Risk free interest rate">2.99</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210601__20220531_znsfUIdEBGDh" title="Expected life">6</span> years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220601__20230531_zg7UlC9rYN1f" title="Expected life">5.75</span> years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210601__20220531_zGQO7Jz4VtEk" title="Expected volatility">457</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220601__20230531_zTHHLU5on1Lc" title="Expected volatility">447</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Expected dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210601__20220531_zk1ZrYGzTG5" title="Expected dividend">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220601__20230531_zcTopQGsShhg" title="Expected dividend">0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A3_zxYqioVDoFPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the activity relating to the Company’s stock options held by executive officers:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleofsummarizesrelatingcompanysstockoptionsTableTextBlock_zqONTB2w1nS6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span id="xdx_8BD_z1J8A9bY8uRk" style="display: none">Schedule of summarizes relating to the Company’s stock</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of Options</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average Remaining Term</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Outstanding as June 1, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zejcZF4eZxX6" title="Number of option outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0865">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_zZt77yYVzFPc" title="Weighted average exercise price, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0867">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-left: 5.4pt">Granted</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210601__20220531_pdd" style="width: 11%; text-align: right" title="Number of option outstanding, granted">5,300,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_pdd" style="width: 11%; text-align: right" title="Weighted average exercise price, granted">0.09</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--WeightedAverageRemainingTermGranted_dtY_c20210601__20220531_zk3QdESH8isj" title="Weighted average remaining term, granted">10.0</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210601__20220531_pdd"><span style="-sec-ix-hidden: xdx2ixbrl0874">—</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_pdd"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Outstanding at May 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210601__20220531_zSBJY0BTteZ2" style="text-align: right" title="Number of option outstanding, ending">5,300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210601__20220531_zJbHNG1DWFa" style="text-align: right" title="Weighted average exercise price, ending">0.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210601__20220531_z1TpZmcUOdG7" title="Weighted average remaining term, ending">9.92</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220601__20230531_pdd" style="text-align: right" title="Number of option outstanding, granted">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_pdd" style="text-align: right" title="Weighted average exercise price, granted">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--WeightedAverageRemainingTermGranted_dtY_c20220601__20230531_zxwv3H5O4fik" title="Weighted average remaining term, granted">9.68</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Less: Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220601__20230531_zUSS9FjWQSZh" style="text-align: right" title="Number of option outstanding, forfeited">(225,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220601__20230531_pdd" style="text-align: right" title="Weighted average exercise price, forfeited">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--WeightedAverageRemainingTermForfeited_dtY_c20220601__20230531_z8sT6RGqtCaf" title="Weighted average remaining term, forfeited">9.68</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Less: Unvested at May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iNI_di_c20230531_zWGB1iJ2u8S5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unvested number of option">(2,725,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230531_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unvested weighted average exercise price">0.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531_zOPOIjCiEAB" title="Unvested weighted average remaining term">8.92</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Vested at May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220601__20230531_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Vested number of option">2,650,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220601__20230531_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Vested weighted average exercise price">0.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--VestedWeightedAverageRemainingTerm_dtY_c20220601__20230531_zlOrP3yon4o2" title="Vested weighted average remaining term">8.92</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zHxMCgy96Wek" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 450000000 0.0001 300000000 0.0001 450000000 0.0001 300000000 250000000 3100000 250000000 250000000 0 0 117076949 117076949 73183893 907480 1947175 0.23 447850 5300000 0.09 300000 0.20 75000 225000 477000 207342 21967 <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBsvmVOLHan4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt"><span id="xdx_8B6_zmppLdcI9MIk" style="display: none">Schedule of stock option assumptions</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-left: 5.4pt">Risk free interest rate</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210601__20220531_zzHLkueyfsLh" title="Risk free interest rate">4.07</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220601__20230531_zWhi7Cltzsmf" title="Risk free interest rate">2.99</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210601__20220531_znsfUIdEBGDh" title="Expected life">6</span> years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220601__20230531_zg7UlC9rYN1f" title="Expected life">5.75</span> years</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210601__20220531_zGQO7Jz4VtEk" title="Expected volatility">457</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220601__20230531_zTHHLU5on1Lc" title="Expected volatility">447</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 5.4pt">Expected dividend</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210601__20220531_zk1ZrYGzTG5" title="Expected dividend">0</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220601__20230531_zcTopQGsShhg" title="Expected dividend">0</span></td><td style="text-align: left">%</td></tr> </table> 0.0407 0.0299 P6Y P5Y9M 4.57 4.47 0 0 <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleofsummarizesrelatingcompanysstockoptionsTableTextBlock_zqONTB2w1nS6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Equity (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span id="xdx_8BD_z1J8A9bY8uRk" style="display: none">Schedule of summarizes relating to the Company’s stock</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of Options</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Weighted Average Remaining Term</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Outstanding as June 1, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210601__20220531_zejcZF4eZxX6" title="Number of option outstanding, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0865">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210601__20220531_zZt77yYVzFPc" title="Weighted average exercise price, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0867">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; padding-left: 5.4pt">Granted</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210601__20220531_pdd" style="width: 11%; text-align: right" title="Number of option outstanding, granted">5,300,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210601__20220531_pdd" style="width: 11%; text-align: right" title="Weighted average exercise price, granted">0.09</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--WeightedAverageRemainingTermGranted_dtY_c20210601__20220531_zk3QdESH8isj" title="Weighted average remaining term, granted">10.0</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210601__20220531_pdd"><span style="-sec-ix-hidden: xdx2ixbrl0874">—</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210601__20220531_pdd"><span style="-sec-ix-hidden: xdx2ixbrl0875">—</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt">Outstanding at May 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210601__20220531_zSBJY0BTteZ2" style="text-align: right" title="Number of option outstanding, ending">5,300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210601__20220531_zJbHNG1DWFa" style="text-align: right" title="Weighted average exercise price, ending">0.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210601__20220531_z1TpZmcUOdG7" title="Weighted average remaining term, ending">9.92</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220601__20230531_pdd" style="text-align: right" title="Number of option outstanding, granted">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220601__20230531_pdd" style="text-align: right" title="Weighted average exercise price, granted">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--WeightedAverageRemainingTermGranted_dtY_c20220601__20230531_zxwv3H5O4fik" title="Weighted average remaining term, granted">9.68</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Less: Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220601__20230531_zUSS9FjWQSZh" style="text-align: right" title="Number of option outstanding, forfeited">(225,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220601__20230531_pdd" style="text-align: right" title="Weighted average exercise price, forfeited">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--WeightedAverageRemainingTermForfeited_dtY_c20220601__20230531_z8sT6RGqtCaf" title="Weighted average remaining term, forfeited">9.68</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Less: Unvested at May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iNI_di_c20230531_zWGB1iJ2u8S5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unvested number of option">(2,725,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20230531_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unvested weighted average exercise price">0.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220601__20230531_zOPOIjCiEAB" title="Unvested weighted average remaining term">8.92</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Vested at May 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20220601__20230531_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Vested number of option">2,650,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20220601__20230531_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Vested weighted average exercise price">0.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_ecustom--VestedWeightedAverageRemainingTerm_dtY_c20220601__20230531_zlOrP3yon4o2" title="Vested weighted average remaining term">8.92</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 5300000 0.09 P10Y 5300000 0.09 P9Y11M1D 300000 0.20 P9Y8M4D 225000 0.20 P9Y8M4D 2725000 0.09 P8Y11M1D 2650000 0.09 P8Y11M1D <p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zaGWrusGAvoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 11 – <span id="xdx_82E_ztxoknpNwzZ6">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Leases</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As discussed in Note 2 above, the Company adopted ASU No. 2016-02, <i>Leases </i>on June 1, 2019, which require lessees to report on their balance sheets a right-of-use asset and a lease liability in connection with most lease agreements classified as operating leases under the prior guidance. <span id="xdx_90A_eus-gaap--LesseeOperatingLeaseDescription_c20220601__20230531">The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent was $7,567 per month for the first year and increased by a certain amount each year. In November 2022, the Company entered into an extension of the lease for a two</span><span> </span><span>year term beginning December 1, 2022. The rent is $</span><span id="xdx_909_ecustom--MonthlyBaseRent_pp0p0_c20220601__20230531_znWZ7BCKJNg1" title="Monthly base rent">6,098 </span><span>per month for the first year and will increase by a certain amount the following year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lease expense is recognized on a straight-line basis over the lease term, while variable lease payments are expensed as incurred. Variable payments change due to facts or circumstances occurring after the commencement date, other than the passage of time, and do not result in a remeasurement of lease liabilities. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the new standard, the Company recorded an initial lease liability of $<span id="xdx_909_ecustom--InitialLeaseLiability_c20230531_pp0p0" title="Initial lease liability">235,748</span> and an initial right of use asset in the same amount in 2019. <span style="background-color: white">The Company computed another initial lease liability of $<span id="xdx_909_ecustom--InitialRightOfUseAsset_c20230531_pp0p0" title="Initial right of use asset">131,970</span> for the new lease agreement and an initial ROU asset in the same amount which was recorded on books at the commencement of the <span style="background-color: white">new </span> lease on December 1, 2022.</span> During the fiscal years ended May 31, 2023 and 2022, the Company recorded a lease expense in the amount of $<span id="xdx_90D_eus-gaap--LeaseCost_c20220601__20230531_pp0p0" title="Lease expense">84,435</span> and $<span id="xdx_90B_eus-gaap--LeaseCost_c20210601__20220531_pp0p0" title="Lease expense">94,235</span>, respectively. As of May 31, 2023, the lease liability balance was $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_c20230531_pp0p0" title="Lease liability">102,576</span> and the right of use asset balance was $<span id="xdx_90E_eus-gaap--OperatingLeaseRightOfUseAsset_c20230531_pp0p0" title="Right of use asset">101,845</span>. A lease term of three years and a discount rate of <span id="xdx_90F_eus-gaap--LesseeOperatingLeaseDiscountRate_c20230531_pdd" title="Discount rate">12%</span> was used.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Supplemental balance sheet information related to leases was as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_zUvvG4j1EyXf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span id="xdx_8B8_zMztUkB4nQH1" style="display: none">Schedule of Supplemental balance sheet information</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230531_z0tjIMNWJ5l5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20220531_zPUJ1yPf6Qqi" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2023</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b> </b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2022</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--RightOfUseAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 10pt">Right of use assets</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">131,970</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">235,748</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated reduction</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(190,295</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Operating lease assets, net</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">101,845</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">45,453</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Lease Liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">131,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">235,748</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--AccumulatedReduction_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated reduction</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(188,582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Total lease liability, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">47,166</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseLiabilityCurrentPortion_iNI_pp0p0_di_zKFYFQ1OYKF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,824</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Non-current portion</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">36,752</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">—</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_zXpWADSkgaYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Maturities of operating lease liabilities were as follows as of May 31, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zyYotSOnR3B8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"> <tr style="vertical-align: bottom"> <td><span><span id="xdx_8BD_zqHxnskGQ4Rc" style="display: none">Schedule of maturities of operating lease liabilities</span></span></td><td> </td> <td colspan="3" id="xdx_492_20230531_z7Em2lL4KX7j" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating Lease</td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 70%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">2024</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">65,824</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,752</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-left: 8.65pt">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LessImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqA9Ynj2s2Nb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Present value of lease liabilities</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">102,576</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zsSSNoLv2P62" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 23, 2020, the Company was served a copy of a complaint filed by Jacksonfill, LLC in the Fourth Circuit Court for Duval County, Florida. The complaint alleges breach of Agreement for non-payments for certain products against the Company. The allegations arise from alleged discrepancies discovered by the Company in the manufacturing of certain product. The Company has retained counsel and intends to vigorously defend the allegations. The product was delivered to the Company, however, the Company believes that the product was defective. The litigation process has not progressed and the amount of the claim of $<span id="xdx_903_eus-gaap--LiabilityForTitleClaimsAndClaimsAdjustmentExpense_c20230531__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_pp0p0" title="Claim amount">204,182</span> has been recorded as accounts payable, in the accompanying consolidated financial statements as of May 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> The Company has a lease agreement in connection with its office and warehouse facility in California under an operating lease which expired in October 2019. On December 1, 2019, the Company signed an extension of the lease for 3 years. The rent was $7,567 per month for the first year and increased by a certain amount each year. In November 2022, the Company entered into an extension of the lease for a two 6098 235748 131970 84435 94235 102576 101845 0.12 <table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_zUvvG4j1EyXf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"><span id="xdx_8B8_zMztUkB4nQH1" style="display: none">Schedule of Supplemental balance sheet information</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20230531_z0tjIMNWJ5l5" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49D_20220531_zPUJ1yPf6Qqi" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2023</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b> </b></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2022</b></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--RightOfUseAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 10pt">Right of use assets</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">131,970</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">235,748</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--OperatingLeaseRightOfUseAssetAccumulatedAmortization_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated reduction</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(30,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(190,295</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Operating lease assets, net</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">101,845</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">45,453</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Lease Liability</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">131,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">235,748</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--AccumulatedReduction_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated reduction</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(188,582</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 5.4pt">Total lease liability, net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,576</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">47,166</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseLiabilityCurrentPortion_iNI_pp0p0_di_zKFYFQ1OYKF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(65,824</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Non-current portion</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">36,752</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">—</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> 131970 235748 -30125 -190295 101845 45453 131970 235748 -29394 -188582 102576 47166 65824 47166 36752 <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zyYotSOnR3B8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"> <tr style="vertical-align: bottom"> <td><span><span id="xdx_8BD_zqHxnskGQ4Rc" style="display: none">Schedule of maturities of operating lease liabilities</span></span></td><td> </td> <td colspan="3" id="xdx_492_20230531_z7Em2lL4KX7j" style="text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td>Operating Lease</td><td> </td> <td colspan="3" style="text-align: right"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 70%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">2024</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">65,824</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,752</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-left: 8.65pt">Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">102,576</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LessImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zqA9Ynj2s2Nb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt; text-indent: -8.65pt; padding-left: 8.65pt">Present value of lease liabilities</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">102,576</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 65824 36752 102576 102576 204182 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zasQ5FweovC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12 – <span id="xdx_826_z08XqRmuddQb">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s Chief Executive Officer, Jeff Toghraie, is the managing director of Intrepid Global Advisors (“Intrepid”). Intrepid has, from time to time, provided advances to the Company for working capital purposes. At May 31, 2023, and 2022, the Company had amounts payable to Intrepid of $<span id="xdx_902_ecustom--PayableToRelatedParty_iI_pp0p0_c20230531__srt--CounterpartyNameAxis__custom--IntrepidMember_zvwdxAPJtrE1" title="Payable to related party">124,378 </span>and $<span id="xdx_90C_ecustom--PayableToRelatedParty_c20220531__srt--CounterpartyNameAxis__custom--IntrepidMember_pp0p0">25,452</span>, respectively. These advances were short-term in nature and non-interest bearing. Additionally, pursuant to a voting agreement, <span style="background-color: white">effective June 16, 2022 as amended effective November 7, 2022, with AXIL and Intrepid Global Advisors, we are subject to certain limitations on our ability to sell our capital stock until June 2024. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended May 31, 2023, the Company paid $<span id="xdx_908_ecustom--ConsultingFee_c20220601__20230531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--WestonT.HarrisMember_pp0p0" title="Consulting fee">218,696</span> as consulting fee for product development to Weston T. Harris, a major stockholder of AXIL, and also paid $<span id="xdx_903_ecustom--CompensationPaidForServices_c20220601__20230531_pp0p0" title="Compensation paid for services">126,097</span> to immediate family members of the major stockholder as compensation for services relating to packaging design and affiliate marketing. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended May 31, 2023, the Company paid $<span id="xdx_905_ecustom--ConsultingFee_c20220601__20230531_pp0p0" title="Consulting fee">135,484</span> as consulting fee for inventory management and operations consulting to an immediate family member of a major stockholder of AXIL, $<span id="xdx_90E_ecustom--CommissionsAndContractorFee_c20220601__20230531_pp0p0" title="Commissions and contractor fee">74,620</span> to an immediate family member of the major stockholder in commissions and a contractor fee, and $<span id="xdx_90B_ecustom--BonusForServicesPaid_pp0p0_c20220601__20230531_zbi74aIm1SH1" title="Bonus for services paid">15,928</span> to an immediate member of the major stockholder as compensation for services relating to travel and event coordination<span style="font-size: 8pt"></span>. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2022, the Company and its wholly owned subsidiary Reviv3 Acquisition Corporation completed the acquisition of both (i) the hearing protection business of AXIL, consisting of ear plugs and ear muffs, and (ii) AXIL’s ear bud business pursuant to the Asset Purchase Agreement, dated May 1, 2022, as amended on June 15, 2022, by and among the Company, Reviv3 Acquisition Corporation, AXIL and certain stockholders of AXIL. One of the stockholders of AXIL is Intrepid Global Advisors, Inc. As of May 31, 2023, Intrepid Global Advisors, Inc. held no outstanding common stock of AXIL and 19.50% of the outstanding common stock of the Company.</p> 124378 25452 218696 126097 135484 74620 15928 <p id="xdx_802_eus-gaap--BusinessCombinationDisclosureTextBlock_z8PjfPMKWdN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <br/> <span style="background-color: white"><b>Note 13 – <span id="xdx_829_zK8AxvUu9iCh">Business Combination</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On June 16, 2022, the Company completed the acquisition of certain assets of Axil &amp; Associated Brands Corp. (“AXIL”), a Delaware corporation, pursuant to the Asset Purchase Agreement dated May 1, 2022 and amended on June 15, 2022 and September 8, 2022. by and among the Company, its subsidiary, AXIL, and certain of AXIL’s stockholders, providing for the acquisition of AXIL’s hearing protection business and ear bud business. The business constituted substantially all of the business operations of AXIL but did not include AXIL’s hearing aid line of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">One of the stockholders of <span style="font-variant: small-caps">AXIL</span> is Intrepid Global Advisors (“Intrepid”). As of June 16, 2022, Intrepid held <span id="xdx_90F_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AxilMember_pdd">4.68% </span></span><span style="background-color: white">of the outstanding common stock of <span style="font-variant: small-caps">AXIL</span> and <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--JeffToghraieMember_pdd">22.33% </span></span><span style="background-color: white">of the outstanding Common Stock of the Company. As of May 31, 2023 Intrepid held no outstanding common shares of <span style="font-variant: small-caps">AXIL</span>, as they were distributed with the Asset Purchase Agreement. Jeff Toghraie, Chairman and Chief Executive Officer of the Company, is a managing director of Intrepid.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">As consideration for the Asset Purchase, <span style="font-variant: small-caps">AXIL</span> received a total of <span id="xdx_902_ecustom--SharesConsideration_c20220601__20220616_zeWfoykvx1Yh" title="Shares consideration">323,183,893</span></span><span style="background-color: white"> shares of the company comprised of (a) <span id="xdx_90A_ecustom--SharesConsideration_c20220601__20220616__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zCGWiS5d3vP7" title="Shares consideration">73,183,893</span></span><span style="background-color: white"> shares of the Company’s Common Stock and (b) <span id="xdx_90D_ecustom--SharesConsideration_c20220601__20220616__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_zyHzCPXFuIK" title="Shares consideration">250,000,000</span></span><span style="background-color: white"> shares of the company’s non-voting Series A Preferred Stock, which are convertible into shares of Company Common Stock on a one-to-one ratio. The Preferred Shares may not be converted or transferred for a period of two years following the closing of the acquisition. Thereafter, no holder of Preferred Shares may convert such shares into a number of shares of Company Common Stock that would cause the holder to beneficially own more than 5% of the Company’s Common Stock, as determined in accordance with Sections 13(d) and (g) of the Securities Exchange Act of 1934 (the “Exchange Act”). The purchase price was computed to be $<span id="xdx_902_eus-gaap--AcquisitionCosts_c20220601__20220616_pp0p0">4,007,480</span></span><span style="background-color: white"> based on a fair value of $<span id="xdx_90F_ecustom--AcquisitionPricePerShare_c20220601__20220616_zDMHXcxRCXsf" title="Acquisition price per share">0.0124</span></span><span style="background-color: white"> per common share on the date of acquisition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is utilizing the <span style="font-variant: small-caps">AXIL </span>assets to expand into the hearing enhancement business through its newly incorporated subsidiary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The acquisition is accounted for by the Company in accordance with the acquisition method of accounting pursuant to ASC 805 “Business Combinations” and pushdown accounting is applied to record the fair value of the assets acquired by the Company. Under this method, the purchase price is allocated to the identifiable assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. Any excess of the amount paid over the estimated fair values of the identifiable net assets acquired was allocated to goodwill.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the fair value of the assets acquired and liabilities assumed at the date of acquisition:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zMVednYXjYc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Purchase Agreement (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt"><span id="xdx_8B6_z3TVXGqGFPPc" style="display: none">Schedule of estimated fair value of the assets acquired</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_490_20220616_zP3OMfx3yIW4" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Cash</td><td style="width: 10%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,066,414</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Accounts receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">227,786</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">1,342,461</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">62,452</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Other assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">108,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_zN88mikfXDH" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Accounts payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">(285,665</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_pp0p0_di_zo1wxsqDqKKc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Contract liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,043,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iNI_pp0p0_di_zgNCSJNrxI6a" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(79,826</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedtangibleAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 10pt; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Net tangible assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,398,320</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Identifiable intangible assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LicensingRights_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Licensing rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">11,945</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationship_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">70,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNames_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Tradenames</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">275,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWebsite_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Website</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-indent: 10pt; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Total Identifiable intangible assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">456,945</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ConsiderationPaid_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Consideration paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">4,007,480</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,855,265</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 3.5pt; padding-left: 5.4pt">Goodwill purchased</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">2,152,215</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_z3lr0iomTDpg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Pro Forma Information (Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited pro forma condensed combined financial statements are based on Reviv3 and AXIL’s unaudited historical consolidated financial statements as adjusted to give effect to the Asset Purchase Agreement. The unaudited pro forma combined statements of operations for the fiscal year ended May 31, 2023 and 2022, for Reviv3 and AXIL, give effect to the Asset Purchase Agreement as if it had occurred on June 1, 2022 and 2021, respectively. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zUjGH0vu5xo2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Purchase Agreement (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt"><span id="xdx_8BF_z5vRn4pxuCei" style="display: none">Schedule of proforma information</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_490_20220601__20230531_zy1cDXX12zYg" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_495_20210601__20220531_zs5BPp2VvWw6" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="vertical-align: bottom; text-align: center"><b>For the fiscal year ended</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="vertical-align: bottom; text-align: center"><b>For the fiscal year ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>May 31, 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>May 31, 2022</b></td></tr> <tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Revenue</td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">25,428,163</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,356,862</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Net income (loss)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2,032,954</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,212,320</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareProFormaAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Earnings (loss) per common share</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--BasicEarningsPerShareProForma_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DilutedEarningsPerShareProForma_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z9pzMtJ51BYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">The pro forma financial information is not necessarily indicative of the results that would have occurred if the acquisition had occurred on the date indicated or that result in the future. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> 0.0468 0.2233 323183893 73183893 250000000 4007480 0.0124 <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zMVednYXjYc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Purchase Agreement (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt"><span id="xdx_8B6_z3TVXGqGFPPc" style="display: none">Schedule of estimated fair value of the assets acquired</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_490_20220616_zP3OMfx3yIW4" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Cash</td><td style="width: 10%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,066,414</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Accounts receivable</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">227,786</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Inventory</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">1,342,461</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">62,452</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Other assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">108,030</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_iNI_pp0p0_di_zN88mikfXDH" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Accounts payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">(285,665</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_pp0p0_di_zo1wxsqDqKKc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Contract liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,043,332</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_iNI_pp0p0_di_zgNCSJNrxI6a" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Other current liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(79,826</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedtangibleAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 10pt; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Net tangible assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,398,320</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Identifiable intangible assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--LicensingRights_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Licensing rights</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">11,945</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationship_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Customer relationships</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">70,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNames_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Tradenames</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">275,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWebsite_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Website</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-indent: 10pt; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Total Identifiable intangible assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">456,945</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ConsiderationPaid_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Consideration paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">4,007,480</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,855,265</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 3.5pt; padding-left: 5.4pt">Goodwill purchased</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">2,152,215</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 1066414 227786 1342461 62452 108030 285665 1043332 79826 1398320 11945 70000 275000 100000 456945 4007480 1855265 2152215 <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zUjGH0vu5xo2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Asset Purchase Agreement (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt"><span id="xdx_8BF_z5vRn4pxuCei" style="display: none">Schedule of proforma information</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_490_20220601__20230531_zy1cDXX12zYg" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td id="xdx_495_20210601__20220531_zs5BPp2VvWw6" style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="vertical-align: bottom; text-align: center"><b>For the fiscal year ended</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="vertical-align: bottom; text-align: center"><b>For the fiscal year ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>May 31, 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>May 31, 2022</b></td></tr> <tr id="xdx_40E_eus-gaap--BusinessAcquisitionsProFormaRevenue_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Revenue</td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">25,428,163</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 8%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,356,862</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessAcquisitionsProFormaNetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Net income (loss)</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2,032,954</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,212,320</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareProFormaAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Earnings (loss) per common share</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--BasicEarningsPerShareProForma_i01_pdd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DilutedEarningsPerShareProForma_i01_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 5.4pt">Diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 25428163 18356862 2032954 -3212320 0.02 -0.03 0.01 <p id="xdx_801_eus-gaap--ConcentrationRiskDisclosureTextBlock_zvSAPFqad2F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 14 – <span id="xdx_823_zEjelGftYkjk">Concentrations</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Concentration of Credit Risk</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits, investments and cash equivalents instruments. The Company maintains its cash in bank deposits accounts. The Company’s account at this institution is insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_c20230531_pp0p0" title="Cash, FDIC insured amount">250,000</span>. At May 31, 2023 and 2022, the Company held cash in various accounts of approximately $<span id="xdx_903_eus-gaap--CashUninsuredAmount_c20230531_pp0p0" title="Cash, uninsured amount">4,582,682</span> and $<span id="xdx_902_eus-gaap--CashUninsuredAmount_c20220531_pp0p0" title="Cash, uninsured amount">123,731</span>, respectively, in excess of federally insured limits. The Company has not experienced any losses in such accounts through May 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Concentration of Revenue, Accounts Receivable, Product Line, and Supplier – Hair and Skin Care Products</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023 hair and skin care product sales to three customers, which each represented over 10% of our total sales, aggregated to approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_pdd" title="Concentration risk, percentage">94%</span> of the Company’s net sales at <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_pdd" title="Concentration risk, percentage">61%</span>, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_pdd" title="Concentration risk, percentage">12%</span> and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_pdd" title="Concentration risk, percentage">21%</span>. During the fiscal year ended May 31, 2022 sales to two customers, which each represented over 10% of our total sales, aggregated to approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_pdd" title="Concentration risk, percentage">31%</span> of the Company’s net sales at <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_pdd" title="Concentration risk, percentage">15%</span> and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_pdd" title="Concentration risk, percentage">16%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023 hair and skin care product sales to customers outside the United States represented approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__custom--OutsideTheUnitedStatesMember_pdd" title="Concentration risk, percentage">25%</span> which consisted of <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__country--CA_pdd" title="Concentration risk, percentage">20%</span> from Canada and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__country--IT_pdd" title="Concentration risk, percentage">5%</span> from Italy and during the fiscal year ended May 31, 2022 sales to customers outside the United States represented approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__custom--OutsideTheUnitedStatesMember_pdd" title="Concentration risk, percentage">16%</span> which consisted of <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__country--CA_pdd" title="Concentration risk, percentage">14%</span> from Canada and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__country--IT_pdd" title="Concentration risk, percentage">2%</span> from Italy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023, hair and skin care product sales by product<span style="font-size: 8pt"> </span>line which each represented over 10% of sales consisted of approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--HairShampooMember_pdd">15% </span>from sales of hair shampoo, and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--ShampooAndConditionerMember_pdd">10% </span>from sales of hair conditioner and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--BundledKitsMember_pdd">7% </span>from bundle kits. During the fiscal year ended May 31, 2022, hair and skin care product sales by product line which each represented over 10% of sales consisted of approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--HairShampooMember_pdd">10% </span>from sales of hair shampoo, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--HairShampooAndConditionerMember_zysue66xtETb">12% </span>from sales of hair shampoo and conditioner, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--IntroductorykitMember_pdd">25% </span>from sale of introductory kit (shampoo, conditioner and treatment spray) and 29% from sale of bundle packs (shampoo, conditioner and spray).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal years ended May 31, 2023 and 2022 sales for the hair and skin care product lines comprised of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfSalesByProductLineTableTextBlock_zgWoMYuG5gr2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentrations (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_8B1_zexfWPG21Yi" style="display: none">Schedule of Sales by Product Line</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td><b> </b></td> <td colspan="7" style="text-align: center"><b>For the Fiscal Years ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Hair Care Products</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2022</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Shampoos and Conditioners</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--ShampoosAndConditionersMember_zFQNo2bs7eU4" title="Total">77</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--ShampoosAndConditionersMember_zCRqrn1xNz6k" title="Total">84</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Ancillary Products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--AncillaryProductsMember_zRVFbqxKlTY9" title="Total">23</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--AncillaryProductsMember_zsiT5foT1nSd" title="Total">16</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zg6kfTckusj4" title="Total">100</span></td><td style="padding-bottom: 3.5pt; text-align: left">%</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zY3BnWXyZNBa" title="Total">100</span></td><td style="padding-bottom: 3.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8AF_zEemACTc3fS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At May 31, 2023, hair and skin care product’s only accounts receivable from one customer accounted for more than 10% of sales transactions, which was Amazon and the second largest customer accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_pdd" title="Concentration risk, percentage">8%</span>, which is due to the fact that products are sold primarily through direct-to-consumer. At May 31, 2022, accounts receivable from four customers represented approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_pdd" title="Concentration risk, percentage">74%</span> at <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_pdd" title="Concentration risk, percentage">11%</span>, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_pdd" title="Concentration risk, percentage">12%</span>, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_pdd" title="Concentration risk, percentage">14%</span> and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerFourMember_pdd" title="Concentration risk, percentage">37%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Hair and skin care product purchased inventories and products from three vendors totaling approximately $<span id="xdx_90C_ecustom--PurchasedInventoriesAndProducts_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_pp0p0" title="Purchased inventories and products">297,833</span>, (<span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorsMember_pdd" title="Concentration risk, percentage">95%</span> of the purchases at <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_pdd" title="Concentration risk, percentage">61%</span>, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_pdd" title="Concentration risk, percentage">12%</span> and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_pdd" title="Concentration risk, percentage">22%</span>) during the fiscal year ended May 31, 2023 and four vendors totaling approximately $<span id="xdx_90A_ecustom--PurchasedInventoriesAndProducts_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_pp0p0" title="Purchased inventories and products">343,015</span> (<span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorMember_zx1huyB4Ts3f" title="Concentration risk, percentage">97%</span> of the purchases at <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorOneMember_pdd" title="Concentration risk, percentage">10%</span>, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--VendorTwoMember_pdd" title="Concentration risk, percentage">23%</span>, 30% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_pdd" title="Concentration risk, percentage">34%</span>) during the fiscal year ended May 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Concentration of Revenue, Accounts Receivable, Product Line, and Supplier – Ear Protection and Enhancement Products</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">AXIL is sold direct-to-consumer, therefore, during the fiscal year ended May 31, 2023, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--AxilMember_pdd" title="Concentration risk, percentage">97.3%</span> of sales was direct to customers. There was no single customer that accounted for greater than 2% of total sales.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023 AXIL sales to customers outside the United States represented approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__custom--OutsideTheUnitedStatesMember__srt--MajorCustomersAxis__custom--AxilMember_pdd" title="Concentration risk, percentage">4.5%</span> which consisted of <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--StatementGeographicalAxis__country--CA__srt--MajorCustomersAxis__custom--AxilMember_pdd" title="Concentration risk, percentage">3.7%</span> from Canada and the remaining from various countries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Manufacturing is outsourced primarily overseas via a number of third party vendors, the two largest vendors accounting for 82% and 10% of all purchases.</span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023, AXIL sale of ear buds for PSAP (personal sound amplification product) and hearing protection by product line which each represented over 10% of sales consisted approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--AxilMember__srt--ProductOrServiceAxis__custom--EarBudsMember_pdd" title="Concentration risk, percentage">87%</span> from Ghost Stryke Extreme model GS-X ($18.1M) and 9% of sales of Trackr earmuffs ($1.9M).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023 sales by hearing enhancement and protection products comprised of the following:  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSalesByProductComprisedTableTextBlock_zUIc2xb71j5i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentrations (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B6_zRtNPUjWuYD5" style="display: none">Schedule of sales by product comprised</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td><b> </b></td> <td colspan="3" style="vertical-align: bottom; text-align: center"><b>For the fiscal year ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Ear Protection &amp; Enhancement Products</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2023</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Ghost Stryke</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--GhostStrykeMember_zqGaZnrdfOHa" title="Total">86.7</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trackr Earmuffs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--TrackrHeadmuffMember_zeRVltSH1EU1" title="Total">9.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Bluetooth and ear buds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OtherBluetoothAndEarBudsMember_zJUpeqfQNIsi" title="Total">3.9</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accessories, other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--AccessoriesOtherMember_zeRPZjGGduB9" title="Total">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z4YW4dANSIM6" title="Total">100</span>.0</td><td style="padding-bottom: 3.5pt; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 250000 4582682 123731 0.94 0.61 0.12 0.21 0.31 0.15 0.16 0.25 0.20 0.05 0.16 0.14 0.02 0.15 0.10 0.07 0.10 0.12 0.25 <table cellpadding="0" cellspacing="0" id="xdx_894_ecustom--ScheduleOfSalesByProductLineTableTextBlock_zgWoMYuG5gr2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentrations (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span id="xdx_8B1_zexfWPG21Yi" style="display: none">Schedule of Sales by Product Line</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td><b> </b></td> <td colspan="7" style="text-align: center"><b>For the Fiscal Years ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid"><b>Hair Care Products</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2022</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Shampoos and Conditioners</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--ShampoosAndConditionersMember_zFQNo2bs7eU4" title="Total">77</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--ShampoosAndConditionersMember_zCRqrn1xNz6k" title="Total">84</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Ancillary Products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--AncillaryProductsMember_zRVFbqxKlTY9" title="Total">23</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--AncillaryProductsMember_zsiT5foT1nSd" title="Total">16</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zg6kfTckusj4" title="Total">100</span></td><td style="padding-bottom: 3.5pt; text-align: left">%</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_dp_c20210601__20220531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zY3BnWXyZNBa" title="Total">100</span></td><td style="padding-bottom: 3.5pt; text-align: left">%</td></tr> </table> 0.77 0.84 0.23 0.16 1 1 0.08 0.74 0.11 0.12 0.14 0.37 297833 0.95 0.61 0.12 0.22 343015 0.97 0.10 0.23 0.34 0.973 0.045 0.037 0.87 <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfSalesByProductComprisedTableTextBlock_zUIc2xb71j5i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Concentrations (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B6_zRtNPUjWuYD5" style="display: none">Schedule of sales by product comprised</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td><b> </b></td> <td colspan="3" style="vertical-align: bottom; text-align: center"><b>For the fiscal year ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Ear Protection &amp; Enhancement Products</b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>May 31, 2023</b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Ghost Stryke</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--GhostStrykeMember_zqGaZnrdfOHa" title="Total">86.7</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trackr Earmuffs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--TrackrHeadmuffMember_zeRVltSH1EU1" title="Total">9.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Bluetooth and ear buds</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--OtherBluetoothAndEarBudsMember_zJUpeqfQNIsi" title="Total">3.9</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accessories, other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__custom--AccessoriesOtherMember_zeRPZjGGduB9" title="Total">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left"> </td><td style="border-bottom: Black 3.5pt double; text-align: right"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z4YW4dANSIM6" title="Total">100</span>.0</td><td style="padding-bottom: 3.5pt; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.867 0.091 0.039 0.003 1 <p id="xdx_80C_eus-gaap--SegmentReportingDisclosureTextBlock_z4FBEzMtiJy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 15 – <span id="xdx_82E_zdNM8oJiHHrk">Business Segment and Geographic Area Information</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Business Segments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, directly or through its subsidiaries, markets and sells its products and services directly to consumers and through its dealers. In June 2022, the Company acquired a hearing enhancement and hearing protection business. The Company’s determination of its reportable segments is based on how its chief operating decision makers manage the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s segment information is as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsJNCREozDbh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Business Segment and Geographic Area Information (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BC_zBEg0WgmVd0c" style="display: none">Schedule of segment information</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center">The fiscal years ended</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: left; padding-bottom: 1.5pt">Net Sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 10pt">Hair care and skin care</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="width: 12%; text-align: right" title="Total net sales">1,588,958</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="width: 12%; text-align: right" title="Total net sales">2,336,257</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total net sales">21,932,069</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--Revenues_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total net sales"><span style="-sec-ix-hidden: xdx2ixbrl1177">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total net sales</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_c20220601__20230531_pp0p0" style="text-align: right" title="Total net sales">23,521,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_c20210601__20220531_pp0p0" style="text-align: right" title="Total net sales">2,336,257</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating earnings (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Segment gross profit:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--GrossProfit_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Total segment gross profit">1,076,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--GrossProfit_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Total segment gross profit">1,507,671</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total segment gross profit">16,633,977</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--GrossProfit_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total segment gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1189">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total segment gross profit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--GrossProfit_c20220601__20230531_pp0p0" style="text-align: right" title="Total segment gross profit">17,710,811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--GrossProfit_c20210601__20220531_pp0p0" style="text-align: right" title="Total segment gross profit">1,507,671</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling and Marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingAndMarketingExpense_c20220601__20230531_pp0p0" style="text-align: right" title="Selling and Marketing">11,675,206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SellingAndMarketingExpense_c20210601__20220531_pp0p0" style="text-align: right" title="Selling and Marketing">1,199,305</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and Administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OtherGeneralAndAdministrativeExpense_c20220601__20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="General and Administrative">4,051,394</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--OtherGeneralAndAdministrativeExpense_c20210601__20220531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="General and Administrative">519,769</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated operating income (loss)</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ConsolidatedOperatingIncomeLoss_pp0p0_c20220601__20230531_zwzv4mZLcmh6" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated operating income (loss)">1,984,211</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ConsolidatedOperatingIncomeLoss_pp0p0_c20210601__20220531_zCk6ZDJEyfI1" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated operating income (loss)">(211,403</td><td style="padding-bottom: 3.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsNet_iI_pp0p0_c20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_zTtnUaY36rMg" style="text-align: right" title="Consolidated total assets">3,785,732</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsNet_iI_pp0p0_c20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_zyjtuiuHbmM8" style="text-align: right" title="Consolidated total assets">893,915</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsNet_iI_pp0p0_c20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_zCIwhlAmXIkj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total assets">6,383,582</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsNet_iI_pp0p0_c20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_zEFkmpQfT8rf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total assets"><span style="-sec-ix-hidden: xdx2ixbrl1213">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated total assets</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsNet_iI_pp0p0_c20230531_zkdMTknEUMCh" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total assets">10,169,314</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsNet_iI_pp0p0_c20220531_z7HwaYD0rJH5" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total assets">893,915</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payments for property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1219">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1221">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total payments for property and equipment">65,650</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1225">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated total payments for property and equipment</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220601__20230531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total payments for property and equipment">65,650</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210601__20220531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1229">—</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total depreciation and amortization">5,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total depreciation and amortization">7,872</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total depreciation and amortization">89,504</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total depreciation and amortization"><span style="-sec-ix-hidden: xdx2ixbrl1237">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated total depreciation and amortization</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total depreciation and amortization">95,179</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total depreciation and amortization">7,872</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Geographic Area Information</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended May 31, 2023, approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomersMember_pdd" title="Concentration Risk, Percentage">94%</span> of our consolidated net sales were to customers located in the U.S. (based on the customer’s shipping address). All Company assets are located in the U.S.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zsJNCREozDbh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Business Segment and Geographic Area Information (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8BC_zBEg0WgmVd0c" style="display: none">Schedule of segment information</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="7" style="border-bottom: Black 1.5pt solid; text-align: center">The fiscal years ended</td></tr> <tr style="vertical-align: bottom; font-weight: bold"> <td style="text-align: left; padding-bottom: 1.5pt">Net Sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center">May 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: center">May 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left; padding-left: 10pt">Hair care and skin care</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--Revenues_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="width: 12%; text-align: right" title="Total net sales">1,588,958</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="width: 12%; text-align: right" title="Total net sales">2,336,257</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--Revenues_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total net sales">21,932,069</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--Revenues_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total net sales"><span style="-sec-ix-hidden: xdx2ixbrl1177">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total net sales</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--Revenues_c20220601__20230531_pp0p0" style="text-align: right" title="Total net sales">23,521,027</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--Revenues_c20210601__20220531_pp0p0" style="text-align: right" title="Total net sales">2,336,257</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating earnings (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Segment gross profit:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--GrossProfit_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Total segment gross profit">1,076,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--GrossProfit_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Total segment gross profit">1,507,671</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--GrossProfit_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total segment gross profit">16,633,977</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--GrossProfit_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total segment gross profit"><span style="-sec-ix-hidden: xdx2ixbrl1189">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total segment gross profit</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--GrossProfit_c20220601__20230531_pp0p0" style="text-align: right" title="Total segment gross profit">17,710,811</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--GrossProfit_c20210601__20220531_pp0p0" style="text-align: right" title="Total segment gross profit">1,507,671</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Selling and Marketing</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SellingAndMarketingExpense_c20220601__20230531_pp0p0" style="text-align: right" title="Selling and Marketing">11,675,206</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--SellingAndMarketingExpense_c20210601__20220531_pp0p0" style="text-align: right" title="Selling and Marketing">1,199,305</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">General and Administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OtherGeneralAndAdministrativeExpense_c20220601__20230531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="General and Administrative">4,051,394</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--OtherGeneralAndAdministrativeExpense_c20210601__20220531_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="General and Administrative">519,769</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated operating income (loss)</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--ConsolidatedOperatingIncomeLoss_pp0p0_c20220601__20230531_zwzv4mZLcmh6" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated operating income (loss)">1,984,211</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--ConsolidatedOperatingIncomeLoss_pp0p0_c20210601__20220531_zCk6ZDJEyfI1" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated operating income (loss)">(211,403</td><td style="padding-bottom: 3.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsNet_iI_pp0p0_c20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_zTtnUaY36rMg" style="text-align: right" title="Consolidated total assets">3,785,732</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsNet_iI_pp0p0_c20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_zyjtuiuHbmM8" style="text-align: right" title="Consolidated total assets">893,915</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AssetsNet_iI_pp0p0_c20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_zCIwhlAmXIkj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total assets">6,383,582</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AssetsNet_iI_pp0p0_c20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_zEFkmpQfT8rf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total assets"><span style="-sec-ix-hidden: xdx2ixbrl1213">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated total assets</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsNet_iI_pp0p0_c20230531_zkdMTknEUMCh" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total assets">10,169,314</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsNet_iI_pp0p0_c20220531_z7HwaYD0rJH5" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total assets">893,915</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Payments for property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1219">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1221">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total payments for property and equipment">65,650</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1225">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated total payments for property and equipment</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20220601__20230531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total payments for property and equipment">65,650</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20210601__20220531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total payments for property and equipment"><span style="-sec-ix-hidden: xdx2ixbrl1229">—</span></td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Hair care and skin care</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total depreciation and amortization">5,675</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HairCareAndSkinCareMember_pp0p0" style="text-align: right" title="Consolidated total depreciation and amortization">7,872</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Hearing enhancement and protection</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total depreciation and amortization">89,504</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531__us-gaap--StatementBusinessSegmentsAxis__custom--HearingEnhancementAndProtectionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Consolidated total depreciation and amortization"><span style="-sec-ix-hidden: xdx2ixbrl1237">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 3.5pt">Consolidated total depreciation and amortization</td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--DepreciationDepletionAndAmortization_c20220601__20230531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total depreciation and amortization">95,179</td><td style="padding-bottom: 3.5pt; text-align: left"> </td><td style="padding-bottom: 3.5pt"> </td> <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DepreciationDepletionAndAmortization_c20210601__20220531_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Consolidated total depreciation and amortization">7,872</td><td style="padding-bottom: 3.5pt; text-align: left"> </td></tr> </table> 1588958 2336257 21932069 23521027 2336257 1076834 1507671 16633977 17710811 1507671 11675206 1199305 4051394 519769 1984211 -211403 3785732 893915 6383582 10169314 893915 65650 65650 5675 7872 89504 95179 7872 0.94 <p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zgGsAKHLaUF9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Note 16 – <span id="xdx_82E_zjUVoOevRTOg">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred aggregate net operating losses of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_c20230531_pp0p0" title="Net Operating Loss Carryforward">1,500,000</span> for income tax purposes as of May 31, 2023. The net operating loss carries forward for United States and California income taxes, which may be available to reduce future years’ taxable income. Management believes that the realization of the benefits from these losses appears more than likely due to the Company’s current year net income results and should be able to fully utilize that benefit in the current year tax filings. Management will not provide a valuation allowance for the losses as they appear to be fully realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The items accounting for the difference between income taxes at the effective statutory rate and the provision for income were as follows: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zHhbAUqNBbkc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8BD_z2vtMdawBvy9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of effective statutory rate and the provision for income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_49E_20220601__20230531_zTrAWLxIcdRg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_499_20210601__20220531_zyE2xs6Dpc4j" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Fiscal Years Ended May 31,</b></span></td></tr> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax expense (benefit) computed at statutory rate of 21%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">431,653</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State tax expense (benefit) blended rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">297,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,289</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in federal tax rate estimate for prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1259">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46,109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible expenses: Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1262">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non deductible expense: Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1265">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_iN_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non taxable: COVID related grants/loan forgiveness</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1268">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_ecustom--BenefitOfTaxAmortizationOfIntangibles_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit of tax amortization of intangibles</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49,773</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1272">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--DeferredTaxTrueUp_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax true up</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,929</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1275">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--NetOperatingLossBenefit_zkUUkTzWfJNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(452,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--TaxExpenseBenefit_z4KN9sn5ZLti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax expense (benefit)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1281">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease) in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(101,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--IncreaseDecreaseInIncomeTaxes_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--NetIncomeTaxBenefitexpense_zHcXbKsuTQX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income tax (benefit)/expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1290">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A1_z7JxRNzf0WQa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a deferred tax asset which is summarized as follows at:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zs4pXVzSN0se" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span id="xdx_8BC_zo9d4dFCUzU6" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_495_20230531_zS23nqrLNUb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_499_20220531_zQAqf0tCyyDj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 31, 2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTANza0r_z9Xzfu1oeBR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryover</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1294">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">452,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANza0r_z9eCebeJkMR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: valuation allowance</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1297">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(452,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANza0r_zgbOkcLEXgWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">— </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A6_zOG2PCM5VLza" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the net income at May 31, 2023 the Company reversed the valuation allowance against the deferred income tax asset at May 31, 2023 as current year taxable income will be sufficient to utilize the total loss carryforward. There is <span id="xdx_908_eus-gaap--DeferredTaxAssetsNet_iI_do_c20230531_zAohGqU1jx16" title="Deferred tax assets">no</span> remaining deferred tax asset at May 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2020, 2021 and 2022 Corporate Income Tax Returns are subject to Internal Revenue Service examination.</p> 1500000 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zHhbAUqNBbkc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span id="xdx_8BD_z2vtMdawBvy9" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of effective statutory rate and the provision for income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_49E_20220601__20230531_zTrAWLxIcdRg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_499_20210601__20220531_zyE2xs6Dpc4j" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Fiscal Years Ended May 31,</b></span></td></tr> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax expense (benefit) computed at statutory rate of 21%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">431,653</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38,410</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State tax expense (benefit) blended rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">297,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15,289</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in federal tax rate estimate for prior years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1259">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46,109</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible expenses: Stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1262">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,590</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non deductible expense: Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1265">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,082</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationTaxExemptIncome_iN_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non taxable: COVID related grants/loan forgiveness</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1268">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,500</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_ecustom--BenefitOfTaxAmortizationOfIntangibles_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefit of tax amortization of intangibles</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49,773</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1272">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_ecustom--DeferredTaxTrueUp_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax true up</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,929</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1275">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--NetOperatingLossBenefit_zkUUkTzWfJNf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss benefit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(452,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_ecustom--TaxExpenseBenefit_z4KN9sn5ZLti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax expense (benefit)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1281">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease) in valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(101,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_eus-gaap--IncreaseDecreaseInIncomeTaxes_i_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101,636</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--NetIncomeTaxBenefitexpense_zHcXbKsuTQX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income tax (benefit)/expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1290">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 431653 -38410 297928 -15289 -46109 6590 2082 -10500 -49773 3929 -452824 230913 -101636 101636 101636 230913 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zs4pXVzSN0se" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income taxes (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span id="xdx_8BC_zo9d4dFCUzU6" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule of deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_495_20230531_zS23nqrLNUb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_499_20220531_zQAqf0tCyyDj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 31, 2023</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>May 31, 2022</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTANza0r_z9Xzfu1oeBR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating loss carryover</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1294">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">452,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANza0r_z9eCebeJkMR6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: valuation allowance</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1297">—</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(452,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANza0r_zgbOkcLEXgWe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">— </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 452824 452824 0 0 0 EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -6#%5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #5@Q57$TUQJ>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TU!)71S43PI""XHWD(RNQMLTI",M/OVIG6WB^@#>,S,GV^^ M@>E,E&9(^)R&B(D97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MU8,55QN -YF!P T3 !@ !X;"]W;W)K6SW9D_9[W!#"$>OOA>$MXT-Y]M/K59H;XB/PVNZ M)8'X9D69C[DX9.M6N&4$.TF1[[4,3>NV?.P&C>%-3[ MF+W=$8_N;QMZXW!B[JXW/#[1&MYL\9HL"/^^G3%QU#JJ.*Y/@M"E 6)D==L8 MZ9_NS4%/(9Q4U94OH[/I@ZMPTMOB/B$9O'$EC\V!&+>%ZL).[C MOTRT'IYX/Z)&F\:,P2A\2BW@_7X9O;1K^!'++"D\&Z4_\FH$X*3#:)05&5F"\*]#+"LRLP*Q: MT,X*V@F9M"D)AWO,\?"&T3UB\=5"+?Z0P$RJ1?/=(/Y_7W FOG5%'1]:=$<8 M:J+OBWOT\<^_;EIQ,X"X5,$H$= ,]T(!O0C0.'.(4!5KB;HZW9!QN MZ1@G4X MBZ2@P*JZH!2)%4#UCJ!Z%8<:P^*-GKR0RV'!6J7="BRK2TN16(%6_TBK7XW6 MC#"7.O%[#XEWK_09!2L=WG2EKSJPO"XS16(%9H,CLT$U9A,WM,50S-!-Q.E0 MQ@U6F_R4P0)KZL)2)%: I6NY*=-JX?I),"N'=4:LK'/!976!J5(K$CNQL3K8 M2"MB[#TP:&">D6LVM4[3U*78P,K:V!2I%;$9.38#;. :T[6;NSG17][Q+Z\?\%"\_'+ M],5$L_F3-9J/D?7T,!L]2I]JL%!M?I=P]'INZ778E&?\+#%2F1BE4Y$87]%7 M\B8E"$N)3J?W]'Y'TZ34E-I\56I%:KG1UV&GGE%[QJ]HZ@AT[LJU<6+2@"$+ M2[9[S;9N= R]+Z6G- *H4BO2RT. #KOWC-XTL"D3EC8!=X467+P8$&7(HI'H MC*)/4D<^D,]DC+$4H-)HH$JM"# /!SKLZ#. (\<1ZN'5X0/Z)JY#3X&<&BPY MT'2T0!-&?!K'LQT)Y D+EJG-\1*I0<]C@PZ[?9#C\YY*.<*2WP.7([TC'\1* MPX,JM2*[/#[HL.-_S\Z*C\3H?:;[0,H-EAMY&^PO&99R4YHC5*D59U+S(&' MWO\]M^-C;\;HS@ULZ> ]HVF-I+.R2M.$*K4BMCQ-&+#]?X]M1D,N_,H_[K;T M/7%&<:#W-?ELMM(XH4JMR"V/$P:0QPH#=_S>:S(%L: "EKC,B7;/?%+3DG4II:%"E5J25AP:C4FCX03RO^3L0 M#WRT(#@4[!PT#<.H!!ZL^2A[VUIP46ULET@-1IX:C$JIX85ZPN!BEH9\)IU M.J-4 DMI2%"E5H25AP2C4D@XS"*ED]]NL$Y>F/)9MS.*/XFLRH*K:E.[1#(P M\F1@5$H&TX 3EB[@Q_-M^(!12@U6+*.F- >H4BM2RW. 42D'),,16<*/K2F3 MSH"GD2,"HE@86//0_=1:'X.I2/3UBG M;%$/+JL-ZQ+VW\SMOUG)_H]]PM;QT^R+4. ;8<[\+0ZD?>Z,8.GJ'EQ7>]_! M)>R_F=M_LY+]7VR$Y0!AP3+EL)1Z?E5J15BYYSY*(T#F5HG48MWRNV&'(BY29>"(@2D%IG9;4*K6/6FBKO>T7G?0'AP;F=&XA-TW<[MOPM;\L/89 MGDS9BK?;,EYV61'A*VR"?CV35X[N/(%3OJ/JG/N7SEI:<%GM7G4)_V_F_M^$ M7?O4FLS1*')<3AD:<4Y$9TL6#-W&9 MCZ;W4DZP@JYUI924Y@%5:D5*>1XP81]_H%2VE'RF?#'Z=C>>?TEOZ /VMY\/ MR\E7:'8]NI;R4YH(5*D5^>6)P#PSF9_QBV?5XE$I90A+W(E2-,<\7AD4#H:Y MCG1I %:IC4UI-FB=[ &/[7ZRESY$=KR\F6X'/YX][MN>>"2S=/]\>L#I-ME1OJ2<4S_YN"'8(2R^0'R_HI0?#N)?&PO=V]R:W-H965T M&ULM9IK;]LV%(;_"N$610>X-2\2):6) =?Q6F-NG,7.AGU4 M9"86*HNN1"?-?OVH2ZP+*;7C/ 1))/OPZ+R\'#XD=?[$DZ_IEC$!ON^B.+T8 M;(78GXU&:;!E.S]]S_@X3=7PPFZ&QJP:Q ;O%'R)[2VC7(I-QQ_C6[F6\N!C"+ MB$4L$)D+7_Y[9%,619DG&<>WTNG@^,RL8/WZQ?NON7@IYLY/V91'?X8;L;T8 MN .P8??^(1(W_.DS*P79F;^ 1VG^%SR5MG @D,J^*XL+"/8A7'QW_]>5D2M M "(=!7!9 /]L 5(6(+G0(K)_G1IW"P]DO*.&O%1(\[=$;V[;"2X3.6M4 SE6 M S'U/O73K4Y[X=#.'68)X7%LN0135[;*8UV6:D<<^8..9HV K6/ EFG DR#@ MAUBD,I,$+'ST[R(V!#$3.A'%0VA=!'(@HBT-JAF"MH<[--A'#;:IAGG\R&+! MD^?.R&TU)(*02ZU6Z*H=P82XKCYT>@R=FH9^G;"]'VX ^RZGDY2EP(\W@(LM M2V3.2A(I"_AIRD2J4T65:%V("(4M40;!@9Y1XAQ5.Z:JUUSX$9B6 B>= AU% MH$,H]G![U*AV+B30@OIF =*\$S[[N2 M@1+QG/=9]NT0[B65B,XQZ*ECT'8L2EIMJ9IA#UFVOBD1K&9G:)X^A!\_A#+S ME6.M4T+YC$9^<#%UVFG$)):^(8=J$(),9>9@"?@].*2E4*U$I,G>R*TU0"E1 MM;-LRR8=[501!C*>N9=Y6NQ.AZ7G1N@8>4KD&C.*':)O#7KHP(+9$P61YS=^\\9RVKK0L4%VHU\P392A012K0;-K&^[T&G/0!H[++FF8\S@B@ZP,1TLF"^);%%VM>?^ MCJ;2 I4YJ3T5: MH5+! C:&A65C95[+#EJEFMT$:%-ET\$DG%ZE%5A@XXFZN41?_$"INA.!7=NB M%+6EJH8.="#LF%)QA038,46DQ?+J$UC/;K[\$)*P,79H=RA/Y*U9(Q5D8&/( M4"9I;648N ?:>E II#')-_55$(*-(:1(J%&54",>/P#!DIU6J 8OJ&,K$X-! M.'VCE%2@0DX,*KURB8HJ%-J>I>Q$GQA52(4JQ!A5BJRTR/2MI;X?Y26B @FU M,/7:&5ACU]U%284MQ!A;2B$_"%]E$6)Y#K';6P,:0P=ZN"NMDMI!A_E)!]_M M0I%ED6+3.I!=,8P?6!Q(->!MRAC(P!(@I#WU,GFP-KV_?5XN+FO7(R<#V#V^^U\_9=VXB'&U*6MD1-Y:U9+A4^DEU?&UPF[ M9Q(;-D N98.O0_ :OH<0HHS-P:,?'=@'(-<$0UC\@G3K)]G!QT%L>1+^S38? M +:KK[.^%?,7JS!-#])S?DIR$*F0%[+3 3_--C;K9Z6Y2?WXY8?= MD99,BG%MG TY'G=6ZQFP[-YJ1<@90H<./NBYJ5N_P?ZI?%?YD1+"]BM286?5=W&;E581(>GEK/-ELPNQ]!YEVLQ.W M=V$, G\?RC2LC57=^T$029E6>YVBL;0M!T/7ZHBX(CC2BUCC21 <=H=B7;MA M]V$0:I>$1.6K=T2RMZ?LKNHL;>S)-7K'YC>I:(P8TU@QU:VR3KOET88EZ3$C M2@[5+Q*)RF24.K(7>&U)FE,E5RYU.];K5@5=EC%T%3O&M<4$F%Q=@NZ4KSU* MA\I!?\>NLL92NZL\JKVZDKTW],5/'L(X!1&[EP7A>T=Z2(I7<8H;P??YVRQW M7 B^RR^WS)?MDQG([^^YG+[+F^P%F>,+4>-_ %!+ P04 " #5@Q57@U 5 M8BH# "Q# & 'AL+W=OICTXX 2K@)EMDG:_?C90E@M0J):'!,-W MSO$Y^"-FO"7TD04(@*%0-31NH$<2QXHRS3MSC=<#E M"=49)W"-%HA_2^94C-22Q<<1BADF,:!H-5&F^JFK:Q*057S':,MVCH&TLB3D M40ZN_(FBR1FA$'E<4D#QLT$S%(:22[*]1(6AON3S2,BR;[#-:_NV KR4<1(58#&#",?Y+WPJ M@M@!Z&8-P"@ QB' J@&8!2Y>!"#ITQ)5M 9;5@DP=9F!E: MV,>QO.\+3L55+'#7<5C6W;/13ED /3131R0S1#5*<#^_T@?:E*K;_2>;^)[*] M3,TR4[.)W9F+AD>4(A^(1>\]GH $4K"!88JJ,LRY[(Q+/MLVCM;3-$T?JYO= M=-J5N:^6[3FR2D=6-T=YZP"8\H!0_ ?Y5A7VVM4[KJRCV5KG ]*YX,W.1?_K8S#V,?QNLK^H+7] M1OFN]H]E:^S;I7V[T?Z,1)%XT+5I5;M=JS;J=?7[JN:>Z6%I>MC!=*MN'AX% M;]7<[]:5;IO*/7^CTM^HN[_Z5AX=S4/7;C*S1@;=&V:[W]EC6TD=6?SBL MN;NZ]F\OI'7W_TI#%Y1M4FA6[QI#A7!-#NK.]E!NYF\@7>.8@1"M!%3KV>+A M2//]<3[@),EVC$O"Q?XS.PS$.P6BLD!<7Q'"7P9R$UJ^I3A_ 5!+ P04 M" #5@Q57.?1CWC'F$ ?@1_&-[V=$/OK?C]>[UA XRN^ M9R'\LN510 4THY=^O(\8W:2= K]/%,7H!]0+>\-!^FX1#0?\5?A>R!81BE^# M@$:_;IG/WV]ZN'=XL?1>=B)YT1\.]O2%N4P\[1<1M/J%EXT7L##V>(@BMKWI MC?#UF%A)A]3BJ\?>XZ-GE%!YYOQ'TIAL;GI*@HCY;"T2%Q2^WMB8^7[B"7#\ MS)WVBC&3CL?/!^_W*7D@\TQC-N;^-V\C=C<]JX^@ID0S M9"FM.RKH4CG)NT-;+PP":,K(OC5@WYB.)[/W/F7R=UHY=PA M=P5?4V>V2AV,7+"#=N<.N@#V@(R.4"^):T>I_074O%G1!2B2O",?[LW:0&C%O.GIN[4 M!G>3<,T#AEQ!!8/5+= _H^=81+ Z_Y7-5>9,DSM+MNQUO*=K=M.#/1FSZ(WU MAG_]@0WE;QG1,SD[X:T5O+6NWEWJLUA&/O.HIQZ3]/(V)*I.L$+,0?_MF)C, M4#6(7MJ=8-8+S'I7S&,>"\2W*&["GGDVCB#I%B#'1@5ZWD(&W*@!PJ:)%0OC"G*)H:Z8AHGET,T"NMFV0=J@YPEF]H"< M[PMGYCKNM8R!>5QM0LR=O?-%"2X:5:G@4_$?$B/&R3HAYR,7<>H M:J:EVA4N$CL=$UO.!"ME#52Z3(;SZ<.^O1E[KH7Z'XYGQY),"D?M8[2MC122^T2PTNPTA2U@4ZI K#6*G_F MJT=GB0[(\S1^(4WCN+.@D.7QBC9Y9HV=H1HU=W4IMRG6E1L"=14(!/"\\:?[F::2V7DC#-4/K M'8U>&K)?70A<$I#?55(2,T-OY%7*!=RJ%X;9BLJ/2Y_R-'WQ&\N%J]-V1)FXB MJ?F*KFN65:$G,;S$L,V:$C<];KA7-Y.YZ"4&J1S2;^EL;>63D#FTCJ*B'*ED&K4@L0HW6%?7,F#X_)'>#H*TC. M!^=D<;EH_K1R5Z/9'1S6Y2NML]*0KK0S>3N=BU([D,[:H7FEU;4 AE.2K6LU M-2XQU;"MZ9;5<-5"2O% .HN'ME57+_FJ;JJ63H[..SGVNFD#]O[1G73 0)0D M5_4Q')]?0Y'=]19OB[\#1NDE>.7]+;X>9Y?ZI9OL/X8I:!TOC)'/MN!2N3)A M1T39M7W6$'R?WGP_*2V9Q(;FDQO'HV3=CJ=?E!L.68"R!?D./?? M5\*$F(<5D^&+C6#WK'2.M-+"<,O2YVQ%*0>O<91D(VW%^?I4U[/YBL8D.V%K MFH@G2Y;&A(MF^J1GZY221>X41[II&+8>DS#1QL/\WFTZ'K(-C\*$WJ8@V\0Q M2;^?TXAM1QK4WF[XX*N1YFI@09=D$_$[MKV@Q8#R#LY9E.6_ M8+NSM3T-S#<99W'A+'H0A\GNG[P61.PYF/B @UDXF'4'\X"#53A8-0?+/N" M"@=4C^ <<,"% ZXY0.N @UTXV#GW.[)RIJ>$D_$P95N02FN!)B]RN7)O07"8 MR)DUXZEX&@H_/I[<7,]NOEY.S^[]*9C=B[\K__I^!FX",+DXN_[=GX'+:_'@ M9O+'QB)Q)/GQ=1SW=1S0-1;\7T MH6E*%V#&V?P9_'M%XT>:_M>"-%$C35@B+U4W74A=ZFV6>ILY#CJ M'@BGP_ 1;\ DS#A&VB*J%E#CS-UF1.1YI( MS;&6W32PG30:^><*:HH;L)/;N^ M1'J*%GP4K<(]+KG'2NZOQ?$I3.8L;B5+C_< LTT0)6X'0>QC]@"[,7J,'--P:ZG=;]H-L.E!7%\) M0=,0NLB!9CN;3LFFTXG-]@V@E4XE< -YEPR;(V#=W&5#:Q81A5XB=-*\>" M;DT=MR&CY3D8VF9MPBM'TR&C-^,APW"0:[0O"*^DT^N'SK>UTD:KU]QM)*U& MD]JFI:36]UU\O<)%O0$5E$+&N]%H-'/^4>-TR%?]04T+8 JT\1P M+%1?,7T%##X.6!5AKQ*''1?-G&2K5A640%U4@(VDU-R$"Z-*DD".C7&=X9YZ M%;0'=/&!I 3?:U^H+G[;&5;E(#5@QT4^*= JQP]/'#^G[1!&KR"Y]H@5]H>VTTO=>C,L/)5B2P%OG#@B6KK[]K!K<+;.WY4_,LY9G%^N*%G05!J(YTO&^%M#OGXO MOP"-_P=02P,$% @ U8,55S&R5T%Z" :2@ !@ !X;"]W;W)KT/,)*$O\^OW.$D)Q(YORXTJE1#LD_/8Q^=Y?.++5Y[\2->,9>AM$\7I M56>=9=N+7B\-UFSCI[_S+8OAEV>>;/P,OB:K7KI-F+_,.VVB'C$,N[?QP[C3 MO\SOS9+^)=]E41BS68+2W6;C)^_7+.*O5QW<^;CQ$*[6F;C1ZU]N_16;L^QI M.TO@6V]O91EN6)R&/$8)>[[J#/#%T+1$A[S%]Y"]I@?72$!9?UB_S<$#F(6?LB&/_@J7V?JJ MXW;0DCW[NRA[X*]_LA)0[F# HS3_CU[+MD8'!;LTXYNR,WBP">/BTW\K!^*@ M [8;.I"R ZEWH T=:-F!YD +SW)8-W[F]R\3_HH2T1JLB8M\;/+>@":,Q33. MLP1^#:%?UA].)_/IW?AF\#BZ0?-'^+@?31[G:'J+AH/YG^CV;OK7''71T_P& MG?W[_+*7P4-%UUY0/N"Z> !I> FZ)['V3I%HWC)EL<&>N#MWF7RX?(UT5J\ M]]\1Q?]!Q"!4X<_PT[V)QAFZ'S^:FZ--XU<-TNW#]!Y-9Z.'P>-X\@T-AH_C M[^/'\6BN&K3"JJFV*M;N1;KU W;5@<69LN2%=?J__0O;QA\JQ"T9.QH SD$(K?K0D//H/MV M1SY:>Q\M[20-EO^#E03))TM1QB'[!#P.PHBAN.Z\^%G<#/QTC;8)?PDA9M'B M'9WM4K@(XW,$&33QLS!>%2DHS$*67JA 6VU.<4O&CH;/W@^??:KUIO\W#%H& MH5^DZGB)_ U/LO"?_(9JL H/[(.9]RSL>+7XD%LYKH/5P>'LT3EMH[OVET 5 MBRQ5(7%D'VW/KB.16]F>V8#$W2-QVT8RCE]@5?#D'?%%RB.6!BP.F K6"8]& MJD!VY>'!IMN W-LC]]I&/L]X\"-7 $L$"0!D4=H8G)[D,S$<:I+:G"J:8<]V MU-"P43&TT3:X;Z#?$*P\$:0(M-X*I%+,4F6\ED\_=+MK&99AU-"IVE%H9C3@ M.U @N&U\$\"6I^B(P00B]B:F3QFVISQ;&;>EH2/XV,$-S(1)A9[H!<3:CU<, MB?FJB"5-&5"5R)M1Z"_"J)ED2NLML4Q;UH['HM)26*M4^H,@X#M!TL =+'SQ M%Y%Z3JEB*FR#.$X]9!4-84FZ5L.D59H'ZT7//FTJW3.EIU*+'CZU]$YNYUF> MVQ11E=C!6C'0GR5LZX?+CU51Q!'/UBR!#462@.-E@"F=M^0ALVV,L>2]W)"8 MM"D95%(#:[5&'X0#3\,&WV3Z[U(72XGJ!#6#=/%;*0FLE1)5_&[]=Q&\A?() M@F3'JNE0(I/E ,&@?Z1!E]MU':.!/'&E&["6O?O3H^ X2#E*7V4&MZGA>M+B M^W7%< RG$@-8JP;ZPWS;#(B6NF Z05&HB4&F_:YGF,16SPJI>)_\(N\/85^= MP";D9S-&9.:F,%_8KLW8*?[H9HQ4$H!H:;@_&3T6Y8;9P_3[^&9T@Z[_B\Z> MYG QGIQ_>E--9(XF'G8QE9"JR)S8AM7 #*2B<_(3.J_5 \:3[Z/Y9UQOE ;*MJ#$H@3NACJ'%5PD+8G]I8=Z.)X/)\!/03JZ- M*!=F2]:.!Z$2*$0O4/*%F?BAV/3"ME!L?#>P/--\+YQQM("-2)KNZF7:QY<,6-?(S M6$9;'PA B4[6&)@2F]2G0M&N2US7:E#UM)(B5,ORZHS^V;17VC[TRC(-X\"K MTGNY'7%-K\'W@[@4A?!]/A@^CP7R$SFY&Q=4YW,LA*3V6M8-I6JXGNZPJ M'Q!*C ;%3BMM0/7:(!_M+KIFJS".12$'%L$[\Q.ENXHJ@0-_DK=R.].S/=I0 M5J05X5,]X9?.CD1Q0..FS.RF"V'LUHN?BH8U/,=^5L1-?T+<^:L84=!8[A(Q MJ+!912"[0IYSF+(J1ELE[;:L'0] 1=I43]KC.&-@5ZDKJ:)P8!$IAN165F.N MK]B6ZMEV7+PXR_PW];93W_T+_-J"H6.(%0-33QM[\Z?9["Y_(SZX0S?C^?!N M.G]Z&(FWXY/II)LOH0.-/+E1YE=UB)[\1D,Y1"U9.WX%7-&^J:?]XF5*(1US M8;G?\$&(+$"O-&WX3%D" ,LXIEMG2;T#7X\!L]( IEX#Y"=;1(K ML;<@VBU%PA5O6LZK_7P8?WYZ976 '=-P2%WBZ9T[ 7>E-$R]TH#L6D-^$E"% M^+!LSY0..+1O812=!D\6(01;A$AO!?1.G("ODC.F7L[< M5350,9&[S1<16O(1%=-P74+K"-NJ8/0.#FUM6++*S[()/W=Q5AR&VM_=GY<; MY*?$:O>O\<6P./56F2D.X=W["2A1D:">P:3QNP.^)\6YMN)+QK?YT; %SS*^ MR2_7S%^R1#2 WY\Y;.'*+^(!^].%_?\#4$L#!!0 ( -6#%5=WX31J1P, M H' 8 >&PO=V]R:W-H965T&ULC57;;MM(#'W/5Q J M$+2 U[HX2=WX MCN!LTB;8-DVRZPV(>Q1%N#CF:4F9&5[->7E&35 ;+>ODAS M(0\/#REJ6AO[W>6('AX+I=TLR+TO+\/0I3D6P@U-B9IN-L86PM/6;D-76A19 MXU2H,(FBB[ 04@?S:7-V:^=34WDE-=Y:<%51"/NT1&7J61 '^X,[N(_^2WEK:1?V*)DL4#MI-%CNUPA4HQ$-%XZ#"#/B0['J[WZ%=-[I3+6CA<&?5-9CZ?!>, M,MR(2OD[4W_ +I]SQDN- M;:"&Y7OAQ7QJ30V6K0F-%TVJC3>1DYJ+P1-/0$R*? MAVGGO6R]D__PCA/X:+3/'?RN,\R> X1$I>>3[/DLDZ.('\43C.(!)%$R.@(W MZM,;-7"C7TAO "NCG5$R$VU#Z QN+3K4OCTP&[B26NA4"@7W=(C4?=[!WXNU M\Y;ZYY^7%&H)G+U,@+^I2U>*%&=!R;'L#H/YZ:OX(IH<2>^L3^_L&/K_5N^H M]\O?@ W M-RNH_B<30:PC7A MEKG1"+HJUFCA]7@\?G-R,1K_1@LVX'PM\:8N3P:-*'MVSP03-"O73F:2QB4\ M$QD6Z4,EG6RD674>M.[$/^'>EBP#D6B#I!1 (:-R..$<#7QQ $+Z\L7B42HX M%44Y@85SACX%=EE:!N0X0UA7COK(N;[LB[^N;_9%'\)+71T>S*<"[;:9PJQ] MI7T[JOK3?M OVOGVT[S]2Y!N6ZD=*-R0:S1\>QZ ;2=ON_&F;*;=VGB:GA^8ZC!NPT'Z']_\Q]02P,$% @ U8,55]X/?J<*(0 VF$ !@ M !X;"]W;W)K2_KW_BH'7M[" $4U2 MLBS;B0%9CC<^Y&%8R?H.A_MAR&F2$P]GF'E(9O[ZJZ^J^C'D2#86>\!N(I(S MW=75]?CJT9WO[NKF<[NQMDN^;,NJ_?[1INMV+Y\^;9<;N\W:2;VS%?VRJIMM MUM''9OVTW34VR_FE;?ET/IU>/-UF1?7H]7?\W8?F]7=UWY5%93\T2=MOMUFS M?V/+^N[[1[-'[HN/Q7K3X8NGK[_;96M[8[O?=Q\:^O34CY(76UNU15TEC5U] M_^AJ]O+-.9[G!_Y9V+LV^CO!2A9U_1D?WN??/YJ"(%O:98<1,OK7K;VV98F! MB(P_=U+++67M?EIR+O-M\_NGR4Y':5]67WL;[[T>IZ MGF&\95VV_,_D3IZ]>/$H6?9M5V_U9:)@6U3R[^R+\B%ZX7)ZSPMS?6'.=,M$ M3.7;K,M>?]?4=TF#IVDT_,%+Y;>)N*+"IMQT#?U:T'O=ZS=96[1)O4H^-+:U M59<)KZH\N9%MPF\WQ;HJ5L4RJ[KD:KFL^ZHKJG7RH2Z+96';[YYV1 G&>[K4 M6=_(K/-[9IW-DY_KJMNTR0]5;O/A $]I"7X=<[>.-_,'1_PYVR=GLS293^=G M#PQWYMERQL.=W3/W M]M'KO_]M=C%]]0"UYY[:\X=&_W_;Q =G'5_3+W5GDWGR][]=SF>S5\E7*3-? MI^R!03XT1;4L=J7EGZ_KJJ5WKHLKHZ:Q,6AK"DF7IVH3, M6M+1DZNB76:EV=NL:1,+H4QBD>+9Z(]YLLEN;;*PMDIHT;NLH0<7^Z1ODP(F M9EDW.4UB28N[#7_6Q>P"I6M;V28KRSU^MSN01N^"B-^K@CZ9&Y#'*[K:VH;X MDCP!/^?35[_?)/^XNOK GV:O3IBJ7=^T/5C7U3Q(TV,2_-+8=5\R,W@P_'AC MEWU3=(4^\<.7Y2:KUI98M]T6+5M:-]?-#]=N'H-GB?ZRSRT/HPOSP]+KNZS: M\Y@%?3W@>]LOVB(O:+,GR55)W(^VNZ@ZVRSE;>-'Q3"D:56;+87ZP'1;%F0% M,V7:,M[Q2?)3\6=/,W5"R'6V*SK:[8^VK?MF24O^9 UM&)G5IJ'-IPVPU9H\ M#P]%C] FU7F_[)(VC \\?) M67I^<9&^>#%/LA8Z="2LS#(B#6O-'0TDB&7=MKHXIK1O=?V'5":[K*5%?QKP MZ\N.O"DD#>L_6+W9U6T!'RL#K\C?DWXU]38>.R?Q(RHPO@Z;'' #/T>K.6<2 M%K3OM!6\2^X]GF61E="W-B59Z$F]YENPJ67]VY!-VV8P;3:,[-CM9*3=U$UW2CJ\ M!2%%=6M;B(0??$V>K-M,S!4-2E^VA)7"\HF%$!@B *;NO][_Q%[C^:LV6?0M M.9NV556@C1>C";I!G,KAG95]BYGA'HQW4B2@;@S6X861EEM9F],D8MI8),B( MZ=Y"X18=:<&>^9^.;W/RKV^S&=_FG[.*M@H?:"B:=,D:2DP"+YWNJ,'U#+-? MBE;]#)LPK*GC/_%E1>!8?Z!U9"TQCKB6X34:!0LW;+49;EJ!N:ELZ)*0/@D M?M8])1)_BTP^F?&J[I(U]#ZCI3>\]FY#G"K ^6HXR%"*B*.PYYW_R8!!_7;G M/;R*(:V&_G^TIWX@[ W&V-'G*M@[]GRT1WW7-P.)HT6\DR^=J-%N;VG"6!H, MF7LB6\06?/1[33Z7'&=KCP27.& [UH[_[$E"@!A2UB*2&M%;MKE=419_*8R! M1)&3(5Q 7")- N^@0,M@/4T++G'_'=F+5N4K!U-5A#569X7 MJ@'.H!&7Z@7SN**9VQ:@4>63%L[A$[ *QC%0=^*3J ,!F0F!N<4?ZA@83-4$ M/6IZ$6OWTJPVO!7B8MA K!QNK="$_2^]2Z>Q5[WBB["]YM^ME?<8W]]EL\F\ M%5M&9]@*08"9,V&"(T= IB 51-"T$/.O0E"EN^I8?B\[&%AY'&"$'N8$27J=$]!:=CT[62@>T&1?Y@D6UQ3,G+R@U81- M;J/53P;11&#*-B,=(3 6<4X!;6H6/?&'3 '4B+ M;M67'@"G[/.JKB9UN=0/AP<)^UD&XJ'(M.]_'P*RTU3DVC3?O';J< #PCI^<_=I MM"P:7^!N8\D>$IUF,'')ECL2"XTL9/<;Y#SP&$""(VN5%4U$5X@XH(-0,&*D MM[I$Z@)X7E@47C5>*,5L-^KY!Y1 R$5%1L?SPCJDJ*JK4S;#"'IHE3?@G#<0 M)$'7^-$#9&P+O,YN@%_W]D<9BMY:SD$2-Y7S@]=UPTIMX9G M5RZ^@W.CB>&3V%B-ZE@(!T?>XXTFPRE6.?X>1L$X)..D=?@SP7JPKV+G"6=7 M-P>@!@Z)@#,2$'O54W*R A"_9A(8/>6&N 5/M0 @=F;(.Q\VO#KP@OE $(F\ MG(O."GG9H[KLF -#@L5RDJTA\T@&]1;)2QYBY$V(3&XA@:0RD">6R\'":(L# M#!";XL*$K-QK-@;Q(=GQ*!L0I'Q%]H:X:EA@@'^*"M1U-CA_0CL>!$'9*S<. M/[] L"/,]8(3A#2W=LM&&L_U%(&6G.5E@4* O\D:"NL-?L]4&]6%)5$JPSO7 ML/!L!00&A=[:3-(F;G B,TI#?-ED)&-JE!@2UA2:=5 82 5QN[ZUQ+RB-]$GDJ('.3'6P&N2Q;H3"FGX\ M+@$X$LDF8:(%L.@0S7@.B1*5=\@HST1^!C\7;5#&/($;$R-#/$#$SD-L246! MBV)JB8D]J8().^@XE2-#UCN]XKG2PR#&9;KJ!7'$MDO$%RDAMRUG"1J5,';8 MK6)'O"L"X%$$^0^2=P']1D 9!B)9Z.Z@)?&^X>^AM,$\C3,F7J<5.&+%G#F9 MYY")<;T?TJD9Q'-#NU8C)4])NWL?, M(>4H'56L7,!+JE35VV()WDC$1_#.1_D2\&*W&2]VDHJ)L;6D63(-F _ #S(N M==^6\1:Q]$LT.]B;C2W%4N)=_[61KQ>D[_RF3TWYW97-4V97]@OIUYTM;QTJ M2J$]?J<0]0BX4R'Q$\'@"M"6K+<#VL.O/?X6'Y(U#8_9R=X!?<7I6)-;LFNP M/HQMWD:?F"IB5-]YC19AH>B;C-,I"BFJTPG;.EZ\;GP>8H1;ZQ/L8@TG6M1H M6:38,S3.,G-JT#EO]1;,$9<#?D4/_<&N:5=FRR@4*[: -^X+7CK'WS#ED^03 M\*9#X@W<=@I*TCSL@(6YHN3[U !-NT9I *K*M9 MZL8>.>M8YTS0N4GR47..\""D*+X(Y&1V59>UR2?#8UZX+"_S\1=I0?)VEDGO%RW9%TGI\0:I Z97VTVQVPF:C=]S#L QJGU@8R?F6KV?J!E# MQH/Q\)EF!0 5DI #'LLE>^82;=U^)T$%,ZO)Q:1D@C[$UOEDOW+72W&K2/A8 M#;#_6>L4\N50=+UL2Y[,TS_Y)@EW5L*/\B.!L5MP,Q,&1M" %F$UURU3M,AY]L"%E9@ XV-,GNQ5--X+P_8:>S%?&X=0(U9 U>JKF7([UAB)E\S M%3YZ5[L)"1LG299[/("2="B"7F:7WL8ZBW1(B9&!5-B_52KN,5RR>7%JVFN? M%-)&!D^NV$L?%6"C+^8A"6<&":RM2@U1_SB9I>=G9^GT_#*9>M]B#O)=@W#' MVY#JMB8>Y D2F9 B;XP6^R1*A4ATHD%T(CU?G*R]HT4_GC+5CZ>I(7\,($8C ME/M7Q^G#,5+ZBB#+BN) ^N*^/8!J>,7R24%BQ)Q0YQAR:))<[4@HOC"0))O]^'+^/)U-+QPD#*,GT>BD M&SP6R>KC<^+MQ?S%\0MFY(6YC8[^[99SHZ VE_ @E%?P%%WA!EV M1W &Z4Z0[0 9'B>ZO; [V;?KHJHTGE=V/ADI1)_(IB9G+V;I?'HND3HZE1@* M2.FGX,8J'^2U213EN;C%=\R8. QV>LM>&,Z?PW++Q0OW$;_]2/\H\0'3#Y// M/N4&"6WCES;N)0QH1IJ2"-0"S +9%Z7U$J@Y,ZY1>I,Q&#V K@-4'NI$<65H MR42#&3I 0&V#.3CB"#$?33!ZGX.^HJ<''-!'#9+J8K >',7=D==CH3J>T MQQ>S9#X[3Y_-GI/=UM=2_PZ[N9R4D'R!M*=\]1$AQZDU8C$SH-M%"RYGWH9O M-II\XP!KFYH Q/0>-^CZ5C2&RX-R<5S05OS!2%J O8]W<(NQL7-);<6#% M8DY:Y84HZ@>(D9T1O#1)WH6*R]9F*!:$>'-8C1D6&K1>,I3UO.9** 3WDNQ3 MHM$9S_%/'N?G: [.D+X-94F-X)(HJ,,P+K#3O@X-< \J3$H[9P%BLBN&P-A+ M[#4WS4P-F:+ MZ(O#6F=DYH9Z6KP-:4PC L\FVUJT.#%M\B2;D$"E=MV@0R*J^2)Y0YBC[2E. M68UON8@C[R$$! 96^913C *TPEEU](G0=B,E.0X)@YQ(FUG-:"TT.VF1)*HFVAJA0/3&>!.P*JD+10C7.$E3)KH8S<.+-!%;1)G'TE&EF!)3X MD O0=,7^.KBA@HLG'"PB_HO0JTN5BK&B41II7&-E$:<5<9/A&DF:[]\ XG&+ M&1, G]$TG5UNJN+/WHG+-B.8X$R"/ETO ,LX$UM4NUX5@O#_T9-]=?2LRV>Z M-QMF8HUZ)OS_ OW_+\U/G-J;O4Q^/9J+I8C8_V=?0]0=1YI"^\VD@5^_U_(% M1X1 "ZK W%#D]5=GFP]FD_>U4JY3TVLC*]+."?BGNFGJ12T-:(N]HXUV(],Y MSEXFOX^,P)B7PWC$RY65F4GB7?N*C)P!]6_$$4";*$R%SS]8.-Y-.2-S7] MTY/H3.^[JYLWH7IQ&S9UP/^1RA[[.V:+1C4A-:$/<'53] M4@\*T@#]R(F'$OIRV:"W(H"D80H[RGHP$F67Y20N"T%#*TPR@6XD/I99)(A1 M T/%0J,_L.I'N_;&M61D#[SX5"US$_II6]H^ZSA57[>1$0JOU M"R1M0W.@^! $;^:X"X73&%FUYJ(URF"1&*-;0W\Y7 .75<>8ARJYY\ZI ^$# M>0CQEG'9*5='NK]_)H:P0^C]7A8Q]JKK2A0#*,6B-;?VQ6G*U(SMH(ODQMXX MP&'J(., 3ASD-9]J8*]QH('W#&P.ZJ-:WY9V@+$Y4N^NT E_2B@(XC)@\B#% M^61VHFFY^Q>'7H%!,4N,;OJUMS3GE-ZRN,&,7QW=!6>N+(\2XJ1AK@!RABLPC.)B8\E5'T4S$JP)! *R: 7"E'NLS)A"<8E MN+< 'W\=5FMHN?3:VBV3(=D654D6-->4':!+7Q72 W)PXH";B3D#JXI7+\G* M\+?+HEGV6_A]Z7;P;42'^YX=S .F,^C4YO*FX5[?D18#S?YIPY20Y=<4UF,D M.2^EQTKSNY+5L1G9 DY8208Y8H)2C)8#^J-C\_1)5BK87+->H7\H>ED;!D!( M:J+6U571M*Y8P!%XZ'%T9!0HV=]:U^H0GV]P&>*XS76;+9MZK%4 M/?D MT?>#_@$Q"MHP0+/8ZK9HZDH:5R.=XM!%X*VKJMU;:9($C62$4W=NS7:68@YD'-XQ5??!N1.K&UVT21"C-"D.&X!"SL7G5"SBIPC0N"$>,IJN.62P_=QPCG?14-.*+ER/[ :MN\/9J7V=X-VD!C M1A\ESML#3!%>-42TCRX#23JNFW\H+6I]W"$G%@3$";<,IW! *C3-:P;)R!JU M-VV4,0.Y$)(T%=L>C">=2=$)05EP.-^U""K-N2_GLSB#*AWFT0DF/=\_($RJ MN7Q\CP&1RWH"J<>R4W,[Z,A!0=KF'X1H!H2')!N?:8GCPC_Z?"W=0Z'#%.<. M^-Q@?!Y#'$$W<]85]1%T*(A*W#G(/*#^N MI3'7-,J]-V'M(9$6;+UX20W]7'M?-U@+8<6PO:MPU"K:7VE@$U-OHV$T88=N M3#89OV5?[ -%#C4L'3\5G7DV6E&Y+5I7P+FY3IZ?3T]G(54]@T\])P9B& ?74/*12P1F=K80=>X:S(P=AHB3;R&DS\RW. M=#"R\)_!'QY:N%;U0_#K^LD>$$!7#$.)YD &?Z]<-BA(8_*A]L<3V4ICD:Z/ M&5YP591\YH-SB=HFW[N!("9L6B1IW!12?G/IL7#X"8?NS45T]YRBTQ8/ ME&VU8,S['C7R#K# 7'E@Q3,[)=LJZ%: M##U$.]NZ]'W8I,$D19JA[ESOB#;Z663_< 8"U3O:\X,]\Z?35!D09*S7!)-# M-X,8HUV0GX-A..6/A@\6CI$EF]B8H*>@W=2EI'_B*ACG2E$I;KM8A&@RM\4N M9\J3\.C/INX,NIL4P:Z5JHUHEG;:^22%\5+%A;&EG%O)OK"MZY#]9NKY0Q M:[P(WW_X=-B!E1X)*,4,G'U.'9>CX@,^$L_U#A MHD-0(^2D@;%&Q'?8LL!5@%%SDW+&R"4K#SD/B8IF?D!:@UF7XWLX%@-#56G/ MG)YY8TW@2BKR$>ID'>B!K^KEE!_G5S2!1PA=VMI)3[5%5L]+L>ZY0X?'3PVS@@9I/G3D^E1?$R=G!NF^D5.#AT'NX'P$0R+%;!"9O3M- M!C/H+BS@FP*,I/G*_;T=X=J0H,O'>01)4/)&]]O!52I]%<7$QQ'0(!<3+\*, M+$)C@+'40!$WI CNO.?0%8\4+@<9*T>Z&@$NS#,C25'ISI##T2/'RN__X:B\ MX+"9$5 4G51REU)M2.9.W_!C'Z0S*?FMWE'HZY#D[-);\.MX+E[B_)4>X8Y_ M&@WK9I<^IC/#F&X02CT$0GW3M"9^R7C6>ROLS&DDA.JAN=5WC$@27^[:XGXC MPG1WJ'AC#"FMQS5Y?RI(P2Y';&XJ/GFC,S%ZUM)@Z+X6(75$',[- G+'IU"0 M%.%8GGMG>8-N-=$G,Y],W :0NV_KZ :*J"GEW\V306%^C7[A4VY3/BZ@\O/B M;G#PR\UL^#($UZ,OP_&C[1!T^!-!-[\G\^GL\O2Y/W31+V"#.KEO@C#JNL)! M#=C&$9'GY+#.+>X@IH9 RB^V,VKBG\"4\-$8'8]+5MPC)E3CMKME?+76T1OQ M\;+%WN2%GDUWD:R^I\>HG'LXR@]5_7;ASJG*_!A]<$67NY#C;5'R;!B=QXR) M,2-GW;YY,DGP:^F#K_9 R 2@'>Z-0'&UDWN*1H@S5]U!K_T05^;)L_1L.DVG MTZG@DLU(B_'!!6P*-0=RA)PCU\*UPS0<].'EAZLZE%?#=<9K$-N]5Z#NVM\@ M;:=^^;X9+JZ1>XL>=ED!!0LR,X81OV]+X#;%FJQ867@"%RQ@HIQA6U5H=E*P M(,H-4_[2W"P)TO6E7)UQM/_&L?2=L/2_P=(?CKJVS2]A"C3=7L[/TV?/GYE/ MAW(BQ"G3T%1_^>)9>CZ;F;?'@O$2IYZXY5;7K DCY+IR\NS,U@ M'VG \\OT^<7SX^F#^ D%9\^>IV>7S]+Y\W/S@Y:DCQ3RI1&=?9Q,)].Y<5\E[^RBZ9%8(ZMS(0*+WBAW0PKLT2_UA'\]G9)$_R3U[B%4 MJ>R=S?6"%E=J7>I]&Q9'X?(_:8X.'<+842M7.;TE\\NJZ-5%>KID'#[W)C[H MH+A?Q7<(XME)\D'>:6^BTWI=;<="ZW$'/"T*>Z#I6#J4(OO>5\O/GHRS(1_TRP_=<*-N:7 MT]2]E(27/MJ#FWR2:PU$F\-?3+@@@N\;2T ;)QL;3B(8_O;J/'79T]DKR M\V+LOS?/G%/A/Y8K4M[2"6ZXLBL/YT>9K4.@&#R=Y:5=_&+97_GI7\8%Q M0FBT@E\)RT!YB,C9@TN8G4XO4Z-"/=X*]T3$[G+Z[.3E87;84914GMC)>A*2X]H=<_(-'6E'I4Q. M,/@(1F&)CM,XO'?8:)73))_N"@8@)=ON@E'L=UY">X2 M*JHAA7&"YIOYIW%KFVW#61N?Y!(>&)V!3.J/OD\3FBV=#/H2HX\H%73(OV%K M7!$NB8HZ;04M^,7&N2F^'S/"16UT6$JR \%S/'.N(R2\.2%9;'T[E/:429$U M'G:2D!\M]_Y$ -=[D$+K.N2!PN6+N -I.*@>U:CVXZ$9YPC8[B$%L+>=V#_1 MS6%PRRE"%&68"FG+@'ID'.#QU8WJ'H?'%USF2OFWUEDLD,6-/X=ONN?,L*E)[@N+#(A")QG*: MM'1/$12*;E?U%6UW#4X[O*XEC9,UW]B[HC M.\9_ MK9!@_0[ZN:H)=^P 3^/^?P^O\ 4$L#!!0 ( -6#%5>ZJYD0R0( M "X& 8 >&PO=V]R:W-H965T&ULE57;;MLP#'W/5Q!N M46R 4=N*+%,FC M0TJDQWNI?ND,T"+!NI2FY(5=M [Q3RU 65 M1<#"L!^4/!?>=.SV5FHZEI4IYUC(_<2+O)>-^WR;&;L13,<[ MOL4'-%]W*T5:T*"D>8E"YU* PLW$FT6C>6S]G<.W'/>Z)8/-9"WE+ZM\2B=> M: EA@8FQ")R61UQ@45@@HO'[@.DU1]K MOR"_L'E3KFLN<:%++[GJ\*LR]W'_$0SX]BY?(0KLO[&M?UO,@J;21Y2&8&)2YJ%?^=*A#*V 8G@A@ MAP#F>-<'.9;ON.'3L9)[4-:;T*S@4G711"X7]E(>C")K3G%F.DL260FCX1X3 MS!_YND ?!)IQ8 C=^@3) 6E>([$32!&#I10FT_!>I)C^#1 0K88;>^$V9V<1 ME_P9NI$/+&3=,W#=)M6N@^N>@%LH3',#=U)K^#%;:Z/H2?P\EFB-$Q_'L6TR MTCN>X,2C/M"H'M&;7EU$_?#V#,NX81F?0_^O"SF+=)SG9VD0NG!U,611= NG M3GLUJ)8AD=2,VF *<@,F0]C(@KHZ%]M1YX'&15H5:$W\W^!.^S*AI;#.PKUR M5&T2< G=N.>S?DQ2%/7\01QUEJB2C L#*R43U%JJ=D34'_BLR^K4V&WGCCQ& M,+,$N4@L5P6IK-9F4Q74MVNB]^:FY\?#$-Z2Y \9"9VC>=N"7$(<#?PPZEM" M8<^_81%\H1(L9+GCXMGZ2T7OGF9$ZN !GVAR:E>02QCT_9O^#= WCN#8,PE: M/4S%V+I)I<&QJ=NYV6V&X:R> :_N]21=&ULC55-;]LP#+WG M5Q#>L),Q1[*;.ET2H!_[.G0H6FP[##NH-A,+DR5/4IKFWX^24S?=NFR76)3X M'A\ID9EMC/WA&D0/]ZW2;IXTWG:J!EOA7IL.-9TLC6V%)].N,M=9%'4$ MM2KCX_$D:X74R6(6]Z[L8F;67DF-5Q;+&[:TA9')KS(]@?*SG MR3@(0H65#PR"/G=XCDH%(I+Q<\>9#"$#<'_]P/XNYDZYW J'YT9]E;5OYDF9 M0(U+L5;^VFP^X"Z?H\!7&>7B+VQZWYPG4*V=-^T.3 I:J?NON-_580]0CO\" MX#L C[K[0%'EA?!B,;-F S9X$UM8Q%0CFL1)'2[EQELZE83SBX_Z#K4W=IN" M1C_+/'&&DZS:X<]Z//\+GG&X--HW#M[J&NNG!!F)&13Q!T5G_"#CI=A"SE+@ M8YX?H,N'!/-(E_\K0;B0KE+&K2W"M]-;YRV]B._/9=P3%L\3ABXY<9VH<)Y0 M&SBT=Y@L7KU@D_&; W*+06YQB/T_[N,@_GEUGXQ'*.#5BY(S]@:>QG@TH3+4 M;,YC#68)OD%8&D5=*_7J9'1#XZ!>*PQ' V*T?UFP9_#1.ZDE/K10JNK \G123Z%"D+)^.?I,:6'+&TG)2T#KG M>9J7)9QZ>*)#Z#IJ2$$.J36H:A">LI*V'G7"^BTH4XDP&AR(UJQUR-L;XAT# MFZ33@C[Y45J4G#8NUI:JT->$GI%0L$5A'6!X]']$'_71@_>Y:3NAJ;0T,4, M08,HU%3H*I8R1#MF%(6!-O#< \KVFKM%NXHCS-%=D>*^SX?=84J>]L/AT;T? ML9?"KB2EJW!)T/'KXZ,$;#^V>L.;+HZ*6^-I\,1E0Y,>;7"@\Z6AE[0S0H#A MOV/Q"U!+ P04 " #5@Q57_(C/FO " !P!@ &0 'AL+W=O7@.)='CK52_]0;1P&-5UGKB;XQI M1F&H\PU67'^0#=:TLY*JXH9,M0YUHY 7+JDJPSB*>F'%1>U/Q\ZW4-.Q;$TI M:EPHT&U5VG@7\%W@5A^LP2I92OG;&I^+B1]90EAB;BP"I[\'O,*RM$!$X\\. MT]^7M(F'ZV?T&Z>=M"RYQBM9_A"%V4S\@0\%KGA;FCNY_80[/9G%RV6IW2]L MN]B4*N:M-K+:)9-=B;K[YX^[/APD#*)7$N)=0NQX=X46V.]<+/V5(;15?DURGI'7)Z&MD^FY%N>(X3G]Z%1O6 _O3M!>M%EV=X MIWO>Z3GT_SB@LSBG67Z5!B&#MQ>#F+%+.%WKV(W/[@"TX08+X 9RJP2S/VZHM'?N/ M2 W.!7=3YUV?!5$VA/?P+AD&+$GAO4Y M)A:.'6QGA?WZG9U2BBC5OB3V^>ZYYRZ^)Z.ETO>F1+3P6 EIQD%I;3T,0Y.5 M6#%SI&J4=+)0NF*6MKH(3:V1Y3ZH$F$21<=AQ;@,)B-ON]*3D6JLX!*O-)BF MJIA^FJ%0RW$0!\^&:UZ4UAG"R:AF!=Z@_5%?:=J%:Y2<5R@-5Q(T+L;!-![. M>L[?._SDN#0;:W"5S)6Z=YMO^3B('"$4F%F'P.CU!\]0" =$-!Y6F,$ZI0O< M7#^C?_:U4RUS9O!,B3N>VW()D2QC]AV?KVTP"R MQEA5K8*)0<5E^V:/JSYL!)Q$[P0DJX#$\VX3>9;GS++)2*LE:.=-:&[A2_71 M1(Y+]U%NK*933G%V\DU:)@L^%PA38]":46@)UAV&V0IBUD(D[T#$"5PJ:4L# MGV2.^6N D/BL227/I&;)3L1+]@1IW(4D2M(=<.FZQM3#I>_ ?5$J7W(A@,D< MWA0,Y]QD0IE&(_R:SHW5=%-^;VM#FZ6W/8N;GJ&I68;C@,;#H/Z#P>1@+SZ. M3G?4T%O7T-N%_G_?:2?$=H+?E44XAH.]DR2.3[=TY[9$.%-5S>13AV4/#=>8 M W]Q8ZV;+;5JBI+>"+/&4&IC7-R<2^;&[P@^W"""3Q>GAT<.U^ 6H$S1P!M+ M2=3"HRV4(.7@LAAV;DB2\H9\Z>A-9.>3L9S&E"(O^ )A\Q)U+GCFA$06X&7' M0 K[$,?=C[U^Y\Q/&6JX1N&YFI+7SF,0=:,HZMQJEA-S5J&!.()DT/?F.YP; M3M7TR=@Z7E#-0YAF65,UPA.95DI;_M>CPH=!KYL,8CCL[$-ZDG2/!SUXN9J: M>WJ;?9P_]S%[Z6-GR0Q13[IQ/^DF2/8=@_# M#>V@)A1>(5U* FAE9&U=B_"TU9X7]U;!+YDNN#0@<$&AT=&@'X!N5;'=6%5[ M)9HK2QWWRY)^)*B= YTO%%V/U<8E6/^:)O\ 4$L#!!0 ( -6#%5&PO=V]R:W-H965T)4%)*!;=:7=%BU]'*H>3#(AUCIV:CL+?/O:3DBI!$B]$-LS M\_-_/,Q,=D*^JAQ1P[Y@7$V]7.MR[/LJR;$@ZDZ4R(TE$[(@VFSEUE>E1)*Z MH(+Y41 ,_()0[LTF[FPE9Q-1:48YKB2HJBB(/"R0B=W4"[WCP0O=YMH>^+-) M2;:X1OVM7$FS\UM*2@ODB@H.$K.I-P_'BY[U=P[?*>[4R1IL)ALA7NWF,9UZ M@16$#!-M"<1\WG")C%F0D?&[87KME3;P='VD?W2YFUPV1.%2L!\TU?G4&WF0 M8D8JIE_$[A,V^?0M+Q%,N5_8U;YQ[$%2*2V*)M@H*"BOOV3?O,-)P"BX$! U M 9'375_D5'X@FLPF4NQ 6F]#LPN7JHLVXBBW15EK::S4Q.G9%YVCA&4E)7(- M3Y1L**.:HIKXVN"MDY\TJ$6-BBZ@P@B>!=>Y@@>>8OHOP#>Z6G'14=PBNDI\ M)@>(PRY$011?P<5MKK'#Q1=P*W(@&X8*"$]AGB2R(DS!S_E&:6G^';_.I5P3 M>^>)MF/&JB0)3CW3$@KE&WJSVYMP$-Q?T=MK]?:NT?^O-E=1YX5^%AIA"+&ULI55-;]LP#+W[5Q!>L%-0?R1INRX)T'8;MD.+8MW'6;7I6*@L>9(\-_]^ ME.1XR=H% W9)9(E\?(^BR&6O]*.I$2T\-4*:55Q;VUXDB2EJ;)@Y42U*.JF4 M;IBE3[U)3*N1E=ZI$4F>IJ=)P[B,UTN_=Z?72]59P27>:3!=TS"]O4*A^E6< MQ;N-SWQ36[>1K)8/2<"5!8[6*+[.+J[FS]P;?./9F M;PU.R8-2C^[C4[F*4T<(!1;6(3#Z^XG7*(0#(AH_!LQX#.D<]]<[] ]>.VEY M8 :OE?C.2UNOXO,82JQ8)^QGU7_$0<_"X15*&/\+?;#-R+CHC%7-X$P,&B[# M/WL:\K#G<)[^Q2$?''+/.P3R+-\QR]9+K7K0SIK0W,)+]=Y$CDMW*?=6TRDG M/[M^_Z/C+279PAW;L@>!R\02K#M,B@'B*D#D?X'(YK,C<+-1X\S#S?Y'8X"8OPSAGL:%:5F!JYAJWZ#^ MB?'Z]:OL-'U[A.!\)#@_AOYO!(]"O$SP5EF$0@D,J"\\"EY9Z,A) Y/ MI;%,"!]H9PFM8/($OE @HD83!TFY/\;$&<2@*R2'FQ!X?S_ 0N#3 + M^Q7G[6F1>]'TYHEZ@4 =C;C(TH>3/A]>2L](1#ZE+N@=)PLG9TH-R[3H6X[8 M3EVTON9%[1$'ZQTP)6$GON>VYAX;)#Y9?QLA:[O4:RR4=K?C$QTT1?A$/9J2 M[#0M1AZ.!3-&%9Q9D(+'G?' 789^O9O\S#];IC>4+&#P(IBQ#Q\NP#C6U[\ 4$L#!!0 ( -6#%5>MD+F?A@, (( M 9 >&PO=V]R:W-H965TBJ*+C:WF(N-V,O\O8;7[+5VMB-8#(J M^0J?T/Q1SA5I08.29@4*G4D!"I=C[R8:W':LO3/XEN%&'\E@,UE(^6R5^W3L MA980YI@8B\!I><$IYKD%(AI_[S"])J1U/);WZ)]=[I3+@FN_X2Z?KL5+9*[=%S:U+;OV(*FTD<7.F1@4F:A7_KJKPY%#/WS# M@>T,H, 1I?P3)SOVV=F=ON$<,'J4P:PUW(L7T%" @+@TAMB=TRRXB/O(MQ)$/ M+&3Q!;BXR2]VQ[/T8Z)(G M./;H FA4+^A-/KR+>N'P M-.P[1S"?WGG;CH?IZD YC*HN1B M2X:YY *N[)Z-RL+A VTX,1JV(1/.G!>R$@;D$MY#U W], PA_G3=_06B6CDL M<8=!%/F]?N=_$XY/*,F%H;<)TU8FZ 1PD5AO0:O%<@RZL1_'UQ#[4:\#+"*E MVWJBUR^MJ$ID(5S9RKILK=,B9XAL;@"@DSS!7%+!^PDBDNA=P-9_//P)K[QVAY\=AV#I@3]=-J\,^H-8#F%9*(?6TE,IQO=H;MDFL+:%-Q1,?DW]9-OD?25^;0^+JZPX5 M-8"F 6VD%>X/DL!7'@2O7H:7,:?CHP?FNO@7Z@@Y2UZG;;G8.^?^G M'N=>@.#H7:;;LW+31]-=HKSJ)[K9;0;<3?VN'\SKZ?A(#:4###DNR36DN^*! MJB=.K1A9NE=^(0W-#">N:4BCL@;T?RDIWYUB S1C?_(/4$L#!!0 ( -6# M%5=&F2HW/A, .HV 9 >&PO=V]R:W-H965T6>V["K%EF0[MN,D5\Y!8)(%&HR]?7T"^?G+U5[\TIE'?5F7EWYPLFV;]ZN+" MYTNSTO[3,?CEQIVLS?G#Q,7KV[PG@>\$]KGGSOM\).9LY]Q<5/Q9N3,1@RIV)*LQ_U=/,G9**^:M;]PJ3*;KE:WDK_X6Y-";<#L^,F$:)DR9 M;UF(N?Q1-_KMZ]H]J1JCB1I^\%9Y-C%G*RCEL:GIJ:5YS=O'QN5?EZXL3.W_ M^I?;Z>3F7KW_K;7-]O5%0_0QZB(/M-X)K>D16I.I^ME5S=*K]U5ABB&!"V(L M<3>-W+V;/DOQ9[U5EY.1FHZGE\^0NTR;O61RET?(R<;4_SS,?%.3/?SOH3T* MB:O#). CK_Q:Y^;-"3F!-_7&G+S]ZU\F+\?WSS!XE1B\>H[Z?ZB-9VD=YO2# M:XR:C!43G]RKXPNJQZ6F:>JA;9:NMK^;0CUXY>:JKY.1:I9&Z6Y(KM>VT65& MX_#D![=:ZVJK[!N>?W4]'HW'_$^-S^G_B;H<[]WZI:3H: MT-,$"V1ARA+)^%M7!:&$;W0#/DS=V+G-Z0)KVBIW]=K5FI&@<;A!$.8-4ZW: MU-%&L(^4,??S%;*D31F6^P09\N>UOD8BO:[>QA5&$[CP%#.@J9Z'ILL2"H" $LR03'KM.>_"\ MAX,\CE@OM-+F,34!'!/0)5V,F"NC\R6%#/PG!#.^V+C&5@NU M=D]DN32R%69+N[*D_Q%^5VXXBE?BR87Q=E&Q,=!A70=N:U-JQ IZI,F, MG?4>)(3T;X*([^S@SJ&-9$9B09I[9DWO[6F:MB^ V=F.+Y9ZB;9 M^4\5(M^X0[VQ$A)E!F"YQ5@B$Q,L@<"+0KH0P!-]Z69BNMVJI"Y*@A6L( MFRQP2#YX0$\7))6%)=,@(9&E1XD+K]F UQZ?Y^K'M@YCL[GUN2[5UF@R>D:T M?:3M/)IQ8MH#'ED 2U6N>A$,_U'$\;"+-R/UM+3$!DT!-F^ EK.2]%#13CM6 MXW(#!(3AP=%?-.X%_)U!E5REK6%=4"G;P /9;:,^MG6^A+0?%K4Q*ZC\]-$8 M)7'HDJU\JYF"8VNB0,\&7C(A_Y(,@AQ_L+"F6=L 3Y+'DPF5FHL30/7VA80 M6=!>)\:V*LFG6 #BW!U]L3_E*;)!NJ;/_,R8*A"MNX48?DC<&H"5M>NPX''U M(Y&EA>/ 0SXUX)8-0VSF.<(;5GJY#Y1PW(3!L> M^$O(JRCF+"GWV""9B7$E;@ZN OT%8?#S[) C'I6D^..3:TLDWFV(CU%VCBPC M=R&VS4QE*"NQ%&#<4R4K<)9&JU;J^OL#EA#* 3_,?RE329E:@91/YY1:%RQ: M1M!'$Y*;R>5I<<8".UV<==:34\1K;,C[WG^CZ% M*#SD;(R3N\LK20CA@NMU M28D4A%RW!):9Y&:+MM2]]*FE4%F?'ZQ-^N&1 'RPCT/C)Y.;T?CFY>CNZJX7 MF-6?",S93F"^H;AU>SFZO;M4=^.;T=7M^#\DF!"'T+)0$V+I9C2YN:;R8GJI MKNCB]IKW= 2N*=U-Q41Q<.%L;^'I>9C\RUK$VV6%I FR9\HT>YQ%\^"IL6;\ MB2K!%5-\(8%* M/Q$;/E1)&8,GV3FV!FF[FY-U4K>QB/ MQZ@K'XAD:0E(O#IEJY]'D^?BAY@\R\(%>F,@B(82O,4#)>4),*>$^H'5X7R(;EXF,T#:,2G4#V0*O@Y[F_.HDFSD.@6W?EH:F[8P2VE MD+\'EI]N[)F2@GPULY7N8RZ"U\*1J4CD804^60HRXNU 5.0+; -YZ3R#WJSU M)!7O8XI3 -3,MP9%56XXFO<5?4EU?$A\$E4JM5XONJ*M MH(E-\RTWHAD15N,:\JM=\";S(*CCFJ!7.*&H3=&H'5B]>J)]3"BQ4"L2/'33 MK]!X1 @LGLE@LU5%)M,KQ2KU0#5+J2;@ \5S1BY/6R>L@=]3ZF>H4*F@&=H( M.R^7FI)Z\2T 0F_3?0R@I5)%)*4T"9* S\3#Z&986#,L72"SJ42@I-0DWX#:8Q*-N&; 050%F?:U8K,CYA#Y$ZV* "8,?)R9()32:*_ M(CT1"_OMB4' ZY?:HI7]"7]2U:3AC.._1,#H%AWH$OZ@[4Q0 @,2" 9Z=8*V M1[+W8RPDU?5,!-&K%VDAFO/8^_,M91M@6VH9N,G2E-(XDD2?/,'4N?5,.[2- MHGK6,9^$K= ^_)RFZ&]"AIP,"D$B2L",9-EGC#8AI=4%PM-,$Z%@0?N[W&A; M,M-#T9)>7."MX1[#,J2/G6T-[(B#B^PP6'V&YD9*&&O4ME+%]HK<&)-VU(ID M$%LH".LW47!QOO2E,(3TE_/.DTFE4F<>,G"HF/)V I&\;%E8&L_FQC:M9)QU MB@91Y+6:DTSP&-%&UQ7*DQ0(9/_,0\35$ -&Z/'8K@+(,;XL4WS065^GH]06 MY)JL1T=Z,2*:A*JQ&)H9;(*#]T[:I@YG/ M.:IP\:_6-^)2&>=Z!]I?^R[91ZDC^T0/JN1^#3=^4_'8^5+L#0#G^E-'61SA MR8.;8,(8[:,FAX'^, >B4.+#U0M=V=^3'=1H,'B?&IJ')U;;T P-4!9D0,;9 MYM%6CRW\'+P^_FD%BY+"*4,V;.1+AR4DPRF>/I$U;=?"D0LI&L4M] P7-7DX M]US[2[Q2IY.CV5WLIR'R(:/K]?*/I'W[.:? @H " (C;/?OPVBN6@3,A:.C@ M4-JBL*R_FD91K&[3C&'@E,&\3P[@4.,HJHT;K6Y.)GYDMTE $'UV53(-C&P M?YJ$:FJW0NH'Z!G5153L(:P39U2O$J-^#IVO2U,LY 3'XXBE MWT0]VP/E]YQ%Q[,G;X8\L4_$(.,IH5L[OP,1HZ[5&82U'Q1'H5-/F["PT86I M3,TY.6,&JSZT@SO #37 ;DLX]/P']&,//]MM671[01"VKMCE)#: 1(@FM$(. MBY.%\ 33+*Q?A^+K(#O9T(CX $>$$Y!S-_H\[RF,T$_$(?YV% ZE%=V1@HS+ MH-BN9TQA#=F ]0.3S)?6;$R,=VPN?=J.1UHDOCC:G976+_?BQ,<]9B(8>-.@ MQXLZG6!M&7J4^ZV%"&G9D=AO./SFLG)*<'0ZTY##*C(3X)/?KUK#^'A(2 F- ME9/$X?F@S*%AZ)W+D%3:=BI-\7(4(QY82.4R5XA>W+I?,Z<>O,MSSNM#NIYU M49O(-;4K4XW>65WL9W*-OK?_5US4\7EQ/]OII8P^BI([DOWB+& N? 9J0J\U MM$-VZ>W;G!#=H),=ID):=K[;/NS/[$F6NV3! HM( >?+>_6^Y'YN>-6(5[Z/56;8SAZ(,YV^./J;$5]F0Y3N$QF#VM,6EH3X MFYT#2LT]*F[TFGHAO7S8BRO#FT,W8/SV'=R:^[\_/X@H379*?X'4!:G88B"(S""*3!O>4)CO!J$6+J M<-MG@G8S&'=L$97E\9,GZ=ZQ'84T3<\\7!C)KI3UPS9->#,'1::W4=M=QW\Z M_GYGA=1C.2ABAKTM'(EJ4K:4P,;*:/22P,:GML29;O'BLA=#!AW^OJSZ-L#5 M1Z#-4"K-VC*<\J6K8/'D@W*(A(N209D+$>L#?H?X%AT$[ ZZZF?H6"4GCQ"9 M$AR&X5'/+*AV%W3A%TDD,Y$"0]*@[MV5<$XY4GQ<2CL)/0@I0CBGP-W>F 20,SAKIMA!WW?.7<:6F^>*P-A M[[;Q&>$6)S]49X-U29:C =&6[(I;]0 )SM13?LVA(@1[,@P2E!<4:QO*8W^/ M9R/O2IU_??&8$X2A/A,811W 30M7F#)F.!:\LKQI1YR >ISPD:]L=&T!^Y[W MG87(;;XA?X14A2BV.>KN;ASZ+)Q1'_%('XX4N0+@5H5U)C"]TA3Y>,]LS_X?&'[+-;VUS= M3&X'O4?> >4Y>N5:),'\AD R*CF1;'U*V6=P@WDIJ2E'C;Q!LWO>W$K.$2'?AV+&#Z5*X]RBHEE^:,7\.@X..U##O,!+ MH'BY@^2;-,;[I"# K^1M8$12CZ37ZS(&G.%RXAS!H3P57Z'T%B6RY(-XAE9! MPT2=?ZPQ67"?-@Y!6D[-?=\=LL(1.Y ^0Y9O<>3'J$)F1CJW.-JDS :9R8+V MLYN")D0+"Q]R0!*; 4-[U'M1DA*MN]CXB3]Z>#\R_DCK87&8%MOQ9O">T:2 MZ4,Q&YS.I#@TE&.J\4K=\SAYC2#CER'""!8O5:)#QSVRFP8]?1+"KTM;FD$< M[GDNS+#G -*RIO@,>!O%MD>RP@Q\5US!X_R.EI1+NP92\^2Z%"4< M,/.A,K\I2.+<[E@Y2NG0ZD_M-+U8P![1"&K78.-Z=-F]*WQ'8U0X5)TH>2,' MP61+(:=JEGCQK-II^_D,VD"=("XR?(UAVNTYOHF7]OR!((';TI-G]OW,_D;2 M1$(IQ5JB5#?@'\MF[Z6MOCBR0^+ B$X8T[&ZN>;?TZG\[0,2S*UE".E3Z37: M.&)D*6)\IZYN;D EFXYO1I=7TVPZ&=V]O)'^R(%@[X?17B"(TPE*,MT3)V8D M(GFYRK_*:+8ID/+NA*?^J PO=+"LLT^$&>H 9ER=CV_4]VIZ?G>GOL_>#QSD MI;H^O[GN;O;\X>H:LZZN;OJ34N >TS/\^\R'+)']1EY8XL]O(K;+9S&@*&\] MHY'EGLE"HJSX''"VW;>"7TJS1S6 >+7V+I?]Y>/QT]/)ZP"<&JT-?N5STOC_B9@.^LD*>0HF/ M?(J4[J8/N1[D^Z5NN'P%]K.N%Y:47IHY31V3^9](>S9>-&[-7S/-7-.X%?]< M&DV5%0;0\[ES3;S NGSMK?_!E!+ P04 " #5@Q57"1AK+#() !W%@ M&0 'AL+W=OO(#S=00=0 M8ENV$Z?Y -)TB^V@G19-._NPV =:HFVBDN@E*3O>7S_G7DJRY*;>F7U)))D\ MO)_GWLN;G;'?W%HI+YZ*O'2W@[7WFU?#H4O7JI#NW&Q4B5^6QA;2X]6NAFYC MEYV,!XT'S[K MU=K3A^'=S4:NU*/R7S>?+-Z&+4JF"U4Z;4IAU?)V<#]^]7I*ZWG![UKM7.=9 MD"8+8[[1R[OL=C B@52N4D\($O^VZD'E.0%!C/_4F(/V2-K8?6[0W[+NT&4A MG7HP^3]UYM>W@_E 9&HIJ]Q_-KM_J%J?&>&E)G?\5^S"VEDR$&GEO"GJS9"@ MT&7X+Y]J.W0VS$<_V)#4&Q*6.QS$4KZ17M[=6+,3EE8#C1Y85=X-X71)3GGT M%K]J[/-W#Z8HM(>5O1.RS,2#*;TN5ZI,M7(W0X\C:.$PK>%>![CD!W#C1'P MPMJ)OY>9ROH 0\C6"I@T KY.3B)^D'LQ&<L$ Z9/G\()=(KMY&INAT@4YRR6S6X^_FG\<7H^H0* MTU:%Z2GTO^ZRDW#/"_N;\4J,Q^+GG^;)>'PM3IOMO4)>.''O1 8#5LZI3.A2 M,$@BY,)L52S\6A',1I;[2&9FX['H_O$K5IW#N>.+LU$2-TA?UBJJUXJUQ)$B MIQ^$7%FE2 J"3TU9UKF]TWXM-&0SRZ5.%8NXDU:M385=2YGJ7/L];7J0N0:5 ME5J*"A%JL52 X:PD=>I3=FN=KB/UM-$V*/(Q]6:!M1#SZEQ\+,4;E:J"OG!@ MCJ]ZV@FG5R4V ED]^9J_S)*7A ,@@)B(O9+6G9.N8#>HM),N>G$9SRXN!002 M!>41+Z6-2VV=YRVLG"Y32U"96.QAG519#P(6LC 5D)1,U[SV7+PC-VR#L$BA MI"\ICE5!1V^ &YV05PJ_,PP:84\A%FJERY*,UC=&DG14TDZ\$!?QZ&I.*D4G M5=KI/&_U>E8MWF1RU!$Z-NCWI:.-QU:*3XH,3EW1"9W=6I6$$+4_XF&K]HYA M+9&W@!$H7J38K/=.IS+/]Q31" W&IX!N"IW" M Z5:AJ _ +!%7.TX:&_)$ZFQ&06D"WJ>F>49'?R2LCL977_^^)6?QM>_1 P2 MT;'185TCFC@EVKM24]C4L893G0_!@%#.JSH8-M*V,APT MJ3:F_+&8Y]$C(!1_T,P>R&$$.MZ*3:Y3S=3<6 +YCQJ!1* +@U6HF_4E%6* M7*5+NA MFXTU5#;PD&N(MNRSUB%9\!$RFG)UEJ.?SFK0'XM!\0\%FY2 *-]MCIB6I"47DG7GY!"2'NHG"UY*]511'69,S\&C#>P18AMSK4 ]''S6T M7 "H!PS!UR&X-NQBZH!@@:VTFA/TB'B(1^I3F$>0/)5%&W$N?F]VM&OKJIA5 MG!'HQ&H/?^]6"TM%8/3C$@-]7HAD,HLO MI_->#L* F\KS9C9<=!)AC!GKZG+$PLRG\70R$U?3&+ABC+Y\=GF!_^-X/L5[ M\C?Q6($E6KZ4.;E1A$L$78:;@C"TAR!%/6]Z!>K(7-W%N5?18[I6696S$_\< M:'0?2 QS8=3,A=V7).*+!0+D'B*L/BC8&BNZ1]0559 0T5N%4>+E9!2/DYGX M1;P<7XWBY J/T<>C"2&@QK"6)^C:,B_$=!9/9Y/H_2&THI"4[UMK_P5)DJMX M;S>#9/(,D7X[]WX4&0X"H(. M[_N]^+/('3>P52-@36G 8*7H;5;+79NIM0B\X-PK\:[.B+9V']3[=-PI?*_7 MP;[]Z?=C=\2:L(:CN-\6P 0\6&?< FPXYR1G: XF034 W?(H]ZM,OSE3XCW' M,/S^@1B,&.&MJ2PJ]0/1)EJL!WKE$OVF@L3T7E(8O,V-U9D,?-;"1VB_%-73 MA>7)$(??MX,T@90(@9:Q>8"I!R_T!!2-\.&*)I)>^UP73X(.!0AU0=.P2)4M MG)CQ?0 :*,F6BKC ;7GBA*[=YJY6LY!E136BHF) CI&RA3U)I9YJRMD+-9FAR;% M]OO2!9;CJSLT(GVPI>(*$,ZA4*I'#:Q"[7.L!945O,,I?';-.Q%/RX1H>O+"W [TMC?/-"![1WS7=_ %!+ M P04 " #5@Q57E_+3Y6P$ ."@ &0 'AL+W=O;%%*_! MU&7)].8:A5I?=:+.=N*!+POK)GKS6<66^!7M[]6]IE%OAY+Q$J7A2H+&_*JS MB"ZNA\[>&_S!<6T.OL%%DBCUS0UNLZM.WQ%"@:EU"(S^5GB#0C@@HO&]Q>SL MMG2.A]];])]][!1+P@S>*/$GSVQQU9EV(,.F\AQZ9+RU6I:Y>1GYP\HF,4,[IFV&WC43!KF]3*SGB5\9]5+6ZSK!BM^ M 2N*X4Y)6QCX*#/,C@%Z1&S'+MZRNXY/(MZQ#0RB$.)^/#@!-]@%._!P@U<' M"W\O$F,UC?YY+NX&=O@\K.N;"U.Q%*\ZU!@&]0H[\W=OHG'_\@3IX8[T\!3Z M*S-T&NNSL@B4IG=OIG$47<()01X+A!M55DQNO/7DTL!-P3&'CT^8UJZ7X$N> M\Q1U&'S"/(='M2PTXQ@"-V#)O622+;E<0L8U-:'2H'*XE59CQ3/X1:B$"5AD M*VZ4-G#FMHG[EUL#/XPNWW?W+@4S(>1:E6#I8 "K_'\(E58K3A47L&S%9(K& M+^T# #J\_.G@R*2LXI8VKFI=*8.F"PL+AX46 I.9^XK#(Y""9.@GM+X@[#P60:Q*-P.(J!=$%_[@2?:DG2C_T6,3!#4.BZ9&\"G]4* MRP0U3,)V^S6W!2S^NOW-4WI).K)#8!KI9$W^)2S'BM)BZ4@&P4N*MDFIDH&J M-;"$"T[I)BLZ'06XN:TH=-ZDWX!"Y (\8^(Q[,*'6COIG!HY-RD9;I!I: (X MTBXX5*QB1/8MQ-$T')^/29MQV#^?O +-V03_0XL&).UT")-A.([[$(W"\W@* M7R0<*7R<.J<>I[2M"R7$)E!K23N16H9GG*XBZH,57PU@D7ZON>'^NKA15![: M*P) V8$5Y3Q1E*,S_MZO%12(BXTJTK;W3E(;ZD)CG*U+94AP=*<9 M2W8!S;G0*U$OC6?I1F6=YZ:IPC-.P,YKUX/.(*FS/2S5L:F9M-N:7QA#=_E] MK5-J%QHN-2*5F@TA\[WN!(ZV(NWK,%!;!4?;Q:01CFJ^S58K9_@#O<)]R6[+ MT-<5B9^AW@G1I:2A&SCH0X.@-7#GR,LU?RM3:EV/=EPS/W I4&0@%96]-98X M^C-!E11D6_WM[H'C'YUW1_V?MB1/N1SHTWWNU.\=W-$EZJ5_B1B"H69KKNO= M[.ZQLVCN^+UY\U*Z8YJ.50,"C#NCF]=$,K*K\C4^E2>\'_TF%2=(Z M UK/%55G.W ;[)Z \_\ 4$L#!!0 ( -6#%5?1KOU_9@@ $L4 9 M>&PO=V]R:W-H965T&8*!U!M/6S' M:1Z DW9VLYA.BZ;=66"Q'VB)MKB510U)Q"Y.[0I MQTD4S<8;+JO!S95;^ZQOKE1C2UF)SYJ99K/A^OE6E&I[/8@'W<(7N2XL+8QO MKFJ^%@_"?JL_:[R-=UQRN1&5D:IB6JRN!XOXW>V$Z!W!WZ78FMYO1I8LE?I. M+_?Y]2 BA40I,DL<.!Z/XDZ4)3&"&K^W/ <[D72P_[OC_K.S';8LN1%WJOQ- MYK:X'LP'+!@7GTPH&D/9 XO;T@I^5[;OG-E59;IHD:W.B',]6=AG*RHJ \6(U=B7/V MYK8Q6#&&W:G-4E:<7'4UMN!,^^.LY7+KN20O<(D3]E%5MC#L0Y6+_)#!&"KM M]$HZO6Z35SE^Y,\LC4.61$GZ"KMT9V;JV*7_AYF,5SE;& /D+[+?&VFD6_WG M8FFL!EK^=FYIFX'B!%C-"/8G#SYH=X%EV^8L1D9\3D->Y_ M.E:OE'S+M0@RD"GME M9W6C3\,HRJYP&/K2?&YT52%NV M6&LA4$XLRYTD0I@'6.*0P+$'[#+EC63QM+?Y(&HK-DNAV=ROCMCRN3VFJG70 M\T/() PTS=+(7*+.A8S4#QUQYP4RO[4I/K\$M579]T*5N= &AFCUB+/5FJ'H MGG+FP=E"<$VT.&5]J0N67?!()K;9LLE9MSAB7\%Q1Y*IREAI&W()*6WA01>F4]^ 5*" MOA=V[">CV?RGH-4#7844=+X!W.!Z[[H=-0*3IB?)[SSY0T?>B]@(4*&E?LUA M]Y75HH;*A2CSH%(G91< X5[5A?>FS%L?!5WX#I'H <'2) WC>1K.+](>(R+/ MO%H!/;4TA,D5&_(S=GY\(C@T9(>) V,)!,/E&4NF41A%[O_1\>SH>*6JMX_* MDJ4/0DMHMF"?T2V%UE#&<0W9MI!9P<"&C'X$L.6R%$ LF]O3E<;#KV/,H _ MXJU5;_%@SEL>ECLIP8/GL4%,"%G+G1AR!]R*.F%:A4CGAF&E65N@0\IA'(?FG9_=>HU85) QL M:ER9P,G_X05;<(N1I2E1%GB# D4Z>;E4P9:B$BN9N50,U+9B&Z6)AE=L^A/[ M$W%'Q3&83V 1Q@:H3\4W0\',>94)3!FV0' SG\MQ.LS//%#69QUS[#8:[H$- M'YZ W&HM@D5F:3N^2"=L2$1MA>X(T$EM5ZE]1.NN_@+*))<;!S=7;YR9[$BUJ02DZ30[E&[CE'$OQ#NXXZ9 _L1A-)N%DWB")'8P,@0;(1^=#Y+D/#R?SX)[%#84 M,DVS43I)PLDL#E "R;5P.JZ"!MK.L#Y-@D^0ICMQ<30/HS3:,Z_YL^,\3.;3 M<#:;LK/@#G<$FJP/3!]"L4D:IFD""L\2=4?3H'9 =GX1SI,9:'Y%N-"(UZ[? M'#N6[$POYF&:1,%]/\@HSX=G@E\ Z\HU!$U7-T-GX_!B,@WNW+T+BF@,FBX= M"UD;=NYZ9_!5)F$23]'%%'.W6,PU_B9/DH;?*M[D M4!S%GU#==*\T3#)'1ZTNIZCG5+:7KI.L4*0JZDR8V(!!FJF-&P1VJ?U%/,K' MU%^P^K/J7@"J#5 F,QA&,Y,JI9_*=[Q9GS?^Y?]&4-I4Q#V>B=4*W0NOP6NS M_N@5NUIK>G*00+T!MYO>5M*0FC11,']%.!@4R4AW&7+CWI'EX9&RKU],8*=< MX?K "@XW9BX->A>2WGT$/_"*\:(6[K-&^3PZJ ^PTYLI]^$.?G[1H!=W@@-3 M>R]) $M%U5#[3J;A))F'\2RE%$+N =;S6>(2%3<"9!(;8O0R&$%1(I+P8HKA M(04N$TI39/0'KBODH>G(:JH!O1X?W'(C,S\#)'@,\4QQ[KTLW1SAAP-_=TTN M_=C1!3K8(ZKG"RK;-%96@OH([B"1O=I44_FU*X*(WJA6!C/G^\8V6HS8J0\%X]X''M2EM?N,18,4*JW_UK-; MW7TI6_@/1'MR_YGM(]=K"7278H6CT>A\.O#UKWNQJG:?BY;*H@BZG[C!H3H1 M ?97"O?,]H4$[+X?WOP74$L#!!0 ( -6#%5=::B 8/P8 +H/ 9 M>&PO=V]R:W-H965T3RIYD'@!^N!T M]^DF<++5YM9F4CKZ5.2E/1UDSE6O)Q.;9+(0=JPK66)DK4TA'![-9F(K(T7J MC8I\$DVGAY-"J')P=N+?79FS$UV[7)7RRI"MBT*8^W.9Z^WI(!QT+Z[5)G/\ M8G)V4HF-O)'N0W5E\#3I45)5R-(J79*1Z]/!,GQ]/N/Y?L(_E=S:G7MB3U9: MW_+#N_1T,&5",I>)8P2!RYV\D'G.0*#QL<4<]$NRX>Y]AW[I?8ENF,MT'F(!,SRCJ&)U' MSR*^%_<4AR.*IE'\#%S<.QA[N/@)N&ME;RV),J4/\-0XZ-0I:>D_RY6%VXG[ M_3&G&\S9XYA<**]M)1)Y.D E6&GNY.#LU3?AX?3X&<:SGO'L.?07I.19^\?9 M_:R=I'!&K[Y91&%X3/N+[#^27M.%D:ERQ-&C2U6*,E$B)U4B9C5JTEERF7!4 M 1;Q%'E^C[I>_8%:PX ,+G11B?*>G*;D<^BD@38,C4&K+'",0D]00,$$S$TE MZC71-2]D9"+5G5CETJ/&+8OE8 E C9TJ4>+E;0_?D]BS]#&<'_>C)-AI97UXE*N]H\UC#5]I=>]C M-A!)9Q3:7; 'W+Z-'T^/+-NPM_&QY_1W7%D?P'10?3T70Z MI=GH8!&-#A<1A5$\FL?A?@(#!/%:WLFREB-:=G&\[N,XHBNCTQJY^@G:&?FX MW=15E2MI>H7\*)1I1FX1E@MA9&=EZ4UM5+EAKVBM; *G[J4P)+D%T&X!4P:4 M@%$LHR2,4K5K6R3(LE\N,U*VS4X:Y'2;J01)%/@STFNX= #6=Z 73H>L$5T; MF#JL[&'@PV9CY$;P/$"*"JM\@J:R[M\XS *8)_+;40M*.O8#CZOQ0#2+%[@0 $"&8P M;RZ(38#U@\=7LX\%! L%N(E:][%#\&99)YPO27"K0JFAC%#]G-%ULY#.L3G MLJ^#&^PZTAJECJ$;#PO*NVH-+MME+AMV_WY@%WC)[BMUC_#.0Q3<9**HM&ZZ M!LH'/0FEPZF;SVE(BQD-@R7:7IYCL_( "!C.#@9_]?(+48[#]G_I7IR/OH?H M$HE_K->MC2XP*H-.4]TLQ(U#76C#ZA)E5Q*M"-%2K/!;GKZ2ML+2LA#_Y5T0 MR'#TK$3K30F^;= ^Z8DU%D.:0X1A6SLLR'@^]*WA"9E5M4DRP;GEQEPZ;?AC MRW.K+H+L6-#4/&:DVMBFDEEV^_6 AG$E%'\W'\=Y^NM&?K836[I0@065=K!!(7^/*8*(P[KY+N8\'N:WN)=AI MH54@^^LEB&QST%N18Z?1:PQ?Y:_HC7UD& :3@E6=-DWKZF9Y1=]6(*]+_J!@ M>82B@ [6*FF^RJUXO_-4,ECSJM6#+';Z*O>XEWS!FB2U&R TK_W8+^9?DW7; M=LJ@HR9W)-H67T>UK\.7MN$.O/>P-^Q[\1?T@L_*YA7">?QXX>PZ$OR0:4@! MN]G[6TF+P_&<^RQVZ;>&"[&HUVM+1^,0;W_A>J+SO)9.:Y=Y+WEYG]5X?,3= M.TFDM;X#C4C[^=-Q_%GG?FS#/MDY3Z%Z-O[4R &#+INC5?^V/Y@NF_/8P_3F M5/L>ZN8M9B[7,)V.YS@'FN:DV#PX7?G3V4H[E*J_11*Q4^0)&%_#N^Z!%^B/ MZV?_ U!+ P04 " #5@Q57;O4XK:\$ "B"P &0 'AL+W=OI[;J GU9D=R9<\X,.4.>WDEUHVL 0[ZUC=!G MB]J8[GBYU&4-+=-'L@.!_VRD:IG!J=HN=:> 5V< WFU^Y*X6PYH52\ M!:&Y%$3!YFQQ'AQ?Q-;>&?S&X4X?C(F-9"WEC9U\J,X6OA4$#93&(C#\W,(E M-(T%0AE?1\S%1&D=#\=[])]<[!C+FFFXE,WOO#+UV2)?D HVK&_,9WGW'L9X M$HM7RD:[7W(WV,;%@I2]-K(=G5%!R\7P9=_&/!PXY/X3#N'H$#K= Y%3^889 MMCI5\HXH:XUH=N!"==XHC@N[*==&X;\<_XHC6YABWFVA F*O(.Y%:Q MKN8E.<>=)A_$L/N8QM.E05;KNRQ'AHN!(7R"(0C)1RE,K JY8,Z[K1SJ93LNK+:5G=\A+T/:*1I)0">PZHP>00OP+6X/H1 M:B4_]P+LD0HIFDS:L&U\[1&K(HS4@$+$U@-1,U'"%/BX;I68L=FLQWB/#N-T MV M!25W+;)E-S;&E@GLIBZ&>14C"^$'^X2$3).-;+!9ZV/O&N^ JD=%J/$1<\_" M;K@N64-VF 1-P):X]PDODVO,K":'I7HX";WWC"M2,@7#OMUP,#3/ @>,%UC95@FB_[158R=!0'^F=#03]$T* H: M^8GW#@1&W3C3\PH/)+=MSUZ3)*9^$M"HB$D2%#1+"^\2JT@VO&+&GLX8?&?D1>CY&<:XT%/)>]B&9Y0K,HQ'%>8#:"Y#FY2VF4 MX\;FX92Z!W*-8V>.W6KT:9!B"H+X@.6*[8:BP^-MH3%"LW,\@!V@L__-Z!YI M[T?/4IW0-/'G)'?_+@HI1YQ[[C> O;OD0TU;:];:J^VOH6J?CB*QAP2_&NW@N@FI."E(5"0VR8L\Y>XF\Z9T<\[#I##W'-A=OWVDH81V*_,;1 M$? .*.(?R6.7[_+@W83WP]:]#K'#REZ8X0DUK4X/T//AW75O/KQ>L=*V7&C2 MP 9=_:,L61 UO B'B9&=>X6MI<$WG1OBO5&!L@;X_T9B4L>))9B>Y:N_ 5!+ M P04 " #5@Q57E2AE(2T% "O"P &0 'AL+W=OON'"[(0'<6)+MQ'$2 TVR8@76#R1=AV'8 RU= MVUPE4B.I..ZOWR$E*T[JIL!>;(J\]]QS/\GSM39?[(K9T7U9*'O16SE730<# MFZVX%/9(5ZQPLM"F% Z?9CFPE6&1!Z6R&*1Q?#PHA52]V7G8^VAFY[IVA53\ MT9"MRU*8S247>GW12WK;C1NY7#F_,9B=5V+)M^Q^KSX:? TZE%R6K*S4B@PO M+GJOD^GER,L'@<^2UW9G3=Z3N=9?_,?;_*(7>T)<<.8\@L#?'5]Q47@@T/BW MQ>QU)KWB[GJ+_B;X#E_FPO*5+OZ0N5M=]"8]RGDAZL+=Z/6OW/HS]GB9+FSX MI74C.QSV**NMTV6K# :E5,V_N&_CL*,PB;^CD+8*:>#=& HLKX43LW.CUV2\ M--#\(K@:M$%.*I^46V=P*J'G9F]5IDNF3^*>[?G ='O#[)6^[+13K^CG:3T M3BNWLO2+RCE_## E8Y/NN5SF3Z+^$YL:)CT*8W3X3-PP\Z]88 ;_M ]NI8V M*[2M#=-?K^?6&13$W_M<;A!'^Q%]DTQM)3*^Z*$++)L[[LU^?I$.*3FFGU],TB0YHUTT^K1BNM)E)=2&5L*25%EM#.0"(^&"&$,J]"99)USMM-F0\72$RH, MC-_), 4\<@-!:R 3W%CH H/%3J-;S*N\+M@3_E^0$=H\\H=O4"FBH#]9F+:P MJ2W+R)>EK\TT0E COL=LM$P'(C5 MP7#2'R4Q'4:WD UAH6\QYP4'#@$E/3WIGZ83.DC&_71R"M6KE5!+CB1%%B$S2Z10L=TAG,2^]D#XL@F/S[;W5Y3:./FUH88]J1S" MXKE8>'G:/SD9TN$6)KIF%"9J/T3H01.E.%'5#7/A:%KYAX"BJ9'@,&^UJ M)]%Y2[_Q'%WJ.B%/N^T0?]AQ&6S9O>Q8O>RB^G0TB'T6UBN9K4C:]OZ67Q&^ MA_Y#P4_I^ANM)WWY+6R$SHJV Y]V/M)]& @E6FPM3'[D*P#C%,E5^E$UY)K]GD-9W/GIN:$:](T#^\"STE9ZUW!- M&(+3:%XJ\#;T&?.VM\)NXPM=/-(YVK448GUR9KVC<7 W"/X/!CY,HL<<&P4O;SP=9.X65[3,_$@2>#^%1!SMNZD'.X^H MDLTR/!41)W^K->^I;K=[C;YN'F$/XLU3]IW Y%(^$@NHQD53'9K:S^ 1)-$# (,#LG,K]]W]06" ML%8[53.Q1 *O7[]^]]'Z[J&JOS0;8UK]=5N4S??/-FV[>_WR9;/&;555OTQ9^K=VA8OY]/IY;%C]X^?:[7;HV=Z;];?>IAM]>.BA9OC5E MDU>EKLWJ^VRJ*HO^,O'[/MG4\3(%&;9(H@4 M_KDWMZ8H$!+@\:< ?>;6Q!?#GRWT#[1YV,PB;9^WF^V?7SW1F5FE7 MM)^KAQ^-;.@"X2VKHJ'_Z@=Y=OI,+[NFK;;R,F"PS4O^-_TJA'C,"W-Y84YX M\T*$Y?NT3=]^5U:K?)F6K;Y9+JNN;/-RK3]51;[,3:-?V)].OGO9 M E((^N52$'C'",R/(#";ZY^KLMTT^H=TK\]F MB9Y/YV_S2ZG;T:P/7?8GH]!'SG/3W5>+O-=8>CKVZIL8#<9?3^TB=%E MAC?QI+7UKQNCE^X3D^E57J;P=%KH!D 84 %MHT'_Z!:>7.7-,BW4WJ1UHPUR MC [/FU:#'^9ZD]X;O3"FU(#@+JWAP<5>=XW.414LJSJ#10Q(6[NAW^6(=Q[3 MM2E-G1;%'K\W.T0-WD4D?BMS^$W=(7JTHYNMJ4$\](M__]OU?#Y]\]N=_OO- MS2?Z;?;FA+#:=773H02U%0&I.UP$OZG-NBN(& 0,O[PSRZ[.VUR>^.'KONAUN[CL)G ?^BRPR!D8TYL/#Z+BWW!#.'CR.Z-]VBR;,< M9'ZB;PJ@?B#U>=F:>LEO*P<5P8 8E$VZ9.P]T4V1@[9*A6C+\,0G>H3/+QR? M7XSR^4_YGQT@V_)>;M-=W@+#?#9-U=5+TPQQ]"C 88[^QBKZ=Z. LT!/US5P M*7"**==@RVC/\ AP4Y5URU8WJ3WKS-R#)=PA4R.5VTW5K3?ZP6A@Z!)>+ T2 M&RAMZ/%-FNEEVFP0TGV>,1.#2:Z%79@A%4N%1JD8$(H$X2.DE%B_VR*W&<0% M3C=OD3F>Z[/D_/(R>?5JKM-&P2<'4D5G"ZCA7C.+ TA,436-;(XP[1K9?Q]+ MO4L;V/3O$;V^[L \HTC@_GN[5[NJR=%H,^ 5>!"@".IJ&\+.0$X "X0O8'6/ M&OAUL)MS0F$!# I'0:=DWZ-5%FF!BJ%)@&D[T .98A4!Z@'T M'-81,A ZN0 MBT%2"R3/0806!J1JA50V+/A;=+1P3?15\)6E\%1M@-/J0-FEK2X,$$Q7I:&M M*%H,]XGBBH<&BJ C)2;2C7))$DJ OZ52B0PHURC$%3X/>^B,_;D&5X2(@YO% M8RKIE!N5:MCO$M7[FE;F(S2HQNX- B"=#_\K.UAO03:!%,4&E.\V11UL/&1+ M;LLCS::JVU-0-EM$)"_O38,LX8"O04^TFXFZ :#P80/.E]\^D! 9!A! G?R? M'W]"Q3B[>M/H1=> O#>-B (VKI1_RP!&];OH!]I T0#JB6XFL !3>NR+R0 M_VK8;T[X0)<0.P #X-=RIH#BKX%M GM35JU>H]RGL/6:]MYN@%(Y4KZ,@<1< M!!1%P].ZKQ02J-ONG"LB; B[@?\?G*D#A&>#,';P>^GU'9EH.*.N[>J(XV 3 M'_A#RVIPVEM8,.0&!>H>T&:V13JZLP;G "Q\8PX8%RA@6I*._^B 0]"U24B* M@&M8;DGGMGF1_R7^%G(4&!EP8(!*($E(.Q2@I5>Y->QX:;*)&B"\6!KBW$/Z M6[66+@J2CCK- >LTRW*1 *O0@$K5@FA,/(A?X-D#(^6L8)S[]P)AU@KSIQ MA/SQJG^U5!Y1OB,^T*7S@2Y'?:#?F%] 0^9;]$2'G)Y1",-.3Q\L22<[T:E5 MKNR*#_CI[.QAM@!(K)[F74_N)E9G-N%YH_U,OY@ ,SQ0Y%&6;V&$=+4BUD$? MV^S G(!F3+?.#V:)2H 1T@5(#5MKJXH29^H2T18(1-PE<"O V>D0*^$WRPQ' MR4$NG_-0%.-#E 9K#)P 9=M1^8?50(ZY%V1:=Q)R M3Y1M"M(+;F) .8D)$K7H@#Z@I%#025$:5"()&U 4P.>*EJX()L2L(4$9WSZ-:9W\#%T7RQ:JS2O [Q\T(;: 44?".GL :"Z MP)"(2>1?58XIV:#4XI-$F""3LX@,PG/,&F-45N4I&0B,&V&7=T@YI[K&M="5 MTT)7HUKH%N$[[Q]/%I9'YA]21Z.@AM714?BQUP!$ *M5-WC>>@.'!<+#NI[= MKKQLVKHCJ206K(!:=>ANLJ_)8DMZ"Z3)'B>)>&V,WG*J"MT,]B8WF& 0XYV1 MB[,P!YA&#HZRSH?X+@-;\VY(RB;(ZQ;<1MYVQ+-LDU'GHE*BT!!9X(/)4+/J M]X;B)_VQM$;\MJI!_WP["+]V1W\]>O0W-A& S@7@CCX!J>1Q33+$&*,+#3/& M_VUUG[48>(^$"8P36[[P#C)L 7A =P$$&'\?&YCF_['SZ M]) ",<)LG4"?@PD"HW6/N7 ",? F\GQF4(3@T% @2+"BC0&/>B>0];8-$M-B M+TE#S Z K0R25EY,5Z#3@:J*.!Z]W[Q$[%KC73_P=9T+C JUM'#H^06&NDS< MB64 +V69,5LRA/A<5RZK@HH&Q%"8WMFD]1K. +]/19V(FZ"#C)MS8/S&TQ7Z MWZB1MB;E[)X%#F@&V;*OFQ1X3!0_!005!.8M2CQR!5"[NC= O+Q15M-1Q+V% MQT9%^943Y5>CHOP)_;L\"R)]1WR;'F$;-22\HZ"'A??1Z^G^D^KHDT29!L40 MQ*/."Y(UR9X9&W;C*8,;DP$[<9#GG!I*T@8/4LJY1F<*K,0#8PAPOQB4(84. M(UJ*3;[R M:DC(UU4%KT%\D9TH>*8"N]#*D@$@TF/DYM!&;+1.[XURS&SJ2T?349[Y:$DW M6/49?7>8*1S 2!F1-]/X@TKL05,@N4+CF#<;D$\F#*GH],$YT>C)LXH J02R MD@P")?$YS#>*XD!AIY4FL'!#=M5IM4RCS\7:&DX&$U\$8@NZ#IWX$%LXV@YT MBO)\9<\OPXQX9Q44K97T M.Y!67Z'0;.#4*JR4%$%*/%+Q^$GB;01(46.78@]?0HV0(6C[6?7@,\TN D-4 M@M0-V6$T]>!4E:VRK! )%6T3-+L'BC; A5>)B#Q':O=HT8)"">@<.L?4AG5! M5C=?V;P1"'A9;?,ETH83)Q"+N&09YXWPM"FX:3FC&0:"G*U,)>_4$7$_)X6BL]F8@DT.ONL^5OSQ K00O>DRO.YT^?"$V*7Y"O+U8(I[ZQ\G M*#WNI#!$YTA$F,0M-*Z'@A+V[!NVBT-++I79T')0*8T".F:IAJ#KZ&,7S[*_ MD-8U;;ME]L)0(2R\J,P >%3;Y(B_#WXCPL%9=JU3.LS/=8I:_10Q%K6CR4C0 M^0AO9C[FOC>NYL=F9")UUH:XGDQJ;4T:%0&LHR9FE@[-5GO>P$-_D!NR*X Z M/K61;]&5M1_0UBG3AC9PHG_'X,A&MC6Z:"T&MPK=W+R!X 1E?)5X=42<&!6H M LHPA"TLER6.9[WZ7%-$A8&9U*-J<^"8A6I!>;4PSH9SSX;S43;\+"4*M-^@ M$(X5UL>A#//@ .A([%=50<6QH%?AK@4:D8-Q"YZ\S(#*IA;R:,T^G?T*FYM_(-H$1X8*M15":9B XXD^R#P M<;G!A8F3[?-]+T2P]X=EW9!T71M4%3N7#J.-\_92E\P *(56>L\E)VX%@7N[*C4-=Q<2-1V:$8X/FG MC17(US'K.M[FO+C#?_(H#K=:S$'Y$?S9>Z1FR@0,O"O8A)&B%]4NNQ(/L^IJ M]0#&"1R5O4U'H'Q2# KXLBJN=M828998HFA)9A*%&BX%'#VQB!.SR@@@5,N- ME73D\VV.%H ]+X"-NBY?BNH^2@,R:GM6[UOKXX>D06]$3%],[Y!C)M]2%2Z3 M)'H3.6P8)=[N(0!!J<^"CF>73L=:C=3'1#$@8?;'OGTT2!145?%B 4^S>' MY8(A5+H27*H5!/CPP;$S0-%P@N7XN*+ 2P1'91RJ)A1YDXV0G.6G,VG MR?ET9M'5(;KL]/RK4*8RIR.@<&<_=2!HS>;)Y?G5(%(3_4M7'T%*2FX4/=D( M@E)LREDG<6(#XOB*:TRAB;[9 5-\)4<7=/;SZ_E5,IM>6I?50]/6^5LHGN.VE_HJP8=2@=]6BKNTZ)L MY@-[WI'G>EC8=^L\[*4E(B0\\5 2\P)'ZH^>S5+YM/S4=?7M\C.1GM: MW]Y*%'V'_L2@T_N$GM@(J!2A69BXP(_PGP)_P3T,$^0)_;4C2T0FUR704<:;\*6-?0DW MK@8Z82$LP' 8[>\,$Z&)0-._29.Z4;0O=O:B[M\93VLI2\):3PT >#]WF@- MBBE](@'@N0RL\_3PYZ!!S46M$^T(QLN%:(V"40^@M\EL3:<@)9S MJU%6\:VKL_'>U9_MVHE;F+R-#'0AF&3X?9!CGM"_^NV5]",>8>I9/8[) 161 M>8PHOI=E-M[,8F-,6[8E]TCH>4^DB,0J_,8):FMO5 "4M*TFV@Y)U$!HUR8:"AV'T?)[XO MX<_&:_@??-? UJ183?8YGKBC(*Y$2T%]\*B>4.K_?Z(1*\&LHJ8BU&C78/JU M)#YHC7\2G)^#-:BJ]-YW^$AR1 ?Y$@1CD.>(7ULBON#C16#7=@ MD;/A^JRD98>(ZUM3PF-(0APQIU.G6X-]S(0;/TFVQ6,IK;78!AFT3V%J&=SY MIEMNPH?#M5BTZ R1V=%W$3IE$/YC($#%4VP&A>/&@LEPM.7YA'O)*PJ$?,>V M]%TE%%]DN<56+T'Y8>]BT/,U40X%/!4L_@<;E10&!VSDQ5%]@!U%CEC@D"@Q MD4I2%#%QV0R,^E;D"GL/+Z<:.>5A,+42!(:VD,-6#*#4W)U.PL+^8$!-BH2 MTUR3)@83=C-##.#J+:HURTV9_]E9=MFFX(%;]29/5PL47ZH3Y>6N$X& T/K@ MR:X\>-966^R;-1&QPKX;=*T7.#;X6OU$A8?9:_W+P5K$14#^/[L*6=U2I,ZE MJ9S'_N1S*?E2L@4=<1%@ZAIV\BNKS:/5^'UI.I.EX;6!'4D3(CHN55U7BXJ[ MS!=[BQN<1BIKG+W6OPU H'"2,F28*J&T/*#6%E0"+*L0D$VER3&&U/8-D.3: MP)9;+QC50QEV3L:FC-HR,'>(G0O#JA9MDUH9;)'B4L.B F/5;YY#I("1.?M$ MO4D.V$"J6K^KX+\.1:MZ/]SIT3B')S$QP3@D/A.J>6RQC9%[SW'U:L@H4BA%)DLRW&IC\<; M)I+R>&-.<9D&C!@TVI7$-/(%B7YP:F/NC&]+FXWWI;VS+9*W08ODH)/RA+:S M0>#Z0\5]/L/=F2]L?8,T=5HD:M45U"./V>1HCN DB9)TG)MN]&PZ_3?J:RJ* M1S>+AG,QU!_HAF#81N2A1P&T_WM59>+%[GB"LY'Z+U9L_(P"6SG,W*C#EE/* M8:;EFKJGL(T@$#3L>Y1O^GN@9IDAXF&[EJ/.J8T?(X[UR19E4].V#G^\638, M9^*H\2-O8NA5.QS!*IJ+[6N:, AK%(D:.D&;QAEZH^OTETK7$?6E#:R3.H.) WBGX:<@N$9&C^L:+V8GDY(]O#IO6HF8 M-@O)M]Z2A.^I]Z>E.\67G,"C0KMHAYOB8H4T8=G5JEJ]F#\&VU[K0AIVD].K M@Z=@%:HA*#YFCA.%2%58MN'1&SO)1+Y$9NPODO1[W!'32)1,PG&XZM$+IQ9M M$"E](.3E\I.4"!*=@0XO-4=R"M&V4[7?RI/Y/L/9>*.A53*#ZO@)C81.:;D? MMG'BK2#/@";&VLU,=H8^/!ITM8R@V8MI1UWGUAIS*-;U;);[.,@[K<#:][CZ\JV/[U\+93UNS"@=MMNFR MKH;ZOQ#W#ARA?=04QII*NL!@%5/>YW55\NA,(.@4\7%48.O\1VO?G/#D&E5B M+Q]P#; 5.A'H\063ZH (AP\:*S_HTKIV/6LML$.I->M]J%<0L2^&CKRIRM(4 M?J8*G8B\T9Z-$IWWNSKM4"-\ M"B*'LS]?##4Q@,3@P;GF\J/,KRSS4X\7O7@H #1TW-*D"#:_^'Z(/_$^",M M 2>BI%-;)S5Z544%=/5-S;XMS([*HR<.Y%(OK/:.AM09RHF/B'H+2SO9 W-: M6DOM)-K"83R)&P^9W8F.3UMZJE&+0D!X"(9I(,%%/$.(T[FR!!S@1D,2(:$/2GE-S]'QKRI V@7E'B6!:]>/N46TCQT )T; \.J>?#P< M'O=C>Y)X4[Q':3@>)$S$%XR2E#::'CQN-PUN3^ -^]GWA1=I2AE:FT4I?IYQ M"Z:[Y3*E"#'N+Z&K#[\F/HP?ER M5S*K>A. D3SGJ \W]XW_\V\U_I/>^37].ESM'7_]6.^_AWF\FBD:KZ6G@AMU ME)1X[_/&UKKO;O75^?1TYE/_0 Q,E;J(-9G-Q=!$KRW#FO3-S@_LB#!C]K-?@O_O&+U9&.\\_/3!4PL'>.&*. M@2VK4)E@^U6SJ0I.EH553&Q'V,:8%VA@HN M+W1+=RF9D<&)GRK1HIMW1,-'A$C<<.\;9[DUJDWZV(_M1%!V8M@ZJ_ZR!3N<7SA%X[\KJ6+2Y M<_PFMMZ:>I?L]3JMU!MPEF"'-AYF1AB8?XY(1?V#/*UW3VJ4ELRL'5;@R> X MC R?DQJ4@LY]SK-<71GHQXB;>&Q5,.7:8[PVY@?A)(;6IV.Q.8:",I=\/X<_ M*0P1T@.A(W9$*\,"7( 2*NAN(;1L'8UC3J@F$@M<,+L\@$[B":N8?>-V&JJ9 M#*J;A%)9-K7;ISQR5+#R"+=ZMH+7WJG]Q(XZ7^+N1>N>$3W[\ M?!= /)3V)&@08?;S7%[#0Z?BE.K"G.E.&CA\J5UF.&*X,&F57/\LW'Y_E MNSMRQ= @GSYAH.\8?'WTBX/JEG5V%7N9P:"QO4-V T)\^HX>^\1MB/K7:IO1O8D10_6*-J;_C, M,X"$21D_6.%:JKA.,D/V!*",+CW)&Q:<1.S$CU0"&R7HJE468G" M$:E,^\D?EB2+1']MXN('FH#$/-K$7YZ91[W[3\^GL M^O3*#?QU"U24+=]M!D[_NL0A030V RQ/90!9F^UKB,TWDEE^=F$^/KOP#W_G M[ M4FC3;*4A1V94Z,6GK@]+_A,D&6%(]Y7E0 M36G(>S(:;?V$@PQFV6T7]GH,7A^A1Q?LVDOKWN<%K8;0"6:(C!J87W_T8ER" MDN(<77^'L3-&7/YN->Q):/F6T0'DU$W;FT^+ XQ,7R1GTVDRG4[90=T,C.7T MKD^6F"/B?\R*4PN)S!3XX5C:OK_.3F@5[S/< QO&O41LMJ\5I>34;=]UN8:M M)7)Q=:%^[_,)(R=$PT&T MZU<7R?ELIMX?,L9KG!2FJ079LV3R^-3F9Z^2Z?DLF;ZZ5'?1.0+ \^ODZO+J M<'G/?HS!V<553X[/3O0G?J7YP?WJEUB;C]@5KA*YJ!XC^90FEMEY#M2RYA]0U+YN>*YN-S M17>&:V*?;6ETD"V>,$8D@)4#'-UGZ,W]K?B7\^MIH@^P&=VDGQ.:C\\)?3:] MVT8'-_F$.:$#P/I64DUU_QOE;VZCRU;MA#8VKI,5<>>++=IRHSIYD,$@.I<& MV6H%31K^+V=,]%U0FDUFT6K MK K!7YB@;(*H!H0F]1=*!OXBEN;%7;=H24+.KZ:G\RG_89#W0/=[:L5@_^=' MDZT10PO<7\8"O/A#W,;_RT-)=Q)!H ,[^ 5" E27@.1L= NST^EUHD2-#3G+SN5ZTL1OK&U_3<9S^%=<;X,IF'^#(9T9R*[I1![%P8Y,:=@Z+A MX)#Y"S-93WS13GH<3Q[15WS0^T&)3Y>M$"]9X-0V;.JWR^KC,[0NM+8SX:/$ M$%I,]-]M=@[C1KHXT]^F8V<,J=A/,NW/6 MTOL*%]99\(4X*I3D6]?4*IW!W)42@IUH<.N*O9L\HSHTIO;;%O/3_B9_O%(U M!BHC@>5^.,-!^4#2UICNVYN6M3;+9IS(HM(%%HL)"^YC0_%(*4]"?P= '*)X M3,Z&[XZ"\:R<]K>E1#-SC[BY7H4WU[-.&QC$"3<9; [[5O#V;[KO"_B"=!(] MF552[>'9);HQ_1F3&UL?55M;]HP$/Z>7W'*JFF5HN:%4"@#I-*NVCYT0F5;-4W[ M8)*#6'7LS#:E_?<[.S1E&N4+\=EWSSWWRGBK](.I$"T\U4*:25A9VXSBV!05 MULRJ19PER7E<,R[#Z=C?S?5TK#96<(ES#693 MUTP_SU"H[21,PY>+.[ZNK+N(I^.&K7&!]GLSUR3%'4K):Y2&*PD:5Y/P,AW- MEK2;A,(025VPC[)W:?L9=/'V'5RAA_"]L6]T!*1<; M8U6],R8&-9?MESWM\K!G,$S>,,AV!IGGW3KR+*^99=.Q5EO03IO0W,&'ZJV) M')>N* NKZ963G9W.F.$&U KF&@U*R]IL8[7$G 0T+V KAAIN""?B)3+?%#?9+$WPE2RX+52.<0!H-LSSJ M#_K!O1\C+($]HJ:MX$:.%RVT@33-HN%%/\K3-+CF8N,F&@P6&\TM56847"E) M=I93.P(Q7J'6A$535#Q UKN(DCR-DHOS8.%O5..ZW0 !YL-H<#[XWWW9>6D9 M]/J#J#?L1]D@#SXQ+:DQJ/]="DY?!->H MUWY/&?"]UPYS=]NMPLMV [RJMWOTENDUIZ $KL@T.1OT0]#M;FH%JQJ_#Y;* MTG;QQXK6.6JG0.\KI>R+X!QT?Q#3OU!+ P04 " #5@Q57LJ:M9Y$" "M M!0 &0 'AL+W=O;%+B.3J4 M2$[V0CZI#%'#2UE4:NID6N_&GJ>2#$NNWHD=5K2S$;+DFERY]=1.(D\MJ"P\ MYOL#K^1YY<03N[:2\434NL@K7$E0=5ER^3K'0NRG3N <%Q[R;:;-@A=/=GR+ MCZB_[E:2/*]E2?,2*Y6+"B1NILXL&,\C$V\#ON6X5QT;3"9K(9Z,\SF=.KX1 MA 4FVC!P^CWC HO"$)&,7P=.ISW2 +OVD?VCS9UR67.%"U%\SU.=39V1 REN M>%WH!['_A(=\^H8O$86R7]@WL6'D0%(K+=7\^Y FFMB,85.U:!*75^91'K6DW9QP.IXEB:@KK> !$\R? M^;I %RHJANLOQE8W$T_3,2;82PZ4\X:2O4$9,%B*2F<*/E0IIG\3>*2O%)3PM]S^G]+I7#QV']1:V.%%V2P,C-[L7^E-&5]"% Q=/Q@807[?O64!G'H#;,GE-J\4%+@AJ/]NV'= -L.A<;38V89<"TTW:,V,YBE* M$T#[&R'TT3$'M!,Z_@U02P,$% @ U8,55R>P5?I= @ 204 !D !X M;"]W;W)K&ULA93?;]HP$,??^2LL;YHV*6H2)V6! M021HUZT/E:IV/QZF/9CD(%8=.[,=4O[[V0YD;*+LA=S9=Q]_S]QYUDGUI"L M@YYK+O0<5\8TTS#4104UU1>R 6%WUE+5U%A7;4+=**"E3ZIY2*)H'-:4"9S/ M_-J]RF>R-9P)N%=(MW5-U6X)7'9S'./#P@/;5,8MA/FLH1MX!/.UN5?6"P=* MR6H0FDF!%*SG>!%/EZF+]P'?&'3ZR$:NDI643\ZY+>R,G[MF7@XTB4>VP?ZC:_=UK*B&JXD_\Y*4\UQAE$):]IR\R"[S["OY]+Q M"LFU_T5='YL0C(I6&UGODZV"FHG^2Y_W]W"4D$4O))!] O&Z^X.\RFMJ:#Y3 MLD/*15N:,WRI/MN*8\+]*8]&V5UF\TQ^*[8@C%2[ G; F^_T!4'_6X6&@MW M(6&Q!RU[$'D!%!-T)X6I-/HH2BC_!H16U2"-'*0MR5GB'=VA) X0B4AR!I<, ME28>E_RO4G3-=,&E;A6@'XN5-LJVQL]3%?? ]#30C=O M7L7CZ,,9N>D@-SU'SQ_M^)4M!R37:)!^2N19S&F1)]FCX_M&1PX9W3#!;(N5 MZ).4I4:O41S$DRP@<69M,@E(.AD]T,XF&5",B?5G.4 M)(Z#;)Q:.R%)D&09.G5SX5%[UZ V?H@U*F0K3-_IP^KP3BSZ\?@3WC\R=U1M MF-"(P]JF1A?O+S%2_>#VCI&-'Y:5-';TO%G9MPZ4"[#[:RG-P7$'#*]G_AM0 M2P,$% @ U8,55_U"(Z6P @ ZP4 !D !X;"]W;W)K&ULA53;3N- #'WO5UAAA4"*R+TWVDHM%^U*(%6PEX?5/DP3MQV1 M9,+,A,+?KV?2AB*5\I+8,_;Q.7'LT4;()[5&U/!:Y*4:.VNMJZ'GJ72-!5,7 MHL*2;I9"%DR3*U>>JB2RS"85N1?Z?MS>5D)&J=\Q+G$E1=%$R^ MS3 7F[$3.+N#![Y::W/@34856^$CZE_57)+GM2@9+[!47)0@<3EVIL%P%IMX M&_";XT;MV6"4+(1X,LZ/;.SXAA#FF&J#P.CU@E>8YP:(:#QO,9VVI$GA*#EXIND6<-8 AI\ M!B'_8&4>!"Z(?1$;BH51Q9N.@+Q2[, ME?^7=(>H,<'T8V\S-4%4MQ[-" *)0OZ$Q.3X*N?WF$=]SR MCH^A3QYI'K,Z1Q!+.-RU0XR/8AYF_'6ASHW2G"8",[CC2X3]#NT[8>>VEB77 MM40+<,M?C:T@@6\0Q&XRZ).1N+UDT+D2155KE'N]B""*W"#N0M!SHT'8:?KU M?I] X$/0I?Q>'^+$#<)^9UK3Q(@%)_ITG;B^[\/I23\,PLO.'2HUA&F:UD6= M6_;72+)3SNR"..L%KI\,X!S.HH$;1#&<=XAFTG/C;D0\0SJ,$SC42F]O N4 M*[MF%*2B+G4SB^UIN\FFS0"_AS=K\)[)%2\5Y+BD5/^BES@@F]72.%I4=IP7 M0I-4:ZYI&Z,T 72_%$+O'%.@W>^3_U!+ P04 " #5@Q57X-J1]90" "@ M!0 &0 'AL+W=OPX=6T!SJ-M@*0(DK0Y%#W0TMHB0I$JEXJ3?GU)RE94E5HR.5(W2GBR4KIBQH5Z&5&MDA2^J1)A$ MT7%8,2Z#;.+W;G0V48T17.*-!FJJBNF74Q1J-0WB8+-QRY>E<1MA-JG9$N_0 M?*]OM(W"#J7@%4KB2H+&Q328Q>/3@'V>H/^V6NW6N:,\$R)!UZ8)Y MMXT\RW-F6#;1:@7:95LTM_!2?;4EQZ7[*'=&VU-NZTQV*0V32SX7"#,B- 0? M[IF-Z' 2&HOOLL)\C77:8B5O8,4)7"MI2H(+66#Q+T!HB77LD@V[TV0OXC5[ M@33N0Q(EZ1ZXM!.;>KCT#;@O2A4K+@0P6<#_RL\YY4)1HQ%^SN9DM/UE?NVZ MAK;+8'<79Z,QU2S':6!]0JB?,,C>OXN/HT][- PZ#8-]Z-F=M6716-)J ?Q5 M O,2=I'="[>;[-X>O0LRW-H!"[CB"X3M;]2[XKDSK%R"MS=!"@<0Q_V/@V'O MS/_-J.$6!7.6I)+7+F,4]:,HZMUK5B!\8Q42Q!$DHZ'??L Y<8,PM)MMXA42 MC6&6YTW5"$]D5BEM^!^/"A]&@WXRBN&P=P#I2=(_'@U@U\6'6ZZQM)9^-A#D MJI&F-5"WVXV?6>NZU_1V=ETSO>220.#"ED9'HV$ NIT';6!4[3TX5\;>@5^6 M=H2B=@GV?*&4V02N03>4L[]02P,$% @ U8,55Q-6J3.- @ M@4 !D M !X;"]W;W)K&ULC93;CMHP$(;O>8I16E6MA#8A MX=0M1 +:JBMU5;1LVXNJ%R:9$&N=F-J3!=Z^MA.R5 +4F\2'F<__>#PSV4GU MI'-$@GTA2CWU_K),>"Z1NYQ=+L9%(5C,Q4;7R]5XE*!KHJ"J<,H$5A (3L@1F M?L^X0"$LR,CXTS"]]DCK>#H^TC^[V$TL:Z9Q(<5/GE(^]<8>I)BQ2M"#W'W! M)IZ!Y252:/>%76T;&>.DTB2+QMDH*'A9_]F^N8<3AW%PP2%L'$*GNS[(J?S( MB,43)7>@K+6AV8$+U7D;<;RT25F1,KO<^%'\C7)4L*B4PI+@*V=K+CAQU/#V MD:T%ZG<3G\PYUMI/&N:\9H87F+T0[F5)N89/98KIOP#?"&Q5AD>5\_ J\9X= M(.IU(0S"Z HN:H..'"ZZ@%NR@XL-6)G"+$E4Q82&7[.U)F6>R>]S(=?$_GFB M+9U;O64)3CU3&QK5,WKQFU>]8?#ABMY^J[=_C1ZO3"FFE4"0&4B7L*1)F'A) MV#G15['G1?_769W3A'06"E-.L& JU3".HHZ[4DSAKB0T8()>T(WZ4>=!'IB@ M YC[+RRQN7H8=T?OP\Z*V90\LCTT^7'IJ1_HD?AI;[J1-F;A8-RU9\^RS&AB MA"TL''6'HZAS^6&_AB@8=(?#/IQ+C7]22P6JC>L8&A)9E5275;O:-J5978LO MYG5'NV=JPTL- C/C&MR,!AZHNDO4$Y);5YEK2:;.W3 WC165-3#[F91TG-@# MVE8=_P502P,$% @ U8,55Z,?"((D @ ^00 !D !X;"]W;W)K&ULC911;],P$,??]RDL@Q!(U9*FW1@EB;2.3?!05*T# MGMWDTEAS[,QVEO7;A>86@/+?5 E@B@,+X.*<4G3V*^M=1JKQ@HN8:V) M::J*Z?T2A&H3.J6'A7N^*ZU;"-*X9CO8@/U1KS5:P4#)>072<"6)AB*AU]/% M]5^A3Z?"\?+E##^2]K.-_I$2=88 MJZH^&!547'8C>^GOX2C@*GPE(.H#(J^[.\BK_,(L2V.M6J*=-]+G-0Z2CNM=>R(LP=EF3C#VYZ3MR2:8&6?_7-G$_(=>T6_34XE'1P]QPKT MSA>=(9EJI.U>YK ZU/5U]YS_N'=-8<7TCDM#!!08&IY_O*!$=X76&5;5_G%O ME<52\=,2>Q-HYX#[A5+V8+@#AFZ7_@902P,$% @ U8,55Y(4,F&ULE55M3]LP$/[>7W$* M$Z)2(6\-5*6M!!0T))@J8-N':1_7F(O%T/&=]<%#-D^U.7!'@Y+- M\1'UUW(B:>9X"!Q-G0N_/YE9/2MPK<,%VI#!A/)5(AGL[E-AHYG M"&&.L38(C)87O,(\-T!$X_<*TVE<&L-->8U^8V.G6*9,X97(OV>)3H=.SX$$ M9ZS*]8-8?,95/)9@+')EO["H=:.N W&EM"A6QL2@R'B]LM=5'C8,>MX.@V!E M$%C>M2/+=22_F9DIT=?A$8%$[9DTQSA MZ,DLJCUP-6$;#3=>X5S6.,$.'#^ >\%UJN":)YB\!W")5,,L6#.[#/8BWK,E MA'X' B\(]\"%3:"AA0MWP(UQJF&LR[.-Z%ZH M[41WXK?>-P-31F.S#,!X8H2@97=6NN643L9CA)N,TYKQ.7R"P.^$843"X4$O M\(/SUB/&@HS'DBV, Z(0/\-$DL/Z=I(XEZR H\ED<@Q!>VT(IYW0\UIOV%"*&S@KPE=%%D,M_Q7)9>FT$QIE' GV ;X]>WXK@U^Y'4\SUNOK2>A M64Y<_;.@$_5Z1HIJMW>H5!^N*BF1:RB%M%R/UHIM$FM-:%/R^''\EV83_X:T MIT.BID.BCW<(34JM(*D0,@XZ1>#XJF%&,P^6R*3:UCU[W7R@>_[GNTZQZ9KN M6Y[_R?NVS+@;HZU JKP9X IB47%=3[GFM'DC+NK1^*9>/S#WU#@95Y#CC$R] MDS.*7M9#N]YH4=I!.16:QJX54WKG4!H%^C\3%.]J8QPT+^?H#U!+ P04 M" #5@Q57_*?ZV.@M#D^187L;/W M!E\$;LS>&%PD2Z4>W.3W=!Y$3A 6F%C'P.FSQBLL"D=$,KYO.8/6I0/NCW?L M[WSL%,N2&[Q2Q5>1VGP>3 )(,>-U8>_4Y@-NX_$"$U48_P^;QC:. TAJ8U6Y M!9."4LCFRQ^W>=@#3*)G &P+8%YWX\BK_(U;OIAIM0'MK(G-#7RH'DWBA'2' M;M++3DR)F'R9;T MLB%ESY#V&=PH:7,#US+%]) @)(6M3+:3>4#58%"O,5B\?M$?1>6:=.V$>(-.((*1% M"M*"YA9AV(O&\ I8;SJ%5YWKQXHJ#%,H1(8P@K@WCG\LKE7!K2AQ0PV' MXWU0*M8B19E"1'OT.Y&[N,U=_/^C]+U&_(.&.HA3(E=@%=@MBC9I:)5P_HDZ$0;C5(L&? M]^_0]6/GZ1/JLO.QML9RF;H%;N"/6B(TQ=0'[YR=__?;>:^Y=)1Q=Q!%W2B* MX"5$O6@*??KO[ 2DS^(/?%K8*V#V,^>T-V6MQ_T]%M'>:-+Y$XTY ^K#&0IG M\X:QV!N]/6+V6:[IKI+5H=\!H;KC QRYGCC77X[;L^XH/M#IC.'8%0WW.G") M>N7?&0.)JJ5MFG&[VCYE%TT'_V'>O(,W7*\$'7J!&4$CJJ8 =/.V-!.K*M_/ ME\K2Z^"'.3W'J)T![6=*V=W$.6@?^,6_4$L#!!0 ( -6#%5&PO=V]R:W-H965T<,C97NE/9@=@R9=62#./=]9VUVEJZAVTS+Q2'4C\LE&Z919-O4U- MIX$U/J@5*:F+YMF7Z\ :'V\SB/CQL?^'9G MW4:ZF'5L"_=@?^WN-%KI@-+P%J3A2A(-FWF\S*]O*N?O'7[CL#'? ZQ " >$-#X?,.,AI0L\71_1?_:U8RUK9F"EQ.^\ ML;MY/(E) QO6"_M![7^!0SV>8*V$\;]D'WRK,B9U;ZQJ#\'(H.4R_+,O!QU. M B;9-P+H(8!ZWB&19_F:6;:8:;4GVGDCFEOX4GTTDN/2->7>:OS*,D,O(MZR1U+D":$9+2[ %4/AA8 _EC MN396X^GY\YP*(4EY/HF;J&O3L1KF,8Z, ?T \>+%LWR4_7BAA'(HH;R$OKC' M"6UZ 41MR'W?=0)<.4S@,15,UD#"6',99A>'X%P%_W>.:&D,H*C8K^C8KU.# M1G[R'6!O@+#@_9SD^'TZSG!%BRH9EY-H6==]VPMFH<'Y;_HPQU=%EN2T(B_) M53[-$CK%9?2^ \U<_X@ -J F1"(WA,[R9%)6N"JKI*R*Z"UG:RZXQ59';WW M<>?QOS"ATZ28EI[)9))4$XI,/BJG3F ACJ!/1&A2C4>.R#C)1Z-HU6N->I). MZ0 YJI()]9#! Q'?*?E#_97?^T% M)4H21#16=5!IT-;A@Y@UXVY)F_: MKG<]Y=("4K%/&PO M=V]R:W-H965T"-["G2*Z;QJFGA<@Y';JQ_Y><,\WM;&"<#;IV 8>P/S>W2G< MA0>4BC?0:BY;HF ]]>?Q]2*S^D[A#PY;??1-;"8K*;_:S4TU]2,;$ @HC45@ MN#S"$H2P0!C&MQVF?W!I#8^_]^@_N]PQEQ73L)3B"Z],/?4+GU2P9KTP]W+[ M*^SR<0&64FCW2[:#;I;[I.RUD#NL[&E7AR.#(GK%@.X,J(M[<.2B M?,\,FTV4W!)EM1'-?KA4G34&QUM[*0]&X2E'.S-;]!HE6I.E;%:\9:Y4H\]L M)4!?3$*#+JQB6.[@%@,U%9EKC2TP+[_U7',G_7.^TD8A;?XZ58?!37K: MC6VE:]VQ$J8^]HH&]0C^[.V;.(_>G4DB/221GD.?/6!K5KT (M<$M.%(3JC( MFG%%'IGHG=S40)C-22/S,2GU\C:&-,XZ.IW&__3N+9FNR4\D#J(\#](X]>9E M*?L65124P!\MYPBEXV!H9]9.4!FD>>W<*.L8K D_X)&G0)$=Y M1KW?T)O:NXNC(HB2Z#MXQYX=\H@669#G&;GPEDA1>[%$<+;B J\;P4886)H$ M24)18X L>Z4PBA_5QE=!07/4^81\,:S=<(O^(EF79W)5! F-O)L*0?B:NS!X M^\+&^\A+^\BU&Z+L$Z*M;1Q+E-66"T&Z7I4U/I<6@@9Q1@,:9^0,^;,#^;-_3?Y.23>7,*MA M/F'N(=/V;D:$.]>T"^8^]@ ML;(@I440YXDE C((+Z?(J:,;;TOD QD)J?4%EC5*:'"5I6248'6I)1OR\@-3 M+;))[]4ZRV39-'BENF8*O 73O$3PZ#*BN(QP3=#N/1>]%@IB\?5,@YKN3 M5Q8>#1SDY\:-54UEAE$Z M;(SLW/A:28/-X#YK_/_P\=^?S:"/56B>(!IY2D>FQDQB37[JN#A-,F6[+'#/:B:5*F:&I M6KDZ5\BBTBD5KN]Y?3=E/'."4;DV5\%(%D;P#.<*=)&F3&VG*.1F['2*9FZ#$O$4,\UE!@KCL3/I7$[/K7UI\)WC1N^-P2I9 M2KFVDR_1V/$L(108&HO Z/>(,Q3" A&-/S6FTQQI'??'._3K4CMI63*-,RE^ M\,@D8V?H0(0Q*X2YDYL;K/64!$,I=/F%367;O7 @++21:>U,#%*>57_V5,=A MSV'HO>+@UPY^R;LZJ&3YD1D6C)3<@++6A&8'I=32F\CQS"9E813M_OV5*@_C!R#8%;$S>L@:85D/\*4,>'6YF91,.G+,+H7P"76#74 M_!VUJ7\4\99MH=LY ]_SNT?@NHW2;@G7?07NCNNU!I9%\$"2E:&"-1PU_)HL M->D/S>]#HBO,WF%,>V,N==OG=UA'&O8=P[AAXLZ 9& MA4"0,2P8I0666Y@K&16A@:]D?(CP?T*VJ-;!) C77(=,P$]D2@/:E+9N&%

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 136 342 1 false 67 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://reviv.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://reviv.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://reviv.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://reviv.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Disclosure - Organization Sheet http://reviv.com/role/Organization Organization Notes 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Accounts Receivable, net Sheet http://reviv.com/role/AccountsReceivableNet Accounts Receivable, net Notes 9 false false R10.htm 00000010 - Disclosure - Inventory, net Sheet http://reviv.com/role/InventoryNet Inventory, net Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment Sheet http://reviv.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets Sheet http://reviv.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Other Current Liabilities Sheet http://reviv.com/role/OtherCurrentLiabilities Other Current Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Equipment Payable Sheet http://reviv.com/role/EquipmentPayable Equipment Payable Notes 14 false false R15.htm 00000015 - Disclosure - Notes Payable Notes http://reviv.com/role/NotesPayable Notes Payable Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders??? Equity Sheet http://reviv.com/role/StockholdersEquity Stockholders??? Equity Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://reviv.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Related Party Transactions Sheet http://reviv.com/role/RelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 00000019 - Disclosure - Business Combination Sheet http://reviv.com/role/BusinessCombination Business Combination Notes 19 false false R20.htm 00000020 - Disclosure - Concentrations Sheet http://reviv.com/role/Concentrations Concentrations Notes 20 false false R21.htm 00000021 - Disclosure - Business Segment and Geographic Area Information Sheet http://reviv.com/role/BusinessSegmentAndGeographicAreaInformation Business Segment and Geographic Area Information Notes 21 false false R22.htm 00000022 - Disclosure - Income Taxes Sheet http://reviv.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - Accounts Receivable, net (Tables) Sheet http://reviv.com/role/AccountsReceivableNetTables Accounts Receivable, net (Tables) Tables http://reviv.com/role/AccountsReceivableNet 25 false false R26.htm 00000026 - Disclosure - Inventory, net (Tables) Sheet http://reviv.com/role/InventoryNetTables Inventory, net (Tables) Tables http://reviv.com/role/InventoryNet 26 false false R27.htm 00000027 - Disclosure - Property and Equipment (Tables) Sheet http://reviv.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://reviv.com/role/PropertyAndEquipment 27 false false R28.htm 00000028 - Disclosure - Intangible Assets (Tables) Sheet http://reviv.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://reviv.com/role/IntangibleAssets 28 false false R29.htm 00000029 - Disclosure - Other Current Liabilities (Tables) Sheet http://reviv.com/role/OtherCurrentLiabilitiesTables Other Current Liabilities (Tables) Tables http://reviv.com/role/OtherCurrentLiabilities 29 false false R30.htm 00000030 - Disclosure - Equipment Payable (Tables) Sheet http://reviv.com/role/EquipmentPayableTables Equipment Payable (Tables) Tables http://reviv.com/role/EquipmentPayable 30 false false R31.htm 00000031 - Disclosure - Notes Payable (Tables) Notes http://reviv.com/role/NotesPayableTables Notes Payable (Tables) Tables http://reviv.com/role/NotesPayable 31 false false R32.htm 00000032 - Disclosure - Stockholders??? Equity (Tables) Sheet http://reviv.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://reviv.com/role/StockholdersEquity 32 false false R33.htm 00000033 - Disclosure - Commitments and Contingencies (Tables) Sheet http://reviv.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://reviv.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - Business Combination (Tables) Sheet http://reviv.com/role/BusinessCombinationTables Business Combination (Tables) Tables http://reviv.com/role/BusinessCombination 34 false false R35.htm 00000035 - Disclosure - Concentrations (Tables) Sheet http://reviv.com/role/ConcentrationsTables Concentrations (Tables) Tables http://reviv.com/role/Concentrations 35 false false R36.htm 00000036 - Disclosure - Business Segment and Geographic Area Information (Tables) Sheet http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationTables Business Segment and Geographic Area Information (Tables) Tables http://reviv.com/role/BusinessSegmentAndGeographicAreaInformation 36 false false R37.htm 00000037 - Disclosure - Income Taxes (Tables) Sheet http://reviv.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://reviv.com/role/IncomeTaxes 37 false false R38.htm 00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) Details http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 38 false false R39.htm 00000039 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) Sheet http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) Details http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 39 false false R40.htm 00000040 - Disclosure - Accounts Receivable, net (Details) Sheet http://reviv.com/role/AccountsReceivableNetDetails Accounts Receivable, net (Details) Details http://reviv.com/role/AccountsReceivableNetTables 40 false false R41.htm 00000041 - Disclosure - Accounts Receivable, net (Details Narrative) Sheet http://reviv.com/role/AccountsReceivableNetDetailsNarrative Accounts Receivable, net (Details Narrative) Details http://reviv.com/role/AccountsReceivableNetTables 41 false false R42.htm 00000042 - Disclosure - Inventory, net (Details) Sheet http://reviv.com/role/InventoryNetDetails Inventory, net (Details) Details http://reviv.com/role/InventoryNetTables 42 false false R43.htm 00000043 - Disclosure - Inventory, net (Details Narrative) Sheet http://reviv.com/role/InventoryNetDetailsNarrative Inventory, net (Details Narrative) Details http://reviv.com/role/InventoryNetTables 43 false false R44.htm 00000044 - Disclosure - Property and Equipment (Details) Sheet http://reviv.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://reviv.com/role/PropertyAndEquipmentTables 44 false false R45.htm 00000045 - Disclosure - Property and Equipment (Details Narrative) Sheet http://reviv.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://reviv.com/role/PropertyAndEquipmentTables 45 false false R46.htm 00000046 - Disclosure - Intangible Assets (Details) Sheet http://reviv.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://reviv.com/role/IntangibleAssetsTables 46 false false R47.htm 00000047 - Disclosure - Intangible Assets (Details Narrative) Sheet http://reviv.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://reviv.com/role/IntangibleAssetsTables 47 false false R48.htm 00000048 - Disclosure - Other Current Liabilities (Details) Sheet http://reviv.com/role/OtherCurrentLiabilitiesDetails Other Current Liabilities (Details) Details http://reviv.com/role/OtherCurrentLiabilitiesTables 48 false false R49.htm 00000049 - Disclosure - Equipment Payable (Details) Sheet http://reviv.com/role/EquipmentPayableDetails Equipment Payable (Details) Details http://reviv.com/role/EquipmentPayableTables 49 false false R50.htm 00000050 - Disclosure - Notes Payable (Details) Notes http://reviv.com/role/NotesPayableDetails Notes Payable (Details) Details http://reviv.com/role/NotesPayableTables 50 false false R51.htm 00000051 - Disclosure - Notes Payable (Details 1) Notes http://reviv.com/role/NotesPayableDetails1 Notes Payable (Details 1) Details http://reviv.com/role/NotesPayableTables 51 false false R52.htm 00000052 - Disclosure - Notes Payable (Details Narrative) Notes http://reviv.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://reviv.com/role/NotesPayableTables 52 false false R53.htm 00000053 - Disclosure - Stockholders' Equity (Details) Sheet http://reviv.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details 53 false false R54.htm 00000054 - Disclosure - Stockholders' Equity (Details 1) Sheet http://reviv.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details 54 false false R55.htm 00000055 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://reviv.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://reviv.com/role/StockholdersEquityTables 55 false false R56.htm 00000056 - Disclosure - Commitments and Contingencies (Details) Sheet http://reviv.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://reviv.com/role/CommitmentsAndContingenciesTables 56 false false R57.htm 00000057 - Disclosure - Commitments and Contingencies (Details 1) Sheet http://reviv.com/role/CommitmentsAndContingenciesDetails1 Commitments and Contingencies (Details 1) Details http://reviv.com/role/CommitmentsAndContingenciesTables 57 false false R58.htm 00000058 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://reviv.com/role/CommitmentsAndContingenciesTables 58 false false R59.htm 00000059 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://reviv.com/role/RelatedPartyTransactions 59 false false R60.htm 00000060 - Disclosure - Asset Purchase Agreement (Details) Sheet http://reviv.com/role/AssetPurchaseAgreementDetails Asset Purchase Agreement (Details) Details 60 false false R61.htm 00000061 - Disclosure - Asset Purchase Agreement (Details 1) Sheet http://reviv.com/role/AssetPurchaseAgreementDetails1 Asset Purchase Agreement (Details 1) Details 61 false false R62.htm 00000062 - Disclosure - Business Combination (Details Narrative) Sheet http://reviv.com/role/BusinessCombinationDetailsNarrative Business Combination (Details Narrative) Details http://reviv.com/role/BusinessCombinationTables 62 false false R63.htm 00000063 - Disclosure - Concentrations (Details) Sheet http://reviv.com/role/ConcentrationsDetails Concentrations (Details) Details http://reviv.com/role/ConcentrationsTables 63 false false R64.htm 00000064 - Disclosure - Concentrations (Details 1) Sheet http://reviv.com/role/ConcentrationsDetails1 Concentrations (Details 1) Details http://reviv.com/role/ConcentrationsTables 64 false false R65.htm 00000065 - Disclosure - Concentrations (Details Narrative) Sheet http://reviv.com/role/ConcentrationsDetailsNarrative Concentrations (Details Narrative) Details http://reviv.com/role/ConcentrationsTables 65 false false R66.htm 00000066 - Disclosure - Business Segment and Geographic Area Information (Details) Sheet http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails Business Segment and Geographic Area Information (Details) Details http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationTables 66 false false R67.htm 00000067 - Disclosure - Business Segment and Geographic Area Information (Details Narrative) Sheet http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative Business Segment and Geographic Area Information (Details Narrative) Details http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationTables 67 false false R68.htm 00000068 - Disclosure - Income taxes (Details) Sheet http://reviv.com/role/IncomeTaxesDetails Income taxes (Details) Details 68 false false R69.htm 00000069 - Disclosure - Income taxes (Details 1) Sheet http://reviv.com/role/IncomeTaxesDetails1 Income taxes (Details 1) Details 69 false false R70.htm 00000070 - Disclosure - Income Taxes (Details Narrative) Sheet http://reviv.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://reviv.com/role/IncomeTaxesTables 70 false false All Reports Book All Reports rviv-20230531_10k.htm rviv-20230531.xsd rviv-20230531_10kex10z10.htm rviv-20230531_10kex10z11.htm rviv-20230531_10kex10z9.htm rviv-20230531_10kex31z1.htm rviv-20230531_10kex31z2.htm rviv-20230531_10kex32z1.htm rviv-20230531_10kex32z2.htm rviv-20230531_cal.xml rviv-20230531_def.xml rviv-20230531_lab.xml rviv-20230531_pre.xml image_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "rviv-20230531_10k.htm": { "axisCustom": 0, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 556, "http://xbrl.sec.gov/dei/2023": 36 }, "contextCount": 136, "dts": { "calculationLink": { "local": [ "rviv-20230531_cal.xml" ] }, "definitionLink": { "local": [ "rviv-20230531_def.xml" ] }, "inline": { "local": [ "rviv-20230531_10k.htm" ] }, "labelLink": { "local": [ "rviv-20230531_lab.xml" ] }, "presentationLink": { "local": [ "rviv-20230531_pre.xml" ] }, "schema": { "local": [ "rviv-20230531.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 544, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 67, "http://reviv.com/20230531": 19, "http://xbrl.sec.gov/dei/2023": 4, "total": 90 }, "keyCustom": 76, "keyStandard": 266, "memberCustom": 41, "memberStandard": 21, "nsprefix": "rviv", "nsuri": "http://reviv.com/20230531", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://reviv.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "b", "p", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Inventory, net", "menuCat": "Notes", "order": "10", "role": "http://reviv.com/role/InventoryNet", "shortName": "Inventory, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "11", "role": "http://reviv.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "12", "role": "http://reviv.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Other Current Liabilities", "menuCat": "Notes", "order": "13", "role": "http://reviv.com/role/OtherCurrentLiabilities", "shortName": "Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:EquipmentFinancingPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Equipment Payable", "menuCat": "Notes", "order": "14", "role": "http://reviv.com/role/EquipmentPayable", "shortName": "Equipment Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:EquipmentFinancingPayableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Notes Payable", "menuCat": "Notes", "order": "15", "role": "http://reviv.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "16", "role": "http://reviv.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "17", "role": "http://reviv.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "18", "role": "http://reviv.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Business Combination", "menuCat": "Notes", "order": "19", "role": "http://reviv.com/role/BusinessCombination", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://reviv.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Concentrations", "menuCat": "Notes", "order": "20", "role": "http://reviv.com/role/Concentrations", "shortName": "Concentrations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Business Segment and Geographic Area Information", "menuCat": "Notes", "order": "21", "role": "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformation", "shortName": "Business Segment and Geographic Area Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "22", "role": "http://reviv.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "23", "role": "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "24", "role": "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Accounts Receivable, net (Tables)", "menuCat": "Tables", "order": "25", "role": "http://reviv.com/role/AccountsReceivableNetTables", "shortName": "Accounts Receivable, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Inventory, net (Tables)", "menuCat": "Tables", "order": "26", "role": "http://reviv.com/role/InventoryNetTables", "shortName": "Inventory, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "27", "role": "http://reviv.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "28", "role": "http://reviv.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "29", "role": "http://reviv.com/role/OtherCurrentLiabilitiesTables", "shortName": "Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "rviv:EquipmentFinancingPayableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:ScheduleOfLoanPaymentDueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Equipment Payable (Tables)", "menuCat": "Tables", "order": "30", "role": "http://reviv.com/role/EquipmentPayableTables", "shortName": "Equipment Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "rviv:EquipmentFinancingPayableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:ScheduleOfLoanPaymentDueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Notes Payable (Tables)", "menuCat": "Tables", "order": "31", "role": "http://reviv.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Stockholders\u2019 Equity (Tables)", "menuCat": "Tables", "order": "32", "role": "http://reviv.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "33", "role": "http://reviv.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Business Combination (Tables)", "menuCat": "Tables", "order": "34", "role": "http://reviv.com/role/BusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:ScheduleOfSalesByProductLineTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Concentrations (Tables)", "menuCat": "Tables", "order": "35", "role": "http://reviv.com/role/ConcentrationsTables", "shortName": "Concentrations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "rviv:ScheduleOfSalesByProductLineTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Business Segment and Geographic Area Information (Tables)", "menuCat": "Tables", "order": "36", "role": "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationTables", "shortName": "Business Segment and Geographic Area Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Income Taxes (Tables)", "menuCat": "Tables", "order": "37", "role": "http://reviv.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "38", "role": "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "lang": null, "name": "rviv:WeightedAverageBasicShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://reviv.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:CustomersReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Accounts Receivable, net (Details)", "menuCat": "Details", "order": "40", "role": "http://reviv.com/role/AccountsReceivableNetDetails", "shortName": "Accounts Receivable, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:AccountsAndNontradeReceivableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:CustomersReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProvisionForDoubtfulAccounts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Accounts Receivable, net (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://reviv.com/role/AccountsReceivableNetDetailsNarrative", "shortName": "Accounts Receivable, net (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Inventory, net (Details)", "menuCat": "Details", "order": "42", "role": "http://reviv.com/role/InventoryNetDetails", "shortName": "Inventory, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:InventoryHeldAtThirdPartyLocation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Inventory, net (Details Narrative)", "menuCat": "Details", "order": "43", "role": "http://reviv.com/role/InventoryNetDetailsNarrative", "shortName": "Inventory, net (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:InventoryHeldAtThirdPartyLocation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Property and Equipment (Details)", "menuCat": "Details", "order": "44", "role": "http://reviv.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Property and Equipment (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://reviv.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Intangible Assets (Details)", "menuCat": "Details", "order": "46", "role": "http://reviv.com/role/IntangibleAssetsDetails", "shortName": "Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Intangible Assets (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://reviv.com/role/IntangibleAssetsDetailsNarrative", "shortName": "Intangible Assets (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:CreditCards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Other Current Liabilities (Details)", "menuCat": "Details", "order": "48", "role": "http://reviv.com/role/OtherCurrentLiabilitiesDetails", "shortName": "Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:CreditCards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:EquipmentFinancingPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Equipment Payable (Details)", "menuCat": "Details", "order": "49", "role": "http://reviv.com/role/EquipmentPayableDetails", "shortName": "Equipment Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "rviv:ScheduleOfLoanPaymentDueTableTextBlock", "rviv:EquipmentFinancingPayableTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "lang": null, "name": "rviv:EquipmentFinancingPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2021-05-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Notes Payable (Details)", "menuCat": "Details", "order": "50", "role": "http://reviv.com/role/NotesPayableDetails", "shortName": "Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-05-31_custom_PaycheckProtectionProgram2Member", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Notes Payable (Details 1)", "menuCat": "Details", "order": "51", "role": "http://reviv.com/role/NotesPayableDetails1", "shortName": "Notes Payable (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Notes Payable (Details Narrative)", "menuCat": "Details", "order": "52", "role": "http://reviv.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31_custom_InsuranceFinancingMember", "decimals": "0", "lang": null, "name": "rviv:InsuranceFinancing", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Stockholders' Equity (Details)", "menuCat": "Details", "order": "53", "role": "http://reviv.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "rviv:ScheduleofsummarizesrelatingcompanysstockoptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Stockholders' Equity (Details 1)", "menuCat": "Details", "order": "54", "role": "http://reviv.com/role/StockholdersEquityDetails1", "shortName": "Stockholders' Equity (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "rviv:ScheduleofsummarizesrelatingcompanysstockoptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "menuCat": "Details", "order": "55", "role": "http://reviv.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-11-01", "decimals": "INF", "lang": null, "name": "rviv:NumberOfOptionIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "rviv:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:RightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "56", "role": "http://reviv.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "rviv:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:RightOfUseAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Commitments and Contingencies (Details 1)", "menuCat": "Details", "order": "57", "role": "http://reviv.com/role/CommitmentsAndContingenciesDetails1", "shortName": "Commitments and Contingencies (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Commitments and Contingencies (Details Narrative)", "menuCat": "Details", "order": "58", "role": "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:ConsultingFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "59", "role": "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "rviv:ConsultingFee", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://reviv.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-06-16", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Asset Purchase Agreement (Details)", "menuCat": "Details", "order": "60", "role": "http://reviv.com/role/AssetPurchaseAgreementDetails", "shortName": "Asset Purchase Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-06-16", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Asset Purchase Agreement (Details 1)", "menuCat": "Details", "order": "61", "role": "http://reviv.com/role/AssetPurchaseAgreementDetails1", "shortName": "Asset Purchase Agreement (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012022-06-16", "decimals": "INF", "first": true, "lang": null, "name": "rviv:SharesConsideration", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - Business Combination (Details Narrative)", "menuCat": "Details", "order": "62", "role": "http://reviv.com/role/BusinessCombinationDetailsNarrative", "shortName": "Business Combination (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012022-06-16", "decimals": "INF", "first": true, "lang": null, "name": "rviv:SharesConsideration", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "rviv:ScheduleOfSalesByProductLineTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_ShampoosAndConditionersMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Concentrations (Details)", "menuCat": "Details", "order": "63", "role": "http://reviv.com/role/ConcentrationsDetails", "shortName": "Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "rviv:ScheduleOfSalesByProductLineTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_ShampoosAndConditionersMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "rviv:ScheduleOfSalesByProductComprisedTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_GhostStrykeMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Concentrations (Details 1)", "menuCat": "Details", "order": "64", "role": "http://reviv.com/role/ConcentrationsDetails1", "shortName": "Concentrations (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "rviv:ScheduleOfSalesByProductComprisedTableTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_ProductConcentrationRiskMember_custom_GhostStrykeMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - Concentrations (Details Narrative)", "menuCat": "Details", "order": "65", "role": "http://reviv.com/role/ConcentrationsDetailsNarrative", "shortName": "Concentrations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - Business Segment and Geographic Area Information (Details)", "menuCat": "Details", "order": "66", "role": "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails", "shortName": "Business Segment and Geographic Area Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_GeographicConcentrationRiskMember_custom_CustomersMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - Business Segment and Geographic Area Information (Details Narrative)", "menuCat": "Details", "order": "67", "role": "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "shortName": "Business Segment and Geographic Area Information (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-012023-05-31_us-gaap_SalesRevenueNetMember_us-gaap_GeographicConcentrationRiskMember_custom_CustomersMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - Income taxes (Details)", "menuCat": "Details", "order": "68", "role": "http://reviv.com/role/IncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000069 - Disclosure - Income taxes (Details 1)", "menuCat": "Details", "order": "69", "role": "http://reviv.com/role/IncomeTaxesDetails1", "shortName": "Income taxes (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2022-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Organization", "menuCat": "Notes", "order": "7", "role": "http://reviv.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000070 - Disclosure - Income Taxes (Details Narrative)", "menuCat": "Details", "order": "70", "role": "http://reviv.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "AsOf2023-05-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Accounts Receivable, net", "menuCat": "Notes", "order": "9", "role": "http://reviv.com/role/AccountsReceivableNet", "shortName": "Accounts Receivable, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "rviv-20230531_10k.htm", "contextRef": "From2022-06-01to2023-05-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndNontradeReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "country_IT": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ITALY" } } }, "localname": "IT", "nsuri": "http://xbrl.sec.gov/country/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r714", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r714", "r716", "r717" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r714", "r716", "r717" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r714", "r716", "r717" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFinStmtErrorCorrectionFlag": { "auth_ref": [ "r714", "r716", "r717", "r719" ], "lang": { "en-us": { "role": { "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction.", "label": "Document Financial Statement Error Correction [Flag]" } } }, "localname": "DocumentFinStmtErrorCorrectionFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r715" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r703" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r706" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r709" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r720" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r705" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r714", "r716", "r717" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r716" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r710" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r711" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r704" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r708" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r707" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://reviv.com/role/Cover" ], "xbrltype": "booleanItemType" }, "rviv_AccessoriesOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accessories Other [Member]" } } }, "localname": "AccessoriesOtherMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetails1" ], "xbrltype": "domainItemType" }, "rviv_AccumulatedReduction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccumulatedReduction", "verboseLabel": "Accumulated reduction" } } }, "localname": "AccumulatedReduction", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_AcquisitionPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition price per share" } } }, "localname": "AcquisitionPricePerShare", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "rviv_AffiliateAccrual": { "auth_ref": [], "calculation": { "http://reviv.com/role/OtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Affiliate Accrual" } } }, "localname": "AffiliateAccrual", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_AggregateGrantDateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate grant date fair value" } } }, "localname": "AggregateGrantDateFairValue", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_AncillaryProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ancillary Products [Member]" } } }, "localname": "AncillaryProductsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "rviv_AssetsPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Purchase Agreement [Member]" } } }, "localname": "AssetsPurchaseAgreementMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_AxilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Axil [Member]" } } }, "localname": "AxilMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://reviv.com/role/BusinessCombinationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_Basic": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic" } } }, "localname": "Basic", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "rviv_BenefitOfTaxAmortizationOfIntangibles": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Benefit of tax amortization of intangibles" } } }, "localname": "BenefitOfTaxAmortizationOfIntangibles", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_BonusForServicesPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Bonus for services paid" } } }, "localname": "BonusForServicesPaid", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_BundledKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bundled Kits [Member]" } } }, "localname": "BundledKitsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationship": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Customer relationships" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCustomerRelationship", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rviv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNames": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tradenames" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeNames", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rviv_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWebsite": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Website" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWebsite", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rviv_BusinessCombinationRecognizedtangibleAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net tangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedtangibleAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rviv_CashAcquiredOnBusinessAcquisition": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "CashAcquiredOnBusinessAcquisition", "negatedLabel": "Cash acquired on business acquisition" } } }, "localname": "CashAcquiredOnBusinessAcquisition", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_CashPaidDuringPeriodForAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid during the period for:" } } }, "localname": "CashPaidDuringPeriodForAbstract", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "rviv_CashRaisedForCommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash raised for common stock to be issued" } } }, "localname": "CashRaisedForCommonStockToBeIssued", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_CommissionsAndContractorFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Commissions and contractor fee" } } }, "localname": "CommissionsAndContractorFee", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_CompensationPaidForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Compensation paid for services" } } }, "localname": "CompensationPaidForServices", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_ConsiderationPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consideration paid" } } }, "localname": "ConsiderationPaid", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rviv_ConsolidatedOperatingIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Consolidated operating income (loss)" } } }, "localname": "ConsolidatedOperatingIncomeLoss", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "monetaryItemType" }, "rviv_ConsultingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consulting fee" } } }, "localname": "ConsultingFee", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_ContractLiabilitiesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract Liabilities Description" } } }, "localname": "ContractLiabilitiesDescription", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "rviv_CreditCards": { "auth_ref": [], "calculation": { "http://reviv.com/role/OtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Credit Cards" } } }, "localname": "CreditCards", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_CustomerDepositCurrent": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Customer deposits" } } }, "localname": "CustomerDepositCurrent", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rviv_CustomerDepositPolicytextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Deposits" } } }, "localname": "CustomerDepositPolicytextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rviv_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Four [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_CustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer [Member]" } } }, "localname": "CustomerMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_CustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customers [Member]" } } }, "localname": "CustomersMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_CustomersReceivable": { "auth_ref": [], "calculation": { "http://reviv.com/role/AccountsReceivableNetDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Customers Receivable" } } }, "localname": "CustomersReceivable", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "rviv_DeferredTaxTrueUp": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred tax true up" } } }, "localname": "DeferredTaxTrueUp", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_Diluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Diluted" } } }, "localname": "Diluted", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "rviv_DisclosureEquipmentPayableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equipment Payable" } } }, "localname": "DisclosureEquipmentPayableAbstract", "nsuri": "http://reviv.com/20230531", "xbrltype": "stringItemType" }, "rviv_DueToRelatedParty": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Due to related party" } } }, "localname": "DueToRelatedParty", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rviv_EarBudsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ear Buds [Member]" } } }, "localname": "EarBudsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_EconomicInjuryDisasterLoanProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Economic Injury Disaster Loan Program [Member]" } } }, "localname": "EconomicInjuryDisasterLoanProgramMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetails", "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_EquipmentFinancingPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equipment Payable, Net" } } }, "localname": "EquipmentFinancingPayable", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/EquipmentPayableDetails" ], "xbrltype": "monetaryItemType" }, "rviv_EquipmentFinancingPayableCurrent": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equipment payable, current", "verboseLabel": "2024" } } }, "localname": "EquipmentFinancingPayableCurrent", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets", "http://reviv.com/role/EquipmentPayableDetails" ], "xbrltype": "monetaryItemType" }, "rviv_EquipmentFinancingPayableNonCurrent": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equipment payable" } } }, "localname": "EquipmentFinancingPayableNonCurrent", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rviv_EquipmentFinancingPayableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EquipmentFinancingPayableTextBlock", "verboseLabel": "Equipment Payable" } } }, "localname": "EquipmentFinancingPayableTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/EquipmentPayable" ], "xbrltype": "textBlockItemType" }, "rviv_FinanceCharges": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finance charges" } } }, "localname": "FinanceCharges", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_FinancingChargesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing Charges [Member]" } } }, "localname": "FinancingChargesMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "rviv_GhostStrykeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ghost Stryke [Member]" } } }, "localname": "GhostStrykeMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetails1" ], "xbrltype": "domainItemType" }, "rviv_GoodwillAcquiredInBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Goodwill acquired in business combination" } } }, "localname": "GoodwillAcquiredInBusinessCombination", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_HairCareAndSkinCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hair Care And Skin Care [Member]" } } }, "localname": "HairCareAndSkinCareMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "rviv_HairShampooAndConditionerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hair Shampoo And Conditioner [Member]" } } }, "localname": "HairShampooAndConditionerMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_HairShampooMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hair Shampoo [Member]" } } }, "localname": "HairShampooMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_HearingEnhancementAndProtectionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Hearing Enhancement And Protection [Member]" } } }, "localname": "HearingEnhancementAndProtectionMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "rviv_IncomeTaxLiability": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Income Tax Liability" } } }, "localname": "IncomeTaxLiability", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "rviv_IncreaseDecreaseInCustomerDeposit": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Customer deposits" } } }, "localname": "IncreaseDecreaseInCustomerDeposit", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_InitialLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial lease liability" } } }, "localname": "InitialLeaseLiability", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_InitialRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Initial right of use asset" } } }, "localname": "InitialRightOfUseAsset", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_InsuranceFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Insurance financing" } } }, "localname": "InsuranceFinancing", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_InsuranceFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insurance Financing [Member]" } } }, "localname": "InsuranceFinancingMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetails", "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_IntangibleAssetsAcquiredInBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Intangible assets acquired in business combination" } } }, "localname": "IntangibleAssetsAcquiredInBusinessCombination", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_IntrepidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intrepid [Member]" } } }, "localname": "IntrepidMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_IntroductorykitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Introductorykit [Member]" } } }, "localname": "IntroductorykitMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_InventoryHeldAtThirdPartyLocation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Inventory held at third party location" } } }, "localname": "InventoryHeldAtThirdPartyLocation", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/InventoryNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_JeffToghraieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jeff Toghraie [Member]" } } }, "localname": "JeffToghraieMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_LeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease Liability" } } }, "localname": "LeaseLiability", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_LessImputedInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less: Imputed interest" } } }, "localname": "LessImputedInterest", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "rviv_LiabilitiesAssumedInBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Liabilities assumed in business combination" } } }, "localname": "LiabilitiesAssumedInBusinessCombination", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_LicensingRights": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Licensing rights" } } }, "localname": "LicensingRights", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rviv_LicensingRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Rights [Member]" } } }, "localname": "LicensingRightsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "rviv_LiquidityAndCapitalResourcesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity and Capital Resources" } } }, "localname": "LiquidityAndCapitalResourcesPolicyTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rviv_LoanForgiveness": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loan forgiveness" } } }, "localname": "LoanForgiveness", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_MerchantProcessorReceivable": { "auth_ref": [], "calculation": { "http://reviv.com/role/AccountsReceivableNetDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Merchant Processor Receivable" } } }, "localname": "MerchantProcessorReceivable", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/AccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "rviv_MonthlyBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Monthly base rent" } } }, "localname": "MonthlyBaseRent", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_NetIncomeTaxBenefitexpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net income tax (benefit)/expense" } } }, "localname": "NetIncomeTaxBenefitexpense", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_NetOperatingLossBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net operating loss benefit" } } }, "localname": "NetOperatingLossBenefit", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_NonVotingSeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Voting Series A Preferred Stock [Member]" } } }, "localname": "NonVotingSeriesAPreferredStockMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Non cash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_NumberOfOptionIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of option issued" } } }, "localname": "NumberOfOptionIssued", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rviv_OperatingLeaseLiabilityCurrentPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OperatingLeaseLiabilityCurrentPortion", "negatedLabel": "Current portion" } } }, "localname": "OperatingLeaseLiabilityCurrentPortion", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_OperatingLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accumulated reduction" } } }, "localname": "OperatingLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options [Member]" } } }, "localname": "OptionsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_OtherBluetoothAndEarBudsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Bluetooth And Ear Buds [Member]" } } }, "localname": "OtherBluetoothAndEarBudsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetails1" ], "xbrltype": "domainItemType" }, "rviv_OutsideTheUnitedStatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Outside The United States [Member]" } } }, "localname": "OutsideTheUnitedStatesMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_PayableToRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payable to related party" } } }, "localname": "PayableToRelatedParty", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_PaycheckProtectionProgram2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Second Draw Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgram2Member", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "rviv_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rviv_PurchasedInventoriesAndProducts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchased inventories and products" } } }, "localname": "PurchasedInventoriesAndProducts", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_PurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchases [Member]" } } }, "localname": "PurchasesMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_RepaymentOfEquipmentFinancing": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Repayment of equipment financing" } } }, "localname": "RepaymentOfEquipmentFinancing", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_RevenueRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "RevenueRecognition", "verboseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognition", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "rviv_RightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right of use assets" } } }, "localname": "RightOfUseAssets", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_RightOfUseAssetsRecognizedAsLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right of use assets recognized as lease liability" } } }, "localname": "RightOfUseAssetsRecognizedAsLeaseLiability", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_RoyaltyPaymentAccrual": { "auth_ref": [], "calculation": { "http://reviv.com/role/OtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Royalty Payment Accrual" } } }, "localname": "RoyaltyPaymentAccrual", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_ScheduleOfLoanPaymentDueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of loan payment due" } } }, "localname": "ScheduleOfLoanPaymentDueTableTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/EquipmentPayableTables" ], "xbrltype": "textBlockItemType" }, "rviv_ScheduleOfSalesByProductComprisedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of sales by product comprised" } } }, "localname": "ScheduleOfSalesByProductComprisedTableTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "rviv_ScheduleOfSalesByProductLineTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Sales by Product Line" } } }, "localname": "ScheduleOfSalesByProductLineTableTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "rviv_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental balance sheet information" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "rviv_ScheduleofsummarizesrelatingcompanysstockoptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of summarizes relating to the Company\u2019s stock" } } }, "localname": "ScheduleofsummarizesrelatingcompanysstockoptionsTableTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "rviv_SeveralPrivatePlacementAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Several Private Placement Agreements [Member]" } } }, "localname": "SeveralPrivatePlacementAgreementsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_ShampooAndConditionerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shampoo And Conditioner [Member]" } } }, "localname": "ShampooAndConditionerMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_ShampoosAndConditionersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shampoos and Conditioners [Member]" } } }, "localname": "ShampoosAndConditionersMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "rviv_SharesConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares consideration" } } }, "localname": "SharesConsideration", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "rviv_ShippingAndHandlingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shipping and Handling Costs" } } }, "localname": "ShippingAndHandlingCostsPolicyTextBlock", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rviv_StockIssuedForBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stock issued for business combination" } } }, "localname": "StockIssuedForBusinessCombination", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_TangibleAssetsExcludingCashAcquiredInBusinessCombination": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tangible assets (excluding cash) acquired in business combination" } } }, "localname": "TangibleAssetsExcludingCashAcquiredInBusinessCombination", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rviv_TaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tax expense (benefit)" } } }, "localname": "TaxExpenseBenefit", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "rviv_TrackrHeadmuffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trackr Headmuff [Member]" } } }, "localname": "TrackrHeadmuffMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetails1" ], "xbrltype": "domainItemType" }, "rviv_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_VendorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendors One [Member]" } } }, "localname": "VendorOneMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_VendorThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendors Three [Member]" } } }, "localname": "VendorThreeMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_VendorTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendors Two [Member]" } } }, "localname": "VendorTwoMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_VendorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vendors [Member]" } } }, "localname": "VendorsMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "rviv_VestedWeightedAverageRemainingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested weighted average remaining term" } } }, "localname": "VestedWeightedAverageRemainingTerm", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "rviv_WebsiteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Website [Member]" } } }, "localname": "WebsiteMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "rviv_WeightedAverageBasicShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average basic shares" } } }, "localname": "WeightedAverageBasicShares", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "rviv_WeightedAverageDilutiveShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average dilutive shares" } } }, "localname": "WeightedAverageDilutiveShares", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "rviv_WeightedAverageRemainingTermForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining term, forfeited" } } }, "localname": "WeightedAverageRemainingTermForfeited", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "rviv_WeightedAverageRemainingTermGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining term, granted" } } }, "localname": "WeightedAverageRemainingTermGranted", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "rviv_WestonT.HarrisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weston T. Harris [Member]" } } }, "localname": "WestonT.HarrisMember", "nsuri": "http://reviv.com/20230531", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r205", "r206", "r344", "r371", "r473", "r664", "r666" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r281", "r282", "r283" ], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r278", "r683", "r760", "r779", "r780" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r390", "r477", "r531", "r566", "r567", "r629", "r631", "r633", "r634", "r636", "r657", "r658", "r673", "r680", "r686", "r691", "r759", "r771", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r390", "r477", "r531", "r566", "r567", "r629", "r631", "r633", "r634", "r636", "r657", "r658", "r673", "r680", "r686", "r691", "r759", "r771", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r278", "r683", "r760", "r779", "r780" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r274", "r480", "r525", "r526", "r527", "r528", "r529", "r530", "r660", "r681", "r690", "r729", "r755", "r756", "r760", "r779" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r274", "r480", "r525", "r526", "r527", "r528", "r529", "r530", "r660", "r681", "r690", "r729", "r755", "r756", "r760", "r779" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r322", "r323", "r324", "r325", "r388", "r390", "r402", "r403", "r404", "r476", "r477", "r531", "r566", "r567", "r629", "r631", "r633", "r634", "r636", "r657", "r658", "r673", "r680", "r686", "r691", "r694", "r751", "r759", "r772", "r773", "r774", "r775", "r776" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r388", "r390", "r402", "r403", "r404", "r476", "r477", "r531", "r566", "r567", "r629", "r631", "r633", "r634", "r636", "r657", "r658", "r673", "r680", "r686", "r691", "r694", "r751", "r759", "r772", "r773", "r774", "r775", "r776" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r205", "r206", "r344", "r371", "r473", "r665", "r666" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r276", "r277", "r563", "r564", "r565", "r630", "r632", "r635", "r637", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r661", "r682", "r694", "r760", "r779" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r276", "r277", "r563", "r564", "r565", "r630", "r632", "r635", "r637", "r644", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r661", "r682", "r694", "r760", "r779" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndNontradeReceivableTextBlock": { "auth_ref": [ "r279", "r285" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable.", "label": "Accounts Receivable, net" } } }, "localname": "AccountsAndNontradeReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AccountsReceivableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Other Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r16", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r584", "r645", "r695", "r778" ], "calculation": { "http://reviv.com/role/AccountsReceivableNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts receivable, net", "totalLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AccountsReceivableNetDetails", "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r56", "r172", "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less:Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquisitionCosts": { "auth_ref": [ "r142", "r143" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.", "label": "Acquisition Costs, Period Cost" } } }, "localname": "AcquisitionCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r99", "r689", "r783" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r407", "r408", "r409", "r551", "r743", "r744", "r745", "r765", "r787" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Marketing, selling and advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r406", "r414" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Compensation and related taxes" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r180", "r280", "r288", "r289", "r291", "r778" ], "calculation": { "http://reviv.com/role/AccountsReceivableNetDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsReceivableNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedLabel": "Less: Allowance for doubtful debts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AccountsReceivableNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r4", "r50", "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r145", "r176", "r203", "r243", "r264", "r270", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r439", "r441", "r453", "r501", "r589", "r689", "r702", "r757", "r758", "r769" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails", "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r167", "r183", "r203", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r439", "r441", "r453", "r689", "r757", "r758", "r769" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNet": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net assets (liabilities).", "label": "Consolidated total assets" } } }, "localname": "AssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r203", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r439", "r441", "r453", "r757", "r758", "r769" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total Other Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AutomobilesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vehicles that are used primarily for transporting people.", "label": "Automobiles [Member]" } } }, "localname": "AutomobilesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position)." } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BasicEarningsPerShareProForma": { "auth_ref": [ "r92", "r475" ], "lang": { "en-us": { "role": { "documentation": "Pro forma basic earnings per share or earnings per unit, which is commonly presented in initial public offerings based on the terms of the offering.", "label": "Basic Earnings Per Share, Pro Forma", "verboseLabel": "Basic" } } }, "localname": "BasicEarningsPerShareProForma", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r436", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r70", "r71", "r436", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Schedule of proforma information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r434", "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Net income (loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r434", "r435" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r135", "r437" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Prepaid expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Contract liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Total Identifiable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Identifiable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r72", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "verboseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r72", "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Total net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r73" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Goodwill purchased", "verboseLabel": "Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails", "http://reviv.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r29", "r170", "r662" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r29", "r114", "r199" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH - End of year", "periodStartLabel": "CASH - Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r2", "r114" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r163", "r177", "r178", "r179", "r203", "r223", "r227", "r231", "r233", "r237", "r238", "r284", "r331", "r333", "r334", "r335", "r338", "r339", "r369", "r370", "r373", "r376", "r383", "r453", "r542", "r543", "r544", "r545", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r576", "r598", "r621", "r638", "r639", "r640", "r641", "r642", "r724", "r740", "r746" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [ "r177", "r178", "r179", "r237", "r369", "r370", "r371", "r373", "r376", "r381", "r383", "r542", "r543", "r544", "r545", "r680", "r724", "r740" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r88", "r502", "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (see Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r125", "r319", "r320", "r647", "r752" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r692", "r693", "r694", "r696", "r697", "r698", "r699", "r743", "r744", "r765", "r781", "r787" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative", "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock, par or stated value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r98", "r576" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r98", "r576", "r595", "r787", "r788" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r98", "r504", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value: 450,000,000 shares authorized; 117,076,949 and 41,945,881 shares issued, and outstanding as of May 31, 2023 and May 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r35", "r39", "r79", "r80", "r278", "r646" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r35", "r39", "r79", "r80", "r278", "r537", "r646" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r35", "r39", "r79", "r80", "r278", "r646", "r726" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/Concentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r35", "r39", "r79", "r80", "r278" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage", "terseLabel": "Concentration Risk, Percentage", "verboseLabel": "Total" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r34", "r35", "r39", "r40", "r79", "r138", "r646" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r35", "r39", "r79", "r80", "r278", "r646" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r385", "r386", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r385", "r386", "r387" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract liabilities, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r385", "r386", "r387" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract liabilities, long term" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r110", "r480" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r36", "r278" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r126", "r201", "r340", "r346", "r347", "r348", "r349", "r350", "r351", "r356", "r363", "r364", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r82", "r84", "r341", "r461", "r676", "r677" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r21", "r82", "r359" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r207", "r341", "r342", "r343", "r344", "r345", "r347", "r352", "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r461", "r675", "r676", "r677", "r678", "r679", "r741" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r22", "r63", "r66", "r81", "r82", "r84", "r89", "r128", "r129", "r207", "r341", "r342", "r343", "r344", "r345", "r347", "r352", "r353", "r354", "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r365", "r461", "r675", "r676", "r677", "r678", "r679", "r741" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r763" ], "calculation": { "http://reviv.com/role/IncomeTaxesDetails1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred tax assets", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails1", "http://reviv.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r68", "r764" ], "calculation": { "http://reviv.com/role/IncomeTaxesDetails1": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryover" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r423" ], "calculation": { "http://reviv.com/role/IncomeTaxesDetails1": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r4", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r4", "r55" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r4", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Consolidated total depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DilutedEarningsPerShareProForma": { "auth_ref": [ "r92", "r475" ], "lang": { "en-us": { "role": { "documentation": "Pro forma diluted earnings per share, which is commonly presented in initial public offerings.", "label": "Diluted Earnings Per Share Pro Forma", "verboseLabel": "Diluted" } } }, "localname": "DilutedEarningsPerShareProForma", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dilutive securities:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (loss) per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r192", "r213", "r214", "r215", "r216", "r217", "r221", "r223", "r231", "r232", "r233", "r235", "r451", "r452", "r496", "r512", "r669" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r192", "r213", "r214", "r215", "r216", "r217", "r223", "r231", "r232", "r233", "r235", "r451", "r452", "r496", "r512", "r669" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net income (loss) per share of common stock" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareProFormaAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings (loss) per common share" } } }, "localname": "EarningsPerShareProFormaAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AssetPurchaseAgreementDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r10", "r164", "r187", "r188", "r189", "r208", "r209", "r210", "r212", "r218", "r220", "r236", "r286", "r287", "r384", "r407", "r408", "r409", "r427", "r428", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r454", "r455", "r456", "r457", "r458", "r459", "r467", "r532", "r533", "r534", "r551", "r621" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r7", "r12" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair value measurements and fair value of financial instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Intangible Assets useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r174", "r309" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r307", "r308", "r309", "r310", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r121", "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r51", "r52" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r121", "r481" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, net", "verboseLabel": "Finite-Lived Intangible Assets, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets", "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r4", "r58", "r59" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on debt settlement", "negatedLabel": "Gain on debt forgiveness" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows", "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r111", "r600" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r38", "r646" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r173", "r296", "r495", "r674", "r689", "r749", "r750" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r9", "r49" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r109", "r203", "r243", "r263", "r269", "r272", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r453", "r671", "r757" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Total segment gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails", "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsLineItems": { "auth_ref": [ "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Guarantor Obligations [Line Items]" } } }, "localname": "GuaranteeObligationsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r4", "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment loss" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r1", "r107", "r148", "r243", "r263", "r269", "r272", "r497", "r510", "r671" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r204", "r415", "r420", "r421", "r425", "r429", "r431", "r432", "r433", "r547" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r152", "r162", "r219", "r220", "r251", "r418", "r430", "r513" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r186", "r416", "r417", "r421", "r422", "r424", "r426", "r541" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Increase (decrease) in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Tax expense (benefit) computed at statutory rate of 21%" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.", "label": "Non deductible expense: Other" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Non-deductible expenses: Stock-based compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Change in federal tax rate estimate for prior years" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r762" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "State tax expense (benefit) blended rate" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxExemptIncome": { "auth_ref": [ "r762" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount", "negatedLabel": "Non taxable: COVID related grants/loan forgiveness" } } }, "localname": "IncomeTaxReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r28", "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r3" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r478", "r739" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxes": { "auth_ref": [ "r739" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.", "label": "Change in deferred tax asset" } } }, "localname": "IncreaseDecreaseInIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r3" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r739" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r224", "r225", "r226", "r233" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Stock options" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r228", "r229", "r233" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Convertible preferred stock" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r83", "r150", "r190", "r247", "r460", "r606", "r700", "r784" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense and other finance charges" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r195", "r197", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://reviv.com/role/OtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Interest", "verboseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative", "http://reviv.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory, net" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r733" ], "calculation": { "http://reviv.com/role/InventoryNetDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r182", "r663", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://reviv.com/role/InventoryNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets", "http://reviv.com/role/InventoryNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r732" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, non-current" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r153", "r169", "r181", "r292", "r293", "r295", "r479", "r667" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r734" ], "calculation": { "http://reviv.com/role/InventoryNetDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw Materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r48", "r736" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory valuation reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r294" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory obsolescence" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r465", "r688" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee, Operating Lease, Description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r687" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r767" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of maturities of operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "verboseLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r203", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r440", "r441", "r442", "r453", "r574", "r670", "r702", "r757", "r769", "r770" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities [Default Label]", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r103", "r147", "r506", "r689", "r742", "r748", "r766" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r168", "r203", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r440", "r441", "r442", "r453", "r689", "r757", "r769", "r770" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r14", "r93", "r94", "r95", "r96", "r203", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r440", "r441", "r442", "r453", "r757", "r769", "r770" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LONG TERM LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForTitleClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r90", "r151" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount needed to reflect the estimated ultimate cost of settling asserted and unasserted claims estimated to have been incurred by the insureds on or before the balance sheet date pertaining to the existence of a lien, encumbrance, defect or other matter purportedly affecting the title to the interest as insured.", "label": "Claim amount" } } }, "localname": "LiabilityForTitleClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansAndLeasesReceivableLeaseFinancingPolicy": { "auth_ref": [ "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recording, valuing, and reporting amounts due from lessees pursuant to contractual arrangements, which are secured, at a minimum, by the asset being rented, and in measuring certain revenues, expenses and gains and losses arising from creating, acquiring, collecting, terminating, modifying and holding lease agreements.", "label": "Lease Accounting" } } }, "localname": "LoansAndLeasesReceivableLeaseFinancingPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r146", "r353", "r367", "r676", "r677", "r777" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "verboseLabel": "Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r6", "r207", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Non-current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r57" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [ "r321", "r322", "r323", "r326", "r753", "r754" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r321", "r322", "r323", "r326", "r753", "r754" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r196" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r196" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH PROVIDED BY INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r114", "r115", "r116" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r108", "r116", "r149", "r166", "r184", "r185", "r189", "r203", "r211", "r213", "r214", "r215", "r216", "r219", "r220", "r230", "r243", "r263", "r269", "r272", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r452", "r453", "r511", "r597", "r619", "r620", "r671", "r700", "r757" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "NET INCOME (LOSS)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails", "http://reviv.com/role/ConsolidatedStatementsOfCashFlows", "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersOperationsBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET INCOME (LOSS) PER COMMON SHARE:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersOperationsBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r112" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other Income (Expense), Net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME (EXPENSE):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r14", "r146", "r777" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Total", "verboseLabel": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails", "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable", "negatedLabel": "Less: Current portion" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets", "http://reviv.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r243", "r263", "r269", "r272", "r671" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "INCOME (LOSS) FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total lease liability, net", "terseLabel": "Lease liability", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails", "http://reviv.com/role/CommitmentsAndContingenciesDetails1", "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r463" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease Liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r463" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liability, long term", "verboseLabel": "Non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails", "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r462" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right of use asset", "terseLabel": "Right of use asset", "verboseLabel": "Operating lease assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/CommitmentsAndContingenciesDetails", "http://reviv.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r67" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net Operating Loss Carryforward" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r91", "r137", "r538", "r539" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r144", "r175", "r500", "r702" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Schedule of other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r111", "r786" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "General and Administrative" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInventoryInTransit": { "auth_ref": [ "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported.", "label": "Inventory in-transit" } } }, "localname": "OtherInventoryInTransit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r87", "r499", "r570", "r571", "r702", "r782" ], "calculation": { "http://reviv.com/role/OtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "totalLabel": "Other Current Liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r19", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r194" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r113" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Consolidated total payments for property and equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails", "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r692", "r693", "r696", "r697", "r698", "r699", "r781", "r787" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative", "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r97", "r369" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred stock, par or stated value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r97", "r576" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r97", "r369" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r97", "r576", "r595", "r787", "r788" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheetsParenthetical", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r97", "r503", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value; 300,000,000 shares authorized; 250,000,000 and no shares issued and outstanding as of May 31, 2023 and May 31, 2022, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r737" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r738" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Additional borrowings" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherDebt": { "auth_ref": [ "r26" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from debt classified as other.", "label": "Proceeds from loan payable" } } }, "localname": "ProceedsFromOtherDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Advances (payments) from a related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r700", "r785", "r786" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional and consulting expenses" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r122", "r157", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r123", "r171", "r509" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Plant Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r498", "r509", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets", "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r5", "r157", "r160", "r507" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r193", "r290" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debts", "verboseLabel": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AccountsReceivableNetDetailsNarrative", "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Accounts receivable and allowance for doubtful accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r389", "r471", "r472", "r569", "r570", "r571", "r572", "r573", "r594", "r596", "r628" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r601", "r602", "r605" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r389", "r471", "r472", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r569", "r570", "r571", "r572", "r573", "r594", "r596", "r628", "r768" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r468", "r469", "r470", "r472", "r474", "r548", "r549", "r550", "r603", "r604", "r605", "r625", "r627" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r27" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedLabel": "Repayment of note payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [ "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r100", "r130", "r505", "r535", "r536", "r546", "r577", "r689" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r164", "r208", "r209", "r210", "r212", "r218", "r220", "r286", "r287", "r407", "r408", "r409", "r427", "r428", "r443", "r445", "r446", "r448", "r450", "r532", "r534", "r551", "r787" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r599", "r659", "r668" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r191", "r203", "r244", "r245", "r262", "r267", "r268", "r274", "r276", "r278", "r284", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r453", "r497", "r757" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Sales", "verboseLabel": "Total net sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails", "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Value of common stock sold" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Number of common stock sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://reviv.com/role/OtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales Tax Payable and Other Accrued Expenses" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/OtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r278", "r725" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative", "http://reviv.com/role/ConcentrationsDetails", "http://reviv.com/role/ConcentrationsDetails1", "http://reviv.com/role/ConcentrationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of accounts receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/AccountsReceivableNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r70", "r71", "r436" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of notes payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of deferred tax asset" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of net loss per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of effective statutory rate and the provision for income" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r51", "r52", "r481" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGuaranteeObligationsTable": { "auth_ref": [ "r327", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties.", "label": "Schedule of Guarantor Obligations [Table]" } } }, "localname": "ScheduleOfGuaranteeObligationsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.", "label": "Schedule of intangible assets" } } }, "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r15", "r104", "r105", "r106" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/InventoryNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of notes payments due in the next five years" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of estimated fair value of the assets acquired" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r85", "r86", "r601", "r602", "r605" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r312", "r313", "r314", "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r44", "r45", "r46", "r49" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r44", "r45", "r46", "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of segment information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of stock option assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r60", "r61", "r62", "r63", "r64", "r65", "r66", "r128", "r129", "r130", "r177", "r178", "r179", "r237", "r369", "r370", "r371", "r373", "r376", "r381", "r383", "r542", "r543", "r544", "r545", "r680", "r724", "r740" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r240", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r278", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r315", "r318", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r674", "r729", "r779" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r239", "r240", "r241", "r242", "r243", "r255", "r266", "r270", "r271", "r272", "r273", "r274", "r275", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Business Segment and Geographic Area Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r261", "r276", "r672" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Marketing and selling expenses", "terseLabel": "Selling and Marketing", "verboseLabel": "Selling and marketing expense" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails", "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://reviv.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation", "verboseLabel": "Share-Based Payment Arrangement, Noncash Expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of option outstanding, forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r761" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of option outstanding, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of option outstanding, ending", "periodStartLabel": "Number of option outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Exercise price", "periodEndLabel": "Weighted average exercise price, ending", "periodStartLabel": "Weighted average exercise price, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Unvested weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price, forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r391", "r392", "r399", "r400", "r401", "r402", "r405", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares", "negatedLabel": "Unvested number of option" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options forfeited.", "label": "Shares forfeited" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining term, ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Unvested weighted average remaining term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested number of option", "verboseLabel": "Shares vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Vested weighted average exercise price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r117", "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r165", "r240", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r278", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r311", "r315", "r318", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r674", "r729", "r779" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessSegmentAndGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r163", "r177", "r178", "r179", "r203", "r223", "r227", "r231", "r233", "r237", "r238", "r284", "r331", "r333", "r334", "r335", "r338", "r339", "r369", "r370", "r373", "r376", "r383", "r453", "r542", "r543", "r544", "r545", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r576", "r598", "r621", "r638", "r639", "r640", "r641", "r642", "r724", "r740", "r746" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BusinessCombinationDetailsNarrative", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r10", "r24", "r164", "r187", "r188", "r189", "r208", "r209", "r210", "r212", "r218", "r220", "r236", "r286", "r287", "r384", "r407", "r408", "r409", "r427", "r428", "r443", "r444", "r445", "r446", "r447", "r448", "r450", "r454", "r455", "r456", "r457", "r458", "r459", "r467", "r532", "r533", "r534", "r551", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r208", "r209", "r210", "r236", "r480", "r540", "r562", "r568", "r569", "r570", "r571", "r572", "r573", "r576", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r596", "r599", "r600", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r695" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r208", "r209", "r210", "r236", "r480", "r540", "r562", "r568", "r569", "r570", "r571", "r572", "r573", "r576", "r579", "r580", "r581", "r582", "r583", "r585", "r586", "r587", "r588", "r590", "r591", "r592", "r593", "r594", "r596", "r599", "r600", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r695" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r97", "r98", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Shares issued for acquisition of business, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r10", "r97", "r98", "r130", "r542", "r621", "r639" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued for cash, Shares", "verboseLabel": "Shares issued during the period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r10", "r97", "r98", "r130", "r396" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r10", "r24", "r130" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Shares issued for acquisition of business" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r10", "r97", "r98", "r130", "r551", "r621", "r639", "r701" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares issued for cash", "verboseLabel": "Shares issued value during the period" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r4" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock options expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r98", "r101", "r102", "r120", "r578", "r595", "r622", "r623", "r689", "r702", "r742", "r748", "r766", "r787" ], "calculation": { "http://reviv.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets", "http://reviv.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r127", "r202", "r368", "r370", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r384", "r449", "r624", "r626", "r643" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/IntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r666" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnderlyingAssetClassAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by underlying asset class.", "label": "Underlying Asset Class [Axis]" } } }, "localname": "UnderlyingAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails", "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnderlyingAssetClassDomain": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Major types of referenced/underlying asset classes (for example, corporate debt, sovereign debt, and structured finance)." } } }, "localname": "UnderlyingAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/NotesPayableDetails", "http://reviv.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r41", "r42", "r43", "r155", "r156", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r222", "r233" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r221", "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://reviv.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481161/840-30-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147479664/932-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "310", "URI": "https://asc.fasb.org//310/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "326", "URI": "https://asc.fasb.org//326/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//350-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "460", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "808", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 1.B.3)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147480148/855-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(5)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r703": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r704": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r705": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r706": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r707": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r708": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r709": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r711": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r712": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r713": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r714": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r715": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r716": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r717": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r718": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r719": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r721": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r722": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r723": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org//705/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r752": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4K", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147479910/205-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 1.B.2)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147480922/205-10-S99-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 92 0001520138-23-000335-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-23-000335-xbrl.zip M4$L#!!0 ( -6#%5V2FD )QM - :6UA9V5?,# Q+FIP9XRX M8W E3/3NNV/;MFW;YHYMV[:Y8]NV,Q,[F8F3'7/B23)Q)G/?^Z^ZYYS[[3Q= M_67]:O7JU;4^=#W_-O\= - 5915D 1"0 (#5?POP[QJ (>UMZ>@/@ ! P#_ M$[H%H$I8N5I8 ZR^_Q>!^ <&1 $@_N\%^;\%];_T_['_P1#_)_F_U+_O QX M "=$&A0$!@ 2 P(* ^+?.& " /B?.A" _R5X. 181&@8""@D2 C _XL@_@\( M PL'!0T/"8& #@# 2"@(&$@(6'^R_BO34@HZ/\H/ #$PN! G==-P<;AQ*/ M0X+?#U&#DYJ;AZ\GU]P]W()*B_=G!)>E%8UU-_Y_]X" @@9 0<-!(?R7^C]G M8$## "@P83DHL20RL.$T.)>IM%:TS=UQ)#4MN#J\<'GAP].Y,WG*VMJIO;-_ MWY=+>4KC_=L&(/_7 "0&% 9 ###);0+K#IQ,+!,,O>N* ^X+#1L5"S:-V,3?17Z]'<6$]&0: @D$K?U?)Q*&:I5I!VY",Q!EHROR58T/WRJLE4X^:)-K1_1+=N-80.1&$Q2W>E*9_!K$J$;R"J^'BO]]_IB)HZI MA]H6P;L[90;2X9$\\K"QJZ* U9OK9;RH[P]3&8+>OB1CQK_Z8>/M@)(RXC(J M_'16ZO0D.U&)+TSEH[0,"5)G SF(M DRK[DCJX]=-7/%>;$Y?,6=[0G+U#8U MU8/%F0^E57JKR;$KM2:\R-TF]T[N5\P]:@<-FG;":JEASQFMSY>S5GY%D>;M M2, W_]LK*/7ES6X%@>O]5.R&(%EE6D!H-6#/^MQ]8 M<"HT/YY6EWXOT]/HMS<I:$G,_]NC^>=O,;0##Z-55#J:0@?K7E MN/UNEUM_FPYD+VU/5Q@I22(I-UKE %0HY8;I7MDQE4EL-8"[>LMU<07 9!WG M;_[X:T)_0[6Q*2%$AE6?==JL.[>'<]G<1O*PPF?RTU#;T1>/P^TE=!_&'QS^ WSOMPN0JNF7HO0GZK]= M#Y852_Q#O&GG+W,;R!I:Y\2KA"0/KGJO9N#K;JM8K[MW+1%H6;=!M3O'9"TB M1QQ04)>A03M3&6[P MOPT?SE@*#LL85H!GJ*#<6,#"J_5XOMGR9S[7S\;R?OJ4D^UI344#W4L83-4I MJ@CT)&.]G]8HW!K#4/#2+P+O?04;'ZTV# M:ER:QL+/-10L&$9.2*22N_;:I;,UJ@DR[4K][DP.;7U.$_WVZ.>95UP0#3M)&L4WDR.(MT$0#)9MQ2)@^ .V+$K-YJ?!QMK+0,>VI,]UN3J-B7,]4AK*G$5T'BNK=D"=H"HO ME%[A>=$0KFY+@M&,%H!QL[$X$><$ZW.%?#/35&W5L@Q[]*T[2O?Y:AV.!=<7 MS34G(D(H+C(,@5QW2Q/[YD-\.7Q1U=4#+:' E>!14)8B]]=:L;:].P$,Y9)( MS=):58,O\*?012QO+FYGGL_E1H',LSZ.@9#@.: M[.Q(*D 3?D>Q_)PL=152MP94>CI'Z#4\J.6&T'M9_??::KYMERH?P#IDD98 M63=-?BYQ]].+^.^HU#:-23@!U:2UL*9D==)A\2WAIRP\> M+3">0)]4D><2]R$V+%[2$E//SQ9!5>NJ.8?U7K_GKGS, _UL7\%'1>B*YXZ0 M_#H9R,'YV(@Z9CLJ!QRJL1#Q!#)"V\U_ &&V MLEGZ84*/*01D)IO^M?/;W*?R!@\ER6D?Q;]ZB%UI68F$;>J8OY_A:>>JK8_W M.RDG;RDUKFF@S)>\!KGUL+;ZBY5>8UC)5&SU*=D7D*;]V*A/CI(.LBJTDOEH M.Q=LM]AB_,RX=!J7%(4GK/QY9SC9HPZ MO23U\F1[Q&:-W\S?97PDEW<@\!7KT6DU3T!4@!:M3_2VL++X*P^_66.P55OB M:&$K4IYCK888+ZV9W1 T9BMNXPTY^F.P'&?6_=>QF3K0Z;I:2 M>H^.12(JJLJO#1K%AAMH11*_"0>!>G"F8VB3,3D1+O:<^(0@0B-^ M!NL0""D7[38ED8&9,_\<[\P(-\_'.#12\:(93&,;$AS%H^5\_Z+8D53:[#>5 MN-IB=L(3$$Z;,C&@7E;XW<:A*IVF/=2-W1 M=C@;*[0#KB&REJ^"+ "C#HP2^75]5D_D%$;DH6R0_P!&?+U/!.]9?]P1*OHG MC<9I>GI3K;,Y8?_4,8YV6@O5;=ZIDSX5SZ!9=&?FYB-'#U8+E#N_\K\3A@FF M]YI_^/P,/5UN<,$,,CM>(!$I<&T8D=7O7!EHI=&==Y=G.- ]7>L<\">8&V:) M^8Z0T&A.I2^<;MPG8XT8(OE'2$"7!-?#,!B2E[%N8(O^(S['68 MMBQ(4I)*8'-<))[YH),KC'EOZ]@BM6%8R30S^QW(QLY2UJ)*^8,B]9WV;EO8 M V*+^G.8A*-UPBOI&Q*1(QALU% >;7^9,_Q:4J=NT;U9+7Y)ZV MIF.:ULL%<7KCVLL/)0EJMM7U>B&35I]&A'E)'WF-"Q&UA8E3;B4!%]%H6!E_ ME_5'A>VHT=2IVZ&N5=F%.GM=H65U+1Q;S.H_O/IKI^%K1"-HPK]+0 >3R6X_ M>>B&5KO[HOWP#7QPW='Q?/60[[?$S<-. _D]/>KEQG67MZU(X%!;EY3'U9TM!BS3DKKU(/&Z8WV7(23B[H6$H)P#ER'4LR^ M,F#.<&7HNTZZRB3G3BF[&%'"O"%6.^1DD\F;^IQ+7703B[AB"4YMI1MMLNE6 MY[X^RC?WU^^?-W(K CR]\@G,CFD:!8W6G%T_&?B0IZ,,Z<1^'9U,N8BX\.<4NWQ1,QG0J'"/Q D1$I@J)5-S><:]F9&$0R@T6#IGUNEGHR7C%*:DITI7JVO@:;=MJ&(B MD#DI[&>N.UP6C(R]8MZ8]FDAC.I2R:E^M(&6Y2Z/8NM>W=8@4R6%>D(9^H+\ M<'R5OI661A%L6L3B=#@Q*VBQ6(ALI4^&YNE/^086 N-R:PM= ME;0&BUP=D]\]-*#+QEK#6'3:YJBC+Y8,VE54U9LYO;84D9>-ZJ^VN'P=C^5! M_92S-&'(W"U>JJ3@#R/W#+R=2_1I^J\%R8DN0RD4[T(E+QVWOT\J70\E1 8# MPU8)%(>DP(J= 8%!33)R %>0"5NUM4TJZ,R^1UFPFLK<.!]- MP1UD]/YD68@2P^:]3VK NOK.! E!-H'AZO'1#K"B(I-L6?-/+60G0313GL9G MSA%W"TVOT>A O6IW7(;'BL#PW+>*:8XNG5E&_4?'N,[DO+0ZX^-H&J((IAY. MTUI,^(*?_ SK".^K_*H_!\M/M%4P.^06>%%HUW]ZC M,RPW7JBH:78./KZPYYC$AC8,KHFIN"2/A? Z#F;\1(5KMLXB0#A(8HK@];;(OX?MVAX, MB(6"N^45Z/IAE_I]-Z4E9#[MQ8S4,_JQ3.*GM0+_)AN6P7]1TZNHP, M+4'96XS8-2BP"CMYC-GO. &$.[>L[-7Z/DG4$&8,T KGFX$N>U[-^46@\R:9 MK(&>H11752Y/9WQ9[B9"^5M\R/$4476^LK)2!N8/7Y?^CEC.WESKD3DRP3$W M$S\M)(E[LOQX.866@:"_EGV M$(E'IZ>ZCZ+*),_*59=3+%_L0FH/M)#=]V9/_()K7%4G505DWU8!'6B,C[A: MV"3Z6?M>\LO0Y.EMZT;+Z(049[1\)8?)")!/P5(IHZ$/CGGM&'G@Y^"H& M8L]KKUM.L7$MBLV^XL&L]7TF4BI[92OZT. &(\N !'_\W5%$QHPP:6R(+]9= M^0\RA6GO058A#I\UP]2>=.CLM38 MD6_HGZOO8;BZ%!(G_.VOMY6<^>NEJD$#ZSZ#7"3MCOR+NOJ;P*6C*I8>0:N) MH2=%[[^R,'DGU2$J^O ,,6C7\%,]^M(_O'PNZ*DAPZ/DJH)=B1+F]I%#9,^4 M[*T?)$=%':R=TT3PV357H:-%>6JK;X1P51]1XG,8;"%W J *RCQB5XQW,Z," MVIL/T"$ MSS;]WQ9>G?<[/5RY+^O,+7^)%8 U#7XJPLG'-Q[$K2 2DR8A>=) MK=^''F1&:;]:H3*5I;#'(EO-/$@?RK;)*JUOG:]&L.MT^C+:SB>GSVZTH1J3D$3]J)HJLS%0%*3$:#/8FM.PD?RV/_I3&PNM=3U>WSY+H_$F)7.U? M1(4TU0N@6WL[7CB6V[@U+,X';)VNMN_&6)G>Z\V^NY/YK5ZL[Y:)479?P(QAM0;WMV0 M]_4](H-Z"?B*<0!IT:FPA*0&?U1& KK MK7\]*2P#@TOZ![J5[!2DL)DHN9LDL)TF9019_2BAKH7VFH96=9X#'-S#-T!'@V"4T8F.!.'&XR\;J_[UI] M WT.PG;'*1G#-M@&(6G#*GIY@]N,O'/"1?(/WG:PC-\RX1'T7O7'8^RQ,3E6 M9$:M%-3I<^:KT>_H+C8'13U;#M58ROQF"CQ% M5\81@X]3>Y@7H0Q[>29X^3+RS^SE\N)E_5?GZHW;,TSB>I.(%?<:)N\?K/3) ME8](3:A6+U].7W1,9M(N?I_<-@72=/V,P1X(A]9B-RLN:1H;P9RGCE-HY1MM*TV..@"M!%MI9_H9GWD""QZ^36X=E9I3]Q1L/=M",. MGZ4GTC'DS4H47;["\-EN[!>'QN/PB,.Q6G%+34_:>I013G>+CYW!61% ^>_O MIVM][^NG7/A:\'3LZTHA2SJ;:M?$"+]#Z *_^C#[@!Q=J+L^7N!?H:LI@X:+ M@T.Z(+%S>YIDB]@[5NEZVW"U2UO_\X)*I8P3YQ_ 8Q!,QH@PJ4NU8I>_N%@_ MDP7,Q)ZVI(V@$W.9(,WS5AUBLUN4BI?C$#]K5YI*2^ XNF;D)4(CP^3N:+7Z#2Q$-$6.:.6=VV!.YU'2?/$/3QG:_%VBO< MAZ<, M5Q'_"";=]KNK',MZ7K*U=_)0247V%#70\95:$"^FM#3IE%183@]3N4>QE 'S M%?,,CBXEZNNLL2F/QT]F 0( $XLM\A#M6^^-;$)_+B79L:]WF7V?2> MWFOJ;'C]'6S"97/M170Z)?HU,@N-,F@@I.=!%W$(X&:3B\;T3Y ^56XL?::T MH,*6X#I5ET75^!F%@O.)Y$#XM.XO:N=O'=\_9#NV=U7L.1>0<+S-9!"PJ;[? MW)".\JV5?4QYS(F=HWPD#6;6*X\)#!CQ-P'#P(SW>^3O675:Y[2Y*K)*U#K3 MB#09>#8^T\*9:#_I3 MXL]52PE 89A>2)^141GK"*CED/3 N9IOYSOYFG7TI,#?4A&#K-7/,U=EZW0. M8&3\,,MB,>JK'^9Z_[RQL;ZOHN\=&F\#N_?7=#P&HQR!V*26XQRU^_$6#E=N M1#NX=+FXR50\*ZU$W_#Z7)-DI&%+TNU^_B+59GRXS69V3BBQI[(YMJH6R*+X M#ET*K6"9*:X-%1&)<$,BZC)@[YC1W1_Q A\/U@_P<.U'N0'6^,MHBZH.AKZ)]@ZO",W**3,@M93J[,&-9EV^.]IX87(GVCO M-0NO67.E7H7^$H/I?X!HEW:?.VO7P'18>)/+R[VM$!(4%T(J[EK]W34*&!F< M8/$]74+=H@4]E<*$67G-&HTI;OI%%W-]C0IWHA40)SLV4Q=\K?5OZD@%K=V6 M#Y5 X="0<;&_'$L&8DS_ !VI)07T&+Q ME%"665)!T%+O 4.B)E61G[4WHU\*5*E9J:OBD\5-$KO9PPZ(SFVT UK ?6NG MW%O^DD,E)*-WKHTU9FP6X:E91GD<M[C[!X8&&T^+#0N--D=$VQK]LG':7 M$_'WCMKCSHFF=CA%6O9.DX+*OFS[1P=.OQ^P4"RQ4F+T&\3-9%#+4L]*B@..55.15M#AT[%JQ!3&.4Z5U-H)E\Z?P8_/?/U+I)G7U'> M@8\%['D@F]/A\@DQA?/[F]4S% U"!($-^_J'$&0KZ>1BWL*?80!Q#_/[3:)_ M@$PC3]U_ (@I042^\D_O+'TY/SD)@8.KC!?>YC 4;]")7FY(_3N5WO@KE)FA $6C'B"M@P0!# M>22.( QYEFC,62<-B\;P@+)I5JR!VX0SQ<>P0V.@.];2CU,9(3HO0_ M+14'ZX#%V4*X*A*CL7:@409\\2B.N2/>&M>KS:^EK!'+%K:CUH$"/$CR= 1- M-38" 48:.\")KPW4!67=9=]@-;2-*A<1JQP9J0)X+45:4@(P1!4J\.>E"8(: ML9;.V8"OJPLW\3/UF\=RE6^SO<^BY_[)&UM@JS:&QW83&1L;_CHAF6BTW3W0 M2H,&DI4^/27I0+%_&:&Y+$Z-G%[G'X"=,P\I*:M'?P -5P@-O3LD.3CL3E7$B'!L_:81^U:CQUACZ[U%"R8Y1"F7S]E 0@+ M3J!5'S;_K-^P-0[Y9K#\]G.ZIW^@!SZ;1O_MJ;@7MY160'AP85/MR/@6;,G+U[JS963"\C3N J4L\!8'Y_3L,[GKN5P-E21U:TF>!&RYM;2^81A]7A# M1S0FMC\5REF._0.D!I0B.$2(I70J#H"GU] H/R3%,%?=8/S[V\0E*T9]D)H' M,E*KGM5EM)&4.C2(CRJ95:>L<]4ASH3C$>T6R.I?W>% 0MU7P2=%3&;3#%OQ M_/=E4Z>F VO-(-RSG _*M%^Q-7DP0:?E(S:,GP31*K UA9P],F1ML[ MX$H&1SI(Z<(Y#L3OX2/BFDFH9Z77LE6D#GO,_C7H F*EJ]C8SMSS>,!VW6S4 M/?EY:GH[?/ T _'ZPV%&D-['/<;& M>D]!T:>@[(&411UQ>$T]BBK\:[2;9WOW9_^$EHE F]]WIVTJ.J ^;.OPCP-I M3!/-$>$O6)/S,+&ZR0%:H86 MX.#7U]TCJR@EDU_A):YU\&]J*[[>CL QZJ8E'-HI>0BYF@C4'$195AHE1XEA3.GZXD N0P)J4C>+D1%0N,/]Y4J^IBPRFN[=FO<56F MFFY&:"G;);70CY0)1FW0,>,RI:&+8K_2+F#RY4NX*S ?GE3ML.8FF]RG,SYF M6CZ\[D_[2DX+YGP8W-Q9-%1%,=!YGYW@_KZ/\VN4WD+<5$S,GY,=KZ4<6K6Z M9V=!F/YP6G> AI4@//)IKB O:F/$K=F&O$]C;$04L-N#G^MG".9.(C4QN^O= M,O\'F-K8>&-Z/4P0&E;!G**:]XL65G?[$^^@CNL&$S3F@%VD>LO?VH^!9P^P]0I6N?IF+#@HE"?__@T6%/N340C:&2CU#2DY-C ;'+;-TC$96V M75>.S8!U1[3<$ASOW&*;P2X,4_UY'1^+QW=[Z'F+)P"@6)AH-J; @< WNV/4 MQ\E$E\PZT-XL'^3>W1(:US@D8**-?<$7H>J3:K7P2/ALBX*I(Z\:!%G]) MIWS"CE_-4-M1S3!M$1<6%O8"@=KW#P")>-X8OIG8&]II;)Q7CHI[G8H6G?/! MNS[P=#VG^CQ34KFJ\(Z!&*1O_&#*&6,C59T% MHJ!9[#S6!OT#*,I'E*;&%2KXGK;[W6ZYI__2GY1OY]7M^ = Z_-@Q!:H:L#= MB9#;??N6*8/DOJ:1DO#1<.04:$,C8%'3&=_"LC[HCV,Z'"].@7K2)6_<4VHA M4[GC_7D<=,+6E3*6#J9L?EOXS*)Q@QXDQ+]9V<"P^#:WWK\5M3YU1% M5T>L1T*?*:SBD(9$BI_'+CI.,D/[PA=/OZ6O!0IC]XE3C;%H(RNBV3-78 M?OUO?+H?%!63:]6UA%*YN>AF,H.T94R.(*G9K/=9!RBNBK)Q M"Q$X^*0E/ D L0F2V-<^]>L54]OT$E2&0X\0CH7?%1]*'>?$;:/^ 7CEIRB. MNP_<=PAURF-BU5^Z9&(.9^>;AVZINM+C' .S($E3C9HF^C36/#D6[1Y0C_?' M-Q+J[1$Q\V'6,OIFL@!P,];H+E*(+"# SET3*JSI;UR^KR)+3VJ0Z%.^;4U> MPU&;+"[_E93XO+B-(/!'OLEHTZX':[N)$5T5.B J@9HJIQKU8/Z[T \6N_(" M!W!_,X_5!=$+UVM@P*/81Z_#WX]0-=?,RH$GCC>?":$OE(AL*C8;.P:M?X#< M5'--&+4;\F Z^4"U-UNJOY.AUP4*4[A-1(TMW;K$;8V>$)G="X9^>>(U$I>X M<\:P6,1VDROYK2E$TFV8;4K[)E7H"E!%>NTC67)PP:>#O>G538]\,NJI )H.-C'> 3\+7L!6>)K!ZMEB=Z%*9HN12D]':WI9Z!1 M'%H=Z6A']-/IM4JS&@?XP2_R'Y$-V(=+1&5^L9/*KBGLG/5JG'.,**6%JO5A MW 1].:Q%2ILT74(;AP>T5UE-[VNT2/R22:\/Z"HNP%,)R"(8, MHX43ZK!CHG[6F@D4+D2?.QZ+=*V=9G-R%IJE*#2X\S_B(DAK8"MJS2OE9/X M1.7.;:$9M>CBG*I!ZPGU%-,E;W8 >+60[%(1OHZVK7WKW5 M'5;7(WO^ =Q(TK/>WQ?0S'DL YFP'DA\) M*S7@6%\6J(@A]_VD/CHZ VG!Y=VJ9:#E:/ MZYV9R&XR#Q^(2-Z08>R:Q:"M2Y@+ZW9IAWV2KM16-CC^JQI4/7]>U7,WI*+_ MD!T_J7>\-:UIA5FA%GE&D/%T6!4!J7)/T5P7HOE?=!FM")5^K!WE0E1*GPJEWH4:A M!RUT?[A705Z.S <5CUB_[1\T0S-18A&F#B9F\0I'>C!H]#9H!3B:D!I]P 7& MNG/2>AP,^Q/TG*.SK 53>$SLM9C[S J0J<^)953V2U2U-?C\JCFK2Y/8PF(; MGP1 D/8G5H76[><$-RQW?DN_?[,]XE>LB11"YZ](B "(,FOGHT-PPU8N!;7< MX"M.4_#A=G';U?^!&@.%X6,=/RFF.CID$<-9Z4) 0$%@,X2)*UKDEM)P*&L M_MNHHU#W$)>O+_]MCK!1'AM3X"H> >(T+@A9"&Q>"]R:#C:F84MV2JI-]K]3Z M^P\P %2(>5#+T-/;9+_5N$\-&!BN-6!F]A0YITR(6ZT7' X:'*CA@>NEII5&1?P'P'-I3.I&0RHFFW+376=G#A< *^\EI0_1G^K& MRR:A5Y"'#4;6I? M4;7H^-#GN0)XG@,M(I@Y^]K)*1'^G@N%I-7+\M8O3_ZUC3W%2WJR*QI#16]-^3_DL>A:U?"J8 M,GEGUH5"W="'9R6?W5%^4+NBU_&U;%-'G6Z8P*V/BJX35\U*] ZFU\?=DZ,-\!T4I& M]* NZCM@[G15+RF$3IB3P,@)S=W.N0R-*I*JO>\$D)2.7TM<=V0G7MTI:EX8 MU:.7.&"(]!'7U*SC+T(?%2VC.R/^]$1?X]IP>+9OX_$QOV<$IJWP9!7ZC>4: MVZU792##U/P ^./@PU4LDW?E=>:<01/9K[K%(H%':*WM3#I#O19P4*6,JAE7 M4'L=K-1@2?V:,E+0F3VWS-JVY9EO+QR;\):E2?O$'X-) FID.JQ#'DILW;M/ M18OK3UTE4O+2I%$CV8(26OD>KIAF)RZH(\!"-$2V>Y4X&!MVM'<3,-E[$^>@ MWQU;"BQCC+6D$ZG.*HC;^)-;AQ3)H(1L9)X&\*.AP)%7VZP4"X^MH]/&'PC- M[FO4GSTZGK8FQ*1(/]7'<)[.CKU]]0A>=='&(<_/6D^Q.*5L_6"V"!;)W4<; PT RQJJ6]N0)UV"VT8=]SUB,H+;.F%T26?RG/U(H_P$2NTQ$ MV;O7+7Z9=&9U-_GPM.T,]EM$L,H#ZC*O17/BPP*";>/']C][ M(U'<"\;!^Z(RS7Z#(%Q$*HXL-\IZ$<,T. N(LM^KBMZX\UMM&$W,%LOEY0/1B(D(#GA MZ%S^02B=SI36.)6:.PQ^50?J/&%CJ2"F -"690@9="PX%"]I; MC&;2#.ND%(E!XQ%Y1^J,_MUHBXF"OQ@^E[2ES# P0F&QFDOY'D=L>$3>"3-; MQDJ.YL2L;5P/J-5=BJ7(]!*T]1+0FA4:2]D+Z1$O3"G3EFQ./V_SK?VU Y3) M+!(^!T\T*\-T8J>; G!+T[_5XZ4*ISY?GNKLMKGW<*6=B*'V*=F9JJR[;6=V,KL,)5^[ M!B9'/.7);9&.C1I=\:YI"RY9PAS[VC-2,B1$P$!,\)E-^KI\"3<1D.FH&+4!U5"#'?=]'^IU9R?SYH=\O$+C2+_J(.4WZZ, M35;0=N$1_:&85C*C5>VJ=6(ST&>],;@$<=2\&7W[9%1446&V>U#^$+277P3B MN&8"\\0 [6?R^C+)E[V8<#(MZ1 '.10EB]C9:^&OW?"#?!0)!E!EP:\.Q4XL MB6I, '&^FB@B94[\SRB3I4*0\V6<->7$O&S7@-1A:<[OL%L Z%L^YJ2 )NF MAL,$-M8!"D)U33'Z_<\73+^RV/M9S<7M3&0UT5E MP!QKA\Y>QR-VM,"\*V98ZGA ZOD#A_6CK@"_!HC@S!9(6PGI YT.#BR=2\1VR"P 'X/*O!H$@@HAGZO7%% M9,Z[*,E[G45Z69:U6G,C_-^#58?5?/Q;"CM:B')O1HD==!GX?>V,L<^/C.$U M%.8@N];3ER\-MYFN;(^1J28I,DG.B9J3-*Y4XAFF7/NMD\9*YL),;<MX?#&6];NH[:B.8F'9(]0\VZ6E\/-@'.XK9JTC#]WSIFW3L3*0' M04*QJ1O7W?7(N'+SR+@6/H*Y'P[U&RMRSR2,6?S7&&'F5>MK=0=\_D&.P2;2E+ +!SXLB#_.8+!H)0E'5G5]FZPNP4) M%19%;/9[8#$)AR7<#N*(B!^X3F3)_>D\%*)YFD@"&1RSQ:AHWR>HI\>X[=!; MG6G3L;RY*/IGJ<64;JJ*_2(.''D+[S9T] QT91,P6M31O$, \5"U=V1X CWE MYQ[Z$=<)\--=Y1:.]])YJ(D;XS,QW*[';ZF5B<= D3S9D]Z_;C7W&_44_7CF MLI('SQ1LW'!&%=@!,&60"5U$%T&OUS%T"!DSG2S^FZX:>2 ,TZ\M^7)5&25J M*7 'C^KX#WM3_PF2R"S1GWG%I, M(6SNP9V@*M;%.AR+BGWJ"9U;(,,*&L:EEOLF1[#:F?'NIZZ;E>"P1*&B<[@# M>*F7F)A+)[@S9W_EMD>E5VQ[I,' M1_IU*:%>%0R[NLZ?;=D>MA"_V]*69@I1 M<3 7,*QN\VTS6Y1.U69\)NZ"Z[@RY?+KZX+&'DA/ ])_$Z[$5"S55(%CU)!L M/D&1;JN[F0YD'Q[)/*8].@^62V[NG?JL@Z]OQW)I?EC%Z^)N9#E=[P#U.T#) MK,%D9>!1'.7Z0$<=0:P8YMYC!H$-?WGHW3L?-<8RI>Z*+RN9ZWQ.C0 MAR[YNK+QAUJ-"@K'EZA 6/\QVC/SF>1Z4PK##/7@C^OMU*:Y6=O-R! M6(M#**=W\LN:I;&H_9S*TM?>W]Y'NOZ'$+NZ.#$Q9YDN]B,BNFB1\"\V[F"' M[=&S[^VJ-5E4FO8[+=]T^XLS=C]0"%DN<&4^" MH'\ R!]5Q^8+\D7?EI1(@G5^OW4H$?7!6Y&-CK&&#+[Z*YC6KNRZCC&19884R;A)##B0-G8I$^Q.2QW"JXF, V6!//EK/L&\S;)$7+7\T4^J=! MJ0-.2HNE62"@[R0+K0WYF$]$.FAJ/WRQ7GH&V\+&"H\>NWBOZY;FRHUIZI>Y MIPT;C;.(_*3K8*@E7"E8#Z7296F!DO&H9@""22FDU:GY+B=>S5'19I>*0H5% M50[Z8^:TM8HZ:[-?,='RB$JN*C)M;T[S0Q#9CV0AGDIV]_@)F@KT@]"1&8$2 M,.$4B;!'C9T6O]TR;??OV8AK[-ZB>P0Z5CH4JYW]RNW2V\0/.G N*[6E'^1# M]JFXL(0,?;[5YK/"UV5XY*)YA/FBENWN*>G1IW>:K1FV0!!2P(.O# M^:)0]85NVOG5,D/@0'BU^**F(2LBC,7OOM>82S__)/QRFO5X)@OV-?$Q@*4 M6\OI55DK$S#./W\;>-/L6V&Z91UEOYVD\SM>,NU%O6IT'BJ-89$3P<9Y$Z;L M2SYZ9-E#3_3./#C.GJPQWM974B>-@*52DN^1DSL1#Q,M>U"^],2%*8U70;&9 MKW1&4J/90'KVJ8[?K]X;(1$!B7DPZ1AHH8_1SNG!H0QRR,B)%HK.U*N2@"S\ MFWQ\Q--CVI-PQ>6,O3+FBM=8.T5[G5$6Q,0H%WP^<"55;0A>VJ$Z!,V(\ ML40SLT .'J(.-4(P#+23.CPVJ;- @ R/AG:Y%EZ/.8'M_+&Y-]BE?7.@E_7^ M1=-#)RD_.6:^.HK0]1_ -HY*0RPK^^691':?+*VKM[LW"4M!FX(\0Z4/$Q4< M <,H[,WB=I4A-#S4[:F$O=>AN$!JFF(P#RU":I/%>.;PS7'^SCOS>K5GR620 M$JG&]F^GB%SMNT*$K#;2$4"=(\.%R+57[ MG9%&L*B;M9H(J:X8^QU6$K; MU6"'!R0D?Q=7FYYT7/[5-HK,&-&14TUYG 8> %R =_$FV3SB?]/8VI@#G/9" M]I09]W0(,7<.&^R*AWW [/)KC1<>,C#!U=%(.L'ZLYGEP0R9%W\%@6Q*CG&1 MNN!X9=3S_Y3S54%Q>,V7@VOPP27!G> 0G.#N,+@'=X<$"^[N[C*#NUM@<'<+ M%H*[R__W?_BVOJW:VMV'W=JMW;=3?:N[;I_JJG/[X5Q_Z($=A.6,Q=$!_6BZ M@:-R! [>=+3;#2EJMBB>Z\OUK'F[D.7DYM7BSJ*7?9%X X*6H ;J-#M5?S$Q M$(QT'%M"L>S+]ECNK.F:8\'QAF#&WKBD;6P<,E:M G$5U,_J*;QN?J4 M\KT(VD#W5(;:*@/-=Y=0I2LT4A?W8P/EO@.(3")','BQRX;D/[,/H^%J;?Y\ MU.I0.<-SH8D1CN[VV/QU=_;4MZI#ZQ[XJ:AQ!#/A(17>%^VQ2DE?W1A#^G08 MR2IP9XA?B#C$=^H.I4(>H/F$3HQ-+XY=8V)*X;Z]VB==VY(-I"+T0.M/AX!-0@C2=AND2=[8#TX M_*5Y=XO,_=3]RYVMSRB_',273(O:;I'.*M'N"))$P.D1#CSA]9%L0J!.BH7% M+%_J%1/%"?1)NCD/&'=3R-.&[CDO"IY1Y:ZORWYT! $K._%Y8*@UMVEJ-NH^ M5N#8\*_@/Y.L5SV%.^LJQE4ELQ@C)&'AI@U"L60 MN#QCXAOYH0+[3" '*.*LJ M'=$B ZJ0&AN.;0,[6[O;7'- FO:[,Y$C,!N8)6#$HFCV1SX9"ZI?&J%\6RKHTIA:T"]3(&YX8* M-=G)BF#JW\2C28YQ\)$5;##'A6YFZ E^F.O[I\O]M&="[H;XQZ\4$$:8K$ 2 MIK]Q:GGDHJ:,HD4P=7>HD0^XNY7CRW[GCNQMFG3+PL3!]W:*PI&9KP)'K:\C M5C\>W=]8=:C;MJH'UQ[.Y#7YB4:TM-<+>^N;:4IQ6$ F,>5#G!DJY7(/Z0I? M'W!;7 %A6G%C>GDW_1O-:^^ /XOS)YU_<1$Z/^D$MW'4Q=C K#\SL.QZ0_LC?;U ?>&U?4F]37.^!>2LBV!:!>0?0^\?['+NH M1H24RQHL.<*IMCY]0'[">"JZQQ.(X1-T^+/%P1=[6Q4K>5Z&4NT_JE.B M4'HA*W9BV.;:^0XHYFZH]PM3Z/*TBL?%RT]U50,%JNX#U ) DL$4 M@W/ Q$O/I$],TK DSY\?R.%FC+\ZG"T8&W7KN"VI/[ ]@H,:6J!Z=Z3?2ID= M50TCD:MPU6Y*!'_'/\0<[V^6>6VBO0-,)VG]/4G-WLB7GGY#UMZL1]X!W[.> MI98D;OVO-L+N^?P;#+B.?'(S7C]^K-IV5,##A34M"W^ &*VL'A0Z,3;,//%J$9,-( LI8\QP!7XQ=8;]=<@/05;]\ M_RGJGR_=HIP[5N,BG'.3+902L)C7'"OI[UR:)/,:/.\H)< )]-BG#IB["R0" MO@X>#X_K=SV;A+ZIM'R'6\H+['UK>QWX#O;ZLR*".K8I_Z@K;+I_OH;.>Q72 M<4@>]Z]CTF>ZWR!?J#^3]+]ESUSP42R)M#HV%>69OS"Q>;/M6SU&I?78?=X: MQ3_/]Q%&@GOZ<__AKM'U)"_$XISF!4S![G)_&DKR*+YQ@RG=N^VO__:[>S'V M>])%===>3TK1 :OA:^V /[U>=^#A RGF<=XZ[^K,5/T/8%IGVE6CW]#85C.A MXSZ:Y[00!5S@J^MSZ+,N_YUR?_U]XIM67'J;[]W AY<"AR>DHFTG$8B_TY:M MM##T0R24\RRY;HC1\&TNW4&'_T?@EI:;W#V%T6%GNXPX@+[/-Z<9U[!_1NV1HJ;(1CE0I@#??ZU#N>KIVU M+.7]M\@P;/M_F:O_#\?C?V?+*1B?+$FNF)@SFW!1;6*77>W1AH"*D@M)'OUAD9:ZM#12R_ZX.L M$$*P=^;XT:W)P=K0W J_2B'KW+;U++%0B:2 M#!XXNRZI2KQ)CF\\NJ!+K=H"1CS03P#3::&K>>@KP)8I+7,W!S4]$M!X66&F M;E"AO&;@L,JCDO=R)5K5XEL3"'<:]E,B:$4'QJGX5NW4C= :0A%$F2 M[;O6V2A4M";1R95M6Q2;?@L&H-DHSXGK.,S_];.KPY+I;-Z7.TJ<$RTV" MN,ENQ Z; D81L!%)/^9].$;L:)_:.3=50RI"5: V541 DQF3O.0FA[.773W' MMB--N_/]??[Y$I6)WWJ3C4"]OPT7J!9.-XYQ-.YP9GFLBW8POIIP^&9[/(!/6J(^E/ZDSQS "+J((*DI"8I MB@JRC^9JJ)A_>-L)&QW6U.IHG] =\ZX3F_T;[^+AZPY1S4:P M:4.?^78UY\HA#ZPB/$!?PY9[Y2092W:V8/ FNLC&&J5[9]FM/K8MR(BB1XJF M^5\/0/@?B<(Z>B;N:M*QJBM"NT*MBDSYJ@\KUXW"F5'V^*_VOFK47BZT7:/> MR9,P.ZJDFG#=J6*JO.+PH^-1@"5$\4.S@&N'FTM![X#EAHB\C6'"=T!8TUNK M9_,[(--%9,OR;:9I9L/HI<7D=9+B9$E16_54:&:F2%HJAHR8R\WJOP^Y%9]C MO3/L]>,/W+KO"W2M5/3=AUH?^%.ZB2=H,/RL!4S3CK]GJ4,^QX&HI4;N'&"* MS 0,> $LRU$_^K^2!MONNMRWLE9$-@_V 0?VV!QTS=G#."]NS.0]T D)7_0# M8&@ZI;'EIECB!@X$R)[_T$G&D=G;730?V1.-#QW )W:N1<:*>:@.SN/JU&^= MH4"/UILOS:M$.?)&.3,WG_6JH;I6L2:%8S:#*[_PRQR4Q8GJ<=[.WDYB%=DQ M9ODQ5]5TPBCS&4@QFPC$AI6:FV=;T!XGJJNAC'DTT"+)0^ ^0=E+!+D<.SIJ MO$;AB,";Z='DTY. .EE.@Q&E8-1@DIVXU#M OSID781;E ],'!2B1]S]UZ^D M8NNV+<=7I?@H'LW2#SGI35]ZIKKQR-ZCK_H\5:8V =(1.[V8HCB/(RE265AZ M^EDC*^AO?'@$QA91]!&_@-?'(="$K4<;>B1*]!A5_5=KO ".9,J I3C\*P)F MPD0NR'VM!QKI6%]RVHX)7Q9)$!:73+VBUV4Y21/J3.5N\&@^0QE 0C'O[,F3 MN$(7?\C8'1=\>,:%Z51%)4\2.9%N(<^N/>_TTET^4LL,B266'?Z8/2K%:0K\ MQ.0Q)-::3_3D:HVZ\HH%]4A\X;SI0?:MSOCTF!;F;-33[K:/F=(S7T-#8X_NK_E<4\<^/ MWE&MU'CPDXZ^6C9'OZY)^?I\@>#KIQC<3^8A6%)'N17L=9Z"P;D:*J)%VFKO M !H\9^/M^Y8D;[F4&BVYF4)GEJ;("!A39L4X,5NJQ,G6A$C!W;_MQYH8]4.O MNCO[1PS@0TQG7!0YQO9Q623[R6'TQ3O#G*9MV6+=813/U#+ O 0X.0W(+^7AH/5 MN*?%YS5:3/R0QL4OD#G-BK_TY6>SJFY!;FVI=JZ\88^;4W+R5Z18HTZ7( <" M2I0N)O.E2PD!.TOPA4&FK]Z:?W=KXM&OV0.OA$(FD@+(/%S8PM1492 M#N.I.D7BE#'S&L5?9D^G5+R3;-8#?M5705RJN;*BJ$!D1E%NCP@.>,=R=UC,Q)K6I8>5,H6< M3M**&DX%\XPE#.TL3J_^#&&QLSIG!+RV8;D'_%K9F 7N;(2YGW_V<.\1RQ5( MH>PT$0]Y)HVM&.E?Y6+'=HW2=+" HBWU?1)O2TQ5C@@!,JAH9,M'(KV/"#42 M5"F[1'I/,6KWY=I>KCF?JG6+Z!QCTR7;AKF%4'\8*G706%KV^^A,'!?.I--Z M6)QLC[(R$I9@.:;T_\ZA&[.@\K;;X;TF3!DT]-O71+<>:48OK[!MF?'+M4)7)' MZA:M+6WLXP?V?8\Y0E\M5AGS)[!95*ICO MRO*M SX_R$>ONZIY5.5Y>);F6W^[19$ @SCI08GU'TD#U%"*8!$TFF[N51MEQT8=+[E28)V+.>E"=V+X!W7Y\48:F&M&@LKI&16UM/(.TFBV MR[-Z:''\(^7WO8M#._(&=B*X$L37[Y8RYK%\^A=@?)C[]]L:4YN"*@5,M11& M0_SD]L* J#^.G#=X:\P=ZPS<7NR(F&Y;4B D$3$XWQSD+A$06=G+M]>+JW]> M7<4CKN=,U7*':K/C+$O'#2F[HB%Q4( *0HC,8T5%M\U9H%YUVSP.HDF)2X_* MT$KA,J7^&U#GG%3M.T"873?F']TLZP+SIA2<\!GF% LX]+?'I*KR6>LV5<9* MZ+4#L['GK4?=D37A^TF<;C:KDH8W]NV'3AN==VMH(T +:?--;9%X'SZ%N]Y2 M)265HVJ)27+E+YX8-- AF>L#EPH7KY0!(.3M067X1,(9.-X,XB\+$UZU>&8' ML]/'ZVRI29HE;O3\V848:'PCG&#+?3WG/-EQ@6FR]4=)LU\YBR"%F+YX#;HP=\O1PMTV1M%=90V:WH-.S>C9:&GVDITH">]/J M-L514GF./>;*K(T?6TY!^YC,)_'N881[KSM;W!+0HD^TN-62HDW--&0:XZ!V M'Y2QR5:_!3Z/(8HYVOHCKU#-OMNSI91&*SL0^T1,W<^>0?A8(H--CO5HFUDY MZWMGH,O$SJ!W)/39T!,F0@O09YY%AF)1@)Y&UEJ=$J4JB;8 M"_&'4?(Z)&49C'VI-=Z.Q(DA/GSYB[R=?Z_A68!#O_42KD3:BG$UZ&B#EP-X MK'#IV@;S_3I4Y;M@GHQ#0RDH4DP81@4D=XYB<=[1R MU)59&AXC'6JFE:XF5]M0 ]W@ 3,)30M[G4*_$A6NF]@TX1,"8 M%&]$A( LKQ4I'@;N>>-6[/4>-59A];]0[/RC2;9+$(S:)AZ_M1 MZ=MTDX[%"W0)Y])$./X::9Z05=0N%PE&"&KCU^89BNJ[)%3V_YX/B^E7I;3! M2XBCXX9'U,L5[%IX."]663[P8$R.]L7;Q%+'/20B8=J=VO?UCWR)U M=3&=X6[ \U9 28IT3#XB1ULA!$>=-H0D=[2X("4! M5X/EJR9]KV)S5WW%,M,FP-QZQ'Y;@<6JJE/%IF3SI0\3WI%@M=)2<(R]TD)= M4XZX]CN@G>:)1S8>%X[6U!\KNO:&O"%^!-VBX.PV4K%N@FA2'>:U(QC(.4]BV9].GQ+_/3 M[>5C@IIZ?3".N2B! $(ZHD!UA7NP[2/ MD4N&\I$#A>8V6XEK)?2QS?662HM6):S2\&2A9".6#&NSUA0V8:DR)_"8C T6 MJX25V=UE%Y%ZT=*J>F@_>E/OY2UHRFDQ=33&6\@3:-52D$=0/M)\I6!!S!Y. M/ND_W*7)75[_ZI?0&(0/*U/<[(V'=RL(H=9M8"AB'<5:,LJ>RWQ)K-_TVF7) M'_WFO:B=/\=NR005+%2$SM_&$+\2V: -4A(L5[0AZ6S,?M%%*#C^?%6M-&K0 MD=([.6E*2[/9?;1A!3(/Y> O'?DJ-(-,IW(WW7](24,DVJI6_=U2'8J)B@D& MZRD-K+ ED;%56<-.UC9P/GF'M\17OG9XV]8ECX%;T9RG4 M*E/^@'*M11!QQL%F"][;I4C=*6.YSOS(PP!E9L1I[A1(B@2+REDHF2%5_7X1 MLC9SPM?V_],^W, MG@+;\8&!P]#4VW/#Y6K]ME I MN+@V\L:]\)OJ+^92W6)B^67_''C![1M/$DA%,/I%8P\[@RA1AMNNP0*UI5Q3 M=AFJ5WE[8M%HV.BJZ'N1ZDD3%5 ,_=$\.SP0 \MEKSJ6 :_N,X_4<$\OG)J#\G[ZJ"5RKC1(!::F41:I6S742JSJ O,<22"20V(.,RS$)E]\GW'CDQ-6*?Z /+T%3M!I> MQ*6[*SO;[X!.[;];LCU,C6S?H-5J-B1AA'3TU@)9%4>K%W<3CJ*V EHQ058/ MRF8VQ;:V\&%'I++2A.K*4.P+]<%>X\N'*9]ND5>Q=T XRY\SWF6VBR/MA=@5 M:@Z9#SP(NS RE^@?_"1YRV/N9+N-E"U)('I[E"-PRIWF-X=6LL9H["9R+'RS MI4T72R)KKILD"89KU=6--OHTG&J#D-E).C!(\F][L9UUB^KA4$=*0*ZI:4^$ MP37^WX1^),:3I0N8+^(..U]$>'^(F;Q93F;X6L?$_L SIM:D%M"HO]YZ'/8@ M";RU[JZ[57I,/9KNRD;!6W[428N5++I7 MJ=9&Y(MXDC#E0'PCL3?XRN";L>]%[/+M[O%WK/W0\< BQ@Z)"^*Y=<8F;SG] MO)-"<&, =M_+7J<6P;Z_RXQ4S:U?A^$3#ASN9,;)\K M0M[0ZRKP2+V.RL!:H#6_P=?*)0$Z\P:=/.&,O%HE$4,Y4TO0XV3'"A'=6;+J M0(N#YN?T8?:?_E5/ +BJ]ET"B]"CZUWG.F8>5= (4$,%0&5_=Y=G/<]2VMK> MCKO.*5C=7YRH_#RAU-VJC_\VE"W_7SP:T'_S:!C^5__ Y%D=SA052<7&$'_A M^A] S>98?.>I>()T(5S50G*;"4S27]BKXW;XR(@\1R\*_1Z$/OM/'*AR0C&; ML,3>(@N-UM32*!_KHFD <-D?Z/ON68>66%;7L)W_2DV2:F*/?D;O+&*M-J,6 M0/PMMUA:#(NU]S1)P.Y.=B:.=8\=P*1%FDS\TPD9([!S70?;X'8@]+4KH@$8GNM.GJYAD&/ 4^;0>+HR/A M,(*QB1$&MYZK TY4_U=G.""3[)Y[Y'1=:O?V:#5D=4K,D#;:L/#B]/0BCZ7 M1Q233",:5%?B9H_Q9@\^0M+I R%,\^JM[T*M-]KA^?FG/\S.E0A[?:@%S('Q M6."^"'H=99^ NN>5,5*W;DI'E[XH-:)!<4:?,P)B-N!-3[QDX M50FF<,?_>JT\0B&\5.CIEL+^A#WS1;[!M<6G5DL0K)F*B?T2XJ$BB"RP&*Q3 MQW:3DE'3I55CX[^QF; M0QN%@(G%HS758^JEWVHFY$SXCZF<59)6:Y0K_4&%B,VMA:I.##8,X&9L41YC M=YD]3=[;@D]V!EOC0IQ@;O\O1U Q4EQ6LH^F/&X-CMMD&W>U1]+:M42KPKGAD_; M_:@J]9=LGX:33KGG:+X:,R/6$*\K(!QPT[[%F]B<>[3#S\1]HB;-;DR2.=JW MV42",TI<^!.[.4N8BH2E$=]5HL;19J91K&5[!I4*[F6?'$E'ZWIPG23QJ!]< MKR9O+4BJ&-H>7L+.C6R-.E0'CU6G:3F%_"8DFSE?VR0I">)CG^8HCW\3&@!7 M\UI/N1_F,@L-B-8PNYS@)5!+U;5?(44QT/YT!"NTZ T?\*VWHF560CF MR,4)(,/$802+6ODAP]L68P O.S--=5=!C]BME):QR P32C_Z<1(:!UV7(RZJ M_NIEF9678,&'FP51\=1 9JR:$=$(&_U-"07 M^1*O)BLQXB7#HB#]Y#8Q[(>,=<'@+"=/;.2O]=H1)H0['W@N2U3CNO/-%W;77J)L\&LD^6'$H-%AAV)?&ZX$PRUI-W%L#:HFDKK^(17=3++EDRI\.X'C)3*$%A&BA M=4T,Z>7>?'SWIUG4=3*G'B>6I'><<1J2%@BJ9V67[N5=21QT76V<^*TCOZ!. MXW!$P!50(+5]>\P0<@GBJKF33A*PF 66\$1?$%BS45\A.M83AV^B;H3CYT[T MMY-H5[B%S22O305/S6;%@@8R3(-F6KM$-@;-;2!33)7+^ZQ:-Y/!)I?W1@J '>#?"IR8G5VN9#XR('$/@U_?5'B:/&E^C;WX:U29[^DK\XJD>IT045< M='C%1Q1#JLSR#V+JW<^9-]%><+_X3EXWW18+!&7^M-#+'V=].N=%:,1=J5+% M8'*_#_37,K\KG@FM%-2EJ4=P0RXAK@_'R_^:U0WJ6++(?1+XD^,M%0)O@O5U M*%NFMQ^I]*M,%96FWV2EHA5WU O%DC#V23>1$)+3)@L4I")50MR97 BH^EJ[ MY(_9=\;:JV$P8W(5[L$MW1@YZ;+SB3=Q6.)F]'O?T%T;RE'UJS;L3XNZU3A4 M9[Y*BP\O4I_]OLRGM7I80[2NY*$QLPI757:H4$IX3UT C 6 &-6^EO@IYVN- M-)QN27N49X29145!##5'9'3UNES',>"JUGY/HG^%' M\FBPUDBSZR0;]H??D)E$]-W2K(_@'^L;B:@RM0!$B'Z^9+2R2K14""KNVW%_[0[<-/0'_=4O#8^?%1 MP$+Y!R.8VM4 =;5.3-R++S/IN;1!$T"S\P1=&S36-]6=4<-/UMB/\W;/)61= M.F<;O.52E$OU0:8DM=F]=.S13&P=EO[4U2TM'S[:.H9QH[TJEUO0T_,@+"?) MX=!C],)D"M+RT$13__ Z 'EK7%FKPINL=():Z=64PV';HXJ^=SQD8!Q$5ELZ M_#_#X2";$7%]*E-!= MW-9W;=6756KMQ' S?J8#B1C5I2)JV3*X6H+[*'KQ^+")4$Q^%0H5AK2^Y:F M/6[[.]0:L&;,XEJ-NJS; ,Z8K-!L[RV(@F-[" UHC9.0+_*PTUY$""/XH7(_ M0M[>@LB#G8-Y19Z\SA(D/?/'21)CIC^4'5[P)Q(B0I+;+/^'MUJ(>) MC T!D!%2+%^A)I,[7EP MBJY3@ZP"8 (*U&/N"&\BDI>U5P'IJ!Z7A# WG5AW=3X$ Y);Q!9^A4H(W?EV M@2CT 1E)QZCQVU[&']L,(5ETP4[!?LPCL?R+N#[IF;KR1?8%)TH8VXLC^X!T M>.H4V.U@UG\>_/1Q]M8G!4N>$;Y!W6X?@0MT+ M-8GNO'K%BA[:(UV<*+%#:((?T#VEDNS-!W?UPYG'I>E#7;Q4Y1=SY$$4CA":-5R MMD@']NVUOXI5Z5C58W-RJL\YN8]R-RN"QH1X@C'IJ/=#,%KX!>OR^.SQI08% M:G!?!)$1[.F\3SF8&9<<[SF*FV#$O*E(5?<_?C^F],;KLNKP54HCSUDB*F.Q M0_?$)ESA%P%$V_PF2,'-V&AUKH [7-3,#6I)0NE&:D3[*L2([ Z^JX:;^OMW1!5=LQ M^TMH%A596?GDG"N33P]0C3#UD^6F/K89ANPXK__ YT!MX#D9E__RTY(F@OI2 M!89[MXM!'5(0!^_516);K$]XL&=/D\=;46!HFOT:SG2@%81+4RB2 8G.'YB2 M4T5FAC=G38G3@RQ)Y4D="!C$A?V5-FU$IE/V!; M@F8()B0E4[XBX)%_G+>'9&Z<3@S:MB\BT%UKRU'99G5.@M+K6O6IJ/XH%XO$ M9+9+R'":\&S0V+JFZGC,CDH#@!D6V$R)I:B>V.NUCU%K=0TT0^#1B*)(+OAA M$GO4>HGA1"Q#+LL8BF-X&EM%._FYI]NQCHV^HZ<8*M6;L[H@TU=HLQ_G@Q%]E1RN-=3\S M1,3%JY(. != B -=<76I*DY#'[V@%@AL=!YO*(1L&G*4.RL>"<;'@A%W!1[K8(L,.8XO&*DW8Y7DP)DQ"> M/Q=H?*6=+D]QGT0 =Q9>5=0IP+$B]"_G:CJ7;]0W/X4XO&K3.N[XP1 6,F9'$EC(=MW/NG"1 MK'&L#B"2L?4-JM^?QKC[E%)_"Y'[E/QW0+5_]3O@&*7FMN:M[!W ^?8.^-$C M[M1STRHRWK-0 M 1:Q?.^ >O]U#[VWOG> J?]AN>.=\CL@]AT ?0?LWQU?\W+^0W+[6\,;I?*Q M<,_2/U6,E$^7;-Q[KF[CPEZH#_^-I%7J/D#)$\%FO?_BJYT'L MDP#AQ5GOT_1@,!V.1CWO'W___>\\_M_[/QP<>%<(AL&I=T'\@Q&>DQ^]6["" MI]X'B"$%$:$_>I]!&(L2GJ5_6=6_2-B M?E'YW9N?U^3MTQWZ93'&/\03\(O/IN#+\*_WDW=/ZW^^C?_]L(P^A"?SN_#- M?S>C\*=_3:ZNAB?L>/[X90!^_BE]Y'OF+^$*>!P,S,YZPK[,O*\GAX0NCHY? MO>H?_?+Q9IKP]5+&TZ<0X0<=>__=NW='"35G53B?[FF8BSXY$N1[P& AF5-1 M"S_"+ +8K_$'45&AROSZ*"766)&6]4W*BG+6 $I\#/J'"_)XQ F<__@D9XS9 MP0* =<$\!^P^$9H1:LR,1BHC+Y29#J+-&C(M:TJJ50@B*E6HM1HG'PFRJ'-\ M\.KDX*2?UZ2/Z+&H1"'_2W3E1/BKUX(-AG %<71%Z.H"SD$<EX$Z )&HF^R-?!AFZB\=P.,"1\$?"1F):)LO4:\EQ<%O$CTBE-*0CCCFGOB M!Q^%&OF"2@XZZ4_*Y)R60&<(XR2YV9#KN\=B $6"P/YSZ3F^R.9 M6944,QB,\=^3WVL*&:^>V'/#"[+Z&4M[71^$?ASN5+74KZUF5IZWXC.:%S,2 MH@!$,#@'H1A\TR6$$V'RZDWNN6$\?"GZ_'-Q>7= M],_>Y<^?1K-_.<"[ [8\BHD7[>,U)+-",PW'< <3*^]JYOQ%S=0=;B-Z0)@ M]&NB:0I1K<0(C;?":^3;L)"PF$+^1U6$:W5-JY\#AGBOGU1L'>!@&J]6@&[& M\RE:8+Z=\ &.!KY/8APAO)CP<>,CF VD9TDP0O4'&=7DD1Z9>]6'>@ '7O98 M0:L\V"N?[.6/=KU!TQNR=F)WT(?H$=R'\!9&**>QO'H:1 MPT2#R0@_&C'0<0=;\3GB@%C17Q#*37"X5@=#[D8+Y7C(-"Y:-$2 MTF%,1;C@!H%[%/)'YWY $]$(D!/%<1/2O$R<5Y'G@-$ 4\P<$[ 1JVF*B%)J M!,7W,A2%&"^3XR#00'!+(LAJS5\K,6KZUW+3)R)U/T9L?@3/^-#$%5 MT)_^^,-Q_^V/7BK0X:&-OJQ6*$IB*=P]&I)DTP5QN5UL8S!"2-GC5R0F;E1- MI@-) ](=#$78:P*XYSFC #/@5V+8C50C>)3->B;.2^1Y58$.&UU )F8(0\9X MK[Y'N!(-TQ&,$%&VW[DDKR+*8:$/)?O<2/F$IUIF@L"QLOVN"W%MWS(.IG A MIG:^5GR 9$'!>HG\ 85 9-[0E69\F%0P0DW9K!?C)GM$LMJ4#_'$4[S*8QRN MVFT\_PEGX D6._BRP @7S>9=2/ 2$:[-]QSDWU^POU/0_UB)".PCZ.]]E_]R M:0[[[B@SL4?=0S?)Y!AU$B56L9].DJK@NHCQ$5$5^S8&(U"5*$C3<9$#RO3< MJ(J/IMP(%B4R4C]#JSED.MX MAE*+3C22C9!2@PZ:\Q0'D/G!2GTT:2A&L"AA@[HH!\B>3EMT(\F\FA&42JBA MZ\F+ ]OP"*:^Q96+C>E;DSMAI,TMHPXC9!3PCQ;D'-CK=NA MM[16Z8E&2&D21I1C;S>\ND.C+%M;N(S TD1QFL!R(VJG=(7:P-K"8P29$HMI M25APXZQ#QD(-J2:B$41*V$.3L^"@,4Q:J,&B(YA \EJ)4TAI"PZ.;G#T&_'H MFP&R+8\D7W7Z#A)#2"0'H97#""(E\M D7,,.F;]U*:T9K(12$KPH2KOST7& MCYO?=D&HOP4BP[E."3NT8N2FO(XH21.? 9\1:DK(H2VCSLV%STVNJTV*!GQ& M&"K!B"WI=6Z:?!9X?5/T#"?.;A_]<#/HLP&4IM(N%8P 58(7AH"Z:76G+[OH M437F-H)4"78T?_G%X6F:#2!"KY.8^DO X&!!(53.PMI93)![H^9N")E>+M0K MI+IU<7>T^@9PF:V&;]1LC6UXN870^$V!AI0Y T8C[)18BO[M 3<_[O B@;1S MT)&,,-*\BU-_E<#-@ETQZ;> 8CCK*<&3!E3<7-=L.@W@6'HR2B1$BT:SH\QQ4/)B&MF,,'GK>:ZE.HKC;_Q M.4S\3]P)? ?G7G*7\&G$V Z?;X_V M:'D([KM:SJO \ 5-OA'R7\)6WD&[VBKUZ1>R>%@^Y27LYJ.KJ]WU ?E"9E\4 M#U&M?G]4O]Z9_RU? ?V>&TYHY&'E(NFVZ[_3B\MOB)^(:JDB_CK(ZQV(HH/^ M\<%)__")!:6F790HFZ&;$GF]'91HN(1<]WS6Q"Y^))W)]*$-EYFW/E1;YPB& M$I,ZVVHF?[.=.D'R]B3==.D(U2KY'[NA45Y: M;P9$SI^"(.ZQW_6Q._0"]>&-72"[\#YQ\L3<^Y_!$PH_PM6]N&!>*';6JY6@ M,!0)BF>]B,9B5N3/1:=\MD0DF"63>A"G0:F>ET[RO ^D3S\-R H@/(K@2G!R M6^)[QN?36'!_H"1>G_52<8BSM*DXC%G$?4=:5U,IM4'5\3H)T-4UE0MM4/0& M^1 SA!=W:+&,)(6;B#8H_@7>,\Y35U@NM$'12Y]@LD+^"/\WIAN^%P(L@O2& M #RA(KJSJIM@SFZ#<2/,MW7"W;A"F/_#NTK=FA:Z#>I/P(9/K/X#;]H()OD4 M62,?U\TPX+/!G**1ATM %U :S8U4&U2_)?@S$5E*4_Y TH1DU<_+KKE[RMW<)D@R$#[ LUZ&:2KF>2"@U!L(KG\[K.#30;U$Z^;W0>QC B)%J*3\GIQNE6 M+AM,&?@^9(R(2&"BK]3=FZ@VJ"[8VR9( WK]LQZ-"TPN8_CO"TAQ7Z8=;&6TU*[%00GA[@S<@Y'C,4PJ)JYE=-6 M,._@&FQ$T7BNSB&YA=N8;#5.(#,!*+B(A7LW213B& VX.+X!BJH MK*![%=N M8'??*N7@4O@#]A$2$/TK[5M<4O71NW0M9*U M*]$'0H*O7#LCJTV9;86Z\D%K#EN\VF*N.;NM!I>OH,D?H9:7*1-.ZU:JQHW) M##Y%YR%?G;9N8:J7;13S MNE6QQ,X)Y9X?"K*-ESA;LEM@G;393/2/9K*U,"3>?I"]QM%N]LQ3+6F,\G\;K=4H%X7FZ5D^7$$;R M=<0M'6 7$?:U P@A.\\/36^XZ[/5[.TU++>2NW9K*B(NW4QMKF:)O5^@V,'R M[:K(45] <7^J/UT"*FYOSC.I6SAV=?:2^OM7_P*%L?AR0JL%"M.W-B)ITB+[ M,?OC&?V#!O7M]ZRW,%' MB&.8!8^JJFLIUL8-BB/A\G97Y;2X1MKY>.AE=\@?H=A9+ M[2KN#;V&83"(9DM$TY/5_&7J,I*UG=%2&X=)%Q\"&A3S?[W(UB/).[(!8;3) MM@<#WZ$;K@[H\( M6!:A(J78VC5&?8NZG+0T%%N!2'6$V>O'N0E*J;4P2#[U'13Y6[S)9Y"N/G 4 M*DZC&>N./EA>^L(F\<$QA\C0J"KSMS?K,V1&"KWI)=[_@/ZX HI]!&!>+23N+K;.8?/S=="QN MK[LXYBHD(D$*GV\L=$< 3.@\I.89+D0@WF) MUD:=83_/^0VT\(R" -Z*#]J^1+O6I/\&6C/[CNE+-&4IVM)V%&X1"B MG(FJ MOR03;'7XTCR+FL9E&J..]*WS,2KOBTTH7R(F6<)"&4YHI-N1%I%_62C(SW%1 MD@Z;?^6BV#EL9;/76\6,A"@0^YTB )*^:7M#&*N.DG8V>ST]B.$<\=WI##Q5 MXX?C>?F62;F\&#);:^U%]M%:KO^,J_:I<$AT!&NMX"YP&8WC_2N#I3B;:"1; M:Q%O]BR=7K)%1[!ULK@5Z;792_B9ME!ZY;N-X]N;]?XHO?* __P_4$L#!!0 M ( -6#%5,[N2*DRX^)K,Y!3!.&'%,1YP,I-UZE1*H :T(B1& M%]O,KS_/I;LE@<#8!AML]GO>-0Z(UM/=S_WZV_^Y&3C&E? #VW-_WRGF"SN& M<#N>9;N]WW>BL+M[M/-_WF]O_=8/X3EXU@U^W^F'X?#MFS?7U]?YZW+>\WMO MBL?'QV]N\)D=?NCM3>9SI4*A^.:O+V>M3E\,S%W;#4+3[0C](\=V?TY?'[_5 MC[9]QTX]BI^HEY3?3"P-WUKQ#Y(/'[SA+U./AIF/[O.CH7K4#KR]4O%P%AS\ MA/[!S;1GBP@S[%#\]:%Y%C\>9C\?/_HF]$TWZ'K^P SA#G&E_=U":;=TD%AD M-Q"=U$+P[WS/N[IUG:/=O(%OU8-1L-LSS:%^N&L&;7I0?I%:%3[S/4<$F4_3-ZG'K=#?#4=#$62# M E^_P:_Q-Z7=0CEQ+!TOJ2P#R\GFA2F!?\U\/]^"^W0$>]_>\/_A6\'(C0-7&!7_!WA8E7/#84;[E[" M/G:,#O_K]YU0W(1OF'3?X._>R&5_^Y_=7>/4%H[UUFB)\)UQ;@[$6^/&NGEG MU$_HCQ^%4O7'U]:OI9./E[1<*=UGW M.+%N92!<"_[_\-0Q>S^ZIA.(NRQ53BQUXG4B6LD..J;S79C^*7P2_+CCT>]7 MIJYY(7S;LWC5T^]W6//@ R##R8_B#\GT>''XZ"YKE'ZT^J8O8$,_B,?S(@%] M=I=U3A"6"[E6>0*DARU^_.,B\L6/O>0J0_A$KM'VK!'^U[*OC" <.>+W'FNXGBN(>NV;MTAIPD<2IG_9EB5<(FC\)SQX#K?BVQVFU9NPB8SRU/<& MS(0.=@O%T,-[WRWL$T-R 59XE;#?9B+RSOL8DW][DWK%8MZ:0O.=]X3G2WG1 M%"+8>8^//\(;$R2R\_[T^XPWGOIF!^6I7$I*JK<7OAB:ME6[&0HW$!77:H1] MX5>"0(1!-?)]>--."LI*T.@RE R9;?V^ [A8LA$#04Z"X(AU0J_S\YOI1.). M(.TO7D 1'P&\\A1A,*O;R9+N19;NTP$LE8\7#J!FO5+,?Q"NZ-KA/0'<7[SP MHKOL>PXHH0%RP"FRH<@0_9 _^Y'&A2]BT!;^!+B'B\=!5N8;48BN'?10+0[: MHR1Z\GL6=;Z-(7YSX9BN1(/Y[O^.\"_AM!(Y_$(@;XK0M%UA MU4S?!50+IH!_O'C]"+1KYAQG7A L UF.%\^+'P+S[3ARO'C6]Q" *Y9EXY)@ M!X(-5W>KYM .36<:\(O7M.;DV_=#CL7+P?GX]GV@+1?VE\:WZT$0">LD\M$8 M('N?M)Y*!PX\H/O/QIN2QIORO5A*N5AZ2HXX'?RY+J2X!/19!/"W,IGR$BS= MA4 ^)]:4EH0U4\C@7%S3-W>E@;F0J+0DEKG@O"3?T_-&?OAV*$^_:G;6#M-=[#+J#Q1TM^=K0 M%60&?7)CS<$29\)VN'@\A3OW$;03P?^MNR=BZ('$3[CH[V?"EX^6XF,8@Y; ME#[+A)?UGB O4'M5[N@Q>)6K4)[RO5'A>/$F< :PLWR<]SOBO<+B?,5TQ%4@ M+M)2@<0;HP1^3MO/0DP!<^>O/"$:I+8<6UM%_^ MOC O18[A"0.D5[8EK ^CKP%&R)#A!NB%K,"/KAY @25$XXU8X05H P$",[$>U[LX2]TN*5@J882IQM=,^]4 0R M3G3/(UQ"G$A[G1$V._MNYSF\_:7PTUM!N_W,]A<<(4V8!D @BE\"H;1MUWP MOURTWM2T>_VPT05VPTI(4W2\GFO_(ZQ*D(X)WA?@Q=TX 7R92AJHW72<"+T_ M2?E4=Q=WWH>+DT]254EG/2P%Y@7'L55:Q%)@7;!<2BBG<,#18,'0+D[7)FB_ M"+_3!Z6$)%00>#Z0G["O)GG_[$#H_A)\V5.5IH_^A.4ZQ=E:B4"5]> ZQ!0O MQL$2,HRFR\\Q*#ND:?^HNT'D8U*W3M+(AO5P;_%VUJVPEM.PPJ.=ONC\A+L) M!2T(?_5\#7;/A6]WLJ]NZD[' M4/QBV:$E7C\1+P@4\/?4DH\.]Y[DLH);;DMM*ZB[O//Y[VS^K>\OZ_86FH-W MO&A#Y@STDOI@&(64L2M@RW=*6CP^6'R@XL1V$!P5(8$KI[L 67B*E4;WNN!B M85P"+>Z"F^)*N-,B09,9 5)P?A(FDG+-[:-V0BCO6K'DSY2CQ>(2,J1(X8,7 MSYUE]K =+,&?/5>"^8.@+BW!)_A /^9D'$EMT+3]*J VK-#Z:;OXY[1-+?XJ M%NVT$S'T1<)>@WG@^UBTE7*+W]-062_M+3%U.@PV*CB6L M"'X!QI",W6:KA%5O7/FXPX8.%A]8N,.&0(4"#H4X@X'_!]S+P3+"^IG;H!QS M,1B&,U+@YX)XP1JIS'AO= ' )#$WNK%S]7YALF+I<'%(0K">R+08 /42%O@Z MO"]<"XZ8@RX4FQV D ^I(@#H%GS#BZEN*):.%AP$U\D[ *"$3-PE#WP"P"4D M>BU#V#7N2/NIZ/QO-=*I.*RTB7G@ 5$^?8]G<<[YH[;=P%Q'M)6OPP MKI)&B"F73<#; WX"FU"\#:B[""QM4,N0MWT?WX)HL5N2#0+R-X&U([_&O@Z_ M[P3V8(@.OC?QJ]*+\^L"+_+5V^ QJO]^*S=.FYS!;56O!O4S047:^E/]N6WA M-UU;^ 9M162V[JC6/Z<+NL=_'+_N3>;[Y-N&Y(:9A"((33\\,4/Q/MZ.6BG^ M;N)GPK74C^2^X]=;J9^HSU, J _ED4X_9VT1%HN[Y<*:G2UWIPG?QQO0KY#? M+/20RMC(I7"\OHQY7B_,7[ MH\G^K@X[,4/;0D$U_(KRP YF;HV!T[9%@-RX8GN0];'"V"8\/? M2^7A-W:P\SZ[.)N7^^U-YEN2$+[)!O'!-%9\!$8T?ON3%0(OX^HG M]OW"[GUVH<7+P(&99_#"\&%*3=;+0(3LS;\,#%@S'>N1#VFNXNJ7020KIBPM MU2"9EEWOM&65I=9>DI\&&C+*V2LO0DKJF-1K :&L&*^]SNT<3I9>#. MDZL4ZXXX&YUDQ722=4>HC5+SY$K->J#0'5LDO0P$6CE=:/4R3^[1K>IEX,YJ MZ4)KB#@;76B5=:$U1*B-+K1:NM#JH=!8]X*-!K02&M C9_5M%)@546">^-XW M^L>*Z1]/C \;]>')U8?'PH#;*M'A;)X)'\AHB,H73W5C\3XWBN*=$$1UPUUO M) G\\.T7\[^>K[83)' CO<4-?LSGE]_@Q\;I/@=^R/Y0ZXT>6HF$=2UL?61? MB9;H1#YUN>0.J,+"HT"M(PIE,?QX>Z0/H^P%$KB6.JX-JLVCS9Y&<,IA1(UG M3NT;_.N9H-O4%B\?1CCL/:W73C^&YZK;3LE^V^##ZN+#8V1#9GB]L'>>KT_K M!2+#E#-X89QA@PFKB F/R1- S__QQ7;M033@#28B(U,.<;UQ! V;)C9Q92P@ M.R>Y_]OO?6F8>,N)/W/>E,)(\^9E8V1R_QN,7)$HP3/%OPUF+*#*=(,9JX\9 M3V%K34FX,+'[%\87-K>_*K?_F+0O'?UG=@>/S^W1/+-G@@"G8"N%XLR^ MHM$+J;%A'T8<,'+,(.G SSR&9\X')CQN,F#6% Y%0H*^/7R)"*%]+M//XX5A MQJ5O6N+<'#P7 7$O=!@_A!>" U)._"G: 9S9"[Q_D@^I[3_SFR^D;[X&CW@# MNU-W_QOYHQ,[,(-0^&>>J6;H/0^

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�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�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end